=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehaf194.pdf",
  "converted_date": "2026-01-31T14:46:49.392055",
  "file_size_bytes": 5730399,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehaf194.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
European Heart Journal (2025) 46, 4635–4736
https://doi.org/10.1093/eurheartj/ehaf194
2025 ESC/EACTS Guidelines for the
management of valvular heart disease
Developed by the task force for the management of valvular heart
disease of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS)
Authors/Task Force Members: Fabien Praz *†, (ESC Chairperson) (Switzerland),
Michael A. Borger *†, (EACTS Chairperson) (Germany), Jonas Lanz ‡, (ESC Task
Force Co-ordinator) (Switzerland), Mateo Marin-Cuartas ‡, (EACTS Task Force
Co-ordinator) (Germany), Ana Abreu (Portugal), Marianna Adamo (Italy),
Nina Ajmone Marsan (Netherlands), Fabio Barili (Italy), Nikolaos Bonaros
(Austria), Bernard Cosyns (Belgium), Ruggero De Paulis (Italy), Habib Gamra
(Tunisia), Marjan Jahangiri (United Kingdom), Anders Jeppsson (Sweden),
Robert J.M. Klautz (Netherlands), Benoit Mores (Belgium),
Esther Pérez-David (Spain), Janine Pöss (Germany), Bernard D. Prendergast
(United Kingdom), Bianca Rocca (Italy), Xavier Rossello (Spain), Mikio Suzuki
(Serbia), Holger Thiele (Germany), Christophe Michel Tribouilloy (France),
Wojtek Wojakowski (Poland), and ESC/EACTS Scientific Document Group
* Corresponding authors: Fabien Praz, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Tel: +41 31 632 83 50, Email: fabien.praz@insel.ch and
Michael A. Borger, University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, Tel: +49 341 865 1422, Email: michael.borger@helios-gesundheit.de
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC),
European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA)
Working Groups: Cardiovascular Pharmacotherapy
Patient Forum
Disclaimer. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines represent the views of the ESC and the EACTS and were produced
after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contra-
diction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation
to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgement, as well as in the
determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever, the individual re-
sponsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or
necessary, the patient’s caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or
guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional
obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether
a more recent version of this document exists. The ESC and the EACTS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect.
Permissions. The content of these ESC/EACTS Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS
Guidelines may be translated or reproduced in any form without written permission from the ESC and the EACTS. Permissions can be obtained upon submission of a written request
to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. © The European Society of Cardiology and
the European Association for Cardio-Thoracic Surgery 2025.
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 2 ---
4636 E S C G u id e l in e s
Document Reviewers: Alec Vahanian, (ESC Review Co-ordinator) (France), Carlos-A. Mestres, (EACTS Review
Co-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa (United Kingdom), Enoch F. Akowuah (United
Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs (Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani
(Italy), Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert A. Byrne (Republic of Ireland), Ovidiu Chioncel
(Romania), Lenard Conradi (Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Anna Franzone (Italy),
Kristina Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja Ibanez (Spain), Bernard Iung (France),
Stefan James (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf Landmesser (Germany),
Gregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun
(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark),
Jens Cosedis Nielsen (Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet (Belgium), Thomas Pilgrim
(Switzerland), Eva Prescott (Denmark), Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba (Spain),
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina Urena (France), Ilonca Vaartjes (Netherlands),
Christiaan Vrints (Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), Adam Witkowski (Poland),
and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest,
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines • European Society of Cardiology (ESC) • European Association for Cardio-Thoracic Surgery (EACTS) •
Valvular heart disease • Aortic stenosis • Aortic regurgitation • Mitral stenosis • Mitral regurgitation • Tricuspid
regurgitation • Tricuspid stenosis • Multivalvular disease • TAVI • SAVR • Heart surgery • Transcatheter edge-to-
edge repair • Transcatheter valve replacement
Table of contents 6.3. Cancer and radiation therapy........................................................... 4657
6.4. Prophylaxis of rheumatic fever ........................................................ 4658
1. Preamble.............................................................................................................. 4640 6.5. Cardiogenic shock and acute heart failure.................................. 4658
2. Introduction ....................................................................................................... 4642 6.6. Palliative care............................................................................................ 4658
2.1. What is new ............................................................................................. 4643 7. Aortic regurgitation ........................................................................................ 4658
3. The Heart Team and Heart Valve Centre............................................ 4649 7.1. Prevalence and aetiology..................................................................... 4658
3.1. The Heart Valve Network ................................................................. 4649 7.2. Evaluation................................................................................................... 4658
3.1.1. Composition of the Heart Team............................................. 4650 7.3. Medical therapy....................................................................................... 4660
3.1.2. Procedural volume and clinical outcomes ........................... 4651 7.4. Indications for intervention................................................................ 4660
4. Imaging of patients with valvular heart disease................................... 4652 7.5. Follow-up................................................................................................... 4660
4.1. Initial valve assessment......................................................................... 4652 7.6. Special patient populations ................................................................ 4662
4.2. Associated diseases and conditions................................................ 4653 8. Aortic stenosis .................................................................................................. 4662
4.3. Evaluation of valvular heart disease dynamics and variability 4653 8.1. Prevalence and aetiology..................................................................... 4662
4.4. Assessment of extravalvular cardiac consequences from 8.2. Evaluation................................................................................................... 4662
valvular heart disease..................................................................................... 4653 8.2.1. Echocardiography and cardiac computed tomography . 4662
4.5. Evaluation of eligibility, planning, and guiding of interventions 4653 8.2.2. Additional diagnostic and prognostic parameters ............ 4663
5. Clinical evaluation of patients with valvular heart disease ............. 4653 8.2.3. Procedural planning ....................................................................... 4663
5.1. Clinical examination .............................................................................. 4653 8.3. Medical therapy....................................................................................... 4663
5.2. Assessment of comorbidities and risk stratification................ 4653 8.4. Indication for intervention.................................................................. 4665
5.3. Biomarkers ................................................................................................ 4654 8.4.1. Symptomatic severe aortic stenosis....................................... 4665
5.4. Exercise testing ....................................................................................... 4655 8.4.2. Asymptomatic severe aortic stenosis .................................... 4665
5.5. Invasive investigations........................................................................... 4655 8.4.3. Moderate aortic stenosis............................................................. 4665
5.5.1. Coronary angiography.................................................................. 4655 8.5. Treatment options................................................................................. 4667
5.5.2. Cardiac catheterization ................................................................ 4655 8.5.1. The mode of intervention in candidates for a
5.6. Patient-centred care and shared decision-making ................... 4655 bioprosthesis................................................................................................. 4667
6. Management of conditions associated with valvular heart disease 4655 8.5.1.1. Age and life expectancy....................................................... 4668
6.1. Diagnosis and management of coronary artery disease........ 4655 8.5.1.2. Anatomical features .............................................................. 4668
6.2. Atrial fibrillation ...................................................................................... 4657 8.5.1.3. Lifetime management........................................................... 4668
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 3 ---
ESC Guidelines 4637
8.6. Follow-up................................................................................................... 4671 13.3.3. Mixed mitral valve disease........................................................ 4690
9. Mitral regurgitation ......................................................................................... 4671 13.4. Follow-up ................................................................................................ 4690
9.1. Primary mitral regurgitation .............................................................. 4671 14. Management of patients with prosthetic valves or valve repair 4690
9.1.1. Prevalence and aetiology............................................................. 4671 14.1. Choice of prosthetic valve............................................................... 4690
9.1.2. Evaluation........................................................................................... 4671 14.2. Follow-up of patients with prosthetic valves........................... 4691
9.1.2.1. Echocardiography and right heart catheterization .. 4671 14.3. Antithrombotic therapy in patients with treated valvular
9.1.2.2. Biomarkers................................................................................ 4671 heart disease ..................................................................................................... 4691
9.1.2.3. Cardiac magnetic resonance and computed 14.3.1. Mechanical heart valves ............................................................. 4691
tomography .............................................................................................. 4672 14.3.1.1. Post-operative anticoagulation and therapeutic
9.1.2.4. Genetic evaluation................................................................. 4674 targets ......................................................................................................... 4691
9.1.3. Medical therapy ............................................................................... 4674 14.3.1.2. Prevention and management of bleeding.................. 4693
9.1.4. Indications for intervention........................................................ 4674 14.3.1.3. Management of anticoagulation therapy before and
9.1.5. Follow-up ........................................................................................... 4675 after non-cardiac invasive procedures.......................................... 4693
9.2. Secondary mitral regurgitation......................................................... 4675 14.3.2. Biological heart valves ................................................................ 4695
9.2.1. Prevalence and aetiology............................................................. 4675 14.3.2.1. Patients with a surgical biological heart valve and no
9.2.2. Evaluation........................................................................................... 4675 indication for oral anticoagulation.................................................. 4695
9.2.3. Definition of atrial secondary mitral regurgitation........... 4675 14.3.2.2. Patients with a transcatheter heart valve and no
9.2.4. Management of ventricular secondary mitral indication for oral anticoagulation.................................................. 4695
regurgitation.................................................................................................. 4676 14.3.2.3. Patients with a surgical biological heart valve and an
9.2.4.1. Medical and device therapy ............................................... 4676 indication for oral anticoagulation.................................................. 4696
9.2.4.2. Indications for intervention ............................................... 4677 14.3.2.4. Patients with a transcatheter biological heart valve
9.2.4.3. Follow-up................................................................................... 4678 and an indication for oral anticoagulation................................... 4696
9.2.5. Management of atrial secondary mitral regurgitation..... 4679 14.4. Management of prosthetic valve dysfunction and
9.2.5.1. Medical therapy and rhythm management ................. 4679 complications.................................................................................................... 4697
9.2.5.2. Indications for intervention ............................................... 4679 14.4.1. Structural valve deterioration................................................. 4697
9.2.5.3. Follow-up................................................................................... 4679 14.4.2. Non-structural valve dysfunction.......................................... 4698
10. Mitral stenosis................................................................................................. 4679 14.4.2.1. Prosthesis–patient mismatch.......................................... 4698
10.1. Prevalence and aetiology.................................................................. 4679 14.4.2.2. Paravalvular leak and haemolysis .................................. 4698
10.2. Rheumatic mitral stenosis................................................................ 4679 14.4.3. Endocarditis .................................................................................... 4698
10.2.1. Evaluation ........................................................................................ 4679 14.4.4. Valve thrombosis.......................................................................... 4698
10.2.2. Medical therapy............................................................................. 4680 14.4.4.1. Hypo-attenuated leaflet thickening.............................. 4698
10.2.3. Indications for intervention ..................................................... 4680 14.4.4.2. Clinically significant valve thrombosis......................... 4698
10.2.4. Follow-up......................................................................................... 4680 15. Management during non-cardiac surgery............................................ 4700
10.3. Degenerative mitral stenosis with mitral annular 15.1. Pre-operative evaluation................................................................... 4700
calcification......................................................................................................... 4680 15.2. Specific valve lesions........................................................................... 4700
10.3.1. Evaluation ........................................................................................ 4681 15.2.1. Aortic stenosis............................................................................... 4700
10.3.2. Indications for intervention ..................................................... 4681 15.2.2. Mitral stenosis................................................................................ 4701
11. Tricuspid regurgitation................................................................................ 4682 15.2.3. Aortic and mitral regurgitation .............................................. 4701
11.1. Prevalence and aetiology.................................................................. 4682 15.3. Peri-operative monitoring................................................................ 4702
11.2. Evaluation................................................................................................ 4683 16. Management of valvular heart disease during pregnancy............. 4702
11.3. Medical therapy .................................................................................... 4683 16.1. Management before pregnancy ..................................................... 4702
11.4. Indications for intervention............................................................. 4683 16.2. Management during pregnancy...................................................... 4703
11.4.1. Surgery.............................................................................................. 4683 16.2.1. Patients with native valve disease ......................................... 4703
11.4.1.1. Patients without indication for left-sided valve 16.2.2. Patients with prosthetic valves............................................... 4703
surgery........................................................................................................ 4685 17. Sex-specific considerations in patients with valvular heart
11.4.1.2. Patients with indication for left-sided valve surgery 4685 disease........................................................................................................................ 4703
11.4.2. Transcatheter techniques......................................................... 4686 17.1. Aortic valve disease ............................................................................ 4703
12. Tricuspid stenosis.......................................................................................... 4687 17.2. Mitral valve disease.............................................................................. 4704
12.1. Prevalence and aetiology.................................................................. 4687 17.3. Tricuspid valve disease ...................................................................... 4704
12.2. Evaluation................................................................................................ 4687 18. Key messages .................................................................................................. 4704
12.3. Medical therapy .................................................................................... 4688 19. Gaps in evidence............................................................................................ 4705
12.4. Indications for intervention............................................................. 4688 20. ‘What to do’ and ‘What not to do’ messages from the
13. Multiple and mixed valvular heart disease.......................................... 4688 Guidelines................................................................................................................. 4707
13.1. Prevalence and undertreatment.................................................... 4688 21. Evidence tables ............................................................................................... 4710
13.2. Evaluation and diagnostic pitfalls................................................... 4688 22. Data availability statement......................................................................... 4710
13.3. Indications for intervention............................................................. 4688 23. Author information...................................................................................... 4710
13.3.1. Multiple valvular heart disease................................................ 4688 24. Appendix........................................................................................................... 4710
13.3.2. Mixed aortic valve disease........................................................ 4690 25. References........................................................................................................ 4711
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 4 ---
4638 E S C G u id e l in e s
Tables of Recommendations Table 3 New recommendations .................................................................... 4643
Table 4 Revised recommendations............................................................... 4645
Recommendation Table 1 — Recommendations for the Table 5 Requirements for a Heart Valve Centre ................................... 4651
management of chronic coronary syndrome in patients with valvular Table 6 Complex procedures ideally performed in the most
heart disease (see also Supplementary data online, Evidence experienced Heart Valve Centres................................................................. 4651
Table 1)...................................................................................................................... 4656 Table 7 Clinical and echocardiographic criteria predicting outcome
Recommendation Table 2 — Recommendations for the improvement in patients with severe ventricular secondary mitral
management of atrial fibrillation in patients with native valvular regurgitation undergoing mitral transcatheter edge-to-edge repair 4678
heart disease (see also Supplementary data online, Evidence Table 8 Contraindications for percutaneous mitral
Tables 2 and 3) ....................................................................................................... 4657 commissurotomy in rheumatic mitral stenosis........................................ 4682
Recommendation Table 3 — Recommendations on indications for Table 9 Echocardiographic pitfalls, robust measures, and
intervention in severe aortic regurgitation (see also Supplementary complementary multimodality imaging parameters in multiple or
data online, Evidence Tables 4–8) ................................................................... 4662 mixed valvular heart disease ............................................................................ 4689
Recommendation Table 4 — Recommendations on indications for Table 10 International normalized ratio targets and therapeutic
intervention in symptomatic and asymptomatic severe aortic stenosis, ranges for patients with a mechanical heart valve.................................. 4693
and recommended mode of intervention (see also Supplementary data Table 11 Peri-operative management of antithrombotic treatment
online, Evidence Tables 9–13)................................................................................... 4670 in patients with a mechanical heart valve undergoing non-cardiac
Recommendation Table 5 — Recommendations on indications for surgery based on type of procedure and underlying risk.................... 4694
concomitant aortic valve replacement at the time of coronary artery Table 12 Criteria for the diagnosis of moderate or severe aortic
bypass grafting or ascending aorta surgery................................................ 4671 and mitral haemodynamic valve deterioration..................................... 4697
Recommendation Table 6 — Recommendations on indications for Table 13 ‘What to do’ and ‘what not to do’............................................ 4707
intervention in severe primary mitral regurgitation (see also
Supplementary data online, Evidence Tables 14–16).............................. 4674
Recommendation Table 7 — Recommendations on indications for List of figures
intervention in secondary mitral regurgitation (see also
Supplementary data online, Evidence Tables 17–20).............................. 4679 Figure 1 The Heart Valve Network.............................................................. 4650
Recommendation Table 8 — Recommendations on indications for Figure 2 Integrative imaging assessment of patients with valvular
percutaneous mitral commissurotomy, mitral valve surgery, and heart disease ........................................................................................................... 4652
transcatheter intervention in clinically severe rheumatic and Figure 3 Central illustration. Patient-centred evaluation for
degenerative mitral stenosis (see also Supplementary data online, treatment of valvular heart disease............................................................... 4654
Evidence Table 21) ........................................................................................ 4682 Figure 4 Imaging assessment of patients with aortic regurgitation . 4659
Recommendation Table 9 — Recommendations on indications for Figure 5 Management of patients with aortic regurgitation............... 4661
intervention in tricuspid regurgitation (see also Supplementary data Figure 6 Integrative imaging assessment of patients with aortic
online, Evidence Tables 22 and 23)....................................................................... 4687 stenosis...................................................................................................................... 4664
Recommendation Table 10 — Recommendations on indications for Figure 7 Management of patients with severe aortic stenosis .......... 4666
intervention in tricuspid stenosis ................................................................... 4688 Figure 8 Aortic valve treatment options .................................................... 4667
Recommendation Table 11 — Recommendations on indications for Figure 9 Factors to be considered when selecting the mode of
surgery of concomitant left-sided valvular heart disease..................... 4690 intervention for aortic stenosis....................................................................... 4669
Recommendation Table 12 — Recommendations on indications for Figure 10 Echocardiographic assessment of patients with mitral
intervention in patients with mixed moderate aortic stenosis and regurgitation............................................................................................................ 4672
moderate aortic regurgitation (see also Supplementary data online, Figure 11 Management of patients with severe primary mitral
Evidence Table 24)................................................................................................. 4690 regurgitation............................................................................................................ 4673
Recommendation Table 13 — Recommendations for prosthetic Figure 12 Most frequently used criteria for the diagnosis of atrial
valve selection......................................................................................................... 4691 secondary mitral regurgitation ........................................................................ 4676
Recommendation Table 14 — Recommendations for the Figure 13 Treatment of severe secondary mitral regurgitation
management of antithrombotic therapy in patients with a without concomitant coronary artery disease......................................... 4677
mechanical heart valve........................................................................................ 4693 Figure 14 Management of clinically severe rheumatic mitral stenosis
Recommendation Table 15 — Recommendations for the (mitral valve area ≤1.5 cm2)............................................................................. 4681
management of antithrombotic therapy in patients with a Figure 15 Echocardiographic and invasive assessment of tricuspid
mechanical heart valve undergoing elective non-cardiac surgery or regurgitation............................................................................................................ 4684
invasive procedures.............................................................................................. 4694 Figure 16 Stepwise evaluation of patients with tricuspid
Recommendation Table 16 — Recommendations for the regurgitation............................................................................................................ 4685
management of antithrombotic therapy in patients with a biological Figure 17 Management of patients with tricuspid regurgitation....... 4686
heart valve or valve repair................................................................................. 4696 Figure 18 Antithrombotic therapy following mechanical heart valve
Recommendation Table 17 — Recommendations for the implantation......................................................................................................................... 4692
management of prosthetic valve dysfunction (see also Figure 19 Antithrombotic therapy following biological heart valve
Supplementary data online, Evidence Table 25) ....................................... 4700 implantation or surgical valve repair............................................................. 4695
Figure 20 Management of left-sided obstructive and non-obstructive
List of tables mechanical heart valve thrombosis ............................................................... 4699
Figure 21 Management of non-cardiac surgery in patients with
Table 1 Classes of recommendations.......................................................... 4641 severe aortic stenosis.......................................................................................... 4701
Table 2 Levels of evidence................................................................................ 4641 Figure 22 The Pregnancy Heart Team model of care.......................... 4702
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 5 ---
ESC Guidelines 4639
Abbreviations and acronyms DSE Dobutamine stress echocardiography
DVI Doppler velocity index
2D Two-dimensional EACTS European Association for Cardio-Thoracic
3D Three-dimensional Surgery
4D Four-dimensional EARLY TAVR Evaluation of TAVR Compared to Surveillance
ACE-I Angiotensin-converting enzyme-inhibitor for Patients with Asymptomatic Severe Aortic
ACTIVATION PercutAneous Coronary inTervention prIor to Stenosis trial
transcatheter aortic VAlve implantaTION trial ECG Electrocardiogram
AF Atrial fibrillation EDV End-diastolic velocity
AO Aorta ENVISAGE-TAVI AF Edoxaban vs. Standard of Care and Their
AP Anteroposterior Effects on Clinical Outcomes in Patients
AR Aortic regurgitation Having Undergone Transcatheter Aortic Valve
ARB Angiotensin receptor blocker Implantation–Atrial Fibrillation
AS Aortic stenosis EOA Effective orifice area
ASA Acetylsalicylic acid EROA Effective regurgitant orifice area
ATLANTIS Anti-Thrombotic Strategy to Lower All ESC European Society of Cardiology
Cardiovascular and Neurologic Ischemic and EuroSCORE European System for Cardiac Operative Risk
Hemorrhagic Events after Trans-Aortic Valve Evaluation
Implantation for Aortic Stenosis EVoLVeD Early Valve Replacement guided by Biomarkers
AU Agatston units of LV Decompensation in Asymptomatic
AV Aortic valve Patients with Severe Aortic Stenosis
AVA Aortic valve area FAC Fractional area change
AVAi Aortic valve area indexed for body surface area FFR Fractional flow reserve
AVATAR Aortic Valve Replacement Versus FWS Free wall strain
Conservative Treatment in Asymptomatic GALILEO Global multicenter, open-label, randomized,
Severe Aortic Stenosis event-driven, active-controlled study
AVCS Aortic valve calcium score comparing a rivAroxaban-based
AVr Aortic valve repair antithrombotic strategy to an
BASILICA Bioprosthetic or native Aortic Scallop antipLatelet-based strategy after transcatheter
Intentional Laceration to prevent Iatrogenic aortIc vaLve rEplacement (TAVR) to Optimize
Coronary Artery obstruction clinical outcomes trial
BAV Bicuspid aortic valve GDMT Guideline-directed medical therapy
BHV Biological heart valve GLS Global longitudinal strain
BNP Brain natriuretic peptide h Hour
BP Blood pressure HALT Hypo-attenuated leaflet thickening
BSA Body surface area HF Heart failure
CABG Coronary artery bypass grafting HFpEF Heart failure with preserved ejection fraction
CAD Coronary artery disease HFrEF Heart failure with reduced ejection fraction
CCT Cardiac computed tomography HR Hazard ratio
CCTA Coronary computed tomography HTx Heart transplantation
angiography INR International normalized ratio
CHA 2DS 2-VASc Congestive heart failure or left ventricular IU International unit
dysfunction, hypertension, age ≥75 (doubled), KCCQ Kansas City Cardiomyopathy Questionnaire
diabetes, stroke (doubled), vascular disease, LA Left atrium/left atrial
age 65–74, sex category (female) LAAO Left atrial appendage occlusion
CI Confidence interval LAAOS Left Atrial Appendage Occlusion Study
CIED Cardiac implantable electronic device LAMPOON Laceration of the Anterior Mitral leaflet to
CKD Chronic kidney disease Prevent Outflow ObstructioN
CMR Cardiac magnetic resonance LAVI Left atrial volume index
COAPT Cardiovascular Outcomes Assessment of the LMWH Low-molecular-weight heparin
MitraClip Percutaneous Therapy for Heart Failure LV Left ventricle/left ventricular
Patients with Functional Mitral Regurgitation LVAD Left ventricular assist device
CRT Cardiac resynchronization therapy LVEF Left ventricular ejection fraction
CT Computed tomography LVESD Left ventricular end-systolic diameter
CW Continuous wave LVESDi Left ventricular end-systolic diameter indexed
CYP Cytochrome P to BSA
DAPT Dual antiplatelet therapy LVESVi Left ventricular end-systolic volume indexed to
DEDICATE Randomized, Multicenter, Event-Driven Trial BSA
of TAVI versus SAVR in Patients with LVOT Left ventricular outflow tract
Symptomatic Severe Aortic-Valve Stenosis MA Mitral annulus
DOAC Direct oral anticoagulant MAC Mitral annular calcification
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 6 ---
4640 E S C G u id e l in e s
MATTERHORN Multicenter, Randomized, Controlled Study to STS Society of Thoracic Surgeons
Assess Mitral Valve Reconstruction for STS-PROM Society of Thoracic Surgeons predicted risk of
Advanced Insufficiency of Functional or mortality
Ischemic Origin trial SVD Structural valve deterioration
MHV Mechanical heart valve SVi Stroke volume index
MITRA-FR Percutaneous Repair with the MitraClip TAPSE Tricuspid annular plane systolic excursion
Device for Severe Functional/Secondary Mitral TAV Transcatheter aortic valve
Regurgitation trial TAVI Transcatheter aortic valve implantation
mPAP Mean pulmonary artery pressure TDI Tissue Doppler imaging
MR Mitral regurgitation TEER Transcatheter edge-to-edge repair
MRI Magnetic resonance imaging THV Transcatheter heart valve
MS Mitral stenosis TMVI Transcatheter mitral valve implantation
M-TEER Mitral transcatheter edge-to-edge repair TOE Transoesophageal echocardiography
MV Mitral valve TR Tricuspid regurgitation
MVA Mitral valve area TRILUMINATE Clinical Trial to Evaluate Cardiovascular
MVHD Multiple valvular heart disease Outcomes in Patients Treated With the
N No Tricuspid Valve Repair System trial
NCS Non-cardiac surgery TRISCEND Edwards EVOQUE Transcatheter Tricuspid
NOTION Nordic Aortic Valve Intervention trial Valve Replacement: Pivotal Clinical
NT-proBNP N-terminal pro-B-type natriuretic protein Investigation of Safety and Clinical Efficacy
NYHA New York Heart Association using a Novel Device
OAC Oral anticoagulation TS Tricuspid stenosis
PAWP Pulmonary artery wedge pressure TTE Transthoracic echocardiography
PCI Percutaneous coronary intervention TTR Time in therapeutic range
PET Positron emission tomography TV Tricuspid valve
PH Pulmonary hypertension UFH Unfractionated heparin
PHT Pressure half-time VCA Vena contracta area
PISA Proximal isovelocity surface area VHD Valvular heart disease
P mean Mean pressure gradient VKA Vitamin K antagonist
PMC Percutaneous mitral commissurotomy V Peak transvalvular velocity
max
PMR Primary mitral regurgitation VSARR Valve-sparing aortic root replacement
POPular TAVI Antiplatelet Therapy for Patients Undergoing VTE Venous thromboembolism
Transcatheter Aortic Valve Implantation VTI Velocity time integral
PPM Prosthesis–patient mismatch WHO World Health Organisation
PROM Patient-reported outcome measure WU Wood unit
PVL Paravalvular leak Y Yes
PVR Pulmonary vascular resistance
RA Right atrium/right atrial 1. Preamble
RCT Randomized controlled trial
RECOVERY Randomized Comparison of Early Surgery Guidelines evaluate and summarize available evidence with the aim of
versus Conventional Treatment in Very Severe assisting health professionals in proposing the best diagnostic or thera-
Aortic Stenosis peutic approach for an individual patient with a given condition. ESC/
RESHAPE-HF2 Randomized Investigation of the MitraClip EACTS Guidelines are intended for use by health professionals but
Device in Heart Failure: 2nd Trial in Patients do not override their individual responsibility to make appropriate
with Clinically Significant Functional Mitral and accurate decisions in consideration of each patient’s health condi-
Regurgitation tion and in consultation with the patient or the patient’s caregiver
RF Regurgitant fraction where appropriate and/or necessary. It is also the health professional’s
RHC Right heart catheterization responsibility to verify the rules and regulations applicable in each coun-
RHD Rheumatic heart disease try to drugs and devices at the time of prescription and to respect the
RV Right ventricle/right ventricular ethical rules of their profession.
RVEF Right ventricular ejection fraction ESC Guidelines represent the official position of the ESC on a given
RVol Regurgitant volume topic. Guideline topics are selected for updating after annual expert re-
SAM Systolic anterior movement view of new evidence conducted by the ESC Clinical Practice
SAPT Single antiplatelet therapy Guidelines (CPG) Committee. ESC Policies and Procedures for formu-
SAV Surgical aortic valve lating and issuing ESC Guidelines can be found on the ESC website
SAVR Surgical aortic valve replacement (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/
SGLT2i Sodium–glucose co-transporter 2 inhibitor Guidelines-development/Writing-ESC-Guidelines).
SMR Secondary mitral regurgitation This guideline updates and replaces the previous version from 2021. This
SPAP Systolic pulmonary artery pressure Task Force was selected by the ESC and the EACTS to include professionals
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 7 ---
ESC Guidelines 4641
Table 1 Classes of recommendations
(cid:18)(cid:1)(cid:12)(cid:9)(cid:10)(cid:9)(cid:17)(cid:12) (cid:17)(cid:15)(cid:11)(cid:9)(cid:12)(cid:6)(cid:25)(cid:10)(cid:17)(cid:25)(cid:3)(cid:19)(cid:18)
(cid:29)(cid:21)(cid:20)(cid:19)(cid:19)(cid:25)(cid:8)(cid:25) (cid:31)(cid:7)(cid:9)(cid:11)(cid:18)(cid:12)(cid:14)(cid:18)(cid:25)(cid:20)(cid:12)(cid:11)(cid:28)(cid:17)(cid:15)(cid:25)(cid:6)(cid:18)(cid:12)(cid:18)(cid:15)(cid:20)(cid:21)(cid:25)(cid:20)(cid:6)(cid:15)(cid:18)(cid:18)(cid:13)(cid:18)(cid:12)(cid:10) (cid:8)(cid:19)(cid:25)(cid:15)(cid:18)(cid:14)(cid:17)(cid:13)(cid:13)(cid:18)(cid:12)(cid:11)(cid:18)(cid:11)(cid:25)(cid:17)(cid:15)(cid:25)(cid:9)(cid:19)(cid:25)(cid:9)(cid:12)(cid:11)(cid:9)(cid:14)(cid:20)(cid:10)(cid:18)(cid:11)
(cid:10)(cid:5)(cid:20)(cid:10)(cid:25)(cid:20)(cid:25)(cid:6)(cid:9)(cid:7)(cid:18)(cid:12)(cid:25)(cid:10)(cid:15)(cid:18)(cid:20)(cid:10)(cid:13)(cid:18)(cid:12)(cid:10)(cid:25)(cid:17)(cid:15)(cid:25)(cid:4)(cid:15)(cid:17)(cid:14)(cid:18)(cid:11)(cid:3)(cid:15)(cid:18)(cid:25)(cid:9)(cid:19)
(cid:2)(cid:18)(cid:12)(cid:18)(cid:1)(cid:14)(cid:9)(cid:20)(cid:21)(cid:127)(cid:25)(cid:3)(cid:19)(cid:18)(cid:16)(cid:3)(cid:21)(cid:127)(cid:25)(cid:18)(cid:129)(cid:18)(cid:14)(cid:10)(cid:9)(cid:7)(cid:18)(cid:141)(cid:25)
(cid:29)(cid:21)(cid:20)(cid:19)(cid:19)(cid:25)(cid:8)(cid:8)(cid:25) (cid:29)(cid:17)(cid:12)(cid:143)(cid:9)(cid:14)(cid:10)(cid:9)(cid:12)(cid:6)(cid:25)(cid:18)(cid:7)(cid:9)(cid:11)(cid:18)(cid:12)(cid:14)(cid:18)(cid:25)(cid:20)(cid:12)(cid:11)(cid:28)(cid:17)(cid:15)(cid:25)(cid:20)(cid:25)(cid:11)(cid:9)(cid:7)(cid:18)(cid:15)(cid:6)(cid:18)(cid:12)(cid:14)(cid:18)(cid:25)(cid:17)(cid:16)(cid:25)(cid:17)(cid:4)(cid:9)(cid:12)(cid:9)(cid:17)(cid:12)(cid:25)(cid:20)(cid:2)(cid:17)(cid:3)(cid:10)(cid:25)(cid:10)(cid:5)(cid:18)(cid:25)(cid:3)(cid:19)(cid:18)(cid:16)(cid:3)(cid:21)(cid:12)(cid:18)(cid:19)(cid:19)(cid:28)(cid:25)
(cid:18)(cid:144)(cid:14)(cid:20)(cid:14)(cid:157)(cid:25)(cid:17)(cid:16)(cid:25)(cid:10)(cid:5)(cid:18)(cid:25)(cid:6)(cid:9)(cid:7)(cid:18)(cid:12)(cid:25)(cid:10)(cid:15)(cid:18)(cid:20)(cid:10)(cid:13)(cid:18)(cid:12)(cid:10)(cid:25)(cid:17)(cid:15)(cid:25)(cid:4)(cid:15)(cid:17)(cid:14)(cid:18)(cid:11)(cid:3)(cid:15)(cid:18)(cid:141)(cid:25)
(cid:25)(cid:25)(cid:25)(cid:29)(cid:21)(cid:20)(cid:19)(cid:19)(cid:25)(cid:8)(cid:8)(cid:20) (cid:18)(cid:9)(cid:6)(cid:5)(cid:10)(cid:25)(cid:17)(cid:16)(cid:25)(cid:18)(cid:7)(cid:9)(cid:11)(cid:18)(cid:12)(cid:14)(cid:18)(cid:28)(cid:17)(cid:4)(cid:9)(cid:12)(cid:9)(cid:17)(cid:12)(cid:25)(cid:9)(cid:19)(cid:25)(cid:9)(cid:12) (cid:30)(cid:5)(cid:17)(cid:3)(cid:21)(cid:11)(cid:25)(cid:2)(cid:18)(cid:25)(cid:14)(cid:17)(cid:12)(cid:19)(cid:9)(cid:11)(cid:18)(cid:15)(cid:18)(cid:11)
(cid:25)
(cid:16)(cid:20)(cid:7)(cid:17)(cid:3)(cid:15)(cid:25)(cid:17)(cid:16)(cid:25)(cid:3)(cid:19)(cid:18)(cid:16)(cid:3)(cid:21)(cid:12)(cid:18)(cid:19)(cid:19)(cid:28)(cid:18)(cid:144)(cid:14)(cid:20)(cid:14)(cid:157)(cid:141)(cid:25)
(cid:25)(cid:25) (cid:25)(cid:25)(cid:25)(cid:29)(cid:21)(cid:20)(cid:19)(cid:19)(cid:25)(cid:8)(cid:8)(cid:2) €(cid:19)(cid:18)(cid:16)(cid:3)(cid:21)(cid:12)(cid:18)(cid:19)(cid:19)(cid:28)(cid:18)(cid:144)(cid:14)(cid:20)(cid:14)(cid:157)(cid:25)(cid:9)(cid:19)(cid:25)(cid:21)(cid:18)(cid:19)(cid:19)(cid:25)‚(cid:18)(cid:21)(cid:21) ƒ(cid:20)(cid:157)(cid:25)(cid:2)(cid:18)(cid:25)(cid:14)(cid:17)(cid:12)(cid:19)(cid:9)(cid:11)(cid:18)(cid:15)(cid:18)(cid:11)
(cid:18)(cid:19)(cid:10)(cid:20)(cid:2)(cid:21)(cid:9)(cid:19)(cid:5)(cid:18)(cid:11)(cid:25)(cid:2)(cid:157)(cid:25)(cid:18)(cid:7)(cid:9)(cid:11)(cid:18)(cid:12)(cid:14)(cid:18)(cid:28)(cid:17)(cid:4)(cid:9)(cid:12)(cid:9)(cid:17)(cid:12)(cid:141)
(cid:29)(cid:21)(cid:20)(cid:19)(cid:19)(cid:25)(cid:8)(cid:8)(cid:8)(cid:25) (cid:31)(cid:7)(cid:9)(cid:11)(cid:18)(cid:12)(cid:14)(cid:18)(cid:25)(cid:17)(cid:15)(cid:25)(cid:6)(cid:18)(cid:12)(cid:18)(cid:15)(cid:20)(cid:21)(cid:25)(cid:20)(cid:6)(cid:15)(cid:18)(cid:18)(cid:13)(cid:18)(cid:12)(cid:10)(cid:25)(cid:10)(cid:5)(cid:20)(cid:10)(cid:25)(cid:10)(cid:5)(cid:18) (cid:8)(cid:19)(cid:25)(cid:12)(cid:17)(cid:10)(cid:25)(cid:15)(cid:18)(cid:14)(cid:17)(cid:13)(cid:13)(cid:18)(cid:12)(cid:11)(cid:18)(cid:11)
(cid:6)(cid:9)(cid:7)(cid:18)(cid:12)(cid:25)(cid:10)(cid:15)(cid:18)(cid:20)(cid:10)(cid:13)(cid:18)(cid:12)(cid:10)(cid:25)(cid:17)(cid:15)(cid:25)(cid:4)(cid:15)(cid:17)(cid:14)(cid:18)(cid:11)(cid:3)(cid:15)(cid:18)(cid:25)(cid:9)(cid:19)(cid:25)(cid:12)(cid:17)(cid:10)
(cid:3)(cid:19)(cid:18)(cid:16)(cid:3)(cid:21)(cid:28)(cid:18)(cid:129)(cid:18)(cid:14)(cid:10)(cid:9)(cid:7)(cid:18)(cid:127)(cid:25)(cid:20)(cid:12)(cid:11)(cid:25)(cid:9)(cid:12)(cid:25)(cid:19)(cid:17)(cid:13)(cid:18)(cid:25)(cid:14)(cid:20)(cid:19)(cid:18)(cid:19)
(cid:13)(cid:20)(cid:157)(cid:25)(cid:2)(cid:18)(cid:25)(cid:5)(cid:20)(cid:15)(cid:13)(cid:16)(cid:3)(cid:21)(cid:141)(cid:25)
Table 2 Levels of evidence
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:13)(cid:12)(cid:28)(cid:15)(cid:24)(cid:11)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)(cid:9)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:20) (cid:26)(cid:14)(cid:27)(cid:13)(cid:30)(cid:15)(cid:16)(cid:8)(cid:16)(cid:22)(cid:16)(cid:28)(cid:7)(cid:9)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:16)(cid:27)(cid:9)(cid:24)(cid:22)(cid:5)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:19) (cid:26)(cid:14)(cid:27)(cid:28)(cid:16)(cid:14)(cid:5)(cid:30)(cid:27)(cid:22)(cid:26)(cid:22)(cid:8)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:18)(cid:26)(cid:22)(cid:9)(cid:30)(cid:22)(cid:9)(cid:12)(cid:9)(cid:27)(cid:26)(cid:25)(cid:27)(cid:26)(cid:11)(cid:24)(cid:22)(cid:24)(cid:26)(cid:22)(cid:27)(cid:26)(cid:25)(cid:27)(cid:15)(cid:4)(cid:30)(cid:27)(cid:30)(cid:3)(cid:11)(cid:30)(cid:14)(cid:15)(cid:9)(cid:27)(cid:16)(cid:22)(cid:23)(cid:2)(cid:26)(cid:14)(cid:27)(cid:9)(cid:13)(cid:16)(cid:28)(cid:28)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:18) (cid:14)(cid:30)(cid:15)(cid:14)(cid:26)(cid:9)(cid:11)(cid:30)(cid:21)(cid:15)(cid:24)(cid:29)(cid:30)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)(cid:27)(cid:14)(cid:30)(cid:5)(cid:24)(cid:9)(cid:15)(cid:14)(cid:24)(cid:30)(cid:9)(cid:6)
involved with the medical care of patients with this pathology and to include studies were considered. For recommendations related to diagnosis
patient representatives and methodologists. The selection procedure in- and prognosis, additional types of evidence are included, such as diagnos-
cluded an open call for authors and aimed to include members from across tic accuracy studies and studies focused on the development and valid-
the whole of the ESC region and from relevant ESC Subspecialty ation of prognostic models. The strength of each recommendation and
Communities. Consideration was given to diversity and inclusion. the level of evidence supporting it are weighed and scored according
Guidelines Task Forces perform a critical review and evaluation of the to pre-defined criteria as outlined in Tables 1 and 2. Patient-Reported
published literature on diagnostic and therapeutic approaches including Outcome Measures (PROMs) and Patient-Reported Experience
assessment of the risk–benefit ratio. Recommendations are based on Measures (PREMs) are also evaluated when available as the basis for re-
major randomized trials and relevant systematic reviews and commendations and/or discussion in these guidelines.
meta-analyses, when available. Systematic literature searches are con- Evidence tables summarizing key information from relevant studies
ducted in cases of controversy or uncertainty to ensure that all key are generated to facilitate the formulation of recommendations, to
(cid:19)(cid:12)(cid:17)(cid:9)(cid:10)(cid:20)(cid:11)(cid:12)(cid:18)(cid:13)(cid:13)(cid:17)(cid:14)(cid:18)(cid:15)(cid:25)(cid:16)(cid:17)(cid:25)(cid:19)(cid:18)(cid:19)(cid:19)(cid:20)(cid:21)(cid:29)
(cid:22)(cid:24)(cid:23)(cid:24)(cid:25)(cid:30)(cid:26)(cid:29)(cid:27)(cid:31)(cid:28)(cid:29)(cid:30)(cid:31)©
(cid:157)(cid:143)(cid:144)(cid:143)(cid:27)(cid:129)(cid:141)(cid:18)(cid:20)(cid:127)(cid:2)(cid:18)(cid:129)(cid:127)©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 8 ---
4642 E S C G u id e l in e s
enhance comprehension of recommendations after publication, and to centres, where corresponding expertise is concentrated to ensure
reinforce transparency in the guidelines development process. The ta- high-quality treatment.
bles are published in their own section of the guidelines and reference • Advanced imaging modalities—such as three-dimensional (3D) echo-
specific recommendation tables. cardiography, cardiac computed tomography (CCT), and cardiac
After an iterative process of deliberations, a first Task Force vote on magnetic resonance (CMR) imaging—have gained importance and
all recommendations is conducted prior to the initiation of rounds of become a central aspect in the screening and evaluation of patients
review. A second Task Force vote on all recommendations is con- with valvular heart disease (VHD).
ducted after the final round of review and revision. For each vote, • Emphasis is put on the importance of correctly assessing the cause(s)
the Task Force follows ESC voting procedures and all recommenda- and mechanism(s) of all valve diseases. In particular, the distinction
tions require at least 75% agreement among voting members to be ap- between atrial and ventricular secondary mitral regurgitation (SMR)
proved. Voting restrictions may be applied based on declarations of has clear implications in terms of prognosis and management.
interests. • New evidence has been published regarding the benefits of
The writing and reviewing panels provide declaration-of-interest intervention for the treatment of severe aortic stenosis (AS) irre-
forms for all relationships that might be perceived as real or potential spective of symptoms, left ventricular ejection fraction (LVEF), and
sources of conflicts of interest. Their declarations of interest are re- flow reserve.
viewed according to the ESC declaration-of-interest rules, which can • The criteria used for decision-making concerning the optimal modal-
be found on the ESC website (http://www.escardio.org/doi) and are ity of AS treatment [transcatheter aortic valve (AV) implantation
compiled in a report published in a supplementary document with (TAVI) or surgical AV replacement (SAVR)] based on a Heart Team
the guidelines. Funding for the development of these ESC/EACTS approach have been refined, including the combination of key aspects
Guidelines was derived entirely from the ESC and the EACTS with such as age, procedural risk, and anatomical suitability, incorporating
no involvement of the healthcare industry. estimated life expectancy and lifetime management considerations.
The ESC CPG Committee supervises and co-ordinates the prepar- • Further randomized evidence confirming the mid-term safety and ef-
ation of new guidelines and approves their publication. In addition to ficacy of TAVI in low-risk patients has been published.
review by the ESC CPG Committee, these ESC/EACTS Guidelines • The indications for TAVI in patients with bicuspid AV (BAV) stenosis
underwent multiple rounds of double-blind peer review on a dedicated or severe aortic regurgitation (AR) at high surgical risk, based on ana-
online review platform. The review was conducted by topic experts, in- tomical suitability and a comprehensive Heart Team evaluation, are
cluding members from ESC National Cardiac Societies, EACTS discussed.
Network of National Cardiac Surgery Societies and from relevant • Several advancements have been made regarding the treatment of
ESC Subspecialty Communities. The Guideline Task Force considered patients with primary mitral regurgitation (PMR): refinement of the
all review comments and was required to respond to all those classified criteria for intervention in asymptomatic patients; demonstration
as major. After appropriate revisions, the Task Force, the ESC CPG of the value of minimally invasive mitral valve (MV) surgery to reduce
Committee members and the EACTS Council members approved the length of hospital stay and accelerate recovery; and large-scale
the final document for publication in the European Heart Journal and data confirming the role of transcatheter edge-to-edge repair
in the European Journal of Cardio-Thoracic Surgery. (TEER) in high-risk patients.
Unless otherwise stated, the guideline content refers to sex, under- • Longer-term follow-up data and two new randomized controlled
stood as the biological condition of being male or female, defined by trials (RCTs) concerning the management of patients with ventricular
genes, hormones, and sexual organs. Off-label use of medication may SMR have been published.
be presented in this guideline if a sufficient level of evidence shows • The evidence for the treatment of tricuspid valve (TV) disease is
that it can be considered medically appropriate for a given condition. growing—including new randomized data supporting concomitant
However, decisions on off-label use must be made by the responsible TV repair during left-sided valve surgery, and transcatheter options
health professional giving special consideration to ethical rules concern- (repair and replacement) that reduce tricuspid regurgitation (TR),
ing healthcare, the specific situation of the patient, patient consent, and promote reverse right ventricular (RV) remodelling, and improve
country-specific health regulations. quality of life compared with medical treatment.
• Efforts have been made to provide improved guidance regarding the
diagnostic steps and management of patients with multiple and mixed
2. Introduction VHD.
• Definitions of structural valve deterioration (SVD) have been up-
New evidence has accumulated since the publication of the 2021 dated and unified.
European Society of Cardiology (ESC)/European Association for • The recommendations concerning the use of direct oral anticoagu-
Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular lants (DOACs) in patients with VHD have been updated, and the im-
heart disease, leading to the need for new recommendations (Table 3 portance of education and (self-)monitoring is emphasized.
New recommendations) and revision of existing recommendations • Sex-specific considerations in patients with VHD have been ex-
(Table 4 Revised recommendations) concerning the following topics: tended and regrouped into a new dedicated section (see Section 17).
• The importance of shared and patient-centred decision-making by
multidisciplinary expert Heart Teams working within a regional net- Because of demographic changes, patients with VHD frequently
work has been reinforced. Patients with complex conditions or re- present with concomitant cardiovascular diseases, increasing the com-
quiring complex procedures should be referred to high-volume plexity of treatment strategies. These Guidelines focus on acquired
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 9 ---
ESC Guidelines 4643
VHD and do not deal in detail with overlapping cardiovascular diseases multiple factors influence and ultimately determine the most appro-
such as infective endocarditis,5 chronic coronary syndrome,6 and atrial priate treatment of individual patients within a given community.
fibrillation (AF),7 as well as all scenarios of aortic or congenital dis- These factors include the availability of equipment and technology,
ease,8,9 because these topics are covered in separate Guidelines. and the expertise and volumes, in complex procedures, such as valve
The 2025 ESC/EACTS Guidelines for the management of valvular heart repair or transcatheter interventions. Moreover, given the lack of evi-
disease aim to be concise, focused on relevant issues for clinicians and dence on some topics related to VHD, several recommendations are
patients, and to provide clear and simple practical recommendations, the result of expert consensus opinion. Therefore, deviations from
assisting healthcare providers in their daily clinical decision-making. A these Guidelines may be appropriate in certain clinical circumstances,
compilation of the evidence considered for new recommendations, or and decision-making should always be based on a collaborative, multi-
those with an updated class of recommendation or level of evidence, disciplinary Heart Team approach centred on individual characteris-
can be consulted online (see Supplementary data online, Evidence tics, needs, and prognosis, as well as the preferences of the informed
Tables). The Task Force for these Guidelines acknowledges that patient.
2.1. What is new
Table 3 New recommendations
Recommendations Classa Levelb
Diagnosis of coronary artery disease—Section 6.1
Omission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of sufficient
IIa B
quality to rule out significant CAD.
PCI should be considered in patients with a primary indication to undergo TAVI and ≥90% coronary artery stenosis in segments with a
IIa B
reference diameter ≥2.5 mm.
Indications for intervention in severe aortic regurgitation—Section 7.4
TAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the
IIb B
anatomy is suitable.
Indications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention—Section 8.5
Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS
IIa A
and LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low.
TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. IIb B
Indications for intervention in severe primary mitral regurgitation—Section 9.1
Surgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi
<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled:
• AF
I B
• SPAP at rest >50 mmHg
• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)
• Concomitant secondary TR ≥ moderate.
Minimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. IIb B
Indications for intervention in secondary mitral regurgitation—Section 9.2
MV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal
IIa B
medical therapy.
TEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy
IIb B
including rhythm control, when appropriate.
MV surgery may be considered in patients with moderate SMR undergoing CABG. IIb B
Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis—
Section 10.3
TMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with
IIb C
expertise in complex MV surgery and transcatheter interventions.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 10 ---
4644 E S C G u id e l in e s
Indications for intervention in tricuspid regurgitation—Section 11.4
Careful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,
I C
and likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention.
Surgery of concomitant severe mitral regurgitation—Section 13.3
MV surgery is recommended in patients with severe MR undergoing surgery for another valve. I C
Indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation—Section 13.3
Intervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean
I B
gradient ≥40 mmHg or V ≥4.0 m/s.
max
Intervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation, with V ≥4.0 m/s
max I C
and LVEF <50% not attributable to other cardiac disease.
Prosthetic valve selection—Section 14.1
An MHV should be considered in patients with an estimated long life expectancy, if there are no contraindications for long-term OAC. IIa B
Management of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3
It is recommended that INR targets are based on the type and position of MHV, patient’s risk factors, and comorbidities. I A
Patient education is recommended to improve the quality of OAC. I A
Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive
procedures—Section 14.3
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or
I A
minimal bleeding.
Interruption (3–4 days before surgery), and resumption of VKA without bridging, may be considered to reduce bleeding in patients with
IIb B
new-generation aortic MHV and no other thromboembolic risk factors undergoing major non-cardiac surgery or invasive procedures.
Management of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3
Surgical biological heart valve without indication for oral anticoagulation
Lifelong low-dose ASA (75–100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients
IIb C
without clear indication for OAC.
Transcatheter aortic valve implantation without indication for oral anticoagulation
DAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. III B
Surgical repair without indication for oral anticoagulation
Low-dose ASA (75–100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear
IIb B
indication for OAC and at high bleeding risk.
Surgical biological heart valve with indication for oral anticoagulation
OAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. I B
DOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC. IIb B
Surgical repair with indication for oral anticoagulation and/or antiplatelet therapy
Continuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an
IIa B
antithrombotic therapy.
Management of mechanical heart valve failure—Section 14.4
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. I C
Management of valve thrombosis—Section 14.4
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. I C
4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BAV, bicuspid aortic valve; BHV, biological heart valve; CABG,
coronary artery bypass grafting; CAD, coronary artery disease; CT, computed tomography; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; INR, international normalized
ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; MAC, mitral annular calcification; MHV, mechanical heart valve; MR, mitral
regurgitation; MV, mitral valve; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; RV, right ventricle/right
ventricular; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TMVI,
transcatheter mitral valve implantation; TOE, transoesophageal echocardiography; TR, tricuspid regurgitation; TV, tricuspid valve; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 11 ---
ESC Guidelines 4645
Table 4 Revised recommendations
Recommendations in 2021 version Classa Levelb Recommendations in 2025 version Classa Levelb
Management of coronary artery disease in patients with valvular heart disease—Section 6.1
CCTA should be considered as an alternative to CCTA is recommended before valve intervention in
coronary angiography before valve surgery in patients IIa C patients with moderate or lower (≤50%) pre-test I B
with severe VHD and low probability of CAD. likelihood of obstructive CAD.
Coronary angiography is recommended before valve Invasive coronary angiography is recommended before
surgery in patients with severe VHD and any of the valve intervention in patients with high and very high
following: (>50%) pre-test likelihood of obstructive CAD.
• History of cardiovascular disease
I C I C
• Suspected myocardial ischaemia
• LV systolic dysfunction
• In men >40 years of age and post-menopausal women
• One or more cardiovascular risk factors.
Coronary angiography is recommended in the Invasive coronary angiography is recommended in the
I C I C
evaluation of severe SMR. evaluation of CAD in patients with severe ventricular SMR.
PCI should be considered in patients with a primary PCI may be considered in patients with a primary
indication to undergo TAVI and coronary artery IIa C indication to undergo transcatheter valve interventions
diameter stenosis >70% in proximal segments. and coronary artery stenosis ≥70% in proximal
PCI should be considered in patients with a primary segments of main vessels. IIb B
indication to undergo transcatheter MV intervention
IIa C
and coronary artery diameter stenosis >70% in
proximal segments.
Management of atrial fibrillation in patients with native valvular heart disease—Section 6.2
LAAO should be considered to reduce the Surgical closure of the LA appendage is recommended
thromboembolic risk in patients with AF and a as an adjunct to OAC in patients with AF undergoing
IIa B I B
CHADS -VASc score ≥2 undergoing valve surgery. valve surgery to prevent cardioembolic stroke and
2 2
systemic thromboembolism.
Concomitant AF ablation should be considered in Concomitant surgical ablation is recommended in
patients undergoing valve surgery, balancing the benefits patients undergoing MV surgery with AF suitable for a
of freedom from atrial arrhythmias and the risk factors rhythm control strategy to prevent symptoms and I A
for recurrence (LA dilatation, years in AF, age, renal recurrence of AF, according to an experienced team of
dysfunction, and other cardiovascular risk factors). electrophysiologists and arrhythmia surgeons.
IIa A
Concomitant surgical ablation should be considered in
patients undergoing non-MV surgery with AF suitable
for a rhythm control strategy to prevent symptoms and IIa B
recurrence of AF, according to an experienced team of
electrophysiologists and arrhythmia surgeons.
The use of DOACs is not recommended in patients The use of DOACs is not recommended in patients
III C III B
with AF and moderate-to-severe MS. with AF and rheumatic MS with an MVA ≤2.0 cm2.
Indications for surgery in severe aortic regurgitation—Section 7.4
AV repair may be considered in selected patients at AV repair should be considered in selected patients
experienced centres when durable results are IIb C with severe AR at experienced centres, when durable IIa B
expected. results are expected.
Surgery may be considered in asymptomatic patients AV surgery may be considered in asymptomatic
with LVESD >20 mm/m2 BSA (especially in patients patients with severe AR and LVESDi >22 mm/m2 or
with small body size) or resting LVEF ≤55%, if surgery is IIb C LVESVi >45 mL/m2 [especially in patients with small IIb B
at low risk. body size (BSA <1.68 m2)], or resting LVEF ≤55%, if
surgical risk is low.
Indications for intervention in symptomatic severe aortic stenosis—Section 8.4.1
Intervention is recommended in symptomatic patients Intervention is recommended in symptomatic patients
with severe low-flow (SVi ≤35 mL/m2), low-gradient with low-flow (SVi ≤35 mL/m2), low-gradient
I B I B
(<40 mmHg) AS with reduced LVEF (<50%), and (<40 mmHg) AS with reduced LVEF (<50%) after
evidence of flow (contractile) reserve. careful confirmation that AS is severe.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 12 ---
4646 E S C G u id e l in e s
Intervention should be considered in symptomatic Intervention should be considered in symptomatic
patients with low-flow, low-gradient (<40 mmHg) AS patients with low-flow (SVi ≤35 mL/m2), low-gradient
IIa C IIa B
with normal LVEF after careful confirmation that the AS (<40 mmHg) AS with normal LVEF (≥50%) after
is severe. careful confirmation that AS is severe.
Indications for intervention in asymptomatic severe aortic stenosis—Section 8.5
Intervention should be considered in asymptomatic Intervention should be considered in asymptomatic
patients with severe AS and LV dysfunction (LVEF IIa B patients with severe AS and LVEF ≥50%, if the
<55%) without another cause. procedural risk is low and one of the following
Intervention should be considered in asymptomatic parameters is present:
patients with LVEF >55% and a normal exercise test if • Very severe AS (mean gradient ≥60 mmHg or V max
the procedural risk is low and one of the following >5.0 m/s).
parameters is present: • Severe valve calcification (ideally assessed by CCT)
• Very severe AS (mean gradient ≥60 mmHg or V max and V max progression ≥0.3 m/s/year. IIa B
>5 m/s). • Markedly elevated BNP/NT-proBNP levels (more
IIa B
• Severe valve calcification (ideally assessed by CCT) than three times age- and sex-corrected normal
and V progression ≥0.3 m/s/year. range, confirmed on repeated measurement without
max
• Markedly elevated BNP levels (more than three times other explanation).
age- and sex-corrected normal range) confirmed by • LVEF <55% without another cause.
repeated measurements and without other
explanation.
Mode of intervention in symptomatic severe aortic stenosis—Section 8.5
The choice between surgical and transcatheter It is recommended that the mode of intervention is
intervention must be based upon careful evaluation of based on Heart Team assessment of individual clinical,
clinical, anatomical, and procedural factors by the Heart anatomical, and procedural characteristics,
Team, weighing the risks and benefits of each approach I C incorporating lifetime management considerations and I C
for an individual patient. The Heart Team estimated life expectancy.
recommendation should be discussed with the patient
who can then make an informed treatment choice.
TAVI is recommended in older patients (≥75 years), or TAVI is recommended in patients ≥70 years of age with
in those who are high risk (STS-PROM/EuroSCORE II I A tricuspid AV stenosis, if the anatomy is suitable. I A
>8%) or unsuitable for surgery.
SAVR is recommended in younger patients who are low SAVR is recommended in patients <70 years of age, if
risk for surgery (<75 years and STS-PROM/ the surgical risk is low.
I B I B
EuroSCORE II <4%), or in patients who are operable
and unsuitable for transfemoral TAVI.
SAVR or TAVI are recommended for remaining SAVR or TAVI are recommended for all remaining
patients according to individual clinical, anatomical, and I B candidates for an aortic BHV according to Heart Team I B
procedural characteristics. assessment.1–4
Non-transfemoral TAVI may be considered in patients Non-transfemoral TAVI should be considered in
who are inoperable and unsuitable for transfemoral IIb C patients who are unsuitable for surgery and IIa B
TAVI. transfemoral access.
Indications for intervention in severe primary mitral regurgitation—Section 9.1.4
Surgery should be considered in asymptomatic patients MV surgery should be considered in asymptomatic
with preserved LV function (LVESD <40 mm and LVEF patients with severe PMR without LV dysfunction
>60%) and AF secondary to MR or PH (SPAP at rest IIa B (LVESD <40 mm, LVESDi <20 mm/m2, and LVEF IIa B
>50 mmHg). >60%) in the presence of PH (SPAP at rest
>50 mmHg), or AF secondary to MR.
Surgical MV repair should be considered in low-risk Surgical MV repair should be considered in low-risk
asymptomatic patients with LVEF >60%, LVESD asymptomatic patients with severe PMR without LV
<40 mm, and significant LA dilatation (volume dysfunction (LVESD <40 mm, LVESDi <20 mm/m2,
index ≥60 mL/m2 or diameter ≥55 mm) when IIa B and LVEF >60%) in the presence of significant LA IIa B
performed in a Heart Valve Centre and a durable repair dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm),
is likely. when performed in a Heart Valve Centre and a durable
repair is likely.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 13 ---
ESC Guidelines 4647
TEER may be considered in symptomatic patients who TEER should be considered in symptomatic patients
fulfil the echocardiographic criteria of eligibility, are judged with severe PMR who are anatomically suitable and at
IIb B IIa B
inoperable or at high surgical risk by the Heart Team, and high surgical risk according to the Heart Team.
for whom the procedure is not considered futile.
Severe ventricular secondary mitral regurgitation and concomitant coronary artery disease—Section 9.2
In symptomatic patients who are judged not PCI followed by TEER after re-evaluation of MR may be
appropriate for surgery by the Heart Team on the basis considered in symptomatic patients with chronic severe
of their individual characteristics, PCI (and/or TAVI) IIa C ventricular SMR and non-complex CAD. IIb C
possibly followed by TEER (in case of persisting severe
SMR) should be considered.
Indications for intervention in severe ventricular secondary mitral regurgitation without concomitant coronary artery disease—Section 9.2
TEER should be considered in selected symptomatic TEER is recommended to reduce HF hospitalizations
patients not eligible for surgery and fulfilling criteria and improve quality of life in haemodynamically stable,
suggesting an increased chance of responding to the symptomatic patients with impaired LVEF (<50%) and
IIa B I A
treatment. persistent severe ventricular SMR, despite optimized
GDMT and CRT (if indicated), fulfilling specific clinical
and echocardiographic criteria.
In high-risk symptomatic patients not eligible for surgery TEER may be considered for symptom improvement in
and not fulfilling the criteria suggesting an increased selected symptomatic patients with severe ventricular
chance of responding to TEER, the Heart Team may SMR not fulfilling the specific clinical and
consider in selected cases a TEER procedure or other IIb C echocardiographic criteria, after careful evaluation of IIb B
transcatheter valve therapy if applicable, after careful LVAD or HTx.
evaluation for ventricular assist device or heart
transplant.
Valve surgery may be considered in symptomatic MV surgery may be considered in symptomatic patients
patients judged appropriate for surgery by the Heart IIb C with severe ventricular SMR without advanced HF who IIb C
Team. are not suitable for TEER.
Indications for intervention in tricuspid regurgitation in patients with left-sided valvular heart disease requiring surgery—Section 11.4
Surgery is recommended in patients with severe Concomitant TV surgery is recommended in patients
I C
primary TR undergoing left- sided valve surgery. with severe primary or secondary TR.
I B
Surgery is recommended in patients with severe
I B
secondary TR undergoing left-sided valve surgery.
Surgery should be considered in patients with moderate Concomitant TV repair should be considered in
primary TR undergoing left-sided valve surgery. IIa C patients with moderate primary or secondary TR, to IIa B
avoid progression of TR and RV remodelling.
Surgery should be considered in patients with mild or Concomitant TV repair may be considered in selected
moderate secondary TR with a dilated annulus patients with mild secondary TR and tricuspid annulus
IIa B IIb B
(≥40 mm or >21 mm/m2 by 2D echocardiography) dilatation (≥40 mm or >21 mm/m2) to avoid
undergoing left-sided valve surgery. progression of TR and RV remodelling.
Indications for intervention in patients with severe tricuspid regurgitation without left-sided valvular heart disease requiring surgery—
Section 11.4
Transcatheter treatment of symptomatic secondary Transcatheter TV treatment should be considered to
severe TR may be considered in inoperable patients at a improve quality of life and RV remodelling in high-risk
Heart Valve Centre with expertise in the treatment of IIb C patients, with symptomatic severe TR despite optimal IIa A
TV disease. medical therapy, in the absence of severe RV
dysfunction or pre-capillary PH.
Prosthetic valve selection—Section 14.1
A mechanical prosthesis may be considered in patients An MHV may be considered in patients with a clear
already on long-term anticoagulation due to the high IIb C indication for long-term OAC. IIb C
risk for thromboembolism.
Management of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3
OAC using a VKA is recommended lifelong for all Lifelong OAC with a VKA is recommended for all
patients with an MHV prosthesis. I B patients with MHVs to prevent thromboembolic I A
complications.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 14 ---
4648 E S C G u id e l in e s
For patients with a VKA, INR self-management is INR self-monitoring and self-management are
recommended provided appropriate training and I B recommended over standard monitoring in selected, I A
quality control are performed. trained patients to improve efficacy.
In patients with MHVs, it is recommended to (re)initiate Following cardiac surgery with MHV implantation, it is
I C
the VKA on the first post-operative day. recommended to start UFH or LMWH bridging and
In patients who have undergone valve surgery with an VKA within 24 h, or as soon as considered safe.
I B
indication for post-operative therapeutic bridging, it is
I C
recommended to start either UFH or LMWH 12–24 h
after surgery.
The addition of low-dose ASA (75–100 mg/day) to The addition of low-dose ASA (75–100 mg/day) to VKA
VKA may be considered in selected patients with MHVs should be considered in selected patients with MHVs in
IIb C IIa B
in case of concomitant atherosclerotic disease and low case of concomitant symptomatic atherosclerotic disease,
risk of bleeding. considering the individual bleeding risk profile.
The addition of low-dose ASA (75–100 mg/day) to Either an increase in INR target or the addition of
VKA should be considered after thromboembolism low-dose ASA (75–100 mg/day) should be considered
despite an adequate INR. IIa C in patients with MHVs who develop a major IIa C
thromboembolic complication despite documented
adequate INR.
DOACs are not recommended in patients with an DOACs and/or DAPT are not recommended to
III B III A
MHV prosthesis. prevent thrombosis in patients with an MHV.
Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive
procedures—Section 14.3
It is recommended that VKAs are timely discontinued It is recommended to discontinue VKA at least 4 days
I C
prior to elective surgery to aim for an INR <1.5. before major elective non-cardiac surgery, aiming for an
I B
In patients with MHVs, it is recommended to (re)initiate INR <1.5, and to resume VKA treatment within 24 h
I C
the VKA on the first post-operative day. after surgery, or as soon as considered safe.
Therapeutic doses of either UFH or subcutaneous VKA interruption and resumption with bridging should
I B
LMWH are recommended for bridging. be considered in patients with an MHV and
Bridging of OAC, when interruption is needed, is thromboembolic risk factors undergoing major
recommended in patients with any of the following non-cardiac surgery.
indications:
• MHV IIa B
• AF with significant MS I C
• AF with CHADS -VASc score ≥3 for women or 2
2 2
for men
• Acute thrombotic event within the previous 4 weeks
• High acute thromboembolic risk.
Management of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3
Lifelong SAPT is recommended after TAVI in patients Low-dose ASA (75–100 mg/day) is recommended for
with no baseline indication for OAC. 12 months after TAVI in patients without indication for I A
OAC.
I A
Long-term (after the first 12 months) low-dose ASA
(75–100 mg/day) should be considered after TAVI in IIa C
patients without clear indication for OAC.
OAC is recommended lifelong for TAVI patients who OAC is recommended for TAVI patients who have
I B I B
have other indications for OAC. other indications for OAC.
OAC with VKA should be considered during the first OAC, with either VKAs or DOACs, should be considered
IIa C IIa B
3 months after mitral and tricuspid repair. during the first 3 months after surgical MV or TV repair.
Routine use of OAC is not recommended after TAVI in Routine use of OAC is not recommended after TAVI in
III B III A
patients without baseline indication. patients without baseline indication.
Management of haemolysis and paravalvular leak—Section 14.4
Decision on transcatheter or surgical closure of It is recommended that the decision between
clinically significant PVLs should be considered based on transcatheter or surgical closure of clinically significant
IIa C I C
patient risk status, leak morphology, and local expertise. PVLs is based on Heart Team evaluation, including
patient risk, leak morphology, and local expertise.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 15 ---
ESC Guidelines 4649
Transcatheter closure should be considered for suitable Transcatheter closure should be considered for suitable
PVLs with clinically significant regurgitation and/or IIa B PVLs with clinically significant regurgitation and/or IIa B
haemolysis in patients at high or prohibitive surgical risk. haemolysis.
Management of biological heart valve failure—Section 14.4
Reoperation is recommended in symptomatic patients Reintervention is recommended in symptomatic
with a significant increase in transprosthetic gradient patients with significant valve dysfunction not
I C I C
(after exclusion of valve thrombosis) or severe attributable to valve thrombosis.
regurgitation.
Transcatheter, transfemoral valve-in-valve implantation Transcatheter transfemoral valve-in-valve implantation
in the aortic position should be considered by the Heart in the aortic position should be considered in patients
Team depending on anatomical considerations, features with significant valve dysfunction who are at
IIa B IIa B
of the prosthesis, and in patients who are at high intermediate or high surgical risk, and have suitable
operative risk or inoperable. anatomical and prosthesis features, as assessed by the
Heart Team.
Transcatheter valve-in-valve implantation in the mitral Transcatheter transvenous mitral or tricuspid
and tricuspid position may be considered in selected valve-in-valve implantation should be considered in
IIb B IIa B
patients at high risk for surgical reintervention. patients with significant valve dysfunction at intermediate
or high surgical risk, if the anatomy is suitable.
Management of mechanical heart valve thrombosis—Section 14.4
Urgent or emergency valve replacement is Heart Team evaluation is recommended in patients
recommended for obstructive thrombosis in critically ill I B with acute HF (NYHA class III or IV) due to obstructive
patients without serious comorbidity. MHV thrombosis to determine appropriate
Fibrinolysis (using recombinant tissue plasminogen management (repeat valve replacement or low-dose
activator 10 mg bolus + 90 mg in 90 min with UFH or slow infusion fibrinolysis). I B
streptokinase 1 500 000 U in 60 min without UFH)
IIa B
should be considered when surgery is not available or is
very high risk, or for thrombosis of right-sided
prostheses.
Management of biological heart valve thrombosis—Section 14.4
Anticoagulation using a VKA and/or UFH is OAC using VKA is recommended in BHV thrombosis
recommended in BHV thrombosis before considering I C before considering reintervention. I B
reintervention.
2D, two-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide;
BSA, body surface area; CAD, coronary artery disease; CCT, cardiac computed tomography; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, congestive heart failure
or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, sex category (female); CRT, cardiac resynchronization therapy;
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GDMT, guideline-directed medical therapy; h,
hour; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index;
LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic volume indexed to BSA; MHV, mechanical heart valve; min, minute; MR,
mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OAC,
oral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; PVL, paravalvular leak; RV, right ventricle/right
ventricular; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; STS-PROM, Society
of Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid
regurgitation; TV, tricuspid valve; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
3. The Heart Team and Heart Valve An integrated regional Heart Valve Network, incorporating out-
patient Heart Valve Clinics (for initial diagnosis and ongoing surveil-
Centre
lance) and specialist Heart Valve Centres (for advanced imaging and
surgical or transcatheter intervention), allows optimal patient care
3.1. The Heart Valve Network
through timely access to specialist assessment, accurate diagnosis, im-
Despite increasing attention within the medical community, VHD con- proved decision-making, and matching of patients to healthcare provi-
tinues to be underdiagnosed and undertreated in the general popula- ders with appropriate expertise, experience, and resources (Figure 1).12
tion, and public awareness remains low.10–13 Beside screening using In addition, dedicated Heart Valve Clinics ensure consistent application
auscultation and imaging when appropriate, the co-ordinated imple- of clinical guidelines, efficient use of resources, and overall high-quality
mentation of Heart Teams, Heart Valve Centres, and Heart Valve patient care, which in turn may improve outcomes.14,15 Medical goals
Networks at a local level represents an essential step to timely diagnose include careful clinical and echocardiographic evaluation, monitoring
and treat patients with VHD. at appropriate time intervals (so-called ‘watchful waiting’), application
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 16 ---
4650 E S C G u id e l in e s
(cid:10)(cid:30)(cid:9)(cid:30)(cid:28)(cid:28)(cid:21)(cid:20)(cid:8)(cid:26)(cid:19)(cid:29)(cid:28)(cid:11)(cid:21)(cid:16)(cid:24)(cid:16)(cid:8)(cid:21)(cid:14)(cid:27)(cid:14)(cid:26)(cid:29)(cid:20)(cid:11)(cid:26)(cid:7)(cid:28)(cid:21)(cid:17)(cid:29)(cid:28)(cid:6)(cid:26)(cid:19)(cid:29)(cid:28)(cid:30)(cid:26)(cid:7)(cid:5)(cid:6)(cid:14)(cid:21)(cid:19)(cid:21)(cid:29)(cid:20)(cid:14)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:24)(cid:23)(cid:30)(cid:26)(cid:22)(cid:24)(cid:21)(cid:20)(cid:21)(cid:19)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:29)(cid:26)(cid:27)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)
(cid:21)(cid:26)(cid:20)(cid:29)(cid:28)(cid:25)(cid:24)(cid:29)(cid:30)(cid:25)(cid:21)(cid:28)(cid:22)(cid:21)(cid:19)(cid:22)(cid:18)(cid:29)(cid:26)(cid:23)
(cid:17)(cid:26)(cid:21)(cid:16)(cid:25)(cid:27)(cid:25)(cid:28)(cid:20)(cid:22)(cid:20)(cid:15)(cid:25)(cid:27)(cid:23)(cid:14)(cid:25)(cid:28)(cid:23)(cid:13)(cid:27)(cid:25)(cid:26)(cid:23)(cid:18)(cid:30)(cid:23)(cid:27)(cid:22)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:29)(cid:24)(cid:23)(cid:30)(cid:26)(cid:22)(cid:30)(cid:20)(cid:27)(cid:28)(cid:30) (cid:27)(cid:25)(cid:29)(cid:20)(cid:28)(cid:21)(cid:12)(cid:25)(cid:12)(cid:11)(cid:22)(cid:30)(cid:26)(cid:23)(cid:29)(cid:30)(cid:10)(cid:23)(cid:28)(cid:30)(cid:22)(cid:29)(cid:28)(cid:27)(cid:22)
(cid:19)(cid:21)(cid:14)(cid:14)(cid:21)(cid:9)(cid:13)(cid:15)(cid:17)(cid:22)(cid:21)(cid:19)(cid:22)(cid:17)(cid:29)(cid:30)(cid:25)(cid:23)(cid:28)(cid:30)(cid:12)
(cid:9)(cid:25)(cid:30)(cid:8)(cid:22)(cid:7)(cid:6)(cid:5)
(cid:129)(cid:28)(cid:12)(cid:30)(cid:25)(cid:30)(cid:15)(cid:30)(cid:25)(cid:21)(cid:28)(cid:29)(cid:14)(cid:22)(cid:18)(cid:29)(cid:26)(cid:27)(cid:25)(cid:21)(cid:14)(cid:21)(cid:20)(cid:3)(cid:22)(cid:29)(cid:28)(cid:27)(cid:22)
(cid:18)(cid:29)(cid:26)(cid:27)(cid:25)(cid:29)(cid:18)(cid:22)(cid:12)(cid:15)(cid:26)(cid:20)(cid:23)(cid:26)(cid:3)(cid:22)(cid:27)(cid:23)(cid:17)(cid:29)(cid:26)(cid:30)(cid:10)(cid:23)(cid:28)(cid:30)(cid:12)
(cid:9)(cid:25)(cid:30)(cid:8)(cid:22)(cid:141)(cid:143)(cid:22)(cid:8)(cid:21)(cid:15)(cid:26)(cid:144)(cid:157)(cid:22)(cid:27)(cid:29)(cid:3)(cid:22)(cid:12)(cid:23)(cid:26)(cid:16)(cid:25)(cid:18)(cid:23)(cid:12) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:18)(cid:30)(cid:29)(cid:17)(cid:26)(cid:19)(cid:16)(cid:28)(cid:30)(cid:26)(cid:17)(cid:30)(cid:17)(cid:15)(cid:30)(cid:28)(cid:14)
(cid:6)(cid:23)(cid:29)(cid:26)(cid:30)(cid:22) (cid:23)(cid:29)(cid:10)(cid:22)(cid:10)(cid:23)(cid:23)(cid:30)(cid:25)(cid:28)(cid:20)(cid:22)(cid:21)(cid:28)(cid:22)(cid:29)
(cid:26)(cid:23)(cid:20)(cid:15)(cid:14)(cid:29)(cid:26)(cid:22) (cid:29)(cid:12)(cid:25)(cid:12) (cid:4)(cid:14)(cid:23)(cid:18)(cid:30)(cid:26)(cid:21)(cid:13) (cid:2)(cid:29)(cid:26)(cid:27)(cid:25)(cid:29)(cid:18) (cid:6)(cid:1)
(cid:17)(cid:8)(cid:3)(cid:12)(cid:25)(cid:21)(cid:14)(cid:21)(cid:20)(cid:25)(cid:12)(cid:30) (cid:12)(cid:15)(cid:26)(cid:20)(cid:23)(cid:21)(cid:28) (cid:18)(cid:29)(cid:26)(cid:27)(cid:25)(cid:21)(cid:14)(cid:21)(cid:20)(cid:25)(cid:12)(cid:30)
(cid:6)(cid:25)(cid:20)(cid:8)(cid:22)(cid:17)(cid:26)(cid:21)(cid:18)(cid:23)(cid:27)(cid:15)(cid:26)(cid:29)(cid:14)(cid:22)(cid:16)(cid:21)(cid:14)(cid:15)(cid:10)(cid:23)
(cid:19)(cid:21)(cid:26)(cid:22)(cid:8)(cid:21)(cid:12)(cid:17)(cid:25)(cid:30)(cid:29)(cid:14)(cid:22)(cid:29)(cid:28)(cid:27)(cid:22)(cid:25)(cid:28)(cid:27)(cid:25)(cid:16)(cid:25)(cid:27)(cid:15)(cid:29)(cid:14)(cid:22)
(cid:21)(cid:17)(cid:23)(cid:26)(cid:29)(cid:30)(cid:21)(cid:26)(cid:12)
€(cid:15)(cid:14)(cid:30)(cid:25)(cid:10)(cid:21)(cid:27)(cid:29)(cid:14)(cid:25)(cid:30)(cid:3)(cid:22)(cid:25)(cid:10)(cid:29)(cid:20)(cid:25)(cid:28)(cid:20)
(cid:23)(cid:127)(cid:17)(cid:23)(cid:26)(cid:30)(cid:25)(cid:12)(cid:23)
(cid:31)(cid:17)(cid:23)(cid:18)(cid:25)(cid:29)(cid:14)(cid:25)(cid:24)(cid:23)(cid:27)(cid:22)(cid:28)(cid:15)(cid:26)(cid:12)(cid:25)(cid:28)(cid:20)
(cid:2)(cid:14)(cid:25)(cid:28)(cid:25)(cid:18)(cid:29)(cid:14)(cid:22)(cid:18)(cid:29)(cid:26)(cid:27)(cid:25)(cid:21)(cid:14)(cid:21)(cid:20)(cid:25)(cid:12)(cid:30) (cid:17)(cid:23)(cid:26)(cid:12)(cid:21)(cid:28)(cid:28)(cid:23)(cid:14)(cid:22)(cid:29)(cid:28)(cid:27)(cid:22)
(cid:5)(cid:29)(cid:30)(cid:29)(cid:22)(cid:26)(cid:23)(cid:16)(cid:25)(cid:23)(cid:9)(cid:22)(cid:29)(cid:28)(cid:27)(cid:22)(cid:23)(cid:27)(cid:15)(cid:18)(cid:29)(cid:30)(cid:25)(cid:21)(cid:28) (cid:129)(cid:28)(cid:30)(cid:23)(cid:26)(cid:16)(cid:23)(cid:28)(cid:30)(cid:25)(cid:21)(cid:28)(cid:29)(cid:14)
(cid:9)(cid:25)(cid:30)(cid:8)(cid:22)(cid:23)(cid:127)(cid:17)(cid:23)(cid:26)(cid:30)(cid:25)(cid:12)(cid:23)(cid:22)(cid:25)(cid:28) (cid:21)(cid:30)(cid:8)(cid:23)(cid:26)(cid:22)(cid:12)(cid:17)(cid:23)(cid:18)(cid:25)(cid:29)(cid:14)(cid:25)(cid:12)(cid:30)(cid:12)(cid:11)(cid:22)
(cid:18)(cid:29)(cid:26)(cid:27)(cid:25)(cid:21)(cid:14)(cid:21)(cid:20)(cid:25)(cid:12)(cid:30)
(cid:17)(cid:26)(cid:21)(cid:20)(cid:26)(cid:29)(cid:10)(cid:10)(cid:23)(cid:12) (cid:25)(cid:10)(cid:29)(cid:20)(cid:25)(cid:28)(cid:20) (cid:25)(cid:19)(cid:22)(cid:26)(cid:23)‚(cid:15)(cid:25)(cid:26)(cid:23)(cid:27)
(cid:13)(cid:12)(cid:27)(cid:30)(cid:20)(cid:11)(cid:30)(cid:11)(cid:26)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:18)(cid:30)(cid:29)(cid:17)(cid:26)(cid:26)
(cid:4)(cid:17)(cid:15)(cid:3)(cid:24)(cid:29)(cid:27)(cid:16)(cid:28)(cid:6)(cid:26)(cid:28)(cid:30)(cid:5)(cid:29)(cid:15)(cid:21)(cid:24)(cid:21)(cid:27)(cid:29)(cid:27)(cid:21)(cid:16)(cid:20)(cid:26)(cid:7)(cid:28)(cid:16)(cid:8)(cid:29)(cid:17)(cid:17)(cid:30)(cid:14)
(cid:10)(cid:30)(cid:5)(cid:29)(cid:15)(cid:21)(cid:24)(cid:21)(cid:27)(cid:29)(cid:27)(cid:21)(cid:16)(cid:20)(cid:26)(cid:19)(cid:24)(cid:21)(cid:20)(cid:21)(cid:19)(cid:14)
Figure 1 The Heart Valve Network. HF, heart failure; VHD, valvular heart disease.
of guideline-directed medical therapy (GDMT), timely referral, and 3.1.1. Composition of the Heart Team
post-procedural follow-up.15,16 Broader aims include patient education, The Heart Team is now an established feature of VHD programmes that
the training of physicians and nurse specialists, swift and efficient access has been formally endorsed by previous ESC/EACTS Guidelines19,20 and
to specialist care, and recruitment into clinical trials. corresponding organizations worldwide.17
Heart Valve Centres should ensure that their facilities match institu- The value of the Heart Team approach has become increasingly
tional and local statutory requirements (Table 5), report procedural vo- apparent as options for the treatment of VHD have extended to in-
lumes and outcomes, and monitor treatment quality. They hold clude high-risk and inoperable patients (most of whom now undergo
responsibility for the training and education of surgeons, interventional transcatheter interventions), and low-risk and asymptomatic pa-
and imaging cardiologists, dedicated nurses, and allied professionals.17,18 tients (who derive prognostic benefit from increasingly safe proce-
Expertise in the surgical management of coronary artery disease dures). Despite significant accumulation of data concerning the
(CAD), vascular diseases, and complications must be available. New management of VHD over the last two decades, many patients in
techniques should be taught by trained mentors using simulator mod- daily practice have clinical characteristics that do not match those
els, when feasible, to minimize learning-curve effects. More broadly, of participants included in clinical trials. The Heart Team approach
Heart Valve Centres co-ordinate the management of patients with is therefore particularly helpful when there is uncertainty or a lack
VHD across the entire Heart Valve Network, supporting services at of strong evidence.
community level, encouraging early referral, and promoting education The Heart Team meeting facilitates balanced presentation of all
and communication with other medical departments, referring cardiol- appropriate options for medical, interventional, and surgical
ogists, primary care physicians, and rehabilitation clinics. treatment, using tools and techniques for shared decision-making.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 17 ---
ESC Guidelines 4651
The patient’s preference plays a central role in this process, although 3.1.2. Procedural volume and clinical outcomes
the Heart Team recommendation should be based upon key objective The correlation between high institutional (and individual operator)
medical considerations (particularly the relative risks and benefits of any volume and best procedural outcomes is intuitive, yet complex.
procedure). Nevertheless, there is evidence of such a relationship for many cardio-
Meetings should take place on a regular basis with standardized vascular procedures including SAVR,23,24 surgical MV repair,25,26 mitral
minimum datasets (to ensure that all relevant information is avail- and tricuspid TEER,27–30 and TAVI (particularly in centres with an as-
able) and appropriate administrative support (often provided by sociated high-volume SAVR programme).31–33 Studies have shown
specialist nurses with expertise in the care of patients with VHD). that an annualized operator volume of approximately 25 surgical mitral
In-person meetings of the full Heart Team may not be feasible for valve procedures,26 50 TAVIs (∼100 per centre),33 a cumulative ex-
every patient, and local standardized protocols may be implemen- perience of ∼50 M-TEER procedures per operator/centre,27 and a
ted to facilitate swift decision-making for specific cohorts (e.g. eld- site volume of more than 20 T-TEERs/year30 are associated with im-
erly TAVI candidates or young patients with BAV disease). Equally, proved technical and clinical outcomes. Higher institutional surgical
the need for Heart Team evaluation should not paralyse clinical volume is associated with lower complication rates,34–36 improved
decision-making, and ad hoc discussions remain appropriate in ur- management,37 and better infrastructural support.38,39
gent situations. National procedural activity varies widely between high-, middle-, and
Core members of the Heart Team include the cardiologist treating low-income countries,40 and it is therefore difficult to provide
the patient (who is best placed to present their case and act as their ad- recommendations concerning the precise number of institutional or oper-
vocate), specialists in advanced cardiovascular imaging and peri- ator procedures that is required for high-quality care, excellent facilities,
procedural guiding,21,22 surgeons, and interventional cardiologists and processes. Instead, a network approach that highlights the importance
with training and expertise in surgical and transcatheter valve proce- of centres performing a high volume of procedures (e.g. based upon quar-
dures. Specialized nursing personnel play an essential role to improve tiles in individual countries or regions) seems more suitable, with complex
patient information and education, as well as co-ordinate work-up procedures concentrated in the centres with the highest volumes (Table 6).
and management steps in high-volume centres (Figure 1; Table 5).
Cardiologists with expertise in heart failure (HF) and electrophysiology,
Table 6 Complex procedures ideally performed in the
as well as geriatricians, cardiovascular anaesthetists, and intensivists in-
most experienced Heart Valve Centres
volved in peri-procedural care, should also be available to facilitate the
discussion of particularly complex clinical scenarios when needed (ex-
Transcatheter interventions Surgical interventions
tended Heart Team) (Figure 1; Table 5).
• Transfemoral TAVI in patients • High-risk procedures (especially
with high-risk features: in patients with LV and/or RV
Table 5 Requirements for a Heart Valve Centre – Low coronary ostia impairment)
– Difficult femoral anatomy • Redo procedures
Requirements – Bicuspid valve • Minimally invasive and robotic
– Severe calcification protruding valve surgery
Centre performing heart valve procedures with on-site interventional
into the LVOT • Complex MV repair
cardiology and cardiac surgery departments providing 24-h/7-day services.
– Severe LV and/or RV impairment – Barlow disease
Heart Team core members: Cardiologist with imaging expertise,
– Pure AV regurgitation – Anterior or bileaflet prolapse
interventional cardiologist, cardiac surgeon.
– Multiple valve disease – High risk of SAM
Additional specialists, if required (Extended Heart Team):
– Complex coronary artery disease – Severe MAC
Specialized nursing personnel, HF specialist, electrophysiologist, – Severe extracardiac disease • AV repair
cardiovascular anaesthetist, geriatrician, and other specialists (e.g. renal failure, PH) • Ross procedure
(e.g. intensive care, vascular surgery, infectious diseases, neurology, • Non-transfemoral TAVI • Valve surgery combined with
radiology). • Valve-in-valve (including complex surgery of the aorta
The Heart Team must meet on a regular basis and work according to TAV-in-TAV) • Endocarditis surgery
locally defined standard operating procedures and clinical governance • All leaflet modification procedures
arrangements. (BASILICA, LAMPOON etc.)
A hybrid cardiac catheterization laboratory is desirable. • PVL closure procedures
High volume for hospital and individual operators. • Complex M-TEERa
Multimodality imaging (including advanced echocardiography, CCT, CMR, • Redo M-TEER procedures
and nuclear techniques) and expertise in peri-procedural imaging guidance of • Tricuspid or mitral valve-in-ring or
surgical and transcatheter procedures. valve-in-valve, valve-in-MAC
• TMVI
Heart Valve Clinic for outpatient assessment and follow-up.
• All tricuspid procedures
Data review: continuous monitoring, evaluation, and reporting of procedural
volumes and quality indicators, including clinical outcomes, as well as PROMs AV, aortic valve; BASILICA, Bioprosthetic or native Aortic Scallop Intentional Laceration to
complemented by local/external audits. prevent Iatrogenic Coronary Artery obstruction; LAMPOON, Laceration of the Anterior
Mitral leaflet to Prevent Outflow ObstructioN; LV, left ventricular/left ventricle; LVOT, left
Education programmes targeting primary care and referring physicians,
ventricular outflow tract; MAC, mitral annular calcification; M-TEER, mitral transcatheter
operators, and diagnostic and interventional imaging specialists. edge-to-edge repair; MV, mitral valve; PH, pulmonary hypertension; PVL: paravalvular leak; RV,
right ventricular/right ventricle; SAM, systolic anterior movement; TAV, transcatheter aortic
CCT, cardiac computed tomography; CMR, cardiac magnetic resonance; HF, heart failure; valve; TAVI, transcatheter aortic valve implantation; TMVI, transcatheter mitral valve implantation.
PROM, patient-reported outcome measure. aSee Supplementary Table S2.
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 18 ---
4652 E S C G u id e l in e s
Internal quality assessment (see dedicated document concerning TAVI plan interventions, and identify complications (Figure 2). The use
from the ESC41), systematic recording, and public availability of the volume of imaging for the assessment of each specific valve lesion is de-
and outcome data of the performed procedures are essential. Participation scribed in the corresponding sections. The role of imaging is trans-
in national or international registries should be encouraged. These consid- versal from diagnosis to follow-up and should encompass an
erations are of particular importance regarding asymptomatic low-risk pa- integrative assessment.
tients (where low mortality and procedural safety are paramount), those
with multiple comorbidities (where the need for multidisciplinary collabor-
ation is essential), and new techniques with a steep learning curve (where 4.1. Initial valve assessment
better results may be obtained at experienced centres).
Comprehensive transthoracic echocardiography (TTE) is the first-line
There is a pressing need to ensure higher dispersion and adoption of
examination to confirm valve dysfunction, and determine the aetiology,
interventions for VHD, especially (but not exclusively) in middle- and
mechanism, and severity of VHD, as well as cardiac chamber anatomy
lower-income countries where rheumatic heart disease (RHD) remains and damage.45,46 It should be performed by properly trained ima-
the principal cause of VHD.42,43 Key strategies include awareness pro- gers.47–49 Quantitative imaging analysis (as opposed to visual) should
grammes, increased public and medical education, simplified and im-
be the goal in all patients with relevant VHD, complemented by quali-
proved diagnostic tools, and measures to reduce costs and facilitate
tative and semi-quantitative evaluation. The severity of VHD should be
access to evidence-based treatment options.44
assessed using an integrative approach of all criteria checked for con-
sistency. When TTE is of poor quality or inconclusive, transoesophageal
4. Imaging of patients with valvular
echocardiography (TOE) and/or additional diagnostic imaging modal-
heart disease ities should be applied (e.g. calcium scoring and anatomy of the
valve using CCT). In specific clinical scenarios [e.g. thrombosis, pros-
Multimodality imaging is now the standard approach in VHD thetic valve dysfunction, endocarditis, mitral stenosis (MS), assessment
management to determine the pathophysiology, assess severity, of MV or TV anatomy], TOE has a central diagnostic role.50,51
(cid:17)(cid:18)(cid:18)(cid:22)(cid:26)(cid:27)(cid:30)(cid:23)(cid:19)(cid:28)(cid:25)(cid:28)(cid:27)(cid:18)(cid:19)(cid:30)(cid:18)(cid:19)(cid:18)
(cid:30)(cid:24)(cid:28)(cid:25)(cid:26)(cid:22)(cid:24)(cid:28)(cid:27)(cid:23)(cid:27)(cid:22)(cid:24)(cid:18)
(cid:13)(cid:7)(cid:30)(cid:15)(cid:11)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:22)(cid:16)(cid:25)(cid:141)(cid:143)(cid:10) (cid:17)(cid:18)(cid:18)(cid:19)(cid:18)(cid:18)(cid:21)(cid:19)(cid:24)(cid:23)(cid:25)(cid:22)(cid:16)(cid:25)(cid:19)(cid:12)(cid:23)(cid:29)(cid:30)(cid:7)(cid:30)(cid:15)(cid:7)(cid:11)(cid:15)(cid:30)(cid:29)(cid:25)
(cid:28)(cid:20)(cid:24)(cid:30)(cid:21)(cid:27)(cid:26)(cid:18)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:7)(cid:30)(cid:29)(cid:27)(cid:30)(cid:8)(cid:27)(cid:15)(cid:27)(cid:23)(cid:20) (cid:26)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:26)(cid:22)(cid:24)(cid:18)(cid:19)(cid:3)(cid:11)(cid:19)(cid:24)(cid:26)(cid:19)(cid:18)(cid:25)(cid:16)(cid:29)(cid:22)(cid:21)(cid:25)(cid:141)(cid:143)(cid:10)
(cid:157)(cid:15)(cid:30)(cid:24)(cid:24)(cid:27)(cid:24)(cid:5)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:5)(cid:11)(cid:27)(cid:28)(cid:27)(cid:24)(cid:5)(cid:25)(cid:22)(cid:16)(cid:25)(cid:27)(cid:24)(cid:23)(cid:19)(cid:29)(cid:7)(cid:19)(cid:24)(cid:23)(cid:27)(cid:22)(cid:24)(cid:18) (cid:13)(cid:7)(cid:30)(cid:15)(cid:11)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:22)(cid:16)(cid:25)(cid:19)(cid:15)(cid:27)(cid:5)(cid:27)(cid:8)(cid:27)(cid:15)(cid:27)(cid:23)(cid:20)(cid:25)(cid:16)(cid:22)(cid:29)(cid:25)
(cid:30)(cid:18)(cid:18)(cid:19)(cid:18)(cid:18)(cid:21)(cid:19)(cid:24)(cid:23)(cid:25)(cid:22)(cid:16)(cid:25)(cid:26)(cid:22)(cid:21)(cid:129)(cid:15)(cid:27)(cid:26)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:18) (cid:27)(cid:24)(cid:23)(cid:19)(cid:29)(cid:7)(cid:19)(cid:24)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:29)(cid:27)(cid:18)(cid:144)(cid:25)(cid:18)(cid:23)(cid:29)(cid:30)(cid:23)(cid:27)(cid:14)(cid:26)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)
(cid:31)(cid:31)(cid:29) (cid:31)(cid:30)(cid:29)
(cid:10)(cid:27)(cid:30)(cid:5)(cid:24)(cid:22)(cid:18)(cid:27)(cid:18)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:3)(cid:11)(cid:30)(cid:24)(cid:23)(cid:27)(cid:14)(cid:26)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:22)(cid:16)(cid:25)(cid:7)(cid:30)(cid:15)(cid:7)(cid:19) (cid:143)(cid:27)(cid:5)(cid:9)(cid:19)(cid:29)(cid:25)(cid:29)(cid:19)(cid:18)(cid:22)(cid:15)(cid:11)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:23)(cid:22)(cid:25)(cid:30)(cid:18)(cid:18)(cid:19)(cid:18)(cid:18)(cid:25)(cid:7)(cid:30)(cid:15)(cid:7)(cid:19)(cid:25)
(cid:28)(cid:20)(cid:18)(cid:16)(cid:11)(cid:24)(cid:26)(cid:23)(cid:27)(cid:22)(cid:24) (cid:30)(cid:24)(cid:30)(cid:23)(cid:22)(cid:21)(cid:20)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:26)(cid:9)(cid:30)(cid:21)(cid:8)(cid:19)(cid:29)(cid:25)(cid:30)(cid:24)(cid:30)(cid:23)(cid:22)(cid:21)(cid:20)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:16)(cid:11)(cid:24)(cid:26)(cid:23)(cid:27)(cid:22)(cid:24) (cid:4)(cid:19)(cid:26)(cid:9)(cid:30)(cid:24)(cid:27)(cid:18)(cid:21) (cid:18)€(cid:25)(cid:22)(cid:16)(cid:25)(cid:141)(cid:143)(cid:10)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:28)(cid:30)(cid:21)(cid:30)(cid:5)(cid:19)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:29)(cid:19)(cid:21)(cid:22)(cid:28)(cid:19)(cid:15)(cid:15)(cid:27)(cid:24)(cid:5) ‚(cid:10)(cid:25)(cid:7)(cid:27)(cid:18)(cid:11)(cid:30)(cid:15)(cid:27)ƒ(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:25)(cid:22)(cid:16)(cid:25)(cid:7)(cid:30)(cid:15)(cid:7)(cid:19)(cid:18)
(cid:2)(cid:22)(cid:15)(cid:15)(cid:22)(cid:1)(cid:127)(cid:11)(cid:129) „(cid:11)(cid:27)(cid:28)(cid:27)(cid:24)(cid:5)(cid:25)(cid:22)(cid:16)(cid:25)(cid:27)(cid:24)(cid:23)(cid:19)(cid:29)(cid:7)(cid:19)(cid:24)(cid:23)(cid:27)(cid:22)(cid:24)(cid:18)
(cid:28)(cid:28)(cid:31) (cid:28)(cid:27)(cid:26)(cid:25)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:30)(cid:24)(cid:30)(cid:23)(cid:22)(cid:21)(cid:20)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:30)(cid:26)(cid:26)(cid:19)(cid:18)(cid:18) (cid:31)(cid:9)(cid:30)(cid:21)(cid:8)(cid:19)(cid:29)(cid:25)(cid:7)(cid:22)(cid:15)(cid:11)(cid:21)(cid:19)(cid:18)(cid:25)(cid:30)(cid:24)(cid:28)(cid:25)(cid:16)(cid:11)(cid:24)(cid:26)(cid:23)(cid:27)(cid:22)(cid:24)
(cid:17)(cid:18)(cid:18)(cid:19)(cid:18)(cid:18)(cid:21)(cid:19)(cid:24)(cid:23)(cid:25)(cid:22)(cid:16)(cid:25)(cid:26)(cid:30)(cid:15)(cid:26)(cid:27)(cid:14)(cid:26)(cid:30)(cid:23)(cid:27)(cid:22)(cid:24)(cid:18) (cid:6)(cid:19)(cid:5)(cid:11)(cid:29)(cid:5)(cid:27)(cid:23)(cid:30)(cid:24)(cid:23)(cid:25)(cid:16)(cid:29)(cid:30)(cid:26)(cid:23)(cid:27)(cid:22)(cid:24)
(cid:13)(cid:12)(cid:26)(cid:15)(cid:11)(cid:18)(cid:27)(cid:22)(cid:24)(cid:25)(cid:22)(cid:16)(cid:25)(cid:31)(cid:17)(cid:10) (cid:4)(cid:20)(cid:22)(cid:26)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:15)(cid:25)(cid:14)(cid:8)(cid:29)(cid:22)(cid:18)(cid:27)(cid:18)
Figure 2 Integrative imaging assessment of patients with valvular heart disease. 3D, three-dimensional; CAD, coronary artery disease; CCT, cardiac
computed tomography; CMR: cardiac magnetic resonance; TOE; transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD,
valvular heart disease.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 19 ---
ESC Guidelines 4653
Moreover, in patients with regurgitant lesions, particularly AR, CMR has valve with adjacent structures [e.g. coronary arteries and left ventricu-
gained key value in clinical practice. lar outflow tract (LVOT)], the extension of calcification [e.g. in mi-
tral annular calcification (MAC)], and for sizing of the prosthesis.
4.2. Associated diseases and conditions CT angiography is frequently employed to evaluate the anatomy
of surgical, arterial, or venous access routes and detect cardiac or
Imaging plays a crucial role in identifying associated diseases and condi-
extracardiac complications (e.g. bleeding or embolic events).
tions. The presence of concomitant left ventricular (LV) systolic or dia-
Coronary CT angiography (CCTA) is increasingly utilized to assess
stolic dysfunction, RV systolic dysfunction, red flags indicating
the presence of CAD.
cardiomyopathies (e.g. amyloidosis, hypertrophic cardiomyopathy),
and aortopathy should prompt further examinations to ensure optimal
risk stratification and VHD management. In addition to TTE, advanced 5. Clinical evaluation of patients
imaging modalities, like CCT, may be required to assess the aorta,
with valvular heart disease
single-photon emission computed tomography (CT) for detection of
ischaemia/necrosis, positron emission tomography (PET) for inflamma-
5.1. Clinical examination
tion, nuclear scintigraphy for cardiac amyloidosis, or CMR for tissue
characterization. Patients with VHD can be either asymptomatic or present with a wide
spectrum of symptoms, including acute or chronic HF. An initial meticu-
4.3. Evaluation of valvular heart disease lous history and a comprehensive physical examination of the patient
dynamics and variability with auscultation, documentation of clinical signs of HF such as dys-
pnoea, impaired physical capacity and fatigue, peripheral oedema, and
Serial imaging studies to detect changes over time, or variability due to pleural effusion, as well as a systematic frailty assessment, are crucial.65
haemodynamic conditions or initiation/up-titration of medical ther-
In addition, comorbidities and coexisting cardiac conditions should be
apy, are of utmost importance to guide decisions. The dynamic pat-
documented (Figure 3). Particular attention should be given to recent
tern of VHD may convey additional prognostic information.
changes in symptoms or physical findings indicating a potential worsen-
Exercise echocardiography helps to identify the cause of dyspnoea,
ing of the valve lesion or ventricular function.
unveil symptoms in apparently asymptomatic patients, identifies dy-
namic changes of VHD severity, and can contribute to refinement
5.2. Assessment of comorbidities and risk
of the indication for an intervention, especially for AS and mitral re-
gurgitation (MR).52 stratification
Risk stratification of patients with VHD has been mainly developed
4.4. Assessment of extravalvular cardiac based on surgical populations. The European System for Cardiac
consequences from valvular heart disease Operative Risk Evaluation II (EuroSCORE II)66,67 (https://www.
euroscore.org) and the Society of Thoracic Surgeons predicted risk
Several studies investigating different valve lesions have established
of mortality (STS-PROM) score68 (http://riskcalc.sts.org/
the relevance of extravalvular cardiac damage in terms of progno-
sis,53–55 recovery after intervention,56 and quality of life.57 The pres- stswebriskcalc/calculate) are the most commonly used scoring systems
to estimate surgical risk. Both risk scores have been calibrated to pre-
ence of LV hypertrophy, left atrium (LA) dilatation, LV or RV
dict post-operative outcomes.69–71 The STS-PROM score is dynamic to
dysfunction and/or remodelling, myocardial fibrosis, and pulmonary
account for changes in patient risk profiles, the type of procedure (aor-
hypertension (PH) provide important prognostic information, and
tic, mitral, and tricuspid), and outcomes over time. The outdated (logis- may influence the timing and type of treatment. Although not neces-
tic) EuroSCORE I model systematically overestimated surgical sarily chronological in their order of appearance, the understanding
mortality.70,72
of cardiac damage, particularly damage involving the LV, is essential
In patients considered for TAVI, surgical risk scores have lower ac-
to guide appropriate medical therapy before and after any interven-
curacy and tend to overestimate the risk of events.73–75 Discrepancies
tion. Transthoracic echocardiography (TTE) including global longitu-
between observed and predicted peri-procedural mortality after
dinal strain (GLS) and CMR can be particularly useful in that
regard.58–60 TAVI using surgical risk scores point towards a need for
TAVI-specific scores. Models predicting short- and medium-term sur-
vival specifically designed for TAVI are rarely used in daily clinical prac-
4.5. Evaluation of eligibility, planning, and
tice due to limitations of their predictive performance.76–79 Specific
guiding of interventions
scores have also been developed for patients undergoing mitral
Transoesophageal echocardiography (TOE) (preferentially 3D) is the TEER (M-TEER),80–82 but the high heterogeneity of the population
preferred tool for the assessment of suitability for aortic, mitral, and with MR limits their external validity and therefore routine clinical
TV repair.45,49,61–63 Risk stratification for an intervention should inte- use so far.83 Recently, a dedicated clinical score has been calibrated
grate all the points mentioned above. and validated to stratify the risk associated with first-time and repeat
Transoesophageal echocardiography (TOE), including standard 3D isolated TV surgery (TRI-SCORE; https://www.tri-score.com/), and its
views, is also the modality of choice to guide atrioventricular trans- use should be encouraged for patients with TV disease,84,85 as an al-
catheter interventions and should be performed by specially trained ternative to the more complex Society of Thoracic Surgeons (STS)
interventional echocardiographers.61,64 Cardiac computed tomog- score for isolated TV surgery (https://isolatedtvsurgcalc.research.sts.
raphy (CCT) is frequently used to evaluate the relationship of the org/).
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 20 ---
4654 E S C G u id e l in e s
(cid:31)(cid:30)(cid:29)(cid:14)(cid:30)(cid:26)(cid:23)(cid:24)(cid:25)(cid:29)(cid:24)(cid:22)(cid:14)(cid:25)(cid:27)(cid:20)(cid:23)(cid:25)(cid:14)
(cid:14)(cid:30)(cid:29)(cid:20)(cid:23)(cid:24)(cid:23)(cid:30)(cid:29)(cid:19)
(cid:7) (cid:31)(cid:30)(cid:26)(cid:30)(cid:27)(cid:12)(cid:23)(cid:20)(cid:23)(cid:24)(cid:23)(cid:18)(cid:19)(cid:22)(cid:11)
(cid:21)(cid:27)(cid:25)(cid:23)(cid:15)(cid:24)(cid:16)
(cid:8)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)
(cid:23)(cid:22)(cid:27)(cid:21)(cid:27)(cid:22)(cid:27)(cid:26)(cid:20)(cid:27)(cid:24)
(cid:30)(cid:26)(cid:19)(cid:18)(cid:17)(cid:16)(cid:30)(cid:15)(cid:24)
(cid:11)(cid:27)(cid:30)(cid:22)(cid:29)(cid:18)(cid:10)(cid:27)(cid:30)(cid:12)(cid:18)(cid:27)(cid:9)(cid:30)(cid:15)(cid:8)(cid:30)(cid:29)(cid:28)(cid:16)(cid:26)
(cid:6)(cid:23)(cid:19)(cid:5)(cid:22)(cid:19)(cid:24)(cid:27)(cid:25)(cid:24)(cid:23)(cid:28)(cid:14)(cid:25)(cid:24)(cid:23)(cid:30)(cid:29)(cid:22)(cid:23)(cid:29)(cid:14)(cid:15)(cid:4)(cid:20)(cid:23)(cid:29)(cid:3)(cid:22)(cid:4)(cid:19)(cid:18)
(cid:30)(cid:21)(cid:22)(cid:14)(cid:15)(cid:23)(cid:29)(cid:23)(cid:14)(cid:25)(cid:15)(cid:22)(cid:19)(cid:14)(cid:30)(cid:27)(cid:18)(cid:19)(cid:22)
(cid:2)(cid:23)(cid:26)(cid:23)(cid:29)(cid:3)(cid:22)(cid:25)(cid:29)(cid:20)(cid:22)(cid:24)(cid:16)(cid:1)(cid:18)(cid:22)(cid:30)(cid:21)(cid:22)(cid:24)(cid:27)(cid:18)(cid:25)(cid:24)(cid:26)(cid:18)(cid:29)(cid:24)
(cid:9)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:30)(cid:29)(cid:22)(cid:30)(cid:21)
(cid:20)(cid:23)(cid:19)(cid:18)(cid:25)(cid:19)(cid:18)(cid:22)(cid:19)(cid:18)(cid:17)(cid:18)(cid:27)(cid:23)(cid:24)(cid:16)
(cid:14)(cid:13)(cid:30)(cid:22)(cid:27)(cid:19)(cid:18)(cid:29)(cid:22)(cid:27)(cid:30)(cid:29)(cid:12)(cid:27)(cid:26)(cid:29)(cid:18)(cid:19)(cid:27)(cid:20)(cid:28)(cid:24)(cid:28)(cid:16)(cid:26)
(cid:10)
(cid:31)(cid:15)(cid:23)(cid:29)(cid:23)(cid:14)(cid:25)(cid:15)(cid:22)(cid:18)(cid:13)(cid:25)(cid:26)(cid:23)(cid:29)(cid:25)(cid:24)(cid:23)(cid:30)(cid:29)
Figure 3 Central illustration. Patient-centred evaluation for treatment of valvular heart disease.
Other cardiac conditions and comorbidities—such as CAD, con- The use of PROMs that engage patients in the co-evaluation of their
comitant multiple valve and aortic disease, and RV dysfunction, as health and wellbeing is encouraged. Several scoring systems have been
well as chronic kidney disease (CKD)—are not always appropriately proposed and validated for reproducibility and association with clinical
captured in risk models, even if they are known to impact outcomes.86 outcomes, like the Quality of Recovery 15-item PROM or the Kansas
Similarly, specific unfavourable characteristics like porcelain aorta, mo- City Cardiomyopathy Questionnaire (KCCQ).93–95
bile aortic atheroma, and previous mediastinal radiation therapy in-
crease the surgical risk, and therefore may favour transcatheter
5.3. Biomarkers
treatment options. Frailty, including nutritional state, represents another
important determinant of outcomes after valve interventions,87–89a Biomarker levels indicating either cardiac wall stress [e.g. brain natri-
which can be evaluated using appropriate tools as summarized in a re- uretic peptide (BNP)] or myocardial damage (e.g. troponin), in asymp-
cent consensus statement.90 Several methods have been proposed, tomatic and symptomatic patients, may help to monitor VHD
from the simple Fried Frailty Index to more complex scores91 such progress and determine the most appropriate timing of intervention.
as the Hospital Frailty Risk Score, which has been validated in a large In patients with VHD, the natriuretic peptide ratio [the ratio of
cohort of TAVI and M-TEER patients.92 measured BNP or N-terminal pro-B-type natriuretic protein
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 21 ---
ESC Guidelines 4655
(NT-proBNP) to upper limit of normal for age, sex, and assay] Similarly, the height of the right atrium (RA) v-wave, and the pres-
has been shown to be a powerful, independent, and incremental sure curve mimicking the RV pattern (‘ventricularization’ of the RA
predictor of mortality.96–98 In patients undergoing AV replacement, pressure), are signs of relevant TR, which are frequently accompan-
the accumulation of several elevated biomarkers of cardiovascular ied by increased RV end-diastolic pressure in case of associated RV
stress was associated with higher all-cause and cardiovascular mortal- dysfunction. In patients with severe TR, pulmonary vascular resist-
ity, and a higher rate of repeat hospitalization.99,100 ance (PVR) should be calculated to unmask pulmonary vascular dis-
ease, which may not be captured by echocardiography due to RV
5.4. Exercise testing systolic dysfunction or underestimation of pulmonary pressures be-
cause of TR.
Because of the slow progression of valve lesions, patients may gradually
limit their activity levels over several years and deny having actual symp-
toms that can be unmasked by exercise testing.12 This is particularly im- 5.6. Patient-centred care and shared
portant in cases of AS, because once symptoms occur there is a sharp decision-making
increase in the risk of sudden cardiac death, unless a valve intervention Given that treatment of VHD typically involves several modalities and
is performed.101–104 Exercise testing may provide additional informa- specialities, and may result in a complex and sometimes time-
tion about the haemodynamic severity of VHD and help determine consuming decision-making process, patient education and informa-
the risk and optimal timing of intervention by objectively evaluating tion, using online material and face-to-face conversations, are essen-
functional capacity.101,103 Cardiopulmonary exercise testing has a tial at each step. A clearly defined point of contact for all questions
prognostic role and can assist decision-making in patients with VHD relating to the disease or type of treatments should be communicated
of intermediate severity, particularly those with asymptomatic to the patient and their relatives.120 The symptomatic and prognostic
AR.101,105,106
benefits, as well as the advantages and disadvantages of any treatment
Exercise echocardiography is used for the assessment of LV global option, should be presented in an open and evidence-based manner.
and segmental function, pulmonary artery pressure, and aortic and mi- This includes mortality and risks of reintervention and complications
tral pressure gradients.101,107 It also documents exercise-induced in- (also over the long term), as well as recovery time and the need for
crease of MR and TR severity, especially in patients with secondary cardiac, and if necessary psychological, rehabilitation until return to
disease.108,109 Prognostic impact has been shown mainly for AS and physical activity and work. Other issues to be discussed before the
MR.110,111 Misconceptions regarding its risk and tolerability contribute procedure include the need for oral anticoagulation (OAC) and its
to the overall underuse of exercise testing in patients with VHD,12 des- monitoring, as well as the noise generated by mechanical heart valves
pite data confirming its safety in most asymptomatic patients.112,113 (MHVs). Information regarding centre experience and volume for a
specific procedure should be provided. Misconceptions (e.g. subject-
5.5. Invasive investigations ive overestimation of the risk of surgery) should be addressed and po-
tential interactions with individual lifestyle factors—including social
5.5.1. Coronary angiography
activities, family and professional life, and hobbies—should be dis-
Coronary artery assessment is recommended to evaluate the need for
cussed in detail.
revascularization when valve surgery or an intervention is planned. The
The Heart Team recommendation regarding the treatment and its
information regarding the existence of concomitant CAD should be
modality must be based on evidence and anatomical considerations,
available at the time of Heart Team discussion. CCTA is recommended
balancing the risks and benefits of available treatment options.16 The
as an alternative to coronary angiography to rule out CAD in patients
patient and patient’s relatives need to be well informed about the ra-
who are at low or moderate risk of obstructive CAD.
tionale leading to the Heart Team recommendation, and given ample
Coronary blood flow and fractional flow reserve (FFR) are altered in
time to share personal preferences.121 At the end of the process, a
the setting of concomitant VHD, and functional haemodynamic assess-
shared decision is made between the treating team and the informed
ment of CAD in these patients is not well established.114–118
patient and relatives (Figure 3).
5.5.2. Cardiac catheterization
6. Management of conditions
Right heart catheterization (RHC) should be performed in patients with
equivocal echocardiographic findings, particularly those with MV dis- associated with valvular heart
ease, as well as in all candidates for the treatment of severe TR. In ex-
disease
ceptional cases with unclear AS severity, it can be combined with
measurements of the transaortic gradients allowing estimation of the
6.1. Diagnosis and management of
aortic valve area (AVA). Right heart catheterization contributes to as-
coronary artery disease
sess the repercussions of any left-sided VHD or LV impairment on
the pulmonary circulation and right side of the heart. It provides infor- The presence of CAD plays an important role in decision-making
mation regarding volume state, cardiac output, and vascular resistance, regarding the timing and modality of treatment, and should be
differentiating between pre- and post-capillary PH, and should be ideally assessed before Heart Team discussion. In patients with a low
performed in euvolaemia. or moderate pre-test likelihood of obstructive CAD (≤50%),
Measurements of the pulmonary capillary wedge pressure v-wave CCTA is recommended to rule out relevant CAD with high sensi-
can inform about MR severity, but are neither sensitive nor specific, tivity.122–124
and may also be increased if the compliance of the LA is reduced or Several studies have investigated the value of CCT angiography for
in case of diastolic LV dysfunction, as in patients with MS or chronic CAD screening in elderly TAVI candidates. While sensitivity for the de-
HF.119 tection of obstructive CAD is high (95%–97%), specificity (68%–73%) is
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 22 ---
4656 E S C G u id e l in e s
modest, mainly explained by the high prevalence of coronary artery cal- Optimal timing of PCI in patients undergoing TAVI remains yet to
cification and AF in patients with severe AS, which limit imaging reso- be determined. In NOTION-3, PCI was performed before TAVI in
lution and interpretability.125,126 If CCT angiography obtained during the majority of the patients (concomitantly or shortly after in only
standard pre-TAVI evaluation is of sufficient quality to exclude relevant 26% of the patients). Decision-making concerning the timing of
CAD, omission of invasive coronary angiography should be consid- PCI should take into account the type of valve used for TAVI and
ered.125–129 the complexity of the coronary lesions.142,143 Valves with a high
The value of invasive functional haemodynamic assessment of CAD frame—particularly in the context of a narrow aortic root, commis-
in patients with severe AS may be limited, because AS impacts coronary sural misalignment, or valve-in-valve procedures—can pose chal-
haemodynamics. Therefore, caution is warranted in the interpretation lenges for coronary access following TAVI.144,145 The presence
of functional measurements in the presence of severe AS until more of significant CAD should therefore be considered for optimal
data are available.115,116 transcatheter valve selection and reinforces the importance of opti-
Recommendations for the management of chronic CAD associated mized implantation technique and commissural alignment.143,146
with VHD are provided below (Recommendation Table 1), as well as in Several RCTs comparing the value and timing of PCI with
dedicated guideline documents.6 The indications for coronary artery medical therapy are ongoing (NCT04634240, NCT04310046, and
bypass grafting (CABG) in patients undergoing surgery for the treat- NCT05078619).
ment of VHD are mainly based on observational data, which do not Based on the available data, PCI should be considered in patients with
provide detailed information on the degree of stenosis and the com- a primary indication to undergo TAVI and high-grade (≥90%) coronary
plexity of CAD.130 It has been demonstrated that subendocardial blood artery stenosis in large vessels of ≥2.5 mm. In patients with stenosis of
flow in the myocardium improves early after SAVR, most likely due to ≥70%, PCI may be considered based on symptom status.142,143 In pa-
improved cardiac output and reduction of LV wall stress.131 The pres- tients with ischaemic ventricular SMR, surgical revascularization of
ence of CAD is associated with peri-operative and late adverse events CAD has been associated with MR reduction147 and favourable clinical
in patients with AS undergoing SAVR132 that likely outweigh the in- outcomes in observational studies.148,149 According to very limited
creased risk of peri-procedural adverse events of combined SAVR data, improvement of SMR may occur in a minority of patients (about
and CABG compared with isolated SAVR. Indeed, in a large observa- one-third) after PCI, which may therefore be considered prior to MV
tional study, patients with CAD demonstrated better long-term sur- intervention.150
vival after combined SAVR and CABG compared with SAVR alone, For patients with VHD presenting with acute coronary syndrome,
despite longer cross-clamp times.133 In patients with a primary indica- treatment decisions should be made according to the most recent
tion for valve surgery, CABG is recommended in patients with coron- ESC Guidelines.151 In patients presenting with non-ST-segment eleva-
ary artery stenosis of ≥70% and should be considered in those with tion acute coronary syndrome, it may be particularly challenging to
stenosis of ≥50%–70%, given the opportunity of concomitant full determine the leading cause of elevated troponin levels, which are
revascularization. also frequently observed in decompensated VHD. Therefore, the
The impact of CAD in patients undergoing TAVI remains under inves- treatment strategy should be determined by the Heart Team, taking
tigation. The randomized Nordic Aortic Valve Intervention (NOTION)-3 into account symptoms, as well as coronary, valve, and access
trial compared a strategy of routine percutaneous coronary interven- anatomy.136,138,139
tion (PCI) versus conservative management in 455 patients with severe
symptomatic AS undergoing TAVI, who also had stable CAD and at
least one stenosis of ≥90% based on visual angiographic assessment Recommendation Table 1 — Recommendations for the
or FFR of ≤0.80 in a segment with ≥2.5 mm reference diameter.134 management of chronic coronary syndrome in patients
with valvular heart disease (see also Supplementary
Percutaneous coronary intervention was associated with lower risk
data online, Evidence Table 1)
of a composite endpoint event including all-cause death, myocardial in-
farction or urgent revascularization at a median follow-up of 2 years.
Recommendations Classa Levelb
Exploratory analyses suggest that the increased risk in the conserva-
tive treatment arm was driven by differences in the risk of myocardial Diagnosis of coronary artery disease
infarction and urgent revascularization in patients with a diameter
stenosis of ≥90%, rather than those with positive FFR and stenosis CCTA is recommended before valve intervention in
of <90%. The risk of bleeding was higher in the PCI than in the conservative patients with moderate or lower (≤50%) pre-test I B
treatment group. Another multicentre RCT, the PercutAneous Coronary likelihood of obstructive CAD.122–124
inTervention prIor to transcatheter aortic VAlve implantaTION Invasive coronary angiography is recommended
(ACTIVATION) trial, was discontinued due to slow recruitment.135
before valve intervention in patients with high and
In this underpowered and thus inconclusive trial, a routine PCI strategy I C
very high (>50%) pre-test likelihood of obstructive
of ≥70% stenoses in main epicardial vessels (or ≥50% if protected left
CAD.
main or vein graft) did not meet non-inferiority compared with conserva-
Invasive coronary angiography is recommended in
tive CAD treatment with respect to the composite of all-cause death and
the evaluation of CAD in patients with severe I C
rehospitalization; moreover, PCI was associated with higher bleeding
ventricular SMR.
rates. Observational data show that TAVI can be performed safely in pa-
Omission of invasive coronary angiography should be
tients with untreated CAD with low short- and long-term rates of acute
coronary syndrome and unplanned coronary revascularization.135–139 considered in TAVI candidates, if procedural planning IIa B
In two recent meta-analyses of mostly observational data, PCI was not CT angiography is of sufficient quality to rule out
associated with a mortality benefit in patients with chronic CAD significant CAD.125–129
undergoing TAVI.140,141 Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 23 ---
ESC Guidelines 4657
only 10% of the included population).162 In an RCT including patients
Indications for myocardial revascularization
with severe AS and AF undergoing TAVI, concomitant transcatheter
CABG is recommended in patients with a primary
LAAO was non-inferior to medical therapy with respect to a composite
indication for valve surgery and coronary artery I C
primary endpoint including all-cause mortality, stroke, and major bleed-
stenosis ≥70%.c
ing at 2 years. Of note, rates of major or life-threatening bleeding were
CABG should be considered in patients with a similar in the two groups and arterial or venous thromboembolisms
primary indication for valve surgery and coronary IIa C more frequent in the TAVI/LAAO arm, leaving uncertainty regarding
artery stenosis ≥50%–70%. the usefulness of combining both procedures.163
PCI should be considered in patients with a primary
indication to undergo TAVI and ≥90% coronary
IIa B
artery stenosis in segments with a reference Recommendation Table 2 — Recommendations for the
management of atrial fibrillation in patients with native diameter ≥2.5 mm.134
valvular heart disease (see also Supplementary data
PCI may be considered in patients with a primary online, Evidence Tables 2 and 3)
indication to undergo transcatheter valve
IIb B
interventions and coronary artery stenosis ≥70% in Recommendations Classa Levelb
proximal segments of main vessels.135–137
Anticoagulation
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary
computed tomography angiography; CT, computed tomography; PCI, percutaneous DOACs are recommended for stroke prevention in
coronary intervention; SMR, secondary mitral regurgitation; TAVI, transcatheter aortic
preference to VKAs in patients with AF and AS, AR, I A
valve implantation.
aClass of recommendation. or MR who are eligible for OAC.156–159,164
bLevel of evidence.
The use of DOACs is not recommended in patients
cStenosis ≥50% can be considered for left main stenosis.
with AF and rheumatic MS with an III B
MVA ≤2.0 cm2.165
6.2. Atrial fibrillation Surgical interventions
The interplay between AF and VHD is complex, and has an essential Concomitant surgical ablation is recommended in
role in the prognosis and evolution of VHD during the patient’s lifetime. patients undergoing MV surgery with AF suitable for a
Valvular heart disease is independently associated with AF and almost rhythm control strategy to prevent symptoms and I A
one-third of patients with AF have a history of VHD.152 Conversely, recurrence of AF, according to an experienced team of
AF is the main trigger of the development of atrial secondary MR and electrophysiologists and arrhythmia surgeons.166–173
TR. In a recent cohort study, 8% of individuals with AF developed mod- Surgical closure of the LA appendage is
erate or severe TR within 3 years of follow-up compared with only 2% recommended as an adjunct to OAC in patients with
in those in sinus rhythm.153 While disturbed annular dynamics have AF undergoing valve surgery to prevent I B
been postulated,150,154 the exact pathophysiology leading to secondary cardioembolic stroke and systemic
atrioventricular VHD in some, but not all patients with AF remains thromboembolism.160–162
largely unclear.
Concomitant surgical ablation should be considered
Detailed recommendations on the anticoagulation management of
in patients undergoing non-MV surgery with AF
patients with VHD and AF are provided below (Recommendation
suitable for a rhythm control strategy to prevent
Table 2) and in Section 14, as well as in specific Guidelines.7 Patients IIa B
symptoms and recurrence of AF, according to an
with a combination of VHD and AF have a high incidence of thrombo-
experienced team of electrophysiologists and
embolic or bleeding complications.155 DOACs have replaced vitamin K arrhythmia surgeons.167,169,174,175
antagonists (VKAs) in most clinical scenarios and are recommended for
patients with VHD presenting with AF, except for patients with a MHV AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; DOAC, direct oral
or mitral stenosis with a valve area ≤2.0 cm2. The use of apixaban,156 anticoagulant; LA, left atrium/left atrial; MR, mitral regurgitation; MS, mitral stenosis; MV,
dabigatran,157 edoxaban,158 and rivaroxaban159 is supported by sub- mitral valve; MVA, mitral valve area; OAC, oral anticoagulation; VKA, vitamin K antagonist.
aClass of recommendation.
group analyses of large RCTs. Recommendations regarding the antith- bLevel of evidence.
rombotic treatment of patients with MHVs and biological heart valves
(BHVs) are described in Section 14 of these Guidelines.
6.3. Cancer and radiation therapy
In the Left Atrial Appendage Occlusion Study (LAAOS) III trial, sur-
gical left atrial appendage occlusion (LAAO) in patients with AF and a Valvular heart disease is commonly associated with cancer and repre-
CHA DS -VASc [congestive heart failure or left ventricular dysfunc- sents a well-known long-term side effect of intensive radiation ther-
2 2
tion, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vas- apy176 for treatment of Hodgkin or non-Hodgkin lymphoma, breast
cular disease, age 65–74, sex category (female)] score of ≥2 points cancer, and other thoracic malignancies.177 Clinically significant VHD
undergoing cardiac surgery was associated with a 33% reduction of most commonly appears decades after radiotherapy. The incidence
the risk of stroke or systemic embolism at a mean follow-up of of radiation-induced VHD is increasing owing to longer survival of pa-
3.8 years.160 These findings were confirmed by a large meta-analysis in- tients with cancer. Risk factors are summarized in Supplementary data
cluding four RCTs.161 A subanalysis of LAAOS III showed that the bene- online, Table S1. Patients at risk should be screened for VHD using TTE
fit of LAAO remains consistent irrespective of the use of VKAs or 10 years after radiation exposure and followed up every 5 years
DOACs, as well as in the absence of OAC (although representing thereafter.178
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 24 ---
4658 E S C G u id e l in e s
Radiotherapy may lead to aortic and/or valvular calcification, CAD of cardiogenic shock with similar device success, even if LVEF is low, al-
proximal segments, restrictive cardiomyopathy, pericardial adhesions though 30-day mortality remains higher (13%–19%) compared with
and calcifications with constriction, restrictive lung disease, chest wall routine TAVI.194,197,198 Surgery represents the preferred treatment
scarring, and impaired wound healing, especially in patients who under- in patients with acute AR, while TAVI has only been described in indi-
went radiation by means of older techniques (>20 years ago). The above vidual cases or patients with a failed surgical valve (valve-in-valve). Fast
factors complicate any surgical approach and increase the operative risk, pacing over a temporary pacemaker lead shortens the diastole and may
which is underestimated by traditional risk scores.179–181 TAVI is pro- temporarily improve haemodynamics until the intervention.5,8
posed as an alternative for patients presenting with radiation-induced Except for papillary muscle rupture, acute PMR rarely leads to car-
AS in the 2022 ESC Guidelines on cardio-oncology182 based on favourable, diogenic shock and may be best treated by surgical valve repair or re-
but limited, observational data,183,184 because this category of patients placement. In contrast, increasing evidence supports the use of
has been excluded from RCTs.183,184 Furthermore, M-TEER in patients M-TEER in patients with acute ventricular SMR, particularly following
presenting with radiation-induced MV disease with MR is often limited acute myocardial infarction, due to lower mortality compared with sur-
by thickened leaflets with restricted movement and subsequent risk of gery or medical treatment in propensity-matched analyses.194,202,203
iatrogenic stenosis. This strategy might also be helpful to facilitate weaning from mechanical
In patients with active or stable cancer and severe AS, both TAVI and circulatory support.
SAVR can be considered based on life expectancy, age, prognosis, and
disability following cancer treatment, with a trend towards more TAVI 6.6. Palliative care
utilization.185 TAVI procedural complication rates appear similar com- In some patients with advanced VHD not qualifying for surgical or
pared with those of control subjects without cancer.186 To avoid futil- transcatheter therapies, medical HF treatment remains the only, and
ity, treatment decisions discussed by the Heart Team should involve the sometimes best, available option. These patients usually present late,
treating oncologists.5,182 have extensive cardiac damage, develop terminal HF during the natural
evolution of VHD, and are ineligible for mechanical circulatory support
6.4. Prophylaxis of rheumatic fever or heart transplantation (HTx). Early implementation of expert multi-
Rheumatic heart disease remains the most common cause of death disciplinary palliative and end-of-life care, with the support of HF spe-
from VHD worldwide.187 Prevention should preferentially target the cialists,204–206 reduces the number of hospitalizations and improves
first occurrence of acute rheumatic fever. Correct diagnosis and early quality of life and symptom burden, in particular dyspnoea, pain, and
antibiotic treatment of group A Streptococcus throat or skin infection anxiety.207 Continuous co-ordination between all involved subspecial-
is key for primary prevention. Large-scale screening combined with ties, and transparent communication with the patient and their rela-
prophylaxis in children or adolescents with latent RHD appears to be tives, are key to ensure high quality of care.
an effective strategy to reduce the risk of disease progression and
RHD prevalence.188–190 In patients with established RHD, secondary 7. Aortic regurgitation
long-term prophylaxis with benzathine benzyl penicillin 1.2 million
international units (IU) every 3–4 weeks over 10 years is recom- 7.1. Prevalence and aetiology
mended to prevent recurrent episodes, especially in children and ado-
Chronic AR is mainly due to intrinsic abnormalities of the AV cusps and/
lescents. Long-term prophylaxis into adulthood should be considered
or secondary to progressive dilatation of the aortic root and/or ascend-
in high-risk patients according to the severity of VHD and exposure
ing aorta. In high-income countries, degenerative changes are the lead-
to group A Streptococcus.191,192
ing cause of AR, while RHD is more frequent in middle- and
low-income countries.12 Acute presentations are usually related to in-
6.5. Cardiogenic shock and acute heart
fective endocarditis or extension of aortic dissection into the aortic
failure root. Chronic pure severe AR is more frequent in men and is associated
Acute presentation or decompensation of VHD can result in cardio- with BAV and concomitant dilatation of the aorta in more than one-half
genic shock due to rapid haemodynamic deterioration and altered car- of cases.208
diac function. Alternatively, pre-existing VHD can be a bystander of an
7.2. Evaluation
acute cardiovascular condition further exacerbating circulatory impair-
ment until the occurrence of cardiogenic shock. In this setting, assess- During stepwise AR evaluation, the following aspects should be ad-
ment of the severity of VHD, as well as its contribution to acute HF, dressed: the severity of AR, its mechanism, and aetiology; the haemo-
may be difficult. Evidence concerning acute VHD management in this dynamic impact on LV function and pulmonary pressure; and
context is scarce and only exists for the MV and AV.193,194 evaluation of the ascending aorta. While echocardiography is the first-
Hospital admission for acute decompensated AS is a frequent prob- line modality, CMR and CCT are more accurate for the measurement
lem seen in up to 25% of AS hospitalizations.195,196 However, only a mi- of specific parameters (Figure 4). The results of the evaluation need to
nority of these patients (1.6%–3.2%) present with cardiogenic take into consideration the haemodynamic condition of the patient,
shock.197,198 While intensive care treatment remains the cornerstone particularly the blood pressure (BP), since high pressures can lead to
of haemodynamic stabilization and support, an intervention should be overestimation of the regurgitant volume (RVol).
considered early, because it represents the only way to reverse pro- Assessment of AR severity with TTE follows an integrative approach
gressive organ dysfunction due to low cardiac output. Balloon aortic considering qualitative, semi-quantitative, and quantitative parameters,
valvuloplasty has been used in this context in the past, but has been but remains challenging.45 Consequences of AR on LV size and function
largely replaced by TAVI in recent years, due to the high risk of severe must be carefully assessed. Cut-offs for intervention are mostly
AR and mortality in the acute setting.199–201 Several large observational based on two-dimensional (2D) echocardiographic measurements.
studies have established the feasibility of TAVI in patients with However, 3D echocardiography and CMR allow more accurate
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 25 ---
ESC Guidelines 4659
evaluation of LV volumes and LVEF than 2D echocardiography, and are Given its close relationship with AV function, accurate measure-
useful in borderline cases (Figure 4).45,209 Strain imaging can be helpful in ments of the aortic diameter are required at all levels: the annulus,
identifying subclinical LV dysfunction209–211 and can therefore influence sinuses of Valsalva, sinotubular junction, and ascending aorta.8,215,216
the optimal timing of intervention. Reduced longitudinal strain and con- The largest diameter is used to indicate the specific aortic pheno-
tractile reserve at stress echocardiography,212 elevated biomarkers type: root phenotype, ascending phenotypes, and extended or
(BNP),213,214 and the presence of myocardial fibrosis detected by mixed forms (see Supplementary data online, Figure S1).8 The mech-
CMR need to be integrated in the decision-making process, even if anism of AR and aortic diameters determine suitability for AV spar-
not entirely validated yet.209 ing or repair.217,218
‹(cid:13)(cid:25)(cid:24)(cid:15)(cid:10)(cid:25)(cid:10)(cid:15)(cid:22)(cid:21)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22)(cid:25)(cid:24)(cid:22)(cid:21)(cid:23)(cid:26)(cid:28)(cid:27)(cid:20)(cid:19)(cid:28)(cid:24)(cid:28)(cid:18)(cid:17)
(cid:16)(cid:24)(cid:25)(cid:15)(cid:24)(cid:23)(cid:14)(cid:13)(cid:12)(cid:20)
(cid:11)(cid:25)(cid:27)(cid:18)(cid:21)(cid:23)(cid:14)(cid:28)(cid:25)(cid:20)(cid:10)(cid:25)(cid:10)(cid:15)(cid:28)(cid:29)(cid:23)(cid:9)(cid:21)(cid:8)(cid:21)(cid:14)(cid:10)
(cid:7)(cid:27)(cid:15)(cid:10)(cid:21)(cid:27)(cid:15)(cid:25)(cid:23)(cid:8)(cid:28)(cid:27)(cid:23)
(cid:144)(cid:21)(cid:26)(cid:15)ŒŽ(cid:13)(cid:25)(cid:29)(cid:10)(cid:15)(cid:10)(cid:25)(cid:10)(cid:15)(cid:22)(cid:21)
(cid:12)(cid:21)(cid:22)(cid:21)(cid:27)(cid:21)(cid:23)(cid:31)(cid:6)
(cid:141)(cid:21)(cid:29)(cid:25)(cid:23)(cid:14)(cid:28)(cid:29)(cid:10)(cid:27)(cid:25)(cid:14)(cid:10)(cid:25)(cid:23)(cid:5)€(cid:23)(cid:26)(cid:26)
‚ƒ (cid:23)„…(cid:3)(cid:3)(cid:23)(cid:26)(cid:12)
(cid:11)(cid:25)(cid:27)(cid:18)(cid:21)(cid:23)(cid:14)(cid:21)(cid:29)(cid:10)(cid:27)(cid:25)(cid:24)(cid:23)†(cid:21)(cid:10)(cid:23)(cid:1)≥€‡(cid:2)(cid:23)(cid:28)(cid:8)(cid:23)(cid:11)(cid:141)ˆ (cid:23)(cid:9)(cid:15)(cid:25)(cid:26)(cid:21)(cid:10)(cid:21)(cid:27)(cid:129)
ƒ(cid:28)(cid:24)(cid:28)(cid:9)(cid:15)(cid:25)(cid:12)(cid:10)(cid:28)(cid:24)(cid:15)(cid:14)(cid:23)‰(cid:28) (cid:23)(cid:27)(cid:21)(cid:22)(cid:21)(cid:27)(cid:12)(cid:25)(cid:24)(cid:23)(cid:15)(cid:29)(cid:23)(cid:9)(cid:21)(cid:12)(cid:14)(cid:21)(cid:29)(cid:9)(cid:15)(cid:29)(cid:18)
(cid:25)(cid:28)(cid:27)(cid:10)(cid:25)(cid:23)(cid:1)(cid:143)(cid:157)(cid:141)(cid:23)≥…(cid:3)(cid:23)(cid:14)(cid:26)Š(cid:12)(cid:129)
‹(cid:13)(cid:25)(cid:29)(cid:10)(cid:15)(cid:10)(cid:25)(cid:10)(cid:15)(cid:22)(cid:21)
(cid:143)(cid:6)ˆ(cid:31)(cid:23)≥‘(cid:3)(cid:23)(cid:26)(cid:26)…
(cid:6)(cid:16)(cid:23)(cid:23)(cid:5)(cid:4)(cid:3)(cid:2)(cid:23)(cid:1)(cid:7)(cid:127)(cid:6)(cid:129)
(cid:6)(cid:141)(cid:28)(cid:24)(cid:23)(cid:23)≥€(cid:3)(cid:23)(cid:26)(cid:11)Š(cid:30)(cid:21)(cid:25)(cid:10)
(cid:6)(cid:16)(cid:23)>‡(cid:3)(cid:2)(cid:23)(cid:1)(cid:21)(cid:14)(cid:19)(cid:28)(cid:129)
(cid:7)(cid:13)(cid:12)(cid:20)(cid:23)(cid:20)(cid:27)(cid:28)(cid:24)(cid:25)(cid:20)(cid:12)(cid:21)
(cid:7)(cid:13)(cid:12)(cid:20)(cid:23)(cid:27)(cid:21)(cid:10)(cid:27)(cid:25)(cid:14)(cid:10)(cid:15)(cid:28)(cid:29)
(cid:7)(cid:13)(cid:12)(cid:20)(cid:23)(cid:20)(cid:21)(cid:27)(cid:8)(cid:28)(cid:27)(cid:25)(cid:10)(cid:15)(cid:28)(cid:29)
(cid:31)(cid:12)(cid:12)(cid:21)(cid:12)(cid:12)(cid:26)(cid:21)(cid:29)(cid:10)(cid:23)(cid:28)(cid:8)(cid:23)(cid:31)(cid:6) (cid:127)(cid:21)(cid:14)(cid:19)(cid:25)(cid:29)(cid:15)(cid:12)(cid:26)
(cid:31)(cid:28)(cid:27)(cid:10)(cid:15)(cid:14)(cid:23)(cid:9)(cid:15)(cid:24)(cid:25)(cid:10)(cid:25)(cid:10)(cid:15)(cid:28)(cid:29)(cid:23)
(cid:15)(cid:10)(cid:19)(cid:23)(cid:14)(cid:13)(cid:12)(cid:20) (cid:7)(cid:7)
(cid:26)(cid:25)(cid:24)(cid:14)(cid:28)(cid:25)(cid:20)(cid:10)(cid:25)(cid:10)(cid:15)(cid:28)(cid:29)
(cid:11)(cid:141)(cid:143)(cid:16)(cid:25) (cid:7)(cid:127)(cid:6)
(cid:11)(cid:141)(cid:23)(cid:9)(cid:25)(cid:26)(cid:25)(cid:18)(cid:21)
(cid:11)(cid:141)(cid:143)(cid:144)(cid:157)(cid:15)(cid:25)
(cid:11)(cid:141)(cid:143)(cid:144)(cid:141)(cid:15)(cid:25)
Figure 4 Imaging assessment of patients with aortic regurgitation. AR, aortic regurgitation; CCT, cardiac computed tomography; CMR, cardiac mag-
netic resonance; EDV, end-diastolic velocity; EROA, effective regurgitant orifice area; LV, left ventricle/left ventricular; LVEF, left ventricular ejection
fraction; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic volume indexed to body sur-
face area; LVOT, left ventricular outflow tract; PHT, pressure half-time; RF, regurgitant fraction; RVol; regurgitant volume. aSee Recommendation Table 3
for specific cut-offs.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 26 ---
4660 E S C G u id e l in e s
The morphology of the AV represents a critical aspect in the diagno- the aortic root (see Supplementary data online, Figure S1) paralleled
sis and treatment of AR. Pure AR in the context of BAV uncommonly with favourable long-term results, valve-sparing aortic root replace-
manifests with normal aortic diameters, being more often associated ment (VSARR) and AV repair are increasingly performed in centres
with a dilated ascending aorta and/or root. It is important to define with appropriate expertise (Figure 5).243–255 In patients with root en-
the valve phenotype to determine the repair probability and long-term largement and good tissue quality (i.e. pliable AV cusps with normal mo-
result of AV repair or AV-sparing procedures. The degree of symmetry tion), a valve-sparing procedure has been demonstrated to be superior
is an important predictor of BAV reparability with better long-term re- to the use of a composite valve graft (Bentall procedure) in terms of
sults in more symmetric phenotypes.219–221 long-term mortality and overall morbidity (thromboembolism and
endocarditis, with similar need for reoperation),250–253,255–257 and
7.3. Medical therapy should be therefore favoured by experienced centres, in particular
in patients with an estimated long life expectancy.258 Valve preserva-
Medical therapy, especially angiotensin-converting enzyme-inhibitors
tion or valve repair should also be considered for patients with BAV
(ACE-Is) or dihydropyridine calcium channel blockers, may provide
based on age, anatomical presentation, and centre experience
symptomatic improvement in individuals with chronic severe AR for
(Figure 5).220,245,246,259
whom surgery is not feasible or contraindicated. The value of ACE-Is
When performed by experienced surgeons in well-selected young
or dihydropyridines in delaying surgery in the presence of moderate
individuals, pulmonary autograft implantation (Ross operation) may
or severe AR in asymptomatic patients has not been established, and
also be a good alternative to prosthetic valve replacement.260–263
their use is not recommended for this indication. The use of beta-
TAVI may be considered at experienced centres for selected patients
blockers increases the length of the diastole and therefore the RVol,
with AR who are ineligible for surgery. The use of non-dedicated trans-
and should be used with caution if indicated for another reason.
catheter valves for this indication is off-label and associated with an in-
However, beta-blockers can be used along with ACE-Is or angiotensin
creased risk of valve malpositioning and residual AR, with consecutively
receptor blockers (ARBs) after surgery, if indicated (systolic HF or
higher rates of second valve implantation (about 10%) or surgical con-
heart rate control).222,223
version, as compared with TAVI in AS.264–268 Dedicated devices appear
to minimize the risk of valve migration and residual AR in selected pa-
7.4. Indications for intervention
tients, but are associated with a high new permanent pacemaker im-
Acute severe AR usually requires immediate surgery depending on the plantation rate (24%).267–269
aetiology, such as infective endocarditis or spontaneous, traumatic, Aortic dilatation is closely linked to AR. Dedicated ESC Guidelines
or iatrogenic aortic dissection.5,8 Surgery for the treatment of chronic give guidance regarding the evaluation and management of aortic
severe AR is indicated depending on symptoms and/or the effects of root and ascending aortic dilatation.8 The aortic phenotype (see
the RVol on LV size and function (see Recommendation Table 3 and Supplementary data online, Figure S1), degree and rate of progression
Figure 5). The presence of associated aortic dilatation dictates surgery, of aortic dilatation, and the underlying aetiology all affect timing of sur-
irrespective of AR severity. When the patient is symptomatic and AR gery, with the main indication being maximum aortic diameter.270–272
severe, surgery is recommended unless the anticipated surgical risk is Dilation of the aortic root, which typically occurs in Marfan syndrome
prohibitive.224–228 Concomitant surgical treatment of severe AR and other patients with connective tissue disease, has a worse progno-
is also recommended, irrespective of symptoms, in patients requiring sis compared with isolated dilatation of the ascending aorta and re-
CABG, ascending aorta surgery, or any other cardiac surgical quires closer surveillance.270–272 Surgery is recommended in all
procedures.229,230 patients with a maximal aortic root or ascending aneurysm diameter
For the asymptomatic patient with severe AR, indications for of ≥55 mm. In the presence of additional risk factors, a threshold of
surgery are based on the degree of functional impairment of the 50 mm may be considered for selected low-risk patients treated at ex-
LV [LVEF ≤50%, left ventricular end-systolic diameter (LVESD) perienced centres.8 If the patient has an established indication for AV
>50 mm, or left ventricular end-systolic diameter indexed to body sur- surgery (due to AR or AS), concomitant surgery of the aortic root
face area (BSA) (LVESDi) >25 mm/m2, especially in those with small or the ascending aorta should be considered at a diameter of
BSA (BSA <1.68 m2) and elderly patients with low ventricular compli- ≥45 mm. This threshold has been more clearly demonstrated in pa-
ance].226,228,231–234 If surgery is deemed low risk, there is observational tients with BAV and should also be based on the patient’s height273
evidence from echocardiographic studies that early intervention might or specific intraoperative findings, such as the shape and thickness of
be beneficial for long-term prognosis when LVEF is ≤55%, LVESDi is the aortic wall.
>22 mm/m2, and/or left ventricular end-systolic volume indexed to
BSA (LVESVi) is >45 mL/m2.235–239 A volumetric cut-off value of
LVESVi ≥43 mL/m2 using CMR was recently proposed to guide the 7.5. Follow-up
management of asymptomatic patients240,241 and appears to have bet- A multimodality imaging approach45,274 and biomarkers like BNP213,214
ter predictive value than LV diameter.242 Surgery may also be discussed might help identify patients at increased risk of LV damage early
in selected low-risk asymptomatic patients with significant LV dilatation and guide the appropriate timing of intervention. Yearly follow-up is re-
(left ventricular end-diastolic diameter >65 mm) and progressive in- commended in asymptomatic patients with severe AR. Closer follow-
crease of LV diameters and/or decrease of LVEF during follow-up. up (3–6 months) is recommended for those approaching thresholds
Exercise testing should be performed, when feasible, in patients with for surgery, or showing a progressive dilatation of the LV or decrease
severe AR who do not report symptoms and do not meet criteria of LVEF. Cardiac magnetic resonance can be especially useful in such
for surgery.212 a setting. Patients with moderate AR should be followed on a yearly ba-
AV replacement is still the standard surgical approach in most AR sis, with echocardiography performed every 2 years.
cases (see Section 14.1 regarding prosthesis type considerations). When a dilated ascending aorta is initially diagnosed by TTE, a multi-
However, owing to a better understanding of the pathophysiology of slice electrocardiographic-triggered CCT/CMR scan is recommended
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 27 ---
ESC Guidelines 4661
Patient with AR
Significant aortic root enlargementa
Severe AR Significant AR
VSARR Good tissue quality
Team expertise
Young patient
Symptoms
Bentall VSARR
and AV repair
Eligible for surgeryb
LVEF ≤50% or
AV surgery
LVESD >50 mm
(Class I)
or LVESDi >25 mm/m2
LVEF ≤55% or
LVESDi >22 mm/m2
or LVESVi >45 mL/m2
Good tissue quality
AV surgery
Team expertise
(Class IIb)
Young patient
AV repair TAVI
Follow-up SAVR
(Class IIa) (Class IIb)
Figure 5 Management of patients with aortic regurgitation. AR, aortic regurgitation; AV, aortic valve; LVEF, left ventricular ejection fraction; LVESD,
left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic
volume indexed to body surface area; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve replacement; VSARR, valve-sparing aor-
tic root replacement. aIndications for surgery on the root/ascending aorta are described in the 2024 ESC Guidelines for the management of peripheral
arterial and aortic diseases.8 bConcomitant replacement of the aortic root or ascending aorta should be considered if the maximal diameter is
≥45 mm and the predicted surgical risk is low.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 28 ---
4662 E S C G u id e l in e s
to confirm maximal diameter, rule out isolated single sinus dilatation, TAVI may be considered for the treatment of severe
and provide a baseline reference. When the baseline aortic diameter AR in symptomatic patients ineligible for surgery
is >45 mm, a second TTE examination is recommended at 6 months IIb B
according to the Heart Team, if the anatomy is
to confirm the stability of the finding, followed by serial examinations suitable.264,265,268,269
on a yearly basis thereafter.275 Any increase of >3 mm should be vali-
dated by CT angiography/CMR and compared with baseline data.275 Concomitant surgery of the ascending aorta
After repair of the ascending aorta, patients with Marfan syndrome Valve-sparing aortic root replacement is
and other connective tissue diseases remain at risk for dissection of un- recommended in young patients with aortic root
I B
treated portions of the aorta, and require lifelong regular multidisciplin- dilatation at experienced centres, when durable
ary follow-up at an expert centre.8 results are expected.247,250–253,255
When AV surgery is indicated and the predicted
7.6. Special patient populations surgical risk is low, replacement of the aortic root or
IIa C
Patients with concomitant VHD and those with AS combined with AR ascending aorta should be considered if the maximal
are discussed in Section 13.3.3. In patients with moderate AR and indica- diameter is ≥45 mm.d
tion for CABG or MV surgery, the decision to treat the AV should be
AR, aortic regurgitation; AV, aortic valve; BSA, body surface area; CABG, coronary artery
discussed by the Heart Team based on the aetiology of AR and other bypass grafting; CMR, cardiac magnetic resonance; LV, left ventricle/left ventricular; LVEF,
clinical factors, like the estimated life expectancy and the operative risk, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left
as data show that progression of moderate AR may be very slow.276 ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic
volume indexed to BSA; TAVI, transcatheter aortic valve implantation.
The presence of aortic dilation and AR in asymptomatic patients aClass of recommendation.
poses the problem of limiting the level of physical activity, but consist- bLevel of evidence.
ent data are lacking. Current recommendations for participation in cUsing echocardiography or CMR.
dConsidering age, BSA, the aetiology of the valvular disease, the presence of a bicuspid AV,
competitive sport are restrictive, especially regarding isometric exer-
and the intraoperative shape and thickness of the ascending aorta.
cise in patients with connective tissue disease,277 while a more liberal
approach is likely to be appropriate in other patients.
Given the familial risk of thoracic aortic aneurysms, screening with
appropriate imaging studies and testing for genetic abnormalities in 8. Aortic stenosis
first-degree relatives is indicated in patients with connective tissue dis-
ease.278 Since aortic dilation is present in ∼10% of first-degree relatives 8.1. Prevalence and aetiology
of patients with a BAV, it is also considered appropriate to encourage Even if AS is the most common primary valve lesion referred for inter-
echocardiographic screening in this specific population.275,279 vention in Europe and North America,12 underdiagnosis and under-
treatment remain relevant concerns.10 Degenerative pathogenesis
Recommendation Table 3 — Recommendations on in- with cusps calcification is most common in developed countries and
dications for intervention in severe aortic regurgitation prevalence is rising rapidly because of the ageing population.11,12,187
(see also Supplementary data online, Evidence Tables 4–8)
BAVs, or more rarely unicuspid AVs, are prone to earlier degeneration,
constitute the dominant valve morphology in younger patients requir-
Recommendations Classa Levelb
ing AV replacement, and are frequently associated with dilatation of the
aortic root or ascending aorta.280,281 In low- and middle-income coun-
Severe aortic regurgitation
tries, rheumatic aetiology remains frequent and AS usually presents
AV surgery is recommended in symptomatic patients combined with rheumatic MV disease.282
I B
with severe AR regardless of LV function.224–228
AV surgery is recommended in asymptomatic
8.2. Evaluation
patients with severe AR and LVESD >50 mm or
LVESDi >25 mm/m2 [especially in patients with small I B 8.2.1. Echocardiography and cardiac computed
body size (BSA <1.68 m2)] or resting tomography
LVEF ≤50%.226,228,231,233,234 Aortic stenosis is a disease slowly evolving from mild to severe valve
AV surgery is recommended in symptomatic and obstruction as a consequence of increasing valve fibrosis and calcifi-
asymptomatic patients with severe AR undergoing I C cation, although progression accelerates as haemodynamic severity
CABG or surgery of the ascending aorta.
increases.283
Echocardiography is key to confirm the diagnosis and allows compre-
AV repair should be considered in selected patients
hensive assessment of the anatomy and severity of stenosis. Evaluation
with severe AR at experienced centres, when IIa B
of the haemodynamic consequences on cardiac function and geometry,
durable results are expected.220,245,246,259
and the detection of aortic pathology or concomitant valve disease,
AV surgery may be considered in asymptomatic patients
provide important prognostic information that may influence manage-
with severe AR and LVESDi ment.284 Staging of extravalvular damage has been proposed,53 but
>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2
IIb B it m a y b e d i f fi c u l t t o a t t r i b u t e o t h e r c a r d i a c a b n o r m a l i t ies to AS itself,
[especially in patients with small body size (BSA
because comorbidities are frequent in patients with AS and the
<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical
observed damage may not occur in the expected chronological se-
risk is low. quence. However, the detection of concomitant cardiac conditions
Continued [e.g. HF with preserved EF (HFpEF), amyloidosis, or hypertrophic
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 29 ---
ESC Guidelines 4663
cardiomyopathy] may help to optimize medical treatment before and calculation of LVOT area and may assist evaluation when other para-
after valve intervention.285,286 meters are equivocal (<0.25 suggests that severe AS is highly likely).309
Current European recommendations for the echocardiographic Assessment of GLS can be useful for risk stratification310 and evalu-
grading of AS rely on measurement of the mean pressure gradient ation of extravalvular cardiac damage.311,312 It provides additional infor-
(most robust parameter), peak transvalvular velocity (V ), and effect- mation regarding LV function and a threshold of −15% may contribute
max
ive AVA. Although AVA is theoretically the ideal parameter for asses- to identifying patients with severe asymptomatic AS at increased risk of
sing severity, there are numerous technical limitations associated with clinical deterioration or premature mortality.59
its calculation.284,287 Estimated valvuloarterial impedance has been shown to be prognostic
Aortic stenosis may be further categorized according to flow state of adverse clinical outcomes before and after valve replacement.313–315
based on stroke volume index (SVi) when there is discordance between Transoesophageal echocardiography (TOE) allows morphological
echocardiographic parameters (Figure 6). A threshold of 35 mL/m2 is evaluation of the valve, planimetry of AVA and assessment of potential sub-
conventionally accepted to discern low from normal flow, although valvular obstruction (unless there is acoustic shadowing caused by calcifi-
sex-specific thresholds have been proposed.292 cation), and evaluation of concomitant valve disease, and can be of value for
peri-procedural imaging in challenging clinical or anatomical scenarios.316
Concordant criteria: Natriuretic peptides can be used to arbitrate the sources of symp-
• High-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s, AVA toms in patients with multiple potential causes and help to identify
max
≤1 cm2 (or ≤0.6 cm2/m2)] is considered severe irrespective of LV those with high-risk asymptomatic AS who may benefit from early
function and flow conditions. intervention.97,317
Exercise testing can unmask symptoms and haemodynamic intolerance
Discordant criteria: (fall in BP >20 mm Hg) and is recommended for risk stratification in
• Low-flow, low-gradient AS with reduced LVEF asymptomatic patients with severe AS.102,318 Exercise echocardiography
(mean gradient <40 mmHg, AVA ≤1 cm2, SVi ≤35 mL/m2, LVEF <50%). may provide additional prognostic information by assessing the increase in
• Low-flow, low-gradient AS with preserved LVEF mean pressure gradient and change in LV function.319 Cardiopulmonary
(mean gradient <40 mmHg, AVA ≤1 cm2, SVi ≤35 mL/m2, exercise testing, eventually complemented by echocardiography, can
LVEF ≥50%). help to uncover cardiac dysfunction in asymptomatic patients, discrimin-
• Normal-flow, low-gradient AS with preserved EF ate cardiac from pulmonary limitation or deconditioning in patients with
(mean gradient <40 mmHg, AVA ≤1 cm2, SVi >35 mL/m2, non-specific symptoms, and inform risk stratification.105,106,320,321
LVEF ≥50%). Cardiac magnetic resonance is used to identify altered global LV
• Discordant high-gradient AS (mean gradient ≥40 mmHg, geometry due to remodelling, as well as to quantify myocardial scarring
AVA >1 cm2). and diffuse fibrosis, which are associated with the occurrence of ad-
verse events.322–324
Patients with discordant normal-flow, low-gradient AS usually have
Transthyretin cardiac amyloidosis may coexist with AS in elderly pa-
moderate stenosis.293–295 Discordant high-gradient AS is considered tients and the two conditions may causally interrelate.325 When transthyr-
severe if not caused by a reversible high-flow status.296–298
etin cardiac amyloidosis is suspected, the presence of monoclonal protein
In patients with low-flow, low-gradient AS with reduced LVEF, dobu-
in serum and urine should be excluded using immunofixation and quanti-
tamine stress echocardiography (DSE) can help to discriminate be-
tative determination of free light chains, and diagnosis ascertained by
tween pseudo-severe and true severe AS in the presence of flow means of diphosphonate scintigraphy.326 Despite the limited long-term
reserve (increase in stroke volume of ≥20%).289,299
prognosis associated with cardiac transthyretin amyloidosis, patients
Cardiac computed tomography calcium AV scoring is readily avail- with concomitant severe AS usually benefit from valve intervention.327
able and provides important adjunctive information in patients with
LV catheterization is not recommended unless there are symptoms
low-flow, low-gradient AS because it correlates with haemodynamic
and signs of severe AS, and non-invasive investigations are inconclusive.
severity, progression, and clinical outcomes.300,301 Values of >2000
Agatston units (AU) in men and >1200 AU in women indicate severe
AS with high sensitivity and specificity (∼85%).302,303 While higher 8.2.3. Procedural planning
thresholds (men >3000 AU, women >1600 AU) are very specific, se- Cardiac computed tomography is key to determining suitability for
vere AS becomes unlikely in patients with calcium AV scoring of TAVI and planning the procedure. It is the preferred imaging tool to as-
<1600 AU in men and <800 AU in women.284,302,303 Cautious inter- sess AV anatomy including annulus size, dimensions of the aortic root
pretation is required in patients who can develop severe AS without and ascending aorta, the extent and distribution of valve and LVOT cal-
pronounced AV calcification such as in BAV, concomitant amyloidosis, cification, the distance of coronary ostia from the annular plane, optimal
and predominantly fibrotic stenosis associated with post-rheumatic, fluoroscopic projections for transcatheter valve deployment, and the
radiation-induced and inflammatory disease.304–308 feasibility of vascular access.49,328,329
In low-flow, low gradient AS with reduced LVEF, CCT AV calcium Transoesophageal echocardiography (TOE), which is more operator-
scoring and DSE provide complementary information. If findings are dependent and does not allow assessment of coronary and peripheral
equivocal, an integrated assessment considering all available clinical, vascular anatomy, or CMR may be considered when CCT is difficult to in-
morphological, and haemodynamic factors is required. terpret or relatively contraindicated (e.g. in patients with renal failure).330,331
8.2.2. Additional diagnostic and prognostic 8.3. Medical therapy
parameters No medical therapies have been shown to influence the natural
The ratio of the LVOT to the AV Doppler jet velocity time integral history of AS to date. Neither statins, which demonstrated
(VTI, dimensionless index or velocity ratio) does not require favourable effects in pre-clinical studies,332–334 nor substances
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 30 ---
4664 E S C G u id e l in e s
Patient with suspected AS
Vmax ≥4 m/s and mean PG ≥40 mmHg
AVA ≤1 cm2 AVA ≤1 cm2
(AVAi ≤0.6 cm2/m2) (AVAi ≤0.6 cm2/m2)
Non-severe AS
Exclude measurement errorsa
Reversible
SVi ≤35 mL/m2 high flowb
Normal flow
low-gradient AS
Reassess under
(severe AS less likely)c
normal flow
LVEF ≥50%
AVCS DSE with flow reserved and AVA ≤1 cm2
>1200 AU (female) and/ore
>2000 AU (male) AVCS >1200 AU (female) >2000 AU (male)
DSE with flow reserved
and AVA >1 cm2
Integrated
Severe AS Pseudo-severe AS Severe AS
assessmentf
Figure 6 Integrative imaging assessment of patients with aortic stenosis. AS, aortic stenosis; AU, Agatston units; AV, aortic valve; AVA, aortic valve
area; AVAi; aortic valve area indexed for body surface area; AVCS, aortic valve calcium score; CCT, cardiac computed tomography; CT, computed
tomography; DSE, dobutamine stress echocardiography; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MRI, magnetic
resonance imaging; mean PG, mean pressure gradient; SVi, stroke volume indexed for BSA; TOE, transoesophageal echocardiography; TTE, transthor-
acic echocardiography; V , peak transvalvular velocity. aIn particular, verify LVOT diameter and multiwindow Doppler interrogation. bHigh flow may
max
be reversible (anaemia, hyperthyroidism, or arteriovenous fistulae). Upper limit of normal flow using pulsed Doppler: cardiac index 4.3 L/min/m2, SVi
58 mL/m2.288 cAvailable evidence refers to patients with preserved LVEF. Check for bradycardia or uncontrolled hypertension, which may lead to pro-
longed ejection time and reduced flow rate. Depending on symptoms, integrated assessment complemented by CCT AV calcium scoring may be pur-
sued. dFlow reserve: ≥20% increase in stroke volume in response to low-dose dobutamine or if change in stroke volume of 10%–20%, calculate
projected AVA.289,290 eIf one test is not conclusive, complement diagnostics with the other test. fBased on clinical judgement (typical symptoms without
other explanation), morphological valve changes, LV hypertrophy (in absence of coexistent hypertension), and consistent findings using different modes
of assessment [TTE and TOE, invasive assessment, AV planimetry by CT or MRI (cut-off 1.2 cm2)]291.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 31 ---
ESC Guidelines 4665
targeting calcification pathways alter disease progression.335,336 This approach is reinforced if additional adverse prognostic features
Coexistent hypertension should be treated to avoid additional after- (very high V ,14,353,364 elevated natriuretic peptides,97,317,365,366 se-
max
load, preferably using renin-angiotensin system blockers, although vere valve calcification,303,364 rapid V progression,353,364 or LVEF
max
careful titration is required to avoid symptomatic hypotension.337 of <55%14,354,356–359) are present. Restricted local resources (that
In patients with symptomatic severe AS and HF, initiation of medical may impede close surveillance) or long waiting lists (that preclude
therapy or temporary improvement in symptoms should not delay prompt treatment when symptoms develop) are further arguments fa-
intervention. Medication frequently requires re-adjustment following vouring an early intervention.
valve intervention and preventive therapies should be implemented The Evaluation of TAVR Compared to Surveillance for Patients with
according to current Guidelines.338 In patients with persisting HF Asymptomatic Severe Aortic Stenosis (EARLY TAVR) trial360 rando-
and/or reduced LVEF, medical therapy should be introduced before mized 901 patients to early TAVI or clinical surveillance and demonstrated
and up-titrated after valve intervention according to the current HF a reduction of 50% in the primary composite endpoint of all-cause mor-
Guidelines.339,340 tality, stroke, or unplanned hospitalization for cardiovascular causes asso-
ciated with pre-emptive intervention.360 The result was driven by 26.2%
of the patients in the clinical surveillance group who converted to TAVI
8.4. Indication for intervention
within 6 months of randomization due to the development of symptoms
8.4.1. Symptomatic severe aortic stenosis
or adverse prognostic factors. There was no significant difference in
Symptomatic severe AS has an unfavourable prognosis if left untreated, strokes and all-cause mortality over 5-year follow-up.
and early intervention is strongly recommended in all patients with an In the Early Valve Replacement Guided by Biomarkers of LV
estimated life expectancy exceeding 1 year10 (Figure 7). Decompensation in Asymptomatic Patients with Severe AS
Intervention is recommended in all eligible symptomatic patients (EVoLVeD) RCT, which included 224 asymptomatic patients with se-
with high-gradient severe AS. However, management of patients with vere AS and myocardial fibrosis (late gadolinium enhancement on
low-gradient AS is more challenging: CMR), early valve intervention (with SAVR or TAVI) failed to reduce
the incidence of all-cause death or unplanned AS-related hospitalization
• Low-flow, low-gradient AS with reduced LVEF: reduced LV func-
compared with clinical surveillance.361 However, the study was under-
tion usually improves after intervention if it is predominantly
caused by excessive afterload.341–343 However, improvement is powered and the median time to intervention was prolonged to
5 months in the experimental arm.
unlikely if the primary cause is fibrosis due to myocardial infarction
Two previous smaller trials compared early SAVR with clinical
or cardiomyopathy. Intervention is recommended when severe AS
surveillance. In the Randomized Comparison of Early Surgery vs
is confirmed by CCT (calcium scoring) or stress echocardiog-
raphy,341 while patients with pseudo-severe AS should receive Conventional Treatment in Very Severe Aortic Stenosis
GDMT.339,344 Although the absence of flow reserve is associated (RECOVERY) trial (145 patients), there was a reduction in all-cause
mortality following early SAVR over a mean follow-up of 6.2 years.362
with increased surgical and long-term mortality, both modes of
In the Aortic Valve Replacement Versus Conservative Treatment
intervention improved LVEF and clinical outcomes in observational
studies.341,342,345–347 in Asymptomatic Severe Aortic Stenosis (AVATAR) trial (157
patients), a reduction in the composite primary endpoint was noted
• Low-flow, low-gradient AS with preserved LVEF: outcomes are im-
after a mean follow-up of 2.5 years with a significant reduction in
proved with intervention (either TAVI or SAVR) compared with
HF hospitalizations and mortality at long-term follow-up.363,367
medical treatment alone in patients with low-flow, low-gradient AS
and preserved LVEF.348,349 Intervention should therefore be consid- Limitations of these surgical studies included their small sample sizes,
enrolment of selected young populations at low surgical risk (mean
ered in patients with symptoms after careful confirmation that AS is
ages 64 and 67 years, respectively), and inclusion of patients with most-
severe.
ly very severe AS.
• Normal-flow, low-gradient AS with preserved LVEF: prognosis
A meta-analysis of the four RCTs showed that early intervention is
of these patients is similar to that of moderate AS. Unless
associated with a significant reduction in unplanned cardiovascular or multimodality diagnostic evaluation clearly suggests severe
HF hospitalization and stroke, but not all-cause or cardiovascular mor- AS, regular clinical and echocardiographic surveillance is
recommended.293,294,350 tality. Limitations of this analysis include the heterogeneity of the
pooled trials and lack of granularity with respect to specific events ow-
ing to the study-level analysis.368
8.4.2. Asymptomatic severe aortic stenosis Additional RCTs (NCT04204915 and NCT03972644) will further
Up to 40% of patients with severe AS do not report symptoms at the inform and refine the management of patients with severe asymptom-
time of diagnosis.351,352 In roughly one-third of these, exercise testing atic AS.
can uncover symptoms or reduced exercise capacity attributable to
AS,102,103,318 and such patients should be treated as symptomatic.
However, exercise testing is not always feasible because of frailty or im- 8.4.3. Moderate aortic stenosis
paired mobility.353 Intervention is recommended in asymptomatic pa- Surgical intervention for moderate AS should only be performed in pa-
tients with severe AS and an LVEF of <50% without another tients undergoing CABG,369 surgery of the ascending aorta or other
cause.14,102,318,319,354–360 For patients with severe high-gradient AS valve disease (see Section 13). There is evidence of an association be-
and no adverse prognostic features, close active clinical surveillance, tween moderate AS and adverse outcomes in patients with and with-
so-called ‘watchful waiting’, has previously been the default manage- out HF with reduced EF (HFrEF),370–372 but it is unknown whether
ment strategy. However, four RCTs comparing early AV intervention this is causal or related to comorbidities. In an early terminated trial ran-
with clinical surveillance suggest that early intervention should be domizing 178 patients with moderate AS and HFrEF to TAVI or clinical
considered as an alternative in patients at low procedural risk.360–363 surveillance, no differences with respect to hard clinical endpoints were
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 32 ---
4666 E S C G u id e l in e s
Patients with severe ASa
Symptomsb
LVEF <50% without another cause
Presence of one or more of the following:
• High-gradient AS
• Severe valve calcificationc and V progression ≥0.3 m/s/year
max
• Elevated BNP or NT-proBNP levels attributable to ASd
• LVEF <55% attributable to AS
• Exercise test with sustained fall in BP >20 mmHg
Low procedural risk
Intervention
(Class IIa)
Close active surveillancee Heart Team evaluationf
(Class I)
Patients ≥70 years
All remaining
Patients <70 years with a tricuspid
candidates for
if surgical risk is low aortic valve
a bioprosthesis
if anatomy is suitable
SAVR SAVR or TAVI TAVI
(Class I) (Class I) (Class I)
Figure 7 Management of patients with severe aortic stenosis. AS, aortic stenosis; AVCS, aortic valve calcium score; BNP, brain natriuretic peptide; BP,
blood pressure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replace-
ment; TAVI, transcatheter aortic valve implantation; V , peak transvalvular velocity. aIntegrative imaging assessment of AS (Figure 6). bConfirmed
max
by a normal exercise test, if feasible. cAVCS >2000 in men, >1200 in women. dMore than three times age- and sex-corrected normal range.
eEducate patient and reassess at least every 6 months (or promptly if symptoms occur). fHeart Team assessment based upon individual patient factors
(Figure 9; Recommendation Table 4). Dashed arrow only applies to asymptomatic patients.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 33 ---
ESC Guidelines 4667
(cid:144)(cid:157) (cid:157)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:23)(cid:22)(cid:28)(cid:21)(cid:25)(cid:23)(cid:25)(cid:20)(cid:19)(cid:25)(cid:18)(cid:29)(cid:26)(cid:17)(cid:18)(cid:16)
(cid:11)(cid:5)(cid:25)(cid:23)(cid:9)(cid:16)(cid:25)(cid:26)(cid:6)(cid:30)(cid:3)
(cid:31)(cid:30)(cid:29)(cid:29) (cid:16)(cid:25)(cid:26)(cid:15)(cid:18)(cid:17)(cid:21)(cid:26)(cid:18)(cid:14) (cid:12)(cid:21)(cid:30)(cid:28)(cid:27)(cid:30)(cid:29)(cid:19)(cid:15)(cid:25)(cid:29)(cid:21)(cid:29)
(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:24)(cid:23)(cid:27)(cid:25) (cid:13)(cid:18)(cid:14)(cid:13)(cid:25) (cid:127)(cid:11)(cid:129)(cid:141)(cid:23)(cid:13)(cid:6)(cid:23)(cid:15)(cid:11)(cid:129)(cid:143)
(cid:22)(cid:21)(cid:20)(cid:21)(cid:19)(cid:18)(cid:19)(cid:21)(cid:30)(cid:17)(cid:29) (cid:15)(cid:25)(cid:18)(cid:14)(cid:17)(cid:28)(cid:18)(cid:26)(cid:22)(cid:23)(cid:18)(cid:13)(cid:27)(cid:19)(cid:22)(cid:25)(cid:20)(cid:28)(cid:29)(cid:16) (cid:12)(cid:11)(cid:10)(cid:23)(cid:9)(cid:25)(cid:27)(cid:8)(cid:13)(cid:22)(cid:28)(cid:18)(cid:7)(cid:14)(cid:26)(cid:25)(cid:27)(cid:13)(cid:6)(cid:6)(cid:14)(cid:26)(cid:5)(cid:28)(cid:18)(cid:23)(cid:6)(cid:28)(cid:30)(cid:4)(cid:3) (cid:2)(cid:28)(cid:27)(cid:28)(cid:29)(cid:25)(cid:24)(cid:23)(cid:24)(cid:1)(cid:6)(cid:26)(cid:8)(cid:28)(cid:22)(cid:28)(cid:29)(cid:16)
Figure 8 Aortic valve treatment options. OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve
implantation.
found, while patients undergoing TAVI had improved quality of 8.5.1. The mode of intervention in candidates for a
life (change in KCCQ of 12.8 ± 21.9 points vs 3.2 ± 22.8 points; bioprosthesis
P = 0.018).373 Ongoing trials are expected to provide new insights The two modes of BHV replacement, TAVI and SAVR, have been com-
(NCT04889872 and NCT05149755). pared in RCTs across the spectrum of surgical risk in predominantly
elderly patients with tricuspid AS.
In patients unsuitable for surgery, TAVI was superior to medical
8.5. Treatment options
therapy with a number-needed-to-treat of five to prevent one death
The mode of AV intervention depends on the estimated life expect- at 1-year follow-up.388 Subsequently, RCTs showed non-inferiority of
ancy, expected prosthesis durability, patient preference, and specific TAVI compared with SAVR in patients at high,389–391 intermedi-
trade-offs associated with different treatment options (Figure 8). ate,3,392,393 and low surgical risk,1,394,395 with comparable longer-term
Most patients with AS undergoing valve intervention in Europe and
outcomes demonstrated during follow-up periods ranging from 4 to
North America receive a BHV (by either SAVR or TAVI).374 BHVs
10 years.2,4,396–398 Of note, the majority of patients included in
do not require long-term anticoagulation but have limited durability
RCTs were male, while patients with low-flow low-gradient AS or ad-
that varies between devices and is inversely associated with age.375
verse anatomical characteristics (including BAVs or complex CAD)
MHVs are durable but require long-term anticoagulation, with asso-
were excluded per protocol.
ciated thromboembolic and bleeding risks.260,376 In general, an MHV
Meta-analyses of RCTs show a risk reduction in all-cause death and
should be preferred in patients aged <60 years and a BHV in patients
disabling stroke with TAVI in low-risk patients at 1 year, but no differ-
aged >65 years in aortic position (see Section 14.1).
ences to SAVR at longer-term follow-up or in patients at intermediate
The Ross procedure (replacement of the AV with the patient’s pul-
or high surgical risk.399,400 The early benefit of TAVI in low-risk patients
monary autograft combined with homograft pulmonary valve
has since been corroborated in the investigator-initiated Randomized,
replacement) is associated with excellent long-term survival when per-
formed in selected patients at centres with high expertise.260,263,377,378 Multicenter, Event-Driven Trial of TAVI vs SAVR in Patients with
Symptomatic Severe Aortic-Valve Stenosis (DEDICATE), which met
Although a valuable surgical option in young patients with prolonged life
its non-inferiority target with a composite of death and stroke rate at
expectancy in whom anticoagulation is undesirable or contraindicated,
1 year of 5.4% in the TAVI group vs 10.0% in the SAVR group [hazard
it is associated with procedural complexity and the need for reinterven-
tion in ∼15% of patients within 15 years (Figure 8).263,377 ratio (HR), 0.53; 95% confidence interval (CI), 0.35–0.79] and all-
Balloon aortic valvuloplasty may be rarely considered as a bridge to cause death rates of 2.6% and 6.2% (HR 0.43; 95% CI, 0.24–0.73),
TAVI or SAVR in carefully selected patients with decompensated AS,
respectively.395
and in those with severe AS who require urgent high-risk non-cardiac Rates of vascular complications and paravalvular leak (PVL) are con-
surgery (NCS) (see Section 15.2.1). The procedure carries significant sistently higher after TAVI despite refined transcatheter heart valve
risks of acute complications.379 (THV) designs, whereas severe bleeding, acute kidney injury, and new-
A substantial increase in the number of patients undergoing AV inter- onset AF are more frequent after SAVR.2,4,399,401 Even though PVL has
vention has been observed over the past decade as a consequence of the been associated with adverse clinical outcomes,402,403 it does not seem
introduction of TAVI, improved diagnostic techniques, and evolving indi- to impact the comparison of clinical outcomes between TAVI and
cations for intervention.374,380–383 Nevertheless, there is still wide vari- SAVR in RCTs.2,4,395
ation in worldwide access to TAVI as a result of high device costs in New pacemaker implantations are more frequent after TAVI, par-
comparison with surgical prostheses and variation in healthcare re- ticularly when using self-expanding valves.3,394,404 Conflicting data exist
sources and reimbursement systems between countries.384–386 In add- regarding the long-term impact of new pacemaker implantation or
ition, registries suggest that late referral and undertreatment remain new-onset left bundle branch block following AV intervention.405–407
frequent.12,387 Patients undergoing TAVI have quicker recoveries, shorter hospital
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 34 ---
4668 E S C G u id e l in e s
stays, and more rapid improvements in quality of life compared with In contrast, anatomical findings such as porcelain aorta, severe chest
those who undergo SAVR.1,2,408,409 deformation, or intact grafts post-CABG favour TAVI. Right anterior
Available data do not suggest systematic differences in durability be- thoracotomy or upper hemisternotomy are minimally invasive access
tween the two treatment modalities. Randomized controlled trials and alternatives to sternotomy for performing SAVR, which are being
observational studies have reported comparable rates of BHV failure re- used with increasing frequency.426,427
lated to SVD with transcatheter and surgical valves up to 10 years.2,398,410 In BAV patients, severe AS usually occurs earlier compared with tri-
However, potential selection and survival bias, the use of variable defini- cuspid AV and is frequently associated with aortopathy.219,281,428
tions of SVD, limited follow-up durations, differential attrition Prevalence of BAV anatomy sharply increases in younger AS pa-
rates,2,4,396,400 competing risk of death, and the use of multiple valve tients.429 BAV anatomy adds complexity to TAVI because of asymmet-
types in the surgical arms of RCTs may limit direct comparison.411 ric AV calcification and elliptical annular shape, as well as the lack of
Although conclusive evidence is still lacking, concomitant non- standardization of valve sizing.
complex CAD can be addressed either by CABG or PCI, while Patients with BAV have been excluded from almost all landmark
complex CAD favours CABG (see Section 6.1). In the only RCT com- RCTs comparing TAVI with SAVR to date.429,430 In the NOTION 2
paring these two strategies, the transcatheter valve and vessels trial, the composite of all-cause death, stroke, or valve- or HF-related
(TCW) trial, randomization of patients with severe AS and concomi- rehospitalization was numerically more frequent (seven vs two events)
tant CAD to FFR-guided PCI plus TAVI resulted in fewer deaths and at 1 year in the underpowered subgroup of 100 patients with BAV (HR,
major bleeding events compared with combined SAVR plus CABG at 3.8; 95% CI, 0.8–18.5; P = 0.07).416 Whereas some observational studies
12 months.412 However, inferences from trial results are limited due report favourable outcomes with TAVI in selected BAV patients,430–432
to early termination, modest sample sizes, event rates deviating from others suggest higher stroke, annular rupture, and PVL rates as com-
those observed in registries and other RCTs, and a low prevalence of pared with TAVI in tricuspid AS.433 Heavy cusp calcification, particularly
complex CAD. in conjunction with a calcified raphe, is associated with increased risk
of aortic root injury, PVL, and mortality after TAVI.434 Data on TAVI
in two-sinus BAV (Sievers type 0) are scarce.219,435
8.5.1.1. Age and life expectancy
For the above-mentioned reasons, SAVR remains the primary mode
The relationship between estimated life expectancy and prosthetic heart
of treatment for stenotic BAV, particularly if patients are young or have
valve durability determines the likelihood of a future reintervention.
coexistent aortopathy or unfavourable valve morphology. TAVI may be
Although life expectancy may be a theoretically better guide than age considered in patients at increased surgical risk, if anatomy is suitable.
alone for treatment decisions, it is difficult to estimate for an individual pa- Patients with small annuli in relation to their body stature are at in-
tient owing to large geographical (https://ghdx.healthdata.org/record/ creased risk of prosthesis–patient mismatch (PPM) after valve replace-
ihme-data/gbd-2019-life-tables-1950-2019) and interindividual variabil-
ment. Annular enlargement allows for implantation of larger BHVs
ity.413 In combination with cardiac and extracardiac comorbidities, as
with SAVR. Given its technical complexity it should be performed
well as anatomical factors, age contributes to risk estimation and repre-
in experienced centres, and the benefit must be balanced against a
sents a pragmatic surrogate for life expectancy. In addition, age thresholds possibly higher risk of operative mortality.436 Prostheses with
characterize the populations enrolled in RCTs better than life expectancy. supra-annular design reduce PPM risk with TAVI, although randomized
It is notable that younger patients with AS seem to have lower life expect- long-term data evaluating the impact on clinical outcomes or valve
ancy than the general population despite valve replacement, whereas life durability are pending.394,437,438
expectancy almost normalizes after treatment in older cohorts.414,415
While several trials compared TAVI with SAVR in study populations
aged 70–85 years accross the surgical risk spectrum, the representation 8.5.1.3. Lifetime management
of patients aged <70 years in RCTs is low and therefore evidence
Decision-making concerning the mode of intervention and type of
limited.1,394,395,416
prosthesis needs to integrate expected valve durability, and the poten-
tial risks of future reinterventions (Figure 9). Surgical THV explantation
followed by SAVR is a rare (<1% of all TAVI procedures) but technically 8.5.1.2. Anatomical features
challenging procedure.439–441 Although its incidence among patients
The advantages of TAVI demonstrated in RCTs are largely confined to
undergoing TAVI is stable, absolute numbers are increasing due to
patients treated via the transfemoral approach.401 While SAVR remains
the total increase in TAVI procedures performed and the peri-
the preferred treatment option when iliofemoral artery disease pre-
operative risk remains high (early mortality rates as high as 12%–
cludes transfemoral TAVI, TAVI via a non-transfemoral access (transax-
17%).440–445 The majority of surgical THV explantations are performed
illary, transcarotid, transcaval, transinnominate, or transapical)
in patients at high surgical risk with urgent or emergent,
constitutes an alternative supported by observational data in patients
non-SVD-related indication for reintervention (frequently endocardi-
unsuitable for surgery.417–423
tis) within 2 years after TAVI.440,442–444
Other anatomical factors that favour SAVR or led to exclusion of pa-
Implanting a transcatheter aortic valve inside a surgical (TAV-in-SAV)
tients from RCTs comparing TAVI with SAVR are (Figure 9):
or prior transcatheter valve (TAV-in-TAV) is associated with lower
• Aortic annular dimensions that lie outside sizing recommendations peri-procedural risk compared with redo SAVR.446–451 However,
for currently available transcatheter devices. valve-in-valve implantation (particularly TAV-in-SAV) increases the
• Excessive or bulky calcifications of the annulus or LVOT, which in- risk of severe PPM,448 which has been linked to adverse outcomes in
crease the risk of PVL and annular rupture.424,425 observational studies.452–455 In addition, valve-in-valve implantation im-
• Increased risk of coronary obstruction with TAVI (cusp height greater mobilizes the leaflets of the failed prosthesis in an open position, creat-
than coronary height in combination with shallow sinuses of Valsalva, ing a covered tube (or neo-skirt) that may cause direct coronary
or high calcium burden of corresponding cusp).329 obstruction in patients with shallow sinuses of Valsalva or indirect
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 35 ---
ESC Guidelines 4669
(cid:2)(cid:29)(cid:7)(cid:23)(cid:19)(cid:30)(cid:27)(cid:27)(cid:26)(cid:30)(cid:29)(cid:25) (cid:2)(cid:29)(cid:7)(cid:23)(cid:19)(cid:30)(cid:27)(cid:21)(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)
ƒ(cid:127)(cid:129)(cid:21)(cid:11)(cid:25)(cid:29)(cid:30)(cid:27) (cid:30)(cid:24)(cid:23) ≥(cid:127)(cid:129)(cid:21)(cid:11)(cid:25)(cid:29)(cid:30)(cid:27)
(cid:141)(cid:23)(cid:27)(cid:17)(cid:18)(cid:22)(cid:25)(cid:21)(cid:29)(cid:28)(cid:28)(cid:19)(cid:22)(cid:19)(cid:27)(cid:21)(cid:23)(cid:30)(cid:21)(cid:143)(cid:14)(cid:144)(cid:31)(cid:21)(cid:20)(cid:29)(cid:22)(cid:20)(cid:18)(cid:157)(cid:20)(cid:29)(cid:17)(cid:18)(cid:23)(cid:28) (cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:24)(cid:23)(cid:30)(cid:29)(cid:22)(cid:21)(cid:29)(cid:20)(cid:20)(cid:25)(cid:27)(cid:27)(cid:21)(cid:27)(cid:19)(cid:18)(cid:17)(cid:29)(cid:16)(cid:22)(cid:25)(cid:21)(cid:26)(cid:23)(cid:30)(cid:21)(cid:31)(cid:15)(cid:14)(cid:13)
(cid:18)(cid:20)(cid:19)(cid:27)(cid:10)(cid:18)(cid:5)(cid:21)(cid:29)(cid:23)(cid:30)(cid:17)(cid:18)(cid:20)(cid:21)(cid:7)(cid:29)(cid:22)(cid:7)(cid:25) (cid:30)(cid:22)(cid:21)(cid:20)(cid:19)(cid:18)(cid:17)(cid:16) (cid:12)(cid:23)(cid:30)(cid:20)(cid:25)(cid:22)(cid:29)(cid:18)(cid:28)(cid:21)(cid:29)(cid:23)(cid:30)(cid:17)(cid:29)
(cid:15)(cid:28)(cid:28)(cid:19)(cid:22)(cid:19)(cid:27)(cid:21)(cid:5)(cid:18)(cid:24)(cid:25)(cid:28)(cid:27)(cid:18)(cid:23)(cid:28)(cid:27)(cid:21)(cid:19)(cid:28)(cid:27)(cid:19)(cid:18)(cid:17)(cid:29)(cid:16)(cid:22)(cid:25)(cid:21)(cid:26)(cid:23)(cid:30)(cid:21)(cid:31)(cid:15)(cid:14)(cid:13) (cid:15)(cid:23)(cid:21)(cid:20)(cid:14)(cid:13)(cid:23)(cid:12) (cid:13)(cid:28)(cid:17)(cid:29)(cid:20)(cid:17)(cid:21)(cid:20)(cid:23)(cid:30)(cid:23)(cid:28)(cid:29)(cid:30)(cid:11)(cid:21)(cid:29)(cid:30)(cid:17)(cid:25)(cid:30)(cid:11)(cid:21)(cid:16)(cid:11)(cid:10)(cid:29)(cid:27)(cid:27)(cid:21)(cid:9)(cid:30)(cid:29)(cid:26)(cid:17)(cid:27)
(cid:18)(cid:27)(cid:3)(cid:21)(cid:23)(cid:26)(cid:21)(cid:20)(cid:23)(cid:30)(cid:23)(cid:28)(cid:29)(cid:30)(cid:11)(cid:21)(cid:23)(cid:16)(cid:27)(cid:17)(cid:30)(cid:19)(cid:20)(cid:17)(cid:18)(cid:23)(cid:28) (cid:8)(cid:25)(cid:7)(cid:25)(cid:30)(cid:25)(cid:21)(cid:20)(cid:6)(cid:25)(cid:27)(cid:17)(cid:21)(cid:5)(cid:25)(cid:26)(cid:23)(cid:30)(cid:24)(cid:18)(cid:17)(cid:11)(cid:21)(cid:23)(cid:30)(cid:21)(cid:27)(cid:20)(cid:23)(cid:22)(cid:18)(cid:23)(cid:27)(cid:18)(cid:27)
(cid:144)(cid:17)(cid:6)(cid:25)(cid:30)(cid:21)(cid:30)(cid:25)(cid:22)(cid:25)(cid:7)(cid:29)(cid:28)(cid:17)(cid:21)(cid:10)(cid:30)(cid:18)(cid:24)(cid:29)(cid:30)(cid:11)(cid:21)(cid:14)(cid:141)€ (cid:4)(cid:23)(cid:24)(cid:23)(cid:30)(cid:16)(cid:18)(cid:5)(cid:18)(cid:17)(cid:18)(cid:25)(cid:27)(cid:21)(cid:23)(cid:30)(cid:21)(cid:20)(cid:29)(cid:30)(cid:5)(cid:18)(cid:29)(cid:20)(cid:21)(cid:20)(cid:23)(cid:28)(cid:5)(cid:18)(cid:17)(cid:18)(cid:23)(cid:28)(cid:27)
(cid:4)(cid:23)(cid:24)(cid:10)(cid:22)(cid:25)‚(cid:21)(cid:4)(cid:15)€ (cid:11)(cid:19)(cid:22)(cid:16)(cid:19)(cid:18)(cid:17)(cid:20)(cid:21)(cid:22)(cid:20) (cid:18)(cid:28)(cid:20)(cid:30)(cid:25)(cid:29)(cid:27)(cid:18)(cid:28)(cid:9)(cid:21)(cid:27)(cid:19)(cid:30)(cid:9)(cid:18)(cid:20)(cid:29)(cid:22)(cid:21)(cid:30)(cid:18)(cid:27)(cid:3)
(cid:15)(cid:23)(cid:30)(cid:17)(cid:18)(cid:20)(cid:21)(cid:30)(cid:23)(cid:23)(cid:17)(cid:21)(cid:23)(cid:30)(cid:21)(cid:29)(cid:27)(cid:20)(cid:25)(cid:28)(cid:5)(cid:18)(cid:28)(cid:9)(cid:21)(cid:29)(cid:23)(cid:30)(cid:17)(cid:18)(cid:20)(cid:21)(cid:29)(cid:28)(cid:25)(cid:19)(cid:30)(cid:11)(cid:27)(cid:24) (cid:16)(cid:19)(cid:22)(cid:10)(cid:17)(cid:20)(cid:17)(cid:19)(cid:22)(cid:12)(cid:21) (cid:2)(cid:30)(cid:29)(cid:18)(cid:22)(cid:17)(cid:11)
(cid:8)(cid:25)(cid:10)(cid:17)(cid:29)(cid:22)(cid:21)(cid:6)(cid:11)(cid:10)(cid:25)(cid:30)(cid:17)(cid:30)(cid:23)(cid:10)(cid:6)(cid:11)(cid:21)(cid:30)(cid:25)(cid:1)(cid:19)(cid:18)(cid:30)(cid:18)(cid:28)(cid:9)(cid:21)(cid:24)(cid:11)(cid:25)(cid:20)(cid:17)(cid:23)(cid:24)(cid:11) (cid:8)(cid:25)(cid:1)(cid:19)(cid:25)(cid:22)(cid:29)(cid:25)(cid:21)(cid:23)(cid:26)(cid:21)(cid:20)(cid:6)(cid:25)(cid:27)(cid:17)(cid:21)(cid:30)(cid:29)(cid:5)(cid:18)(cid:29)(cid:17)(cid:18)(cid:23)(cid:28)
(cid:9)(cid:17)(cid:15)(cid:23)(cid:20)(cid:17)(cid:18)(cid:23)(cid:21)(cid:18)(cid:21)(cid:22)(cid:21)(cid:24)(cid:23)(cid:18)(cid:23)(cid:22)(cid:20)(cid:8)
(cid:15)(cid:28)(cid:17)(cid:18)(cid:20)(cid:18)(cid:10)(cid:29)(cid:17)(cid:25)(cid:21)(cid:30)(cid:25)(cid:10)(cid:25)(cid:29)(cid:17)(cid:21)(cid:10)(cid:30)(cid:23)(cid:20)(cid:25)(cid:5)(cid:19)(cid:30)(cid:25)(cid:21)(cid:23)(cid:10)(cid:17)(cid:18)(cid:23)(cid:28)(cid:27)(cid:21)(cid:29)(cid:28)(cid:5)(cid:21)(cid:30)(cid:18)(cid:27)(cid:3)(cid:27)„(cid:21)…(cid:6)(cid:25)(cid:28)(cid:21)(cid:27)(cid:25)(cid:22)(cid:25)(cid:20)(cid:17)(cid:18)(cid:28)(cid:9)(cid:21)(cid:24)(cid:23)(cid:5)(cid:29)(cid:22)(cid:18)(cid:17)(cid:11)(cid:21)(cid:29)(cid:28)(cid:5)(cid:21)(cid:7)(cid:29)(cid:22)(cid:7)(cid:25)(cid:21)(cid:17)(cid:11)(cid:10)(cid:25)(cid:21)(cid:29)(cid:17)(cid:21)(cid:18)(cid:28)(cid:5)(cid:25)‚(cid:21)(cid:10)(cid:30)(cid:23)(cid:20)(cid:25)(cid:5)(cid:19)(cid:30)(cid:25)
(cid:25)(cid:5)(cid:23)(cid:21)(cid:8)(cid:15)(cid:14) †(cid:21)(cid:30)(cid:18)(cid:27)(cid:3)(cid:21)(cid:23)(cid:26)(cid:21)(cid:30)(cid:25)(cid:5)(cid:23)(cid:21)(cid:27)(cid:19)(cid:30)(cid:9)(cid:25)(cid:30)(cid:11)
(cid:8)(cid:15)(cid:14) (cid:21)(cid:29)(cid:26)(cid:17)(cid:25)(cid:30)(cid:21)(cid:31)(cid:15)(cid:14)(cid:13)†(cid:21)(cid:18)(cid:28)(cid:20)(cid:30)(cid:25)(cid:29)(cid:27)(cid:25)(cid:5)(cid:21)(cid:30)(cid:18)(cid:27)(cid:3)(cid:21)(cid:29)(cid:27)(cid:27)(cid:23)(cid:20)(cid:18)(cid:29)(cid:17)(cid:25)(cid:5)(cid:21)…(cid:18)(cid:17)(cid:6)(cid:21)(cid:31)(cid:141)(cid:14)(cid:21)(cid:25)‚(cid:10)(cid:22)(cid:29)(cid:28)(cid:17)(cid:29)(cid:17)(cid:18)(cid:23)(cid:28)
(cid:14)(cid:29)(cid:22)(cid:7)(cid:25)‡(cid:18)(cid:28)‡(cid:7)(cid:29)(cid:22)(cid:7)(cid:25)(cid:21)(cid:31)(cid:15)(cid:14)(cid:13)†(cid:21)(cid:30)(cid:18)(cid:27)(cid:3)(cid:21)(cid:23)(cid:26)(cid:21)(cid:20)(cid:23)(cid:30)(cid:23)(cid:28)(cid:29)(cid:30)(cid:11)(cid:21)(cid:23)(cid:16)(cid:27)(cid:17)(cid:30)(cid:19)(cid:20)(cid:17)(cid:18)(cid:23)(cid:28)„(cid:21)(cid:18)(cid:24)(cid:10)(cid:29)(cid:18)(cid:30)(cid:25)(cid:5)(cid:21)(cid:20)(cid:23)(cid:30)(cid:23)(cid:28)(cid:29)(cid:30)(cid:11)(cid:21)(cid:29)(cid:20)(cid:20)(cid:25)(cid:27)(cid:27)„(cid:21)(cid:10)(cid:30)(cid:23)(cid:27)(cid:17)(cid:6)(cid:25)(cid:27)(cid:18)(cid:27)ˆ(cid:10)(cid:29)(cid:17)(cid:18)(cid:25)(cid:28)(cid:17)(cid:21)(cid:24)(cid:18)(cid:27)(cid:24)(cid:29)(cid:17)(cid:20)(cid:6)
Figure 9 Factors to be considered when selecting the mode of intervention for aortic stenosis. CAD, coronary artery disease; LV, left ventricular;
LVOT, left ventricular outflow tract; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart
valve; VHD, valvular heart disease. aLV thrombus and infective endocarditis are relative contraindications to TAVI and are therefore not listed.
bParticularly relevant for patients in whom the anticipated life expectancy is thought to exceed valve durability.
coronary flow obstruction as a result of sinus sequestration if the as- and, if contemplated, should be performed in carefully selected patients
cending aorta is narrow and the neo-skirt reaches the sinotubular at experienced centres (Table 6).463,464
junction.456,457 The need for a meticulous CT-based anatomical analysis is para-
The risk of coronary obstruction varies considerably depending on mount in patients with an estimated life expectancy exceeding the
the index valve type, and is particularly increased if a stentless SAV or assumed valve durability to anticipate future risks at the time of
stented SAV with externally mounted leaflets is in place.457 The risk the index valve intervention. Based on individual assessment, the
of sinus sequestration at the time of TAV-in-TAV implantation is par- following measures should be considered with respect to lifetime
ticularly increased in supra-annular valves with a high neo-skirt.458,459 management:
Even if coronary flow is preserved, coronary access may be difficult
• Use of surgical and transcatheter valves with proven long-term dur-
or impossible in a relevant proportion of patients after valve-in-valve ability to reduce the likelihood of reintervention.2,4,375,410,411,465–467
implantation, especially after TAV-in-TAV.460–462 • SAVR with aortic root enlargement or implantation of a supra-annular
In patients who require a reintervention due to dysfunction of a sur- transcatheter valve in patients with a small annulus at risk of severe
gical or transcatheter bioprosthesis, but are at increased risk of severe PPM based on the predicted effective orifice area (EOA).436,438,468,469
PPM or coronary obstruction, redo SAVR may be preferable despite • No implantation of stentless prostheses or prostheses with external-
the increased surgical risk. Fracture of surgical valves and leaflet modi- ly mounted leaflets in patients at risk of coronary obstruction during
fication techniques have been proposed for patients at high surgical risk future TAV-in-SAV implantation.457
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 36 ---
4670 E S C G u id e l in e s
• Anticipation of the feasibility and risks of a possible future TAV-in-TAV transfemoral access is feasible, to reduce the risk of early adverse out-
procedure considering related technical aspects at the index TAVI comes and accelerate recovery.
(device choice, neo-skirt height, commissural alignment, and implant- For all other candidates for a bioprosthesis, the most appropriate
ation depth).456,470 mode of intervention should be carefully selected by the Heart
Team, taking into account procedural risk based on anatomical charac-
Considering life-time management aspects and the scarcity of rando- teristics and comorbidities, expected outcomes, lifetime management
mized data in patients younger than 70 years, SAVR remains the pre- considerations, and patient preference (Figure 9; Recommendation
ferred treatment in patients <70 years of age if surgical risk is low. Table 4). Recommendations for concomitant valve replacement at
TAVI is recommended as the primary treatment modality in elderly pa- the time of CABG or ascending aortic surgery are listed in
tients ≥70 years of age with a tricuspid AV, if anatomy is suitable and Recommendation Table 5.
Recommendation Table 4 — Recommendations on indications for intervention in symptomatic and asymptomatic severe
aortic stenosis, and recommended mode of intervention (see also Supplementary data online, Evidence Tables 9–13)
Recommendations Classa Levelb
Symptomatic patients with severe aortic stenosis
Intervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s,
max I B
AVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)].388,471–474
Intervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF
I B
(<50%) after careful confirmation that AS is severe.342,345,346,348,475
Intervention should be considered in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with normal
IIa B
LVEF (≥50%) after careful confirmation that AS is severe.c 293,348,349,476–481
Asymptomatic patients with severe aortic stenosis
Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.14,354–359 I B
Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS
IIa A
and LVEF ≥50% as an alternative to close active surveillance, if the procedural risk is low.360–363,367,368
Intervention should be considered in asymptomatic patients with severe AS and LVEF ≥50% if the procedural risk is low and one of the
following parameters is present:
• Very severe AS (mean gradient ≥60 mmHg or V >5.0 m/s).14,362,363,482–484
max
• Severe valve calcification (ideally assessed by CCT) and V progression ≥0.3 m/s/year.303,353,364 IIa B
max
• Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confirmed on repeated
measurement without other explanation).97,365
• LVEF <55% without another cause.14,354,356–359
Intervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP (>20 mmHg) during exercise testing. IIa C
Mode of intervention
It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have
I C
on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team.
It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural
I C
characteristics, incorporating lifetime management considerations and estimated life expectancy.
TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.d 1–4,389–397,465,485,486 I A
SAVR is recommended in patients <70 years of age, if the surgical risk is low.e 413,429,487 I B
SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.2,4,396,397,429,488–490 I B
Non-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.417–423,491–498 IIa B
TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is
IIb B
suitable.430–432,434,499–502
Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those
IIb C
with severe AS who require urgent high-risk NCS.
AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; BAV, bicuspid aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; BP, blood pressure; BSA, body surface area;
CCT, cardiac computed tomography; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; NCS, non-cardiac surgery; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI,
transcatheter aortic valve implantation; Vmax, peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
cExplanations (such as measurement errors, uncontrolled blood pressure, and conditions lowering the stroke volume) other than severe AS for a small AVA but low gradient despite
preserved LVEF are frequent and must be carefully excluded.
dSuitability regarding transfemoral access, annulus dimensions, device landing zone calcification pattern, and coronary obstruction risk (Figure 9).
eSurgical risk based on STS-PROM (http://riskcalc.sts.org/stswebriskcalc/#/calculate) and EuroSCORE II (http://www.euroscore.org/calc.html) <4% and Heart Team assessment.
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 37 ---
ESC Guidelines 4671
Recommendation Table 5 — Recommendations on in- 9.1. Primary mitral regurgitation
dications for concomitant aortic valve replacement at
9.1.1. Prevalence and aetiology
the time of coronary artery bypass grafting or ascending
aorta surgery Primary mitral regurgitation relates to an anatomical lesion of one or
more of the three main components (not including the annulus) of the
Recommendations Classa Levelb MV apparatus (valve leaflets, chordae tendineae, and papillary muscles).
PMR is observed in 55% of patients with MR who require treatment.507
SAVR is recommended in symptomatic and
While degenerative disease related to fibroelastic deficiency or myxoma-
asymptomatic patients with severe AS undergoing
I C tous alterations (in its most severe form, Barlow’s disease) are the most
CABG or surgical intervention on the ascending
common aetiologies in higher-income countries, RHD is most frequently
aorta.
found in the rest of the world. MV endocarditis is a separate entity of PMR
SAVR should be considered in symptomatic and caused by acute or chronic infectious conditions and is discussed in the
asymptomatic patients with moderate ASc corresponding Guidelines.5 In a small subgroup of patients, PMR is asso-
IIa C
undergoing CABG or surgical intervention on the ciated with a higher incidence of ventricular arrhythmias, and sudden car-
ascending aorta. diac death has been reported in individual cases, especially in patients with
Barlow’s disease.508 The arrhythmogenic burden is independent from MR
AS, aortic stenosis; AVA, aortic valve area; CABG, coronary artery bypass grafting; SAVR,
severity and has been associated with mitral annular disjunction. Atrial dis-
surgical aortic valve replacement.
aClass of recommendation. placement of the posterior MV leaflet hinge point is assumed to cause ex-
bLevel of evidence. cessive mobility of the valvular apparatus and increases tension on the
cDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in
papillary muscles and the posterobasal myocardium, causing local fibrosis,
normal-flow conditions. Clinical assessment is essential to determine whether SAVR is
appropriate for an individual patient. which may lead to ventricular arrhythmias and sudden cardiac death.509
9.1.2. Evaluation
8.6. Follow-up
9.1.2.1. Echocardiography and right heart catheterization
The rate of progression of AS varies widely and asymptomatic patients,
Echocardiography is the diagnostic method of choice for the quantifica-
their family, and medical caregivers need careful education, with particu-
tion of MR, determination of its aetiology, and identification of cardiac
lar emphasis on the importance of regular follow-up (ideally at a Heart
consequences (Figure 10). TTE is used for initial evaluation that includes:
Valve Centre)14 and prompt reporting of symptoms. Asymptomatic pa-
(i) assessment of valve morphology (presence and location of prolapse
tients with severe AS should be followed up at least every 6 months to
or flail, calcifications, and/or mitral annular disjunction); (ii) integrative
allow detection of early symptoms (using exercise testing if complaints
severity grading; and (iii) quantification of LV and LA dimensions and
are inconclusive) and any change in echocardiographic parameters (par-
function, as well as assessment of concomitant RV dysfunction.46
ticularly LVEF). Serial measurements of natriuretic peptides can provide
Quantitative parameters such as the effective regurgitant orifice area
additional useful information regarding the timing of treatment.
(EROA) have prognostic implications.510,511 Volumetric methods pro-
Younger patients with mild AS and no significant leaflet calcification
vide additional information on MR severity [RVol and regurgitant frac-
may be followed up every 2–3 years. With increasing stenosis severity,
tion (RF)].512 Accurate colour flow settings must be used to avoid
progression accelerates and follow-up intervals should be gradually re-
overestimation of MR severity.
duced.283,503 Several studies suggest that the prognosis of moderate de-
Transoesophageal echocardiography (TOE) represents the method of
generative AS is worse than previously considered,504,505 particularly if
choice to assess valve anatomy, leaflet quality, motion, and coaptation, as
there is significant valve calcification, and these patients should be re- well as to confirm MR severity.513 Three-dimensional TOE provides an
evaluated at least annually.
excellent morphological and functional view of the different valve seg-
Cardiac rehabilitation is frequently performed after AV intervention,
ments, and should be used systematically when planning and performing
especially after surgery and in elderly patients, and is associated with im- surgical or transcatheter repair.514
proved activities of daily living and 6-minute walking distance.506 After
Exercise echocardiography evaluates dynamic changes in regurgitant jet
valve intervention, an early echocardiographic examination within the
and pulmonary pressures during peak exercise, and might be helpful in pa-
first weeks after valve replacement is recommended to document base-
tients with discordant symptoms and regurgitation severity at rest.515,516
line prosthetic valve function. Cardiological evaluations and echocardio-
In asymptomatic patients with severe PMR, increased LV or LA di-
graphic examinations are recommended annually in patients with a
mensions, as well as elevated pulmonary pressures (>50 mmHg at
bioprosthesis, and whenever changes in clinical symptoms or signs sug-
rest), moderate or more secondary TR, and AF are important markers
gestive of valve dysfunction are noted.
of worse prognosis, and should be considered for intervention timing
(Figure 11; Section 9.1.4).517,518
Right heart catheterization remains important in patients with PMR
9. Mitral regurgitation
for confirmation of pulmonary artery pressures in case of discrepancy
between echocardiographic MR severity and clinical symptoms, as well
Chronic MR is one of the most common acquired valve patholo-
gies,12,187 while acute MR is observed in the context of infective endo- as in the presence of concomitant lung disease.519
carditis, chordal rupture, or as a complication of myocardial infarction
(papillary muscle rupture). MR either relates to anatomical changes of 9.1.2.2. Biomarkers
the MV apparatus (primary), or to LV or LA dilatation and dysfunction Cardiac biomarkers are recognized indicators of disease
(secondary).193 Since natural history, prognosis, and management differ severity with prognostic implications, but may also be non-
according to aetiologies, populations should be clearly distinguished in specific. NT-proBNP levels are directly related to the
clinical practice and research.12,507 New York Heart Association (NYHA) functional class in PMR.520
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 38 ---
4672 E S C G u id e l in e s
“(cid:5)(cid:29)(cid:30)(cid:28)(cid:24)(cid:29)(cid:24)(cid:28)(cid:13)(cid:26)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:30)(cid:27)(cid:30)(cid:26)(cid:29)(cid:25)(cid:26)(cid:24)(cid:23)(cid:27)(cid:30)(cid:29)(cid:22)(cid:21)(cid:26)(cid:27)(cid:20)(cid:19)(cid:29)(cid:18)(cid:24)(cid:29)(cid:24)(cid:28)(cid:19)(cid:17)(cid:27)(cid:16)(cid:26)(cid:15)(cid:26)(cid:20)(cid:24)(cid:23)(cid:27)(cid:14)(cid:26)(cid:13)(cid:26)(cid:22)(cid:26)(cid:27)(cid:24)(cid:26)(cid:17)(cid:24)(cid:28)(cid:17)(cid:21)
(cid:12)(cid:29)(cid:22)(cid:21)(cid:26)(cid:27)(cid:20)(cid:26)(cid:17)(cid:24)(cid:22)(cid:29)(cid:30)(cid:27)(cid:11)(cid:26)(cid:24)
(cid:12)(cid:29)(cid:22)(cid:21)(cid:26)(cid:27)(cid:10)(cid:19)(cid:30)(cid:19)(cid:14)(cid:9)(cid:14)(cid:24)(cid:19)(cid:30)(cid:28)(cid:20)(cid:27)(cid:20)(cid:19)(cid:17)(cid:13)(cid:26)(cid:22)(cid:21)(cid:26)(cid:17)(cid:20)(cid:26)(cid:27)(cid:8)(cid:19)(cid:17)(cid:26)
(cid:2)(cid:20)(cid:10)(cid:19)(cid:20)(cid:29)(cid:22)(cid:16)(cid:28)(cid:19)(cid:21)(cid:22)(cid:29)(cid:18)(cid:10)(cid:28)(cid:20)
„(cid:26)(cid:4)(cid:28)(cid:1)”(cid:5)(cid:29)(cid:17)(cid:24)(cid:28)(cid:24)(cid:29)(cid:24)(cid:28)(cid:13)(cid:26)
(cid:20)(cid:22)(cid:28)(cid:24)(cid:26)(cid:22)(cid:28)(cid:29)(cid:27)(cid:15)(cid:19)(cid:22)(cid:27)(cid:14)(cid:26)(cid:13)(cid:26)(cid:22)(cid:26)(cid:27)Ž‘
(cid:7)(cid:26)(cid:17)(cid:29)(cid:27)(cid:20)(cid:19)(cid:17)(cid:24)(cid:22)(cid:29)(cid:20)(cid:24)(cid:29)(cid:27)≥7 mm (≥8 mm for biplane)
(cid:6)(cid:5)(cid:30)(cid:4)(cid:19)(cid:17)(cid:29)(cid:22)(cid:9)(cid:27)(cid:13)(cid:26)(cid:28)(cid:17)(cid:27)(cid:14)(cid:9)(cid:14)(cid:24)(cid:19)(cid:30)(cid:28)(cid:20)(cid:27)(cid:25)(cid:19)(cid:3)(cid:27)(cid:22)(cid:26)(cid:13)(cid:26)(cid:22)(cid:14)(cid:29)(cid:30)
(cid:2)(cid:1)(cid:3)(cid:29)(cid:13)(cid:26)(cid:27)(cid:16)(cid:19)(cid:4)(cid:28)(cid:17)(cid:29)(cid:17)(cid:24)(cid:27)(cid:127)(cid:129)(cid:141)(cid:143)(cid:144)(cid:27)(cid:4)(cid:157)(cid:14)
(cid:7) €(cid:27)(cid:4)(cid:28)(cid:24)(cid:22)(cid:29)(cid:30)(cid:27)(cid:157)(cid:27)(cid:7) €(cid:27)(cid:12)(cid:7)‚ (cid:27)(cid:129)(cid:141)(cid:143)ƒ
“(cid:5)(cid:29)(cid:17)(cid:24)(cid:28)(cid:24)(cid:29)(cid:24)(cid:28)(cid:13)(cid:26)
(cid:2)‘‚ˆ ≥40 mm2 (or ≥30 mm2 if elliptical regurgitant orifice area)
‘(cid:7)(cid:19)(cid:30)(cid:27)≥•†(cid:27)(cid:4)(cid:12)(cid:27)(cid:127)(cid:19)(cid:22)(cid:27)≥ƒ‡(cid:27)(cid:4)(cid:12)(cid:27)(cid:28)(cid:15)(cid:27)(cid:30)(cid:19)(cid:3)(cid:27)(cid:25)(cid:19)(cid:3)(cid:27)(cid:20)(cid:19)(cid:17)(cid:16)(cid:28)(cid:24)(cid:28)(cid:19)(cid:17)(cid:14) (cid:27)
ˆ(cid:14)(cid:14)(cid:26)(cid:14)(cid:14)(cid:4)(cid:26)(cid:17)(cid:24)(cid:27)(cid:19)(cid:15)(cid:27)Ž‘
‘(cid:31)(cid:27)≥‡†–(cid:27)
‹(cid:22)(cid:28)(cid:24)(cid:26)(cid:22)(cid:28)(cid:29)(cid:27)(cid:15)(cid:19)(cid:22)(cid:27)(cid:28)(cid:17)(cid:24)(cid:26)(cid:22)(cid:13)(cid:26)(cid:17)(cid:24)(cid:28)(cid:19)(cid:17)
(cid:12)(cid:26)(cid:15)(cid:24)(cid:27)(cid:13)(cid:26)(cid:17)(cid:24)(cid:22)(cid:28)(cid:20)(cid:30)(cid:26) (cid:12)(cid:26)(cid:15)(cid:24)(cid:27)(cid:29)(cid:24)(cid:22)(cid:28)(cid:5)(cid:4) ‘(cid:28)(cid:21)(cid:10)(cid:24)(cid:27)(cid:10)(cid:26)(cid:29)(cid:22)(cid:24)
…(cid:28)(cid:29)(cid:4)(cid:26)(cid:24)(cid:26)(cid:22)(cid:27)≥‡‡(cid:27)(cid:4)(cid:4) „(cid:6)ˆ(cid:6)(cid:27)>‡†(cid:27)(cid:4)(cid:4)’(cid:21)(cid:27)
(cid:12)(cid:7)(cid:2)„…(cid:27)≥ƒ†(cid:27)(cid:4)(cid:4)
(cid:6)Ž‘ (cid:12)ˆ(cid:7)€(cid:27)≥60 mL/m2 „(cid:26)(cid:20)(cid:19)(cid:17)(cid:16)(cid:29)(cid:22)(cid:9)(cid:27) ‘
(cid:12)(cid:7)(cid:2)(cid:31)(cid:27)(cid:27)(cid:27)(cid:27)≤60%
ˆ(cid:24)(cid:22)(cid:28)(cid:29)(cid:30)(cid:27)‰Š(cid:22)(cid:28)(cid:30)(cid:30)(cid:29)(cid:24)(cid:28)(cid:19)(cid:17) ≥ moderate
(cid:7)(cid:26)(cid:17)(cid:24)(cid:22)(cid:28)(cid:20)(cid:5)(cid:30)(cid:29)(cid:22) ‹(cid:30)(cid:28)(cid:17)(cid:28)(cid:20)(cid:29)(cid:30)(cid:27)(cid:29)(cid:17)(cid:16)(cid:27)
Ž(cid:26)(cid:20)(cid:10)(cid:29)(cid:17)(cid:28)(cid:14)(cid:4)(cid:14)
„Ž‘ (cid:26)(cid:20)(cid:10)(cid:19)(cid:20)(cid:29)(cid:22)(cid:16)(cid:28)(cid:19)(cid:21)(cid:22)(cid:29)(cid:18)(cid:10)(cid:28)(cid:20)
(cid:20)(cid:22)(cid:28)(cid:24)(cid:26)(cid:22)(cid:28)(cid:29)(cid:29)
(cid:12)(cid:7)(cid:2)„…(cid:27)≤Œ†(cid:27)(cid:4)(cid:4)
ˆ(cid:24)(cid:22)(cid:28)(cid:29)(cid:30) (cid:12)(cid:7)(cid:2)(cid:31)(cid:27)(cid:27)(cid:27)(cid:27)20%−50%
„Ž‘
Figure 10 Echocardiographic assessment of patients with mitral regurgitation. EROA, effective regurgitant orifice area; LAVI, left atrial volume index;
LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MR, mitral regurgitation; PMR,
primary mitral regurgitation; RF, regurgitant fraction; RVol, regurgitant volume; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery
pressure; TR, tricuspid regurgitation; VTI, velocity time integral. aSee Table 7 for criteria predicting outcome improvement.
In a multicentre registry including more than 1300 patients with PMR, and phase contrast measurement of the MV inflow are used for this
increased BNP level was an independent predictor of long-term mor- purpose.523 In patients with Barlow’s disease and mitral annular disjunc-
tality under medical treatment. However, pre-operative BNP activation tion, CMR-detected myocardial fibrosis524 has been associated with
did not impact long-term mortality after surgical treatment.96 ventricular arrhythmias and sudden cardiac death.525
Cardiac computed tomography provides high-resolution anatomical
9.1.2.3. Cardiac magnetic resonance and computed tomography details of the entire MV apparatus523,526 and increasingly plays a role in
Cardiac magnetic resonance imaging is an alternative to precisely quan- MV intervention planning, particularly in the assessment of arterial access
tify RVol and RF in cases of inconclusive or discordant measurements, for extracorporeal circulation and the presence of MV calcification in min-
and the gold standard to determine cardiac dimensions and chamber imally invasive surgery,527 as well as the feasibility of transcatheter MV im-
volumes.521,522 The combination of planimetered volumetric methods plantation (TMVI) based on annulus size and risk of LVOT obstruction.528
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 39 ---
ESC Guidelines 4673
Patient with severe primary mitral regurgitation
Symptoms
LVEF ≤60% or LV dilatation High surgical risk according
(LVESD ≥40 mm or LVESDi ≥20 mm/m2) to the Heart Team
Anatomical suitability
Presence of at least 3 of the following:
for TEERa
• AF
• SPAP at rest >50 mmHg
• LAVI ≥60 mL/m2 or diameter ≥55 mm
• Concomitant secondary TR ≥moderate
AF or
SPAP at rest >50 mmHg
Significant LA dilatation
(LAVI ≥60 mL/m2 or diameter ≥55 mm)
and high likelihood of durable repair
TMVI
if feasible
MV surgery MV surgery High risk
Surgical
Watchful (preferably (preferably TEER surgery in
MV repair
waiting repair) repair) (Class IIa) selected
(Class IIa)
(Class IIa) (Class I) patients
Medical
treatment
Figure 11 Management of patients with severe primary mitral regurgitation. AF, atrial fibrillation; LA, left atrial; LAVI, left atrial volume index; LV, left
ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diam-
eter indexed to BSA; MV, mitral valve; SPAP, systolic pulmonary artery pressure; TEER, transcatheter edge-to-edge repair; TMVI, transcatheter mitral
valve implantation; TR, tricuspid regurgitation. aSee Supplementary data online, Table S2.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 40 ---
4674 E S C G u id e l in e s
Due its high sensitivity for detection of calcifications, CCT is instru- patient preference. The longer-term efficacy of TEER compared with
mental for procedural planning (surgical and transcatheter) in patients surgery is still under investigation in high- (NCT03271762) and
with MAC.529 intermediate-risk PMR patients (NCT04198870), as well as in
all-risk-category patients >60 years of age (NCT05051033).541 TMVI
9.1.2.4. Genetic evaluation is very effective in abolishing MR in selected high-risk patients, particular-
ly those with complex MV anatomy for TEER (Supplementary data
There is increasing evidence that specific mitral pathologies may be as-
sociated with genetic conditions. A meta-analysis of six genome-wide online, Table S2).542,543 The major drawbacks of current TMVI systems
include limited availability, high screening failure rate, as well as the risk of
association studies identified 14 potential genetic loci associated with
LVOT obstruction and valve thrombosis. Limited data exist for PMR pa-
primary MR. By comprising epigenetic, transcriptional, and proteomic
tients and regarding mid-term prosthesis durability.
data, the following genes could be identified as potential genetic sources
of the pathology: LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3.530 In patients with asymptomatic PMR with signs of LV dysfunction
(i.e. LVEF ≤60%, LVESD ≥40 mm, or LVESDi ≥20 mm/m2) the bene-
However, genetic testing is not recommended in routine practice.
fit of early surgery is well established.544–546 Furthermore, there is in-
creasing evidence that the presence of LA dilatation [LA volume index
9.1.3. Medical therapy
(LAVI) ≥60 mL/m2 or LA diameter ≥55 mm], AF, systolic pulmonary
Medical therapy has a limited role in patients with PMR. Afterload re-
artery pressure (SPAP) at rest of >50 mmHg, and concomitant mod-
duction with sodium nitroprusside has been used as a bridge to an
erate or severe secondary TR are associated with worse long-term
intervention in patients with acute severe PMR without signs of hypo-
prognosis irrespective of LV function after corrective surgery, and
tension. Inotropic agents and diuretics are usually indicated to reduce
should therefore prompt referral in low-risk patients, particularly if
filling pressures and control pulmonary congestion, while the implant-
a high probability of MV repair is expected.517,518,547 A recent study
ation of an intra-aortic balloon pump helps to further reduce afterload
showed that women have a higher risk of long-term mortality after
in exceptional cases of acute PMR.
MV repair than men, even at lower degrees of ventricular dilatation
In chronic PMR without signs of LV dysfunction or criteria for an
and dysfunction, suggesting the potential usefulness of sex-specific in-
intervention, there is no evidence supporting prophylactic afterload re-
dexed thresholds.548 Ventricular arrhythmias in patients with MV pro-
duction. Patients with PMR and impaired LV function should receive
lapse have been linked to impaired prognosis and possibly sudden
GDMT according to HF Guidelines.340
cardiac death, especially in the presence of mitral annular disjunc-
tion.549–551 Ring annuloplasty stabilizes the posterior annulus, reduces
9.1.4. Indications for intervention traction on the subvalvular apparatus,552 and may lower the risk of ar-
Urgent surgery or transcatheter treatment is indicated in patients with rhythmias.553 Minimally invasive surgery via right mini-thoracotomy is
acute severe PMR because it is poorly haemodynamically tolerated. In pa- used with increasing frequency in experienced centres.554–556 A re-
tients with papillary muscle rupture and endocarditis, surgical valve replace- cent RCT demonstrated similar safety and efficacy compared with
ment is generally required, while acute degenerative chordal rupture can be conventional sternotomy. Mini-thoracotomy was associated with
treated with surgical MV repair or TEER in high-risk patients. shorter hospital stay and improved physical activity within the first
Indications for surgery in patients with chronic asymptomatic and 6 weeks after surgery, a difference that disappeared at 12 weeks.557
symptomatic PMR are summarized in Recommendation Table 6 and The use of minimally invasive MV surgery may therefore be consid-
Figure 11. In cases of severe PMR, restoring the anatomy by surgical ered to reduce hospital stay and accelerate recovery in experienced
MV repair, including annuloplasty, is the treatment of choice in operable centres. However, in a national registry, these benefits were less
patients when an optimal and durable result is expected. According clear.558
to contemporary data, the procedure can be performed with
a low mortality risk (1.2%) in appropriately selected patients.531
Compared with replacement, MV repair has been associated with Recommendation Table 6 — Recommendations on
lower peri-operative mortality along with significantly better long- indications for intervention in severe primary mitral
term survival and functional outcomes.532,533 Repair of more com- regurgitation (see also Supplementary data online,
plex pathologies such as valves with annular or leaflet calcifications, Evidence Tables 14–16)
as well as in cases of RHD, is challenging and should be attempted in
experienced Heart Valve Centres.534–536 When MV repair is not Recommendations Classa Levelb
feasible, valve replacement with preservation of the subvalvular ap-
MV repair is the recommended surgical technique to
paratus should be performed.537
treat patients with severe PMR when the result is I B
High-risk and elderly patients with chronic PMR, though uncommon, expected to be durable.26,532,533,559,560
may benefit from a less-invasive M-TEER procedure.538 Peri-
MV surgery is recommended in symptomatic
interventional and mid-term results with regard to residual MR and
patients with severe PMR considered operable by I B
mean transmitral gradient are closely related to patient outcomes.538
the Heart Team.26,532,533,561
The use of latest-generation devices along with a growing team experi-
MV surgery is recommended in asymptomatic
ence have improved results, and allow for the successful treatment
of more complex anatomical conditions (Supplementary data online, patients with severe PMR and LV dysfunction I B
Table S2).539,540 The decision regarding the mode of intervention or (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or
conservative treatment should be made by the Heart Team, considering LVEF ≤60%).522,544,545
clinical and anatomical characteristics, as well as procedural risks and Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 41 ---
ESC Guidelines 4675
Surgical MV repair is recommended in low-risk MR after surgical ring annuloplasty frequently undergo repeat surgery
asymptomatic patients with severe PMR without LV (usually MV replacement), while transcatheter alternatives are reserved
dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, for selected high-risk patients because of the risk of increased gradients
(M-TEER), PVL, and LVOT obstruction (mitral valve-in-ring proce-
and LVEF >60%) when a durable result is likely, if at
dures).569,570 In patients undergoing MV replacement, closer follow-up
least three of the following criteria are
on a yearly basis is required due to the risk of prosthetic valve dysfunction
fulfilled:517,547,562–564 I B
or SVD (see Section 14.4). Following TEER, reported rates of residual MR
• AF
and increased transmitral gradients are higher than after surgical repair,
• SPAP at rest >50 mmHg
suggesting that yearly follow-up is appropriate.571 Although rare, the
• LA dilatation (LAVI ≥60 mL/m2 or LA
need for surgical treatment after failed TEER is associated with increased
diameter ≥55 mm) peri-operative mortality and low valve repair rates,541,572 while trans-
• Concomitant secondary TR ≥ moderate.
catheter solutions to detach TEER implants and replace the valve have
MV surgery should be considered in asymptomatic been described in few cases.573,574
patients with severe PMR without LV dysfunction
(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF Ila B 9.2. Secondary mitral regurgitation
>60%) in the presence of PH (SPAP at rest
9.2.1. Prevalence and aetiology
>50 mmHg), or AF secondary to MR.517,518,562,565
Secondary mitral regurgitation is present when the MV structure appears
Surgical MV repair should be considered in low-risk
grossly normal but the MV is nonetheless incompetent, due to alterations
asymptomatic patients with severe PMR without LV
in LV and LA geometry, dyssynchrony, and imbalances between MV clos-
dysfunction (LVESD <40 mm, LVESDi <20 mm/m2, ing and tethering forces.575 The prevalence of severe SMR in patients with
and LVEF >60%) in the presence of significant LA IIa B chronic HF is ∼10% and higher in patients with reduced vs preserved LVEF
dilatation (LAVI ≥60 mL/m2 or LA (25% vs 4%).576 Secondary mitral regurgitation can be classified as atrial or
diameter ≥55 mm), when performed in a Heart ventricular with different pathophysiological and morphological character-
Valve Centre and a durable repair is likely.517,565 istics, as well as contrasting prognostic and therapeutic implications.577
TEER should be considered in symptomatic patients Ventricular SMR is more common and associated with worse long-term
with severe PMR who are anatomically suitable and prognosis.513,578–580 Dilated or ischaemic cardiomyopathy are the most
IIa B
at high surgical risk according to the Heart frequent causes of severe ventricular SMR. Acute HF exacerbation may
Team.538,540,566 occur in patients with chronic HF due to a renewed ischaemic event, ar-
rhythmia, infection, or volume overload. Atrial SMR is due to pure mitral
Minimally invasive MV surgery may be considered at
annular dilation and is observed in patients with long-standing AF and/or
experienced centres to reduce the length of stay and IIb B
accelerate recovery.557,567 HFpEF.581 Factors predisposing to atrial SMR include age ≥65 years, fe-
male sex, LA dilatation, and diastolic dysfunction.582 From a morphological
AF, atrial fibrillation; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left point of view, ventricular SMR is characterized by leaflet tethering and re-
ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular
stricted motion combined with annular dilation, while annulus enlarge-
end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body
surface area; MR, mitral regurgitation; MV, mitral valve; PH, pulmonary hypertension; ment and flattening leading to planar coaptation are predominantly
PMR, primary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TEER, observed in atrial SMR. The prevalence of atrial SMR has been underesti-
transcatheter edge-to-edge repair; TR, tricuspid regurgitation. mated in the past and was occasionally misclassified as PMR due to
aClass of recommendation.
bLevel of evidence. pseudo-prolapse with leaflet tethering in advanced stages.
9.2.2. Evaluation
9.1.5. Follow-up
Echocardiographic criteria to define significant SMR according to aeti-
Asymptomatic patients with severe MR not fulfilling the criteria for an
ology are reported in Figure 10. Importantly, SMR assessment should
intervention, and with documented preserved exercise capacity, should
be performed after optimization of medical therapy and in a euvolaemic
undergo clinical and echocardiographic follow-up twice per year (watch-
ful waiting strategy), ideally in the setting of a Heart Valve Clinic.568 and normotensive state. When quantifying EROA and RVol in SMR,
lower thresholds may apply to define severe regurgitation because of Follow-up may also include serial measurements of BNP levels, electro-
the potential elliptical regurgitant orifice and/or the low-flow state.
cardiogram (ECG) and/or Holter monitoring, and (in selected cases) ex-
An EROA of ≥30 mm2 and/or an RVol of ≥45 mL has been identified
ercise echocardiography and CMR to confirm MR severity, and cardiac
chamber function and dimensions.46 Asymptomatic patients with mod- as having a significant impact on outcomes,45 with prognosis improved
after treatment.583,584 Cardiac magnetic resonance is used to confirm
erate MR and preserved LV function can be followed on a yearly basis
SMR severity and assess cardiac chamber function and dimensions.
with echocardiographic assessment every 1 or 2 years.
The extent of myocardial fibrosis, as assessed with CMR, has been as-
The frequency of follow-up after an intervention depends on the type
sociated with poor prognosis.585 Owing to the dynamic nature of SMR,
of procedure performed. Very good long-term durability of MV repair in
exercise echocardiography may help to identify patients with severe
PMR due to valve prolapse with a low recurrence rate has been reported
SMR when values at rest are inconclusive.45
at experienced centres with freedom from moderate or severe MR of
87.5% at 20 years.533,559 Serial clinical and echocardiographic follow-up
in patients without pre-operative LV dysfunction or rhythm abnormal- 9.2.3. Definition of atrial secondary mitral
ities every 2–3 years thereafter is sufficient. Patients with atrial or ven- regurgitation
tricular arrhythmias possibly related to MV disease should be further Characteristics distinguishing between atrial and ventricular SMR are
evaluated using continuous ECG monitoring. Patients with recurrent displayed in Figure 12.
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 42 ---
4676 E S C G u id e l in e s
(cid:30)(cid:29)(cid:28)(cid:31)(cid:27)(cid:26)(cid:25)(cid:24)(cid:29)(cid:26)(cid:25)(cid:23)
(cid:31)(cid:30)(cid:22)(cid:21)(cid:20)≥(cid:19)(cid:18)(cid:17)(cid:20)(cid:16)(cid:15)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)(cid:20)(cid:11)(cid:26)(cid:10)(cid:15)(cid:13)(cid:9)(cid:8)(cid:7) (cid:31)(cid:30)(cid:22)(cid:21)(cid:20)…(cid:19)(cid:18)(cid:17)(cid:20)(cid:16)(cid:15)(cid:25)(cid:14)(cid:20)(cid:13)(cid:11)(cid:20)(cid:16)(cid:15)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)
(cid:16)(cid:8)(cid:7)(cid:7)(cid:20)(cid:6)(cid:13)(cid:25)(cid:15)(cid:13)(cid:9)(cid:20)(cid:8)(cid:5)(cid:9)(cid:13)(cid:11)(cid:6)(cid:8)(cid:7)(cid:15)(cid:25)(cid:15)(cid:26)(cid:4) (cid:11)(cid:26)(cid:10)(cid:15)(cid:13)(cid:9)(cid:8)(cid:7)(cid:20)(cid:16)(cid:8)(cid:7)(cid:7)(cid:20)(cid:8)(cid:5)(cid:9)(cid:13)(cid:11)(cid:6)(cid:8)(cid:7)(cid:15)(cid:25)(cid:15)(cid:26)(cid:4)
(cid:22)(cid:24)(cid:26)(cid:25)(cid:23)(cid:18) (cid:10)(cid:29)(cid:19)(cid:24)(cid:26)(cid:25)(cid:27)(cid:9)(cid:18)(cid:23)(cid:26)
(cid:13)(cid:12)(cid:11) (cid:3)(cid:13)(cid:20)(cid:13)(cid:11)(cid:20)(cid:6)(cid:15)(cid:7)(cid:2)(cid:7)(cid:1)(cid:20)(cid:2)(cid:15)(cid:7)(cid:8)(cid:25)(cid:26)(cid:2)(cid:20)(cid:31)(cid:30)(cid:20)(cid:127)(cid:8)(cid:129)(cid:15)(cid:25)(cid:1)(cid:8) (cid:28)(cid:26)(cid:4)(cid:25)(cid:11)(cid:15)(cid:127)(cid:25)(cid:15)(cid:129)(cid:26)(cid:20)(cid:7)(cid:26)(cid:8)(cid:141)(cid:26)(cid:25)(cid:20)(cid:6)(cid:13)(cid:25)(cid:15)(cid:13)(cid:9) (cid:13)(cid:12)(cid:11)
(cid:16)(cid:15)(cid:25)(cid:14)(cid:13)(cid:12)(cid:25)(cid:20)(cid:7)(cid:26)(cid:8)(cid:141)(cid:26)(cid:25)(cid:20)(cid:25)(cid:26)(cid:25)(cid:14)(cid:26)(cid:11)(cid:15)(cid:9)(cid:10) (cid:16)(cid:15)(cid:25)(cid:14)(cid:20)(cid:25)(cid:26)(cid:25)(cid:14)(cid:26)(cid:11)(cid:15)(cid:9)(cid:10)
(cid:29)(cid:15)(cid:25)(cid:11)(cid:8)(cid:7)(cid:20)(cid:8)(cid:9)(cid:9)(cid:12)(cid:7)(cid:12)(cid:4)(cid:20)(cid:2)(cid:15)(cid:7)(cid:8)(cid:25)(cid:8)(cid:25)(cid:15)(cid:13)(cid:9)
(cid:3)(cid:13)(cid:11)(cid:6)(cid:8)(cid:7)(cid:20)(cid:7)(cid:26)(cid:8)(cid:141)(cid:26)(cid:25)(cid:20)(cid:6)(cid:13)(cid:11)†(cid:14)(cid:13)(cid:7)(cid:13)(cid:10)(cid:1)
(cid:143)(cid:24)(cid:144)(cid:31)(cid:157) (cid:19)(cid:20)(cid:6)(cid:6)
(cid:31)(cid:30) (cid:31)(cid:30)
(cid:22)(cid:9)(cid:7)(cid:8)(cid:11)(cid:10)(cid:26)(cid:2)(cid:20)(cid:31)(cid:24)(cid:20)(cid:143)(cid:31)(cid:24)(cid:30)€(cid:20)(cid:31)(cid:157) ‚(cid:20)(cid:6)(cid:31)ƒ(cid:6)„ ‡(cid:26)(cid:9)(cid:25)(cid:11)(cid:8)(cid:7)(cid:20)(cid:13)(cid:11)(cid:20)(cid:26)(cid:127)(cid:127)(cid:26)(cid:9)(cid:25)(cid:11)(cid:15)(cid:127)(cid:20)(cid:27)(cid:26)(cid:25)
(cid:22)(cid:21)(cid:21)(cid:25)(cid:24)(cid:25)(cid:20)(cid:19)(cid:23)(cid:18)(cid:31)(cid:29)(cid:27)(cid:17)(cid:20)(cid:27)(cid:23)(cid:26)(cid:21)(cid:25)(cid:20)(cid:16)(cid:26)(cid:23)(cid:15)(cid:17)(cid:25)(cid:27)(cid:31)(cid:27)(cid:26)(cid:25)(cid:24)(cid:29)(cid:26)(cid:25)(cid:23)(cid:14)
(cid:24)(cid:23) (cid:29)(cid:24) (cid:24)(cid:23) (cid:29)(cid:24)
(cid:3)(cid:13)(cid:11)(cid:6)(cid:8)(cid:7)(cid:20)(cid:7)(cid:26)(cid:8)(cid:141)(cid:26)(cid:25)(cid:20)(cid:6)(cid:13)(cid:25)(cid:15)(cid:13)(cid:9) ˆ(cid:15)(cid:7)(cid:8)(cid:25)(cid:26)(cid:2)(cid:20)(cid:31)(cid:30)
(cid:31)(cid:24) (cid:29)(cid:28) (cid:3)(cid:13)(cid:11)(cid:6)(cid:8)(cid:7)(cid:20)(cid:7)(cid:26)(cid:8)(cid:141)(cid:26)(cid:25)(cid:20)(cid:6)(cid:13)(cid:11)†(cid:14)(cid:13)(cid:7)(cid:13)(cid:10)(cid:1) ˆ(cid:15)(cid:7)(cid:8)(cid:25)(cid:26)(cid:2)(cid:20)(cid:31)(cid:24) (cid:31)(cid:24) (cid:29)(cid:28)
(cid:27)(cid:26)(cid:25) (cid:27)(cid:26)(cid:25)
‰(cid:4)(cid:12)(cid:8)(cid:7)(cid:7)(cid:1)(cid:20)(cid:127)(cid:26)(cid:9)(cid:25)(cid:11)(cid:8)(cid:7)(cid:20)(cid:27)(cid:26)(cid:25) ˆ(cid:15)(cid:7)(cid:8)(cid:25)(cid:26)(cid:2)(cid:20)(cid:29)(cid:30)(cid:20)(cid:8)(cid:9)(cid:9)(cid:12)(cid:7)(cid:12)(cid:4)
(cid:22)(cid:21)(cid:21)(cid:25)(cid:24)(cid:25)(cid:20)(cid:19)(cid:23)(cid:18)(cid:31)(cid:27)(cid:18)(cid:25)(cid:19)(cid:25)(cid:27)(cid:23)(cid:18)(cid:31)(cid:27)(cid:26)(cid:25)(cid:24)(cid:29)(cid:26)(cid:25)(cid:23)
(cid:24)(cid:25)(cid:11)(cid:15)(cid:8)(cid:7)(cid:20)Š(cid:5)(cid:11)(cid:15)(cid:7)(cid:7)(cid:8)(cid:25)(cid:15)(cid:13)(cid:9) €(cid:4)(cid:127)(cid:14)(cid:8)(cid:26)(cid:6)(cid:15)(cid:127)(cid:20)(cid:14)(cid:26)(cid:8)(cid:11)(cid:25)(cid:20)(cid:2)(cid:15)(cid:4)(cid:26)(cid:8)(cid:4)(cid:26)
‹(cid:21)†(cid:22)(cid:21) ˆ(cid:15)(cid:7)(cid:8)(cid:25)(cid:26)(cid:2)(cid:20)(cid:127)(cid:8)(cid:11)(cid:2)(cid:15)(cid:13)(cid:6)(cid:1)(cid:13)†(cid:8)(cid:25)(cid:14)(cid:1)
Figure 12 Most frequently used criteria for the diagnosis of atrial secondary mitral regurgitation. AO, aorta; AP, anteroposterior; HFpEF, heart failure
with preserved ejection fraction; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection
fraction; MA, mitral annulus; MR, mitral regurgitation; MV, mitral valve; SMR, secondary mitral regurgitation. aLV end-diastolic dimension of <56 mm in
females and <63 mm in males; indexed LV end-diastolic volume <71 mL/m2 (in women) or <79 mL/m2 (in men). bAdditional echocardiographic criteria
for atrial SMR may no longer be fulfilled in advanced stages.
Atrial SMR is most frequently defined by the presence of the follow- 9.2.4. Management of ventricular secondary mitral
ing key criteria:513,578–580,586–590 regurgitation
9.2.4.1. Medical and device therapy
• preserved LVEF (≥50%) without regional wall motion abnormalities
In patients with ventricular SMR, GDMT for the treatment of HF is re-
or leaflet tethering; AND commended prior to any MV intervention.339,340 The combination of
• no or mildly dilated LV cavity [LV end-diastolic dimension of <56 mm
ACE-Is/ARBs or angiotensin receptor/neprilysin inhibitors, beta-
in women and <63 mm in men; indexed LV end-diastolic volume of
blockers, mineralocorticoid receptor antagonists, and sodium–glucose
<71 mL/m2 (in women) or <79 mL/m2 (in men)]; AND
co-transporter 2 inhibitors (SGLT2is) at the maximum tolerated doses
• mitral annulus (MA) dilatation [anteroposterior (AP) diameter of is recommended according to the HF Guidelines.340 Initiation and up-
>35 mm]; AND
titration of neurohormonal drugs need to be tailored according to
• enlarged LA (LAVI >34 mL/m2).
the patient profile, mainly based on BP, heart rate, potassium levels,
and renal function.593 Notably, GDMT up-titration must be rapid (with-
Echocardiography frequently reveals normal leaflet motion with pla- in 6 weeks) and take place in the context of close follow-up visits, es-
nar coaptation, and normal leaflet morphology with a central MR jet in pecially in the case of a recent hospitalization for acute HF.594 About
atrial SMR. However, at advanced stages, an overlap between atrial and 40% of patients with ventricular SMR experience improvement of
ventricular SMR criteria can be observed in the case of late LV damage SMR severity after 1–3 months of optimized GDMT.595,596 Cardiac re-
due to continuous volume overload.591,592 Clinical criteria (i.e. history synchronization therapy (CRT) should also be considered as part of HF
of AF and/or diagnosis of HFpEF) are also useful and should be taken management before an MV intervention according to HF guideline cri-
into consideration. teria (LVEF ≤35% and wide QRS).597,598 Although no dedicated RCTs
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 43 ---
ESC Guidelines 4677
exist, SMR reduction by at least one grade has been described in 40%– (Figure 13). GDMT is the only option for very frail patients or those
60% of patients and is associated with reverse LV remodelling and im- with limited life expectancy.
proved clinical outcomes.597,599,600 In the Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients with Functional
9.2.4.2. Indications for intervention Mitral Regurgitation (COAPT) trial, M-TEER was shown to be safe
The management of patients with ventricular SMR should be discussed and reduced recurrent HF hospitalization and all-cause mortality
by a multidisciplinary Heart Team including HF specialists. The indica- at 2 and 5 years of follow-up, compared with optimized GDMT
tion for intervention is based on the persistence of symptoms (i.e. in patients with ventricular SMR without relevant CAD.583,584
NYHA class II–V) despite adequate GDMT and CRT, if indicated In a second study (Percutaneous Repair with the MitraClip Device for
Patient with severe symptomatic SMR without concomitant CAD
Ventricular SMR Atrial SMR
GDMT optimization Optimization of medical treatment
including CRT, if indicated including rate or rhythm control
Persistence of symptoms and SMR Persistence of symptoms and SMR
Clinical and echocardiographic
Medical therapy High surgical risk according
criteria fulfilleda according
and follow-up to the Heart Team
to the Heart Team
Advanced HF
LVAD TEER
or HTx (Class IIb)
TEER MV
TEER TEER
in patients with MV surgery surgery
(Class I) (Class IIb)
contraindication(s) in patients not (Class IIa)
or waiting for suitable for TEERb
LVAD or HTx (Class IIb)
(Class IIb)
Figure 13 Treatment of severe secondary mitral regurgitation without concomitant coronary artery disease. CAD, coronary artery disease; CRT,
cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HTx, heart transplantation; LVAD, left ventricular assist
device; MV, mitral valve; SMR, secondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. aSee Table 7. bSee Supplementary data online,
Table S2.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 44 ---
4678 E S C G u id e l in e s
Severe Functional/Secondary Mitral Regurgitation, MITRA-FR), no dif- recurrent MR rates were high with this technique in an RCT618 and re-
ferences were demonstrated for the combined primary endpoint of all- verse LV remodelling is limited, especially in patients with an increased
cause mortality or HF hospitalization at 1 and 2 years.601,602 These di- tenting area (>1.35 cm2/m2 BSA),619 in whom MV replacement is usu-
verging results might be explained by effect sizes of the trials, differences ally required.620 The addition of subvalvular modification in patients
in trial design, patient selection and follow-up, echocardiographic assess- with LV dilatation and pronounced MV leaflet tenting may improve re-
ment of SMR severity, use of GDMT, and technical factors.603–605 A sults for MV repair,621 but durability and impact on HF symptoms with
third RCT, the Randomized Investigation of the MitraClip Device in this technique require further investigation.
Heart Failure: 2nd Trial in Patients with Clinically Significant The treatment of moderate ischaemic SMR in patients undergoing
Functional Mitral Regurgitation (RESHAPE-HF-2) trial showed a 36% CABG remains controversial. Meta-analyses, including four RCTs com-
reduction in the rates of HF hospitalization or cardiovascular death paring CABG with concomitant MV surgery vs CABG alone, have
at 2 years in the intervention arm driven by reduction of first or recur- shown lower rates of recurrent MR but no benefit in terms of mortality
rent HF hospitalization. When considered in isolation, cardiovascular and clinical outcomes.622–624 Therefore, clinical decision-making should
mortality was not significantly reduced during the observation period. weigh peri-operative risks of more complex surgery against the long-
In addition, there was a significant improvement in quality of life as term risk of MR progression.
measured by the KCCQ overall score (mean difference between study
groups, 10.9 points; 95% CI, 6.8–15.0; P <0.001).606 A recent study-level 9.2.4.3. Follow-up
meta-analysis of these three trials showed a significant reduction of HF Patients with ventricular SMR need to be followed up carefully after
rehospitalization at 24 months (HR, 0.63, 95% CI, 0.50–0.80) and the intervention by an HF specialist, because they remain at increased
composite of death and all-cause hospitalizations (HR, 0.72, 95% CI, risk of events despite intervention. The 5-year cumulative incidence
0.51–0.999).607 However, there was no statistically significant difference of all-cause death or HF hospitalization was 73.6% in the device arm
in death from any cause or cardiovascular death at 24 months. of the COAPT study.584 Clinical, laboratory, and echocardiographic
Transcatheter edge-to-edge repair is therefore recommended to re- evaluation every 3 or 6 months, according to the HF stage, is recom-
duce HF hospitalizations, and improve quality of life, in symptomatic pa- mended. Durability of the procedural result, as well as congestion status
tients with persisting severe SMR despite optimized GDMT fulfilling and the need for further GDMT optimization facilitated by SMR reduc-
specific clinical and echocardiographic criteria (Table 7). Although less tion,613 need to be assessed. Patients and families should be trained in
challenging than in PMR, anatomical suitability for TEER needs to be as- monitoring vital signs, body weight, and HF symptoms to avoid late hos-
sessed upfront (Supplementary data online, Table S2). There is also in- pital admissions and facilitate management of possible decompensation.
creasing observational evidence supporting the use of TEER for the Also, patients must be educated on the importance of not discontinuing
improvement of symptoms, functional capacity, and quality of life in pa- medical therapies after intervention since the two treatments (devices
tients with ventricular SMR not fulfilling the clinical and echocardio- and drugs) are complementary.
graphic criteria for outcome improvement.608–612 This particularly Patients with ventricular SMR, who are asymptomatic and/or have
applies to patients not tolerating GDMT in whom TEER may help up- moderate or dynamic MR, should undergo clinical and echocardio-
titration, as well as those with recent myocardial infarction and persist- graphic follow-up at least twice per year.
ent severe ventricular SMR.203,613
Transcatheter implantation of an indirect annuloplasty device into
the coronary sinus has been proposed as an alternative that preserves
Table 7 Clinical and echocardiographic criteria pre-
valve integrity. Despite rather modest SMR reduction (22.4% decrease
dicting outcome improvement in patients with severe
in mitral RVol) and no significant effect on quality of life in a small sham-
ventricular secondary mitral regurgitation undergoing
controlled RCT, symptomatic improvement and reverse remodelling
mitral transcatheter edge-to-edge repair
were observed in registries at 1 year.614,615 Heart transplantation or
left ventricular assist device (LVAD) implantation should be considered Anatomy deemed suitable for M-TEER
in selected patients with severe ventricular SMR and advanced HF. NYHA class ≥II
In patients with ventricular SMR without relevant CAD, indications LVEF 20%–50%
for isolated MV surgery are restrictive owing to procedural risks and
LVESD ≤70 mm
the absence of proven mortality benefit.616 The Multicenter,
At least one HF hospitalization within the previous year or increased
Randomized, Controlled Study to Assess Mitral Valve Reconstruction
natriuretic peptide levels (BNP ≥300 pg/mL or NT-proBNP ≥1000 pg/mL)
for Advanced Insufficiency of Functional or Ischemic Origin
SPAP ≤70 mmHg
(MATTERHORN) trial, which included a mixed population mainly com-
posed of patients with ventricular SMR (84%), demonstrated that TEER No severe RV dysfunction
is non-inferior to surgical repair or replacement with regard to a com- No Stage D or advanced HF
posite endpoint of death, HF hospitalization, MV reintervention, im- No CAD requiring revascularization
plantation of an assist device, or stroke within 1 year after the No severe AV and/or TV disease
procedure, and showed a better safety profile.617 In patients with se-
No hypertrophic, restrictive, or infiltrative cardiomyopathies
vere ischaemic ventricular SMR and concomitant CAD requiring coron-
ary revascularization, MV surgery at the time of CABG is AV, aortic valve; BNP, brain natriuretic peptide; CAD, coronary artery disease; HF, heart
failure; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
recommended, unless the patient is at high surgical risk and/or the cor-
diameter; M-TEER, mitral transcatheter edge-to-edge repair; NT-proBNP, N-terminal
onary anatomy is suitable for PCI. Although isolated undersized mitral
pro-B-type natriuretic protein; NYHA, New York Heart Association; RV, right ventricle/
annuloplasty is the most commonly performed MV repair procedure, right ventricular; SPAP, systolic pulmonary artery pressure; TV, tricuspid valve.
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 45 ---
ESC Guidelines 4679
9.2.5. Management of atrial secondary mitral
Ventricular secondary mitral regurgitation and concomitant
regurgitation
coronary artery disease
9.2.5.1. Medical therapy and rhythm management
MV surgery is recommended in patients with severe
In patients with atrial SMR, underlying causes need to be recognized and ventricular SMR undergoing CABG.640 I B
treated. Associated HFpEF and AF should be managed according to the
MV surgery may be considered in patients with
relevant Guidelines.7,340 The use of SGLT2is should be encouraged in IIb B
moderate SMR undergoing CABG.622–624,641,642
patients with HFpEF due to their proven efficacy in reducing cardiovas-
cular death and HF hospitalization.625 Limited data show that rhythm PCI followed by TEER after re-evaluation of MR may
control may contribute to reduce atrial SMR severity and reverse LA be considered in symptomatic patients with chronic IIb C
dilatation.626 severe ventricular SMR and non-complex CAD.150
Severe ventricular secondary mitral regurgitation without
concomitant coronary artery disease
9.2.5.2. Indications for intervention
TEER is recommended to reduce HF hospitalizations
Registry data demonstrate that patients with atrial SMR are typically
and improve quality of life in haemodynamically
elderly with associated AF. Mitral valve surgery has been recently asso-
stable, symptomatic patients with impaired LVEF
ciated with lower rates of HF hospitalizations and mortality compared
(<50%) and persistent severe ventricular SMR, I A
with GDMT in a matched population, despite a higher risk profile in the
surgical arm at baseline.627 Data from several observational studies also despite optimized GDMT and CRT (if indicated),
suggest that surgical annuloplasty is effective and durable in patients with fulfilling specific clinical and echocardiographic
atrial SMR, because it counteracts the main mechanism of MR progres-
criteria.c 583,584,606,608,643
sion.628–630 Its combination with surgical AF ablation (Maze procedure) TEER may be considered for symptom improvement
and concomitant LAAO may have further advantages,630,631 while the fre- in selected symptomatic patients with severe
quently associated relevant TR can also be addressed during the same pro- ventricular SMR not fulfilling the specific clinical and IIb B
cedure.627 Transcatheter edge-to-edge repair may also be considered echocardiographic criteria,c after careful evaluation
because observational studies have demonstrated high safety and proced- of LVAD or HTx.203,608–610
ural success,588–590,632,633 as well as compared with surgery in a small sub-
MV surgery may be considered in symptomatic
group (n = 34) of the MATTERHORN RCT.634 However, the risk of
patients with severe ventricular SMR without IIb C
increased gradient due to planar leaflet coaptation, large regurgitant jet, advanced HF who are not suitable for TEER.617
and limited MV area (MVA) needs to be taken into consideration.592,635
Further studies are warranted to investigate the treatment modalities of AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease;
CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF,
patients with atrial SMR.
heart failure; HTx, heart transplantation; LAAO, left atrial appendage occlusion; LVAD,
left ventricular assist device; LVEF, left ventricular ejection faction; MR, mitral
regurgitation; MV, mitral valve; PCI, percutaneous coronary intervention; SMR,
9.2.5.3. Follow-up secondary mitral regurgitation; TEER, transcatheter edge-to-edge repair.
Patients with atrial SMR undergoing surgical or transcatheter interven- aClass of recommendation.
bLevel of evidence.
tion should be followed up on a yearly basis, including clinical and echo-
cSee Table 7.
cardiographic evaluation. In cases of HFpEF, as an underlying cause of
atrial SMR, consultation with an HF specialist is necessary.
Asymptomatic patients with severe atrial SMR not fulfilling the cri-
10. Mitral stenosis
teria for an intervention should undergo clinical and echocardiographic
follow-up at least once per year.
10.1. Prevalence and aetiology
The aetiology of MS is most frequently rheumatic or degenerative,
Recommendation Table 7 — Recommendations on in-
while rare forms can be drug-induced, inflammatory, or
dications for intervention in secondary mitral
carcinoid-related. Rheumatic fever is the most common cause of
regurgitation (see also Supplementary data online,
MS and death due to VHD worldwide. Its prevalence has decreased Evidence Tables 17–20)
in high- and middle-income countries, but remains a major health-
Recommendations Classa Levelb care problem in low-income countries, where it predominantly
affects young patients.12,187,644 Degenerative MS related to MAC
Severe atrial secondary mitral regurgitation is a distinct age-dependent pathology requiring different
treatment strategies.645–647 Both aetiologies are more frequent in
MV surgery, surgical AF ablation, if indicated, and females.648
LAAO should be considered in symptomatic patients
IIa B
with severe atrial SMR under optimal medical
therapy.627–630,636,637 10.2. Rheumatic mitral stenosis
TEER may be considered in symptomatic patients 10.2.1. Evaluation
with severe atrial SMR not eligible for surgery after Echocardiography is the preferred method for screening in endemic re-
IIb B
optimization of medical therapy including rhythm gions and the assessment of the severity, extent of anatomical lesions,
control, when appropriate.588,590,638,639 and haemodynamic consequences of MS. Involvement of other valves,
Continued particularly secondary TR, should be identified. Mitral valve area using
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 46 ---
4680 E S C G u id e l in e s
2D planimetry is the most commonly used measurement to assess commissurotomy should be considered as a first-line treatment for pa-
stenosis severity, but 3D TTE and TOE have additional diagnostic tients with anatomically suitable rheumatic MS and mild-to-moderate
value.649 An MVA of ≤1.5 cm2 in conjunction with clinical factors calcification without severe subvalvular impairment. Selected patients
(symptoms, high risk of thromboembolism, or haemodynamic decom- with unfavourable anatomical and clinical characteristics can still benefit
pensation) is indicative of clinically severe MS. Mean transvalvular gradi- from PMC, particularly if they are at increased surgical risk. When
ent and pulmonary pressures reflect its consequences and have symptomatic restenosis occurs after surgical commissurotomy or
prognostic value.649,650 Leaflet thickening and fibrosis, along with com- PMC, reintervention in most cases requires surgical valve replacement,
missural fusion and shortening of the subvalvular apparatus, are the but redo PMC can be proposed in selected candidates with favourable
most important pathomechanisms of stenosis associated with RHD. characteristics, if the predominant mechanism is commissural refusion.
The presence and extent of leaflet and subvalvular calcifications influ- Long-term follow-up has shown favourable results following PMC des-
ence treatment decisions. Scoring systems have been developed to as- pite a growing number of elderly patients with suboptimal clinical and
sess the suitability of patients for percutaneous mitral commissurotomy anatomical characteristics.663–665
(PMC) (see Supplementary data online, Table S3).651–653 For patients in whom PMC is contraindicated (Table 8), surgical MV
Exercise testing is indicated in asymptomatic patients or patients repair or, more frequently, replacement are good alternatives.
with symptoms that are equivocal or discordant with the severity of Although repair is much more challenging than for PMR, it can be at-
stenosis. Exercise echocardiography provides additional information tempted at experienced centres.663
on exercise capacity and related changes in mitral gradient and pulmon- For patients with multiple VHD including MS, a comprehensive
ary artery pressure, and is preferred over DSE, especially when there evaluation by the Heart Team and an individualized approach is neces-
are contraindications to dobutamine.654 Transoesophageal echocardi- sary. Surgery is preferable to PMC in patients with severe MS and se-
ography should be systematically performed in PMC candidates to ex- vere AV disease, unless the surgical risk is high. In selected cases with
clude LA thrombus or after an embolic episode, and may play an severe MS and moderate AV disease, PMC can be performed to post-
essential role for procedural guidance.52,655 pone surgical treatment of both valves.
In high-risk cases with concomitant severe TR, PMC may be consid-
ered in selected patients with sinus rhythm, moderate atrial enlarge-
10.2.2. Medical therapy
ment, and secondary TR due to post-capillary PH. In non-high-risk
Diuretics, beta-blockers, digoxin, non-dihydropyridine calcium channel
cases, surgery on both valves is preferred.651,652,662,667 Treatment of
blockers, and ivabradine can improve symptoms by controlling volume
patients with low-gradient severe MS (MVA <1.5 cm2, mean gradient
overload and heart rate. Anticoagulation with a VKA with a target inter-
<10 mmHg) is challenging, because these patients are often older
national normalized ratio (INR) between 2 and 3 is indicated in patients
and have unfavourable anatomy.668,669
with AF, and DOACs should be avoided in patients with an MVA of
≤2.0 cm2 according to current evidence.165,656,657 Interventions to re-
store sinus rhythm (cardioversion or catheter pulmonary vein isolation) 10.2.4. Follow-up
are unlikely to be successful in patients with untreated severe MS. If AF
Asymptomatic patients with clinically severe MS who have not under-
is of recent onset and the LA moderately enlarged, cardioversion can be
gone intervention should be followed up yearly by TTE, and at longer in-
attempted soon after successful intervention or in patients with mod-
tervals (2–3 years) in cases of moderate stenosis. After PMC, the
erate MS combined with amiodarone treatment.658,659 In patients in
post-procedural MVA and mean mitral gradient are important para-
sinus rhythm, OAC is indicated after systemic embolism or if a throm-
meters that influence long-term clinical outcomes. Follow-up of patients
bus is present in the LA, and should also be considered when TOE
after successful PMC is necessary because asymptomatic restenosis may
shows dense spontaneous echocardiographic contrast or an enlarged
occur. Progressive rheumatic involvement of other valves should be peri-
LA (M-mode diameter >50 mm or LA volume >60 mL/m2).660
odically assessed, irrespective of the therapy modality. Finally, education
Prophylaxis of infective endocarditis is indicated as appropriate.5
and the engagement of the family is key in patients with rheumatic MS,
since it usually affects young individuals and women of childbearing age.
10.2.3. Indications for intervention
The type (PMC or surgery) and timing of treatment should be decided
10.3. Degenerative mitral stenosis with
based on clinical characteristics, the anatomy of the valve and subvalv-
ular apparatus, and local expertise.661–663 The management of clinically mitral annular calcification
severe rheumatic MS is summarized in Figure 14 and Recommendation Patients presenting with MAC are elderly and have significant comorbid-
Table 8. ities, including disease of other valves. Mitral annular calcification is also an
In general, indication for intervention should be limited to patients indicator of cardiovascular disease severity and is associated with an in-
with clinically severe rheumatic MS (MVA <1.5 cm2) in whom PMC is creased risk of AF, stroke, and death.670,671 The incidence of MAC varies
expected to have a significant impact on clinical outcome. In higher- substantially, depending on the age of the studied population and the im-
income countries, where the incidence of rheumatic fever and the num- aging modality used. It can be a consequence of many different patho-
ber of PMCs performed is low, this treatment should be restricted to logical processes and, depending on the underlying disease, can be
expert operators in specialized centres to improve safety and proced- accompanied by stenosis, regurgitation, or both. However, most patients
ural success rate.661,664 Efforts should be made to increase the availabil- with MAC do not have significant valvular dysfunction.647,672
ity of PMC in lower-income countries, where access to treatment is Generally, MS occurs due to calcific extension into the MV leaflets or
limited for economic reasons.665,666 Percutaneous mitral commissurotomy subvalvular apparatus, and in some patients it is associated with com-
may be also considered in symptomatic patients with an MVA of bined MR.673 Treatment options (including transcatheter and surgical
>1.5 cm2, if symptoms cannot be explained by another cause and approaches) are high-risk procedures and evidence from RCTs is
if the anatomy is favourable (see Table 8). Percutaneous mitral lacking.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 47 ---
ESC Guidelines 4681
Patient with rheumatic mitral stenosis and mitral valve area ≤1.5 cm2
High risk of embolism
Contraindication
or haemodynamic Symptoms
to PMCb
decompensationa
Exercise testing Favourable
anatomical
characteristicsc
Symptoms
Contraindication to Favourable
or unfavourable clinical
characteristics for PMC characteristicsc
Contraindication
or high risk
for surgery
Follow-up PMC Surgeryd Surgery PMC Surgery
Figure 14 Management of clinically severe rheumatic mitral stenosis (mitral valve area ≤1.5 cm2). AF, atrial fibrillation; LA, left atrium; MS, mitral
stenosis; MV, mitral valve; MVA, mitral valve area; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary hypertension;
PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation. aHigh thromboembolic risk: history
of systemic embolism, dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic decompensation: SPAP >50 mmHg at rest,
need for major NCS, desire for pregnancy or pregnant. bSee Table 8. cFavourable = absence of unfavourable characteristics for PMC defined by un-
favourable anatomical characteristics [echocardiographic score >8, Cormier score 3 (calcification of MV of any extent as assessed by fluoroscopy),
severe TR] or unfavourable clinical characteristics (old age, history of commissurotomy, NYHA class IV, permanent AF, severe PH) (for the definition
of scores see Supplementary data online, Table S3). dIf operative risk is low.
10.3.1. Evaluation Calcifications are usually more prominent at the posterior aspect of the
Echocardiography is used for initial evaluation, but is frequently limited annulus.
by acoustic shadowing due to severe calcification. Evaluation of MVA by
planimetry is less reliable than in rheumatic MS, and TOE should
therefore be used liberally. Degenerative MS can coexist with varying 10.3.2. Indications for intervention
degrees of MR. Mean transmitral gradient has been shown to be asso- Intervention is recommended in symptomatic patients who are not re-
ciated with increased mortality irrespective of MR severity.674 sponsive to medical therapy, weighing the potential benefits of the pro-
Electrocardiogram-gated CCT is necessary to assess the degree and lo- cedure against its associated risks. In elderly patients with degenerative MS
cations of calcifications, especially if an intervention is planned.647,674–676 and MAC, surgery is technically challenging and high risk. However,
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 48 ---
4682 E S C G u id e l in e s
surgical MV repair or replacement with extensive decalcification and Table 8 Contraindications for percutaneous mitral
patch reconstruction of the annulus can be performed in selected patients commissurotomy in rheumatic mitral stenosis
at experienced centres (e.g. young patients post-chest radiation), where
mortality rates of <5% have been reported.677–679 Contraindications
Degenerative MS is not amenable to PMC because commissural fu- MVA >1.5 cm2 a
sion is absent. In symptomatic high-risk patients with suitable anat-
LA thrombusb
omy, transcatheter implantation of a TAVI prosthesis in the mitral
More than mild MR
position is feasible but associated with frequent complications, includ-
ing LVOT obstruction, valve embolization, stroke, and haemolysis due Severe or bi-commissural calcification
to PVL. Open surgical valve replacement via the LA with a TAVI device Absence of commissural fusion
is an alternative that allows complete anterior leaflet removal;680 Severe concomitant AV disease, or severe combined tricuspid stenosis and
however, mortality remains high. The use of dedicated TMVI devices regurgitation requiring surgery
is therefore encouraged because it appears to be safer.542,681 Heart Concomitant CAD requiring bypass surgery
Team evaluation should guide the choice of treatment avoiding futility,
AV, aortic valve; CAD, coronary artery disease; LA, left atrium/left atrial; MR, mitral
because mortality remains high, even after successful treatment
regurgitation; MVA, mitral valve area; OAC, oral anticoagulation; PMC, percutaneous
(10%–30% within 1 year).
mitral commissurotomy; TOE, transoesophageal echocardiography.
aPMC may be considered in patients with MVA of >1.5 cm2 with symptoms that cannot be
explained by another cause and if the anatomy is favourable.
Recommendation Table 8 — Recommendations on bWhen the thrombus is located in the LA appendage, PMC may be considered in patients
indications for percutaneous mitral commissurotomy, with contraindications to surgery or those without urgent need for intervention, in whom
mitral valve surgery, and transcatheter intervention OAC can be safely given for 1–3 months, provided repeat TOE confirms resolution of
in clinically severe rheumatic and degenerative mitral thrombus.
stenosis (see also Supplementary data online,
Evidence Table 21)
11. Tricuspid regurgitation
Recommendations Classa Levelb
11.1. Prevalence and aetiology
PMC is recommended in symptomatic patients in the
TR is a common echocardiographic finding in the general population,
absence of unfavourable characteristics for PMC.c I B
with higher prevalence in women and older patients. Trivial or mild
651–653,662,665
TR is mostly a benign condition. Significant TR (≥ moderate) has a re-
PMC is recommended in any symptomatic patients
I C ported age- and sex-adjusted prevalence of 0.55% (4% in people aged
with a contraindication or at high risk for surgery. ≥75 years).682 Severe TR is associated with increased risk of death
MV surgery is recommended in symptomatic and HF, independent of comorbidities, ventricular function, and pul-
I C
patients who are not suitable for PMC. monary pressures.683–686
PMC should be considered as initial treatment in Only 8%–10% of patients with TR present with clear anatomical ab-
symptomatic patients with suboptimal anatomy but IIa C normalities of the TV apparatus (primary TR), which can be due to infect-
no unfavourable clinical characteristics for PMC.c ive endocarditis, RHD, carcinoid syndrome, congenital abnormalities (e.g.
PMC should be considered in asymptomatic patients Ebstein’s anomaly), chest radiation, or myxomatous disease, as well as
without unfavourable clinical and anatomical trauma or iatrogenic valve damage (e.g. after endomyocardial biopsy).682
Cardiac implantable electronic device (CIED)-related TR represents a
characteristics for PMC, and:
separate entity requiring a specific diagnostic approach and manage-
• High thromboembolic risk (history of systemic
ment.687 In patients with a CIED, diagnostic efforts should be made to
embolism, dense spontaneous contrast in the LA, IIa C
clarify if the lead is the cause of TR (CIED-related TR) or incidental new-onset or paroxysmal AF), and/or
(CIED-associated TR).688 • High risk of haemodynamic decompensation
In patients with secondary TR, TV leaflets are structurally normal and
(SPAP >50 mmHg at rest, need for major NCS,
regurgitation is caused by annular dilatation and/or leaflet tethering due
pregnant or desire for pregnancy).
to RA dilatation, and/or RV dilation and dysfunction. Based on the main
TMVI may be considered in symptomatic patients
morphological and haemodynamic characteristics, two phenotypes of
with extensive MAC and severe MV dysfunction at secondary TR have been proposed:689 (i) atrial secondary TR, mainly
experienced Heart Valve Centres with expertise in IIb C due to AF and characterized by the absence of significant leaflet tether-
complex MV surgery and transcatheter ing, but with marked RA and annular dilatation along with preserved RV
interventions.542,680,681
size/function, pulmonary pressure, and LV function; and (ii) ventricular
secondary TR, due to annular dilatation and leaflet tethering as a con-
AF, atrial fibrillation; LA, left atrium/left atrial; MAC, mitral annular calcification; MV, mitral
valve; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary sequence of left-sided ventricular or valvular disease (post-capillary
hypertension; PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary PH), pre-capillary PH, or primary RV cardiomyopathy/ischaemia (also
artery pressure; TMVI, transcatheter mitral valve implantation; TR, tricuspid regurgitation. after left-sided valve surgery).690 At an advanced disease stage, these
aClass of recommendation.
bLevel of evidence. two phenotypes may no longer be distinguishable, and therefore early
cUnfavourable characteristics for PMC can be defined by the presence of several of the characterization is key to determine outcome.691,692 Evidence of an im-
following characteristics: clinical characteristics (old age, history of commissurotomy, NYHA pact on patient management is currently lacking; therefore, current
class IV, permanent AF, severe PH); anatomical characteristics [echocardiographic score >8,
recommendations for intervention consider mainly primary vs second-
Cormier score group 3 (calcification of MV of any extent as assessed by fluoroscopy),
severe TR] (for the definition of scores see Supplementary data online, Table S3). ary TR.
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 49 ---
ESC Guidelines 4683
11.2. Evaluation Electrocardiogram-gated CCT with dedicated protocols ensuring
Echocardiography is recommended to assess patients with TR45 and sufficient contrast enhancement of the right heart cavities provides de-
tailed characterization of the RA, RV, and vena cava anatomy, the loca-
should include evaluation of severity and aetiology (including character-
tion of the right coronary artery, and is crucial to assess suitability and
ization of left-sided heart disease and, if applicable, CIED lead location
device sizing for several transcatheter interventions.689,697
and interaction with the valve apparatus), the impact of TR on the right-
Before any intervention is considered, careful evaluation of TR aeti-
sided chambers (RV and RA size and function), and assessment of cen-
ology, disease stage (TR severity, RV and LV dysfunction, and PH), pa-
tral venous (inferior vena cava) and pulmonary pressures. Transthoracic
tient operative risk, and likelihood of recovery by a dedicated
echocardiography provides sufficient diagnostic information in most
collaborative Heart Team is recommended (Figure 16). Dedicated clin-
patients. Transoesophageal echocardiography is necessary for when
ical risk scores for TR patients have been described recently. The
visualization of the TV apparatus. In candidates for an intervention, ad-
TRI-SCORE709 and the STS isolated TV risk calculator710 take into con-
vanced techniques, such as strain analysis and 3D echocardiography,
sideration clinical and echocardiographic signs of RV dysfunction, and
should also be applied when available.
secondary organ (particularly hepatic and renal) impairment. They Assessment of TR severity should be ideally performed in euvolae-
both allow improved estimates of peri-procedural risk in patients
mic status, with optimized pulmonary and systemic pressures, and
with severe TR undergoing surgery and possibly help to avoid futile in-
based on an integrative approach considering multiple qualitative and
quantitative parameters (Figure 15).45,693 A grading scheme extending terventions.84,711 The importance of risk stratification was demon-
strated in a recent registry analysis (n = 2413) comparing any beyond severe, including ‘massive’ and ‘torrential’ grades, has been pro-
interventions with conservative management. Early TV intervention
posed to refine TR reduction assessment after transcatheter interven-
tions and has been used in several studies.694,695 Although this (transcatheter valve repair or surgery) was associated with improved
mid-term survival in patients with a low or intermediate TRI-SCORE
five-grade scale may be associated with a proportional increase in
symptoms and event risk,694,695 an intervention should be considered (up to 5 points), while patients with a high TRI-SCORE (≥6) did not de-
rive any benefit compared with conservative management.696
without delay, as soon as TR is severe, with the aim of reducing TR
to moderate or less.696,697 Moreover, isolated TV surgery (repair or replacement) improved sur-
vival at 10 years in patients with a low TRI-SCORE (≤3). The same
Echocardiographic assessment of the RV is challenging due to its
benefit was observed in patients with an intermediate TRI-SCORE
complex geometry, imaging constraints, and the high dependency on
(4–5) after successful TV repair only.689,697,709 Patients with moderate
loading conditions. When accurate measurements of RV size and func-
or severe TR should be regularly followed up clinically and by echocar-
tion, as well as RV volume, are necessary for decision-making, CMR
should be used because of its high accuracy and reproducibility.698,699 diography at least every 6 months.
In Figure 15, upper limits of normal for different RV size parameters
are provided to guide definition of RV dilatation and remodelling. In 11.3. Medical therapy
the setting of severe TR, RV function is often overestimated and there- Patients with relevant TR should be first treated according to the as-
fore the most conservative/cautious thresholds are suggested for the sumed aetiology, including optimal HF treatment, pulmonary vasodila-
currently used echocardiographic parameters to identify RV dysfunc- tors for PH, and rhythm control for AF.339,693
tion at the earliest stage possible. Cut-off values for severe RV dysfunc- In the case of HF symptoms, diuretics should be initiated in a step-
tion are also provided to indicate high-risk or possibly futile wise approach,339 beginning with loop diuretics eventually combined
interventions. Although robust validation is lacking, all these reference with aldosterone antagonists, thiazide diuretics, and/or SGLT2is.712
values are chosen based on large multicentre reports of normative data However, according to current knowledge, medical therapy has very
and outcomes.60,697,700–704 limited effect on the evolution of TR severity and none of these mea-
Echocardiography often underestimates pulmonary pressures in sures should delay evaluation of an intervention at an expert centre.713
cases of severe TR.705 Right heart catheterization is therefore recom-
mended in all candidates for an intervention to assess the haemo-
11.4. Indications for intervention
dynamic consequences of TR on the RA and venous circulation (e.g.
ventricularization of the RA pressure curves), measure end-diastolic 11.4.1. Surgery
RV pressure, and document volume overload. The assessment of pul- Patients are often referred too late for surgery when significant RV and
monary pressures and vascular resistance are key to exclude masked other organ failure have occurred. Isolated TV surgery has therefore
severe pre-capillary PH.706 been considered to be generally high risk, with in-hospital mortality
RV–pulmonary artery coupling refers to the ability of the RV systolic rates of 8%–10% in several reports,714,715 but contemporary cohorts
performance to match a given pulmonary afterload maintaining ad- have demonstrated improved outcomes when patients are referred
equate cardiac output, and can be measured invasively or approxi- earlier and more effective techniques are used.716 Valve repair using
mated using echocardiography [i.e. tricuspid annular plane systolic an annuloplasty ring is preferred over replacement, whenever technic-
excursion (TAPSE)/SPAP].707,708 RV–pulmonary artery uncoupling ally feasible, especially in low-risk patients with suitable anatomy.709
(low TAPSE/SPAP) occurs when sustained increases in afterload can- However, TV replacement may be necessary in cases of advanced dis-
not be matched by RV contractile reserve and has been associated ease with marked annular dilatation and leaflet tethering.688,717 For
with poor prognosis in different HF conditions, including severe TR. CIED-related TR, preparation of any entrapped tricuspid leaflet and
Although not yet prospectively validated, this index may improve possibly lead extraction with implantation of an epicardial system has
risk stratification. been associated with improved TV function.688,717
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 50 ---
4684 E S C G u id e l in e s
(cid:1)(cid:6)(cid:27)(cid:16)(cid:29)(cid:15)(cid:27)(cid:15)(cid:29)(cid:4)(cid:17)
‡(cid:16)(cid:27)(cid:29)(cid:16)(cid:25)(cid:16)(cid:17)(cid:27)™(cid:17)(cid:15)š(cid:25)(cid:16)(cid:27)(cid:30)(cid:2)(cid:17)(cid:25)(cid:12)(cid:11)(cid:27)(cid:5)(cid:15)(cid:27)(cid:15)(cid:29)(cid:11)(cid:10)(cid:25)(cid:14)(cid:17)(cid:7)(cid:17)(cid:12)(cid:15)š(cid:25)(cid:8)(cid:17)(cid:4)(cid:17)(cid:30)(cid:17)(cid:25)(cid:15)(cid:17)(cid:10)(cid:15)(cid:29)(cid:10)(cid:2)
(cid:27)(cid:30)(cid:2)(cid:17)(cid:25)(cid:12)(cid:17)(cid:10)(cid:15)(cid:30)(cid:27)(cid:16)(cid:25)›(cid:17)(cid:15)
(cid:27)(cid:30)(cid:2)(cid:17)(cid:25)(cid:3)(cid:11)(cid:16)(cid:11)(cid:8)(cid:26)(cid:8)(cid:15)(cid:11)(cid:16)(cid:29)(cid:12)(cid:25)(cid:12)(cid:11)(cid:10)(cid:4)(cid:17)(cid:30)(cid:2)(cid:17)(cid:10)(cid:12)(cid:17)(cid:25)œ(cid:11)(cid:10)(cid:17)
(cid:19)(cid:17)(cid:10)(cid:8)(cid:17)š(cid:25)(cid:15)(cid:30)(cid:29)(cid:27)(cid:10)(cid:2)(cid:6)(cid:16)(cid:27)(cid:30)(cid:25)(cid:22)ˆ(cid:25)(cid:19)(cid:11)(cid:5)(cid:5)(cid:16)(cid:17)(cid:30)(cid:25)›(cid:17)(cid:15)(cid:25)˜(cid:29)(cid:15)(cid:3)(cid:25)(cid:17)(cid:27)(cid:30)(cid:16)(cid:26)(cid:25)(cid:5)(cid:17)(cid:27)ž(cid:29)(cid:10)(cid:2)
(cid:20)(cid:12)(cid:3)(cid:11)(cid:12)(cid:27)(cid:30)(cid:14)(cid:29)(cid:11)(cid:2)(cid:30)(cid:27)(cid:5)(cid:3)(cid:29)(cid:12)
(cid:13)(cid:17)(cid:28)(cid:29)(cid:18)‘(cid:6)(cid:27)(cid:10)(cid:15)(cid:29)(cid:15)(cid:27)(cid:15)(cid:29)(cid:4)(cid:17)
(cid:12)(cid:30)(cid:29)(cid:15)(cid:17)(cid:30)(cid:29)(cid:27)(cid:25)(cid:7)(cid:11)(cid:30)(cid:25)(cid:8)(cid:17)(cid:4)(cid:17)(cid:30)(cid:17)(cid:25)(cid:24)(cid:23)
(cid:31)(cid:21)(cid:13)ƒ(cid:25)(cid:30)(cid:27)(cid:14)(cid:29)(cid:6)(cid:8)(cid:25)≥ (cid:25)(cid:28)(cid:28)(cid:25)”(cid:27)(cid:15)(cid:25)•(cid:26)‘(cid:6)(cid:29)(cid:8)(cid:15)(cid:25)(cid:129)†–(cid:144)†(cid:25)(cid:12)(cid:28)(cid:143)(cid:8)—
(cid:9)(cid:17)(cid:10)(cid:27)(cid:25)(cid:12)(cid:11)(cid:10)(cid:15)(cid:30)(cid:27)(cid:12)(cid:15)(cid:27)(cid:25)˜(cid:29)(cid:14)(cid:15)(cid:3)(cid:25)≥(cid:157)(cid:25)(cid:28)(cid:28)
Œ(cid:17)(cid:5)(cid:27)(cid:15)(cid:29)(cid:12)(cid:25)(cid:4)(cid:17)(cid:29)(cid:10)(cid:25)(cid:8)(cid:26)(cid:8)(cid:15)(cid:11)(cid:16)(cid:29)(cid:12)(cid:25)™(cid:11)˜(cid:25)(cid:30)(cid:17)(cid:4)(cid:17)(cid:30)(cid:8)(cid:27)(cid:16)
(cid:1)(cid:6)(cid:27)(cid:10)(cid:15)(cid:29)(cid:15)(cid:27)(cid:15)(cid:29)(cid:4)(cid:17)
ƒ(cid:8)(cid:8)(cid:17)(cid:8)(cid:8)(cid:28)(cid:17)(cid:10)(cid:15)(cid:25)(cid:11)(cid:7)(cid:25)(cid:24)(cid:23)
(cid:20)(cid:23)’ƒ(cid:25)(cid:25) ≥ (cid:141)†(cid:25)(cid:28)(cid:28)(cid:129)
(cid:23)(cid:9)(cid:11)(cid:16)(cid:25)(cid:25) ≥(cid:141)€(cid:25)(cid:28) (cid:143)“(cid:17)(cid:27)(cid:15)
(cid:23)‡(cid:25)(cid:25) ≥€†‰
(cid:144)(cid:19)(cid:25)(cid:9)(cid:22)ƒ(cid:25)(cid:25)≥(cid:157)€(cid:25)(cid:28)(cid:28)(cid:129)
Ÿ(cid:17)(cid:12)(cid:3)(cid:27)(cid:10)(cid:29)(cid:8)(cid:28)(cid:8)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:30)(cid:26)(cid:25)(cid:24)(cid:23) (cid:22)(cid:21)(cid:20)(cid:19)(cid:18)(cid:30)(cid:17)(cid:16)(cid:27)(cid:15)(cid:17)(cid:14)(cid:25)(cid:24)(cid:23) (cid:13)(cid:17)(cid:12)(cid:11)(cid:10)(cid:14)(cid:27)(cid:30)(cid:26)(cid:25)(cid:24)(cid:23)
(cid:22)(cid:27)(cid:30)(cid:14)(cid:29)(cid:11)(cid:4)(cid:27)(cid:8)(cid:12)(cid:6)(cid:16)(cid:27)(cid:30)(cid:25)(cid:12)(cid:3)(cid:27)(cid:10)(cid:2)(cid:17)(cid:8)
(cid:23)(cid:9)(cid:25)(cid:14)(cid:29)(cid:16)(cid:27)(cid:15)(cid:27)(cid:15)(cid:29)(cid:11)(cid:10)(cid:27) (cid:23)(cid:9)(cid:25)(cid:14)(cid:26)(cid:8)(cid:7)(cid:6)(cid:10)(cid:12)(cid:15)(cid:29)(cid:11)(cid:10)(cid:27) (cid:31)(cid:6)(cid:16)(cid:28)(cid:11)(cid:10)(cid:27)(cid:30)(cid:26)(cid:25)(cid:5)(cid:30)(cid:17)(cid:8)(cid:8)(cid:6)(cid:30)(cid:17)(cid:8)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:27)(cid:25)(cid:29)(cid:24)(cid:23)(cid:27)(cid:22)(cid:21)(cid:20)(cid:21)(cid:19)(cid:29)(cid:23)(cid:18)(cid:24)(cid:21)(cid:17)(cid:16) (cid:31)(cid:30)(cid:29)(cid:24)(cid:14)(cid:26)(cid:7)(cid:10)(cid:18)(cid:12)(cid:20)(cid:23)(cid:13)(cid:18)(cid:16)
(cid:5)(cid:19)(cid:21)(cid:15)(cid:12)(cid:27)(cid:8)(cid:23)(cid:25)(cid:25)(cid:27)(cid:19)(cid:14)(cid:29)(cid:5)(cid:4)(cid:16)
(cid:127)(cid:129)(cid:141)(cid:25)(cid:28)(cid:28)(cid:143)(cid:28)(cid:129)
(cid:24)ƒ(cid:31)(cid:13)(cid:20)(cid:25)(cid:25) (cid:25)(cid:25)(cid:25)„‚(cid:157)(cid:25)(cid:28)(cid:28)
(cid:28)(cid:31)ƒ(cid:31)(cid:25) (cid:127)(cid:129)†(cid:25)(cid:28)(cid:28)Œ(cid:2)
(cid:23)(cid:9)(cid:25)(cid:24)(cid:19)(cid:21)(cid:25)(cid:8)…(cid:25)(cid:25)(cid:25)(cid:25)„‚†(cid:25)(cid:12)(cid:28)(cid:143)(cid:8)
(cid:31)ƒˆ(cid:31)(cid:25) ≤‚€(cid:25)(cid:28)(cid:28)Œ(cid:2)
(cid:31)(cid:30)(cid:29)(cid:22)(cid:23)(cid:24)(cid:15)(cid:24)(cid:23)(cid:27)(cid:22)(cid:21)(cid:20)(cid:21)(cid:19)(cid:29)(cid:23)(cid:18)(cid:24)(cid:21)(cid:17)(cid:16) (cid:23)(cid:9)(cid:25)‡ˆ(cid:13)(cid:25)(cid:25)(cid:25)(cid:25)„(cid:129)(cid:144)‰ (cid:31)(cid:9)(cid:23)(cid:25) (cid:127)(cid:129)(cid:25)ˆŽ
(cid:127)(cid:129)‚(cid:25)(cid:28)(cid:28)(cid:143)(cid:28)(cid:129) (cid:23)(cid:9)(cid:25)Š (cid:13)(cid:25) (cid:25)(cid:25)(cid:25)„(cid:129)‚‰
(cid:144)(cid:19)(cid:25)(cid:23)(cid:9)(cid:25)(cid:20)‡ „€†‰
(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)
(cid:9)(cid:19)(cid:23)(cid:12)(cid:10)(cid:26)(cid:8)(cid:23)(cid:24)(cid:29)(cid:27)(cid:18)(cid:18)(cid:10)(cid:25)(cid:10)(cid:26)(cid:29)(cid:23)(cid:18)(cid:24)(cid:21)(cid:17)(cid:16) ‡ƒ(cid:22)(cid:25) (cid:25)(cid:25)(cid:25)≤(cid:144)€‰ (cid:5)(cid:13)(cid:26)(cid:20)(cid:15)(cid:12)(cid:27)(cid:8)(cid:23)(cid:25)(cid:25)(cid:27)(cid:19)(cid:14)(cid:29)(cid:5)(cid:4)(cid:16)
(cid:127)(cid:129)‚(cid:25)(cid:28)(cid:28)(cid:143)(cid:28)(cid:129)
(cid:28)(cid:31)ƒ(cid:31)(cid:25) (cid:127)(cid:129)†(cid:25)(cid:28)(cid:28)Œ(cid:2)
(cid:31)ƒˆ(cid:31)(cid:25) >‚€(cid:25)(cid:28)(cid:28)Œ(cid:2)
(cid:31)(cid:30)(cid:29)(cid:21)(cid:18)(cid:24)(cid:15)(cid:24)(cid:23)(cid:27)(cid:26)(cid:20)(cid:13)(cid:25)(cid:23)(cid:12) (cid:6)(cid:21)(cid:11)(cid:21)(cid:19)(cid:21)(cid:29)(cid:31)(cid:30)(cid:29)(cid:24)(cid:14)(cid:26)(cid:7)(cid:10)(cid:18)(cid:12)(cid:20)(cid:23)(cid:13)(cid:18)(cid:16)
(cid:31)(cid:9)(cid:23)(cid:25) ≤(cid:129)(cid:25)ˆŽ
(cid:11)(cid:13)(cid:25)(cid:10)(cid:22)(cid:21)(cid:29)(cid:23)(cid:18)(cid:24)(cid:21)(cid:17)(cid:16) (cid:24)ƒ(cid:31)(cid:13)(cid:20)(cid:25)(cid:25) (cid:25)(cid:25)(cid:25)„‚†(cid:25)(cid:28)(cid:28)
(cid:127) €(cid:25)(cid:28) (cid:143)(cid:28)(cid:129) (cid:23)(cid:9)(cid:25)(cid:24)(cid:19)(cid:21)(cid:25)(cid:8)…(cid:25)(cid:25)(cid:25)(cid:25)„‹(cid:25)(cid:12)(cid:28)(cid:143)(cid:8)
(cid:23)(cid:9)(cid:25)‡ˆ(cid:13)(cid:25)(cid:25)(cid:25)(cid:25)„‚‚‰
(cid:23)(cid:9)(cid:25)Š (cid:13)(cid:25) (cid:25)(cid:25)(cid:25)„ ‰ (cid:6)(cid:21)(cid:11)(cid:21)(cid:19)(cid:21)(cid:29)(cid:5)(cid:4)(cid:16)
(cid:31)(cid:30)(cid:29)(cid:21)(cid:18)(cid:24)(cid:15)(cid:26)(cid:14)(cid:26)(cid:20)(cid:13)(cid:25)(cid:23)(cid:12)
(cid:144)(cid:19)(cid:25)(cid:23)(cid:9)(cid:25)(cid:20)‡ „(cid:144)€‰ (cid:31)(cid:9)(cid:23)(cid:25) (cid:127)€(cid:25)ˆŽ
(cid:11)(cid:13)(cid:25)(cid:10)(cid:22)(cid:21)(cid:29)(cid:23)(cid:18)(cid:24)(cid:21)(cid:17)(cid:16) (cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)(cid:25)
(cid:127)(cid:144)(cid:157)(cid:25)(cid:28) (cid:143)(cid:28)(cid:129) ‡ƒ(cid:22)(cid:25) (cid:25)(cid:25)(cid:25)≤(cid:129)(cid:129)‰ (cid:28)(cid:31)ƒ(cid:31)(cid:25)(cid:25) (cid:127)(cid:144)€(cid:25)(cid:28)(cid:28)Œ(cid:2)
Figure 15 Echocardiographic and invasive assessment of tricuspid regurgitation. 3D, three-dimensional; CIED, cardiac implantable electronic device;
CW, continuous-wave; EROA, effective regurgitant orifice area; FAC, fractional area change; FWS, free wall strain; GLS, global longitudinal strain; mPAP,
mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PISA, proximal isovelocity surface area; PVR,
pulmonary vascular resistance; RF, regurgitant fraction; RV, right ventricle/ventricular; RVEF, right ventricular ejection fraction; RVol, regurgitant volume;
TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TR, tricuspid regurgitation; VCA, vena contracta area; WU, wood unit.
aRV apical focused view.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 51 ---
ESC Guidelines 4685
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:29)(cid:25)(cid:24)(cid:28)(cid:23)(cid:29)(cid:22)(cid:21)(cid:20) (cid:16)(cid:22)(cid:26)(cid:15)(cid:21)(cid:18)(cid:30)(cid:29)(cid:28)(cid:22)(cid:26)(cid:25)(cid:22)(cid:14) (cid:12)(cid:13)(cid:30)(cid:11)(cid:10)(cid:30)(cid:29)(cid:28)(cid:22)(cid:26)(cid:25)(cid:22)(cid:14)(cid:25)(cid:19)(cid:28)(cid:23)(cid:27)(cid:30)(cid:23)(cid:27)
(cid:30)(cid:26)(cid:19)(cid:25)(cid:23)(cid:20)(cid:18)(cid:17)(cid:29)(cid:22)(cid:18)(cid:23) (cid:19)(cid:28)(cid:23)(cid:27)(cid:30)(cid:23)(cid:27)(cid:25)(cid:23)(cid:27)(cid:13)(cid:27)(cid:21)(cid:28)(cid:29)(cid:20) (cid:30)(cid:27)(cid:29)(cid:28)(cid:22)(cid:11)(cid:22)(cid:9)(cid:20)(cid:8)(cid:18)(cid:27)(cid:7)(cid:24)(cid:30)(cid:26)(cid:28)(cid:23)(cid:18)
(cid:6)(cid:23)(cid:23)(cid:27)(cid:23)(cid:23)(cid:18)(cid:27)(cid:26)(cid:29)(cid:25)(cid:22)(cid:14)
(cid:5)(cid:4)(cid:25)(cid:14)(cid:10)(cid:26)(cid:7)(cid:29)(cid:28)(cid:22)(cid:26)
(cid:129)(cid:5)(cid:143)(cid:157) (cid:16) (cid:5)(cid:12)(cid:30) (cid:6)(cid:26)(cid:30)(cid:29)(cid:22)(cid:18)(cid:28)(cid:7)(cid:30)(cid:11) (cid:5)(cid:28)(cid:9)(cid:24)(cid:29)(cid:25)(cid:24)(cid:27)(cid:30)(cid:21)(cid:29)
(cid:23)(cid:10)(cid:28)(cid:29)(cid:30)(cid:2)(cid:28)(cid:11)(cid:28)(cid:29)(cid:20) (cid:7)(cid:30)(cid:29)(cid:24)(cid:27)(cid:29)(cid:27)(cid:21)(cid:28)(cid:3)(cid:30)(cid:29)(cid:28)(cid:22)(cid:26)
(cid:16)(cid:22)(cid:18)(cid:22)(cid:21)(cid:2)(cid:28)(cid:19)(cid:28)(cid:29)(cid:28)(cid:27)(cid:23)
(cid:5)(cid:28)(cid:23)(cid:1)(cid:25)(cid:30)(cid:23)(cid:23)(cid:27)(cid:23)(cid:23)(cid:18)(cid:27)(cid:26)(cid:29)
(cid:127)(cid:27)(cid:30)(cid:21)(cid:29)(cid:25)(cid:129)(cid:27)(cid:30)(cid:18)(cid:25)(cid:29)(cid:21)(cid:27)(cid:30)(cid:29)(cid:18)(cid:27)(cid:26)(cid:29)(cid:25)(cid:21)(cid:27)(cid:7)(cid:22)(cid:18)(cid:18)(cid:27)(cid:26)(cid:19)(cid:30)(cid:29)(cid:28)(cid:22)(cid:26)
(cid:141)(cid:16)(cid:11)(cid:30)(cid:23)(cid:23)(cid:25)(cid:143)(cid:144)
Figure 16 Stepwise evaluation of patients with tricuspid regurgitation. RV, right ventricle/right ventricular. aSee Supplementary data online, Table S4.
11.4.1.1. Patients without indication for left-sided valve Mild TR with associated significant annular dilatation or moderate
surgery TR, if left uncorrected at the time of left-sided valve surgery, will pro-
In patients with severe TR but without the need for left-sided valve sur- gress in approximately one-quarter of patients and is associated with
gery, surgical intervention is recommended in operable symptomatic worse outcome.690,722 In patients with moderate TR, TV repair annu-
patients with primary TR (Figure 17; Recommendation Table 9).718 loplasty during MV surgery should be considered, because large retro-
Furthermore, it should be considered in symptomatic patients with sec- spective studies723,724 and two recent RCTs have shown beneficial
ondary TR, or in asymptomatic patients with primary or secondary TR effects on TR progression and RV remodelling over time.725,726
and signs of RV dilatation or RV function deterioration.719 However, However, no effects on mortality, HF events, or reoperation were ob-
patients with severe LV/RV dysfunction or PH do not qualify due to served in the repair group.725,727 Concomitant TV repair has also
high operative risk.84,686,720 been associated with a higher risk of conduction disturbances requir-
ing pacemaker implantation (up to 14%),725,728 with potential negative
impacts on longer-term outcomes.729,730 In patients with mild TR and
11.4.1.2. Patients with indication for left-sided valve surgery annular dilatation (≥40 mm or >21 mm/m2) undergoing left-sided
Severe primary or secondary TR is unlikely to improve after isolated valve surgery, previous observational studies have demonstrated a
surgical treatment of left-sided valve disease, and reoperation for benefit of concomitant TV repair in terms of TR progression723,724
TR treatment is associated with high peri-operative mortality.721 and RV function,731 and a trend towards improved long-term survival.724
Therefore, TV surgery is recommended at the time of the index However, a subanalysis of a recent RCT did not identify any difference in
procedure. the progression of TR or other outcomes in this category of patients
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 52 ---
4686 E S C G u id e l in e s
during a 2-year follow-up period.725 In turn, the need of pacemaker im- 11.4.2. Transcatheter techniques
plantation after surgery led to a subsequent increase in HF hospita- Several transcatheter approaches for the treatment of TR have been
lizations, endocarditis, and mortality.729 Annuloplasty may therefore developed, including TEER, direct annuloplasty, and orthotopic and het-
be considered after careful evaluation of the risk factors for progres- erotopic TV replacement. Data from large multicentre registries, single-
sive annular dilatation and TR (AF, RA size, pulmonary pressures, arm clinical trials, and two recent RCTs in patients with severe TR at
etc.), balancing against the risk of possible pacemaker implantation intermediate and high risk for surgery have shown the safety of trans-
(Supplementary data online, Table S5).732 catheter repair, as well as the ability to reduce TR to moderate or less in
Patient with tricuspid regurgitation
Need for left-sided valve surgery
Severity/aetiology of TR Severity/aetiology of TR
Severe primary Mild Moderate or severe
or secondary TR secondary TR primary or secondary TR
Severe RV/LV TA dilatation
dysfunction or (≥40 mm or >21 mm/m2)
severe pre-capillary
pulmonary hypertension
No concomitant
TV surgery
Symptomatic
RV dilatation or Appropriate for surgery
RV function according to
deterioration the Heart Team
Transcatheter
Medical therapy TV surgeryb
therapya
Figure 17 Management of patients with tricuspid regurgitation. LV, left ventricle/left ventricular; RV, right ventricle/right ventricular; TA, tricuspid
annulus; TR, tricuspid regurgitation; TV, tricuspid valve. aThe Heart Team with expertise in the treatment of TV disease evaluates anatomical eligibility
for transcatheter therapy including jet location, coaptation gap, leaflet tethering, and potential interference with pacing lead. bRepair whenever possible,
particularly in cases of moderate TR or mild TR with significant TA dilatation.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 53 ---
ESC Guidelines 4687
more than 80% of cases when anatomical suitability was con-
Patients with tricuspid regurgitation and left-sided valvular
firmed.713,733–735 The Clinical Trial to Evaluate Cardiovascular
heart disease requiring surgery
Outcomes in Patients Treated With the Tricuspid Valve Repair
Concomitant TV surgeryc is recommended in
System (TRILUMINATE) Pivotal Trial showed also a lower incidence
patients with severe primary or secondary I B
of the composite endpoint of death from any cause or TV surgery,
TR.725,731,743,744
HF hospitalization, and improvement in quality of life as measured
with the KCCQ score after tricuspid TEER compared with medical Concomitant TV repair should be considered in
treatment that was exclusively driven by improved quality of life patients with moderate primary or secondary TR, to
IIa B
[11.7 points (95% CI, 6.8–16.6); P <0.001].713 At 2 years, a lower inci- avoid progression of TR and RV
dence of HF hospitalizations has been observed in the intervention remodelling.723,724,726,731
group, despite a high rate of crossovers (59%).736 Concomitant TV repair may be considered
Another investigator-initiated RCT (the Tri.Fr trial) demonstrated in selected patients with mild secondary TR
the benefit of tricuspid TEER in combination with GDMT over medical and tricuspid annulus dilatation (≥40 mm or IIb B
therapy alone, for a composite score driven by improved PROMs.737 >21 mm/m2), to avoid progression of TR and RV
Another recent RCT (the Edwards EVOQUE Transcatheter remodelling.723–726,731,743
Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety
Patients with severe tricuspid regurgitation without left-sided
and Clinical Efficacy using a Novel Device (TRISCEND) II trial), compar-
valvular heart disease requiring surgery
ing transcatheter TV replacement with optimized medical therapy in
patients with symptomatic severe TR, showed similar results with a TV surgeryc is recommended in symptomatic
win ratio favouring TV replacement mainly explained by symptom patients with severe primary TR without severe RV I C
and quality-of-life improvement. In these studies, reverse RV remodel- dysfunction or severe PH.
ling was also observed. However, the safety profile of transcatheter TV TV surgeryc should be considered in asymptomatic
replacement was less favourable, including higher risk for major bleed- patients with severe primary TR who have RV
IIa C
ing (15%) and post-procedural pacemaker implantation in about one- dilatation/RV function deterioration, but without
quarter of the pacemaker-naïve patients after 12 months of follow- severe LV/RV dysfunction or severe PH.
up.738 Based on these data, transcatheter treatment should be consid- TV surgeryc should be considered in patients with
ered to improve quality of life and RV remodelling in high-risk patients
severe secondary TR who are symptomatic or have
with symptomatic severe TR, despite optimal medical therapy, but IIa B
RV dilatation/RV function deterioration, but without
without severe RV dysfunction or pre-capillary PH.
severe LV/RV dysfunction or PH.685,720,745–747
Transvenous CIED lead repositioning or extraction can be consid-
Transcatheter TV treatment should be considered to
ered in selected patients to improve TR or avoid lead jailing before
improve quality of life and RV remodelling in high-risk
any tricuspid interventions, although the efficacy of this procedure is
uncertain and the risk of damaging the TV not negligible.688,717,739 patients with symptomatic severe TR despite optimal IIa A
medical therapy in the absence of severe RV
Recurrent TR after previous tricuspid annuloplasty usually requires car-
diac reoperation for surgical TV replacement. Transcatheter valve-in-ring dysfunction or pre-capillary PH.713,733,735,738,748–751
implantation is an off-label procedure to treat residual TR in high-risk pa-
LV, left ventricle/left ventricular; PH, pulmonary hypertension; RV, right ventricle/right
tients. Challenges are the non-circular shape and the open form of the sur- ventricular; TR, tricuspid regurgitation; TV, tricuspid valve.
gical annuloplasty ring.740 However, transcatheter tricuspid valve-in-valve aClass of recommendation.
procedures have been performed with satisfactory results.741 bLevel of evidence.
cValve repair whenever possible.
Transcatheter TV procedures should be performed at an ex-
perienced Heart Valve Centre with expertise in the treatment of
TV disease (Table 6). Careful evaluation of clinical and anatomical 12. Tricuspid stenosis
suitability is key for appropriate patient and device selection to
achieve optimal TR reduction and symptomatic response to the 12.1. Prevalence and aetiology
therapy.
Tricuspid stenosis (TS) is a relatively rare disease that is most commonly
associated with congenital conditions or enzymatic disorders, such as
Whipple’s or Fabry’s disease. It can also be acquired as an isolated mani-
Recommendation Table 9 — Recommendations on in-
festation of RHD or occur in combination with aortic and/or MV involve-
dications for intervention in tricuspid regurgitation (see
also Supplementary data online, Evidence Tables 22 and 23) ment. Moreover, TS can be the consequence of carcinoid disease due to
serotonin-mediated proliferation, causing apposition of fibroblasts and
Recommendations Classa Levelb extracellular matrix on the valve leaflets and the subvalvular apparatus.
Rare causes include medications (e.g. fenfluramine or methysergide) or in-
Careful evaluation of TR aetiology, stage of the
flow obstruction due to CIED-associated thrombus formation or endo-
disease (i.e. degree of TR severity, RV and LV
carditis with large vegetations.
dysfunction, and PH), patient operative risk, and
I C
likelihood of recovery by a multidisciplinary Heart
12.2. Evaluation
Team is recommended in patients with severe TR
prior to intervention.691,742 Valve evaluation and diagnosis of TS is based on echocardiography, and
consists of the anatomical assessment of the leaflet tissue and the sub-
Continued
valvular apparatus. Leaflet thickening with or without calcifications and
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 54 ---
4688 E S C G u id e l in e s
commissural fusions are pathognomonic findings of rheumatic involve- 13.2. Evaluation and diagnostic pitfalls
ment. A mean diastolic transvalvular gradient of >5 mmHg at a normal
In view of the complex haemodynamic interplay of multiple and mixed
heart rate indicates severe TS.649
valve lesions, assessment by a Heart Team at a Heart Valve Centre and
use of an integrative multimodality approach is key to gain diagnostic
12.3. Medical therapy
certainty, detect cardiac damage, and evaluate therapeutic op-
Medical therapy is a bridge to surgical or transcatheter intervention. tions.761,762 In the light of paucity of data on diagnostic and prognostic
Intensive sodium restriction and concomitant diuretic therapy can parameters in patients with MVHD, assessment largely focuses on
lead to symptom improvement and diminish hepatic congestion. pathophysiological considerations and evidence derived from isolated
valve lesions.
12.4. Indications for intervention Echocardiography is the main tool to diagnose MVHD, assess mech-
Although valve repair is preferred in younger patients,752 valve replace- anism, severity, and associated cardiac damage, and monitor disease
ment is frequently required (see Recommendation Table 10). Biological progression.761 Haemodynamic interdependence between multiple
heart valves have demonstrated adequate mid- and long-term results, valve defects alters the loading and flow conditions, thereby limiting
and are preferred over MHVs because of high thrombogenicity in the the diagnostic validity of measures established to grade single valve de-
low-pressure system.753 In the case of BHV degeneration, transcatheter fects (Table 9). In the presence of MVHD, low-flow states are frequent.
valve-in-valve procedures are good alternatives to re-replacement.754 The continuity equation becomes erroneous if transvalvular flows are
Transcatheter TV implantation is an emerging field, although limited ex- unequal, and pressure half-time (PHT)-derived methods are inaccurate
perience is available for the treatment of TS.749,755 In patients with car- if the ventricular compliance or filling is altered.761 In this context,
cinoid disease, a stable oncological situation is a prerequisite for any TOE can provide important detailed anatomical and mechanistic
valve intervention to maximize survival and valve durability.756 flow-independent information.46,761
Although data are very limited, TV balloon valvuloplasty can be an If symptoms or echocardiographic findings are equivocal, multimod-
option in selected patients with TS (and no relevant TR), as well as in ality diagnostics should be considered on an individual basis to assess
those with concomitant mitral and tricuspid rheumatic pathology.757 the cumulative repercussions of MVHD.
However, in contrast to rheumatic MS, tricuspid rheumatic disease Measures obtained during cardiopulmonary exercise testing reflect
more frequently presents as combined stenosis and regurgitation, the effect of MVHD on functional capacity.52,105,654,761,779 Levels of
which limits the applicability of balloon valvuloplasty. natriuretic peptides such as NT-proBNP correlate with functional
and echocardiographic parameters, and provide incremental prognos-
tic value in patients with mixed aortic disease and MVHD.98,780 AV cal-
Recommendation Table 10 — Recommendations on cium scoring confirms the diagnosis of true severe AS under low-flow
indications for intervention in tricuspid stenosis conditions, as described in Section 8.2.777 Cardiac magnetic resonance
imaging enables the independent assessment of valvular regurgitation
Recommendations Classa Levelb using volumetric methods or direct flow quantification.45,46,522,762,781
Surgeryc is recommended in symptomatic patients Importantly, invasive cardiac output-derived measures based on
I C
with severe TS.d thermodilution or the Fick equation using estimated oxygen uptake
Surgeryc is recommended in patients with severe TS are inaccurate in low-flow conditions or severe TR, commonly pre-
I C sent in MVHD.782
undergoing left-sided valve intervention.e
MV, mitral valve; PMC, percutaneous mitral commissurotomy; TS, tricuspid stenosis; TV, 13.3. Indications for intervention
tricuspid valve.
aClass of recommendation. Given the heterogeneity of clinical scenarios and the lack of evidence on
bLevel of evidence. optimal treatment pathways, it is recommended that patients with
cUsually TV replacement.
MVHD are evaluated for intervention by a collaborative Heart Team
dPercutaneous balloon valvuloplasty can be attempted as a first approach if TS is isolated.
ePercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the MV. at a Heart Valve Centre with experience in multimodality imaging
and treatment of complex VHD.16,764
Patients presenting with a lesion fulfilling criteria for an intervention
based on recommendations for single VHD should be treated accord-
13. Multiple and mixed valvular
ingly. In the remaining patients, assessment of symptoms and functional
heart disease status, as well as cardiac damage (which may be masked by the conse-
quences of concomitant lesions and occur before symptoms manifest),
13.1. Prevalence and undertreatment is required. The risk–benefit ratio of intervention needs to take into
account diagnostic (un)certainty, the mechanisms and severity of
Patients frequently present with disease of more than one native heart
MVHD, and patient-specific factors, as well as procedural options and
valve [multiple VHD (MVHD)], or coexisting stenosis and regurgitation
of the same valve (mixed VHD).758 While the main cause of MVHD or risks to determine the mode, timing, and sequence of valve treatment.
mixed VHD has shifted to degeneration in high-income countries, the
leading aetiology in low- and middle-income countries remains 13.3.1. Multiple valvular heart disease
RHD.758,759 Regurgitation of atrioventricular valves secondary to cardio- Multiple VHD with primary (as opposed to secondary) valvular disease
myopathy or long-standing primary valve disease, and late effects of radi- usually requires surgical treatment of all relevant valvular lesions.
ation therapy, are further causes of MVHD.758,760 Challenges in diagnostic Simultaneous treatment of concomitant severe valve defects is recom-
evaluation coupled with limited data to guide clinical decisions contribute mended and treatment of concomitant moderate AS, or moderate TR,
to late referral and undertreatment of patients with MVHD.758 should be considered (Recommendation Table 11).
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 55 ---
ESC Guidelines 4689
Table 9 Echocardiographic pitfalls, robust measures, and complementary multimodality imaging parameters in mul-
tiple or mixed valvular heart disease
Valve lesion to be assessed
AS AR MS MR
— PHT unreliable PHT unreliable Regurgitant volume ↑
Concomitant AS
valve lesion
LV volume increase less (LV compliance ↓ 764) MR colour-flow jet area ↑
pronounced Low gradient due to low (increased afterload and
(hypertrophy, flow possible transmitral systolic pressure
disproportionate diastolic LV (low-flow state669) gradient46)
pressure overload763)
AR Simplified Bernoulli — PHT unreliable Doppler volumetric
equation overestimates (gradient ↓, altered LV method using net aortic
gradient if LVOT compliance766) forward flow invalid
velocity ↑ 765 MVA by continuity Mitral-to-aortic VTI ratio
equation using aortic unreliable
forward flow unreliable46 (increased transaortic
flow46)
MS Low-flow low-gradient LV volume increase less — Mitral-to-aortic VTI ratio
possible pronounced unreliable
(low-flow state761) (reduced preload761) (increased mitral VTI due to
stenosis767)
Calcifications may shadow
jet area
MR Low-flow low-gradient PHT unreliable PHT unreliable —
(MR-induced low-flow (altered LV compliance763) (altered LA and LV
state768) Doppler volumetric compliance769,770)
AS confused with MR jet method using net mitral Continuity equation
forward flow invalid unreliable
(increased flow46) (increased transmitral
flow761)
TR Low-flow low-gradient — Low gradient possible Regurgitant volume↓ in
possible (low-flow state668) SMR possible
(TR induced low-flow PHT may be less reliable (decreased preload774)
state771) (impaired LV filling due to
ventricular
interdependence772,773)
Robust echocardiography AVA (continuity equation), EROA (PISA), vena Planimetry and 3D EROA (PISA), vena
measurements DVI761 contracta46,761 MVA (TOE)529,775 contracta46,761
In mixed AR and AS: V In mixed MR & MS:
max
and mean gradient reflect mean gradient reflects
combined burden765 combined burden674,776
Alternative imaging CT: AV calcium CMR: regurgitant volume — CMR: regurgitant volume
modalities scoring777 and fraction45,46 and fraction45,46
Measures reported refer to assessment of the valve lesions listed in the columns. Adapted from 761.
3D, three-dimensional; AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; CMR, cardiac magnetic resonance; CT, computed tomography; DVI, Doppler
velocity index; EROA, effective regurgitant orifice area; LA, left atrium/left atrial; LV, left ventricle/left ventricular; LVOT, left ventricular outflow tract; MR, mitral regurgitation; MS, mitral
stenosis; MVA, mitral valve area; PHT, pressure half-time; PISA, proximal isovelocity surface area; SMR, secondary mitral regurgitation; TOE, transoesophageal echocardiography; TR, tricuspid
regurgitation; VHD, valvular heart disease; Vmax, peak transvalvular velocity; VTI, velocity time integral; ↑, increase; ↓, decrease; —, none.
Transcatheter treatment options are established for severe AS (aortic, followed by mitral and tricuspid)—is generally preferred to
(TAVI), rheumatic MS (PMC), and primary MR and TR (TEER or trans- avoid potential haemodynamic deterioration.784,785
catheter replacement) in patients with MVHD at high surgical risk, if MVHD with severe secondary regurgitation of both atrioventricular
anatomy is suitable.401,783 In the context of a transcatheter strategy, valves is usually the consequence of either HFrEF with ventricular SMR
a staged approach—typically beginning with the downstream lesion and secondary TR, or atrial dilatation leading to both atrial MR and TR
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 56 ---
4690 E S C G u id e l in e s
(often TR > MR). While surgery aims to address all relevant valve lesions Recommendation Table 12 — Recommendations on
in a single procedure, a stepwise transcatheter strategy offers the possi- indications for intervention in patients with mixed mod-
bility of reassessing the upstream valve(s) under altered loading condi- erate aortic stenosis and moderate aortic regurgitation
(see also Supplementary data online, Evidence Table 24)
tions, usually 3 months after the initial intervention. In very selected
cases simultaneous transcatheter valve treatment may be consid-
Recommendations Classa Levelb
ered.788,789 However, evidence is limited and primarily derived from
modestly sized observational studies.786–789 Intervention is recommended in symptomatic
patients with mixed moderate AV stenosisc and
I B
moderate regurgitation, and a mean
13.3.2. Mixed aortic valve disease
gradient ≥40 mmHg or V ≥4.0 m/s.790–793
The severity of mixed AV disease is often underestimated and patients max
Intervention is recommended in asymptomatic
with balanced moderate AR and AS show adverse event rates compar-
able to patients with severe isolated AS.790,791 patients with mixed moderate AV stenosisc and
moderate regurgitation with V ≥4.0 m/s, and I C
Transvalvular gradients measured by Doppler reflect the overall max
haemodynamic burden of both regurgitation and stenosis, and are strong- LVEF <50% not attributable to other cardiac
ly associated with adverse outcomes.765,791–793 Therefore, the presence disease.791
of high transvalvular gradients justifies valve intervention in patients
AV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; Vmax, peak
with moderate mixed AV disease, even if regurgitation is graded as mod- transvalvular velocity.
erate and the calculated or planimetric AVA is >1 cm2 (Recommendation aClass of recommendation.
bLevel of evidence.
Table 12). Patients presenting with mixed AV disease, but with gradients
cAVA >1 cm2.
below thresholds for intervention, should undergo careful multimodality
diagnostics including assessment of cardiac damage to inform individual
13.4. Follow-up
treatment strategies. Global longitudinal strain and natriuretic peptides
have shown incremental prognostic value beyond symptom status and Due to the cumulative haemodynamic impact of MVHD or mixed
single lesion severity in patients with preserved LVEF.762,794–796 VHD, progression of its severity and the development of cardiac dam-
age may be faster than in single VHD.761 Therefore, follow-up intervals
should be adjusted according to individual patient characteristics.
13.3.3. Mixed mitral valve disease
Mixed MV disease is usually present in patients with rheumatic valve dis-
ease or MAC. If MVA is ≤1.5 cm2, recommendations for isolated MS 14. Management of patients with
apply. However, patients with an MVA of >1.5 cm2 and moderate prosthetic valves or valve repair
MR may be evaluated for valve replacement based on symptoms, ana-
tomical characteristics, transmitral gradient, and signs of cardiac damage 14.1. Choice of prosthetic valve
such as LA dilatation, AF, or PH.529,674,776,797
When choosing between an MHV and a BHV prosthesis for an individual
patient, age, life expectancy, lifestyle, bleeding and thromboembolic risks,
Recommendation Table 11 — Recommendations on
possibility of pregnancy, and patient preference should be considered.
indications for surgery of concomitant left-sided valvu-
lar heart diseasea Life expectancy is estimated according to age, sex, comorbidities, ethnicity,
and geographical area.798 An MHV is preferred in younger patients with
Recommendations Classb Levelc longer life expectancy and in those with a pre-existing indication for long-
term OAC (Recommendation Table 13). Generally, a BHV is implanted in
Concomitant aortic stenosis patients with shorter life expectancy, increased bleeding risk due to frailty
or comorbidities, in women contemplating pregnancy, and in patients in
SAVR is recommended in patients with severe AS whom stable INRs with adequate times in therapeutic range are unlikely.799 I C
undergoing surgery for another valve. Importantly, the performance of different BHV prostheses can vary consid-
SAVR should be considered in patients with erably.800 The impact of the aetiology of the native valve disease, if any, on
IIa C
moderate ASd undergoing surgery for another valve. the choice between an MHV and a BHV remains unexplored.
Concomitant aortic regurgitation Several large observational studies, smaller RCTs, and meta-analyses
have compared long-term mortality with BHV and MHV prostheses in
AV surgery is recommended in patients with severe
I C patients aged 50–70 years.376,801–805 Some of the studies showed
AR undergoing surgery for another valve.
lower mortality with an MHV in AV patients <60 years and MV patients
Concomitant mitral regurgitation <65 years old,801,804 while others failed to show any differ-
MV surgery is recommended in patients with severe ences.376,802,803 Most of these studies were limited by their observa-
I C
MR undergoing surgery for another valve. tional nature and missing information on the type of prostheses
implanted. RCTs with sufficient statistical power comparing biological
AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; MR, mitral
and mechanical prostheses are warranted.
regurgitation; MV, mitral valve; SAVR, surgical aortic valve replacement; TV, tricuspid valve.
aRecommendations for surgery of concomitant TV disease are listed in Section 11 and Section 12. Replacement of the AV using an autograft (Ross procedure) is an
bClass of recommendation. alternative to an MHV in young patients that should be performed
cLevel of evidence. at experienced centres by operators with dedicated expertise (see
dDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal-flow also Section 8).806 General recommendations are summarized in
conditions. Clinical assessment is essential to determine whether SAVR is appropriate for an
individual patient. Recommendation Table 13.
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 57 ---
ESC Guidelines 4691
Recommendation Table 13 — Recommendations for 14.3. Antithrombotic therapy in patients
prosthetic valve selection
with treated valvular heart disease
Recommendations Classa Levelb 14.3.1. Mechanical heart valves
14.3.1.1. Post-operative anticoagulation and therapeutic targets
Mechanical heart valve Mechanical heart valves require lifelong treatment with a VKA
guided by the INR. Bridging with either therapeutic unfractionated
An MHV is recommended according to the desire of
heparin (UFH) or low-molecular-weight heparin (LMWH) and
the informed patient and if there is no I C
VKA should be initiated within 24 h after MHV implantation, or as
contraindication to long-term anticoagulation.
soon as considered safe. Heparin can be stopped when the INR is
An MHV should be considered in patients with an
documented for 2 consecutive days within the therapeutic range
estimated long life expectancy,c if there are no IIa B (Figure 18).814 Two meta-analyses and a prospective study have sug-
contraindications for long-term OAC.801,807–811
gested slightly lower bleeding rates using UFH bridging compared
An MHV should be considered in patients aged with LMWH after MHV replacement or cardiac surgery.814–816
<60 years for prostheses in the aortic position and However, RCTs comparing the timing and dosage of each bridging
IIa C
aged <65 years for prostheses in the mitral strategy are lacking.
position.801,807–811
For all patients with an MHV, lifelong VKA is recommended to
An MHV should be considered in patients with a avoid major thrombotic complications, since cardioembolic or valve
IIa C
pre-existing MHV in another position. thrombosis rates without anticoagulation are substantial (12% per
An MHV may be considered in patients with a clear year and 22% per year for first-generation aortic and mitral MHVs,
IIb C
indication for long-term OAC. respectively).817 The INR target and range should be chosen consid-
ering the type, position, and number of valves, the patient’s thrombot-
Biological heart valve
ic risk, and comorbidities (see Table 10 and Recommendation
A BHV is recommended according to the desire of
I C Table 14). In patients with an MHV developing a major thrombo-
the informed patient.
embolic complication despite adequate INR and time in therapeutic
A BHV is recommended when an adequate quality of range (TTR, usually defined as >60%),820 either increased VKA inten-
anticoagulation with VKA is unlikely, in patients at
I C sity (e.g. INR target and range increased by 0.5 units) or the addition
high bleeding risk, or with estimated short life
of low-dose acetylsalicylic acid (ASA) (75–100 mg/day) should be con-
expectancy.c sidered.818 Direct oral anticoagulants or dual antiplatelet therapy
A BHV should be considered in patients aged (DAPT) are contraindicated to prevent thromboembolism in patients
>65 years for prostheses in the aortic position or IIa C with an MHV.821–824
aged >70 years for prostheses in the mitral position. Given the complexity of lifelong VKA therapy due to high intra-
A BHV should be considered in women and interpatient variability, the need for monitoring, drug and food
IIa C
contemplating pregnancy. interactions,825,826 the narrow therapeutic window, influence of co-
morbidities, and non-modifiable characteristics (e.g. ageing, genetics,
BHV, biological heart valve; MHV, mechanical heart valve; OAC, oral anticoagulation; VKA,
and ethnicity), RCTs have shown that patient’s education, as well
vitamin K antagonist.
aClass of recommendation. as disease and treatment awareness, significantly improves anticoa-
bLevel of evidence. gulation quality and adherence.827–830 International normalized ra-
cLife expectancy should be estimated according to age, sex, comorbidities, ethnicity, and tio self-monitoring and/or self-management increase efficacy, but
geographical area.
not safety, as compared with a standard approach; INR self-
monitoring can be used by motivated patients after adequate
14.2. Follow-up of patients with prosthetic training.827–830
valves The indication for VKA and DAPT combination in MHV patients
presenting with acute coronary syndrome is described in the corre-
All patients with prosthetic valves require lifelong clinical and echocar-
sponding ESC Guidelines.151,831 In patients with an MHV and an in- diographic follow-up to detect deterioration of prosthetic function,
dication for single antiplatelet therapy (SAPT) due to symptomatic
associated cardiac damage, or progressive disease of another valve.
major atherosclerotic diseases and low bleeding risk, low-dose
Serial TTE measurements of transprosthetic gradients, calculation of
ASA in combination with a VKA should be considered, because
the effective valve area, and evaluation of leaflet motion and morph-
ology should be performed in patients receiving a BHV within this strategy has been shown to significantly lower the incidence
3 months after valve implantation, again at 1 year, and annually there- of major adverse cardiovascular events.818 However, the combin-
after, or sooner if new cardiovascular symptoms occur.812 TOE is re- ation of antiplatelet agents (single or dual) and VKA increases the
commended in all cases of suspected prosthetic valve dysfunction or risk of bleeding,825 and therefore their use should be carefully
endocarditis. In the latter case, CCT and PET-CT are also recom- weighted. In a large meta-analysis that included MHV patients, the
mended, if the diagnosis is unclear, and to identify primary or second- combination of VKA with either ASA or clopidogrel increased clin-
ary infection foci.5 ically relevant bleeding compared with VKA alone (clopidogrel odds
Cinefluoroscopy for MHVs and CCT provide useful additional infor- ratio, 3.55; 95% CI, 2.78–4.54; ASA odds ratio, 1.50; 95% CI, 1.29–
mation, if valve thrombus or pannus is suspected.812 Imaging should be 1.74), which may be aggravated because of potential pharmacoki-
repeated in the case of thrombolytic and antithrombotic treatment of netic drug interactions on the cytochrome P (CYP)450s 2C19 and
MVH thrombosis, even if gradients are normalized.813 3A4.825
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 58 ---
4692 E S C G u id e l in e s
Mechanical heart valve replacement
Start UFH or LMWH bridging and VKA within 24 h or as soon as considered safe
(Class I)
Lifelong VKA with INR based on individual patient profile and valve characteristics
Promote patient education and training for self-monitoring to improve TTR
(Class I)
Specific clinical scenarios
Elective NCS Symptomatic
Cardioembolic
or invasive atherosclerotic
complication
procedures disease
Minor or minimally If documented adequate Add low-dose ASA
invasive INR, increase INR target, based on individual
interventionsa or add low-dose ASA bleeding profile
(Class IIa) (Class IIa)
Continue VKA
(Class I)
Thromboembolic risk factorsb
VKA interruption at least
VKA interruption (3–4 days
4 days before surgery and Heparin
before surgery) and resumption
resumption within 24 h or bridgingc
(within 24 h) without bridging
as soon as considered safe (Class IIa)
(Class IIb)
(Class I)
Figure 18 Antithrombotic therapy following mechanical heart valve implantation. AF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normal-
ized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS,
mitral stenosis; N, no; NCS, non-cardiac surgery; TTR, time in therapeutic range; UFH: unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSkin; minor
eye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; and diagnostic cardiac catheter-
ization. bMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF
<35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism).
cBridging needs to be started as soon as INR reaches a sub-therapeutic value and on the first postoperative day or as soon as considered safe.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 59 ---
ESC Guidelines 4693
Recommendation Table 14 — Recommendations for the management of antithrombotic therapy in patients with a
mechanical heart valve
Recommendations Classa Levelb
Following cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as
I B
considered safe.815,816,832–834
Lifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications.821–823,835–838 I A
INR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve
I A
efficacy.827,828
It is recommended that INR targets are based on the type and position of the MHV, patient risk factors, and comorbidities.c 818,819,835–838 I A
Patient education is recommended to improve the quality of OAC.827–830 I A
The addition of low-dose ASA (75–100 mg/day) to VKA should be considered in selected patients with MHVs in case of concomitant
IIa B
symptomatic atherosclerotic disease considering the individual bleeding risk profile.818
Either an increase in INR target or the addition of low-dose ASA (75–100 mg/day) should be considered in patients with MHVs who
IIa C
develop a major thromboembolic complication despite documented adequate INR.818
DOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV.821–824 III A
ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV,
mechanical heart valve; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cSee Table 10 for details.
Table 10 International normalized ratio targets and >10.0, oral vitamin K1 (2.0–3.0 mg) should be administered, avoiding
therapeutic ranges for patients with a mechanical heart overcorrection.841,843
valve In cases of uncontrolled life-threatening or other major bleeding,844
VKA use must be interrupted and reversal with non-activated
MHV type and position Additional INR target
four-factor prothrombin complex concentrates is preferred over fresh
pro-thrombotic and (range) frozen plasma, because of higher safety and effectiveness.845–848 A reduced
factorsa
starting dose (12.5 rather than 25 IU/kg) in patients with more thrombo-
genic MHVs may be considered.849 In addition, vitamin K1 should be ad-
First-line treatment with VKA only
ministered to reverse the effect of VKA. Intravenous route corrects
Ball-in cage, tilting disc valve No 3 (2.5–3.5)
INR ∼4 h faster than oral administration,850 with no differences at 24 h
in any position, all MHV in Yes 3.5 (3–4)b
and an unknown clinical impact. VKA should be restarted as soon as major
mitral/tricuspid position
bleeding is controlled.
Bileaflet, current-generation No 2.5 (2–3)c
single-tilting aortic MHV Yes 3 (2.5–3.5)
14.3.1.3. Management of anticoagulation therapy before and after
AF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normalized ratio; LV, left non-cardiac invasive procedures
ventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart
In patients with an MHV, VKA treatment should not be interrupted for:
valve; MS, mitral stenosis; VKA, vitamin K antagonist.
aInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with minor or minimally invasive procedures on the skin or eyes (including
significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, cataract with topical anaesthesia); dental cleaning, treatment of caries,
deep vein thrombosis, pulmonary embolism). and dental extractions; pacemaker implantation; cardiac catheterization;
bIn patients at very high thrombotic risk, low-dose ASA may be added instead.818 and endoscopic procedures (Recommendation Table 15; Table 11).851–856
cIn patients at high bleeding risk, INR target could be maintained at a lower interval:
2 (1.5–2.5).819 Topical antifibrinolytic or haemostatic agents may improve local
haemostasis.853
In patients with an MHV and high thromboembolic risk
14.3.1.2. Prevention and management of bleeding (Recommendation Table 16; Table 11) undergoing non-cardiac, elective
Since patients with MHVs receive lifelong VKA, strategies to prevent major invasive procedures with high risk of bleeding (see
bleeding need to be implemented. Proton pump inhibitors reduce Supplementary data online, Table S6), VKA treatment must be inter-
the risk of upper gastrointestinal bleeding by approximately 40% in pa- rupted at least 4 days before the procedure, bridging with LMWH
tients taking VKAs825,839,840 and should therefore be prescribed to pa- should be started as soon as the INR reaches a subtherapeutic value,
tients with MHVs, particularly in those with additional bleeding risk and the INR should be <1.5 on the day of surgery.816,857,858
factors (e.g. elderly, antiplatelet agent co-administration, chronic use Measuring anti-Xa activity at peak and trough may be appropriate to
of non-steroidal anti-inflammatory drugs, high INR, or alcohol abuse). manage LMWH dosing in selected patients, such as those with severe
Randomized controlled trials and a meta-analysis did not demonstrate obesity or underweight.859 In cases of urgent, major invasive proce-
a benefit of oral vitamin K1 supplementation in addition to temporary dures, four-factor prothrombin complex concentrate should be admi-
VKA cessation in non-bleeding patients with a supratherapeutic INR nistrated to timely correct the INR for the intervention, if needed. For
(4.5–10.0), with a trend toward reduced safety, which may be relevant the management of antithrombotic drugs in patients undergoing major
for MHV patients.841,842 For non-bleeding patients with an INR of cardiac surgery, please refer to recent EACTS Guidelines.860
5202STCAE/CSE©
5202STCAE/CSE© Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 60 ---
4694 E S C G u id e l in e s
Recommendation Table 15 — Recommendations for the management of antithrombotic therapy in patients with a
mechanical heart valve undergoing elective non-cardiac surgery or invasive procedures
Recommendations Classa Levelb
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventionsc associated with no or minimal
I A
bleeding.851–856
It is recommended to discontinue VKA at least 4 days before major non-cardiac elective surgery, aiming for an INR <1.5, and to resume VKA
I B
treatment within 24 h after surgery, or as soon as considered safe.816,857,858
VKA interruption and resumption with bridgingd should be considered in patients with an MHV and thromboembolic risk factorse
IIa B
undergoing major NCS.816,857,858
Interruption (3–4 days before surgery) and resumption of VKA without bridging may be considered to reduce bleeding in patients with
IIb B
new-generation aortic MHVs and no other thromboembolic risk factorse undergoing major NCS or invasive procedures.816,857,858,861–864
AF, atrial fibrillation; h, hour; INR, international normalized ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac
surgery; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cSkin; minor eye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; diagnostic cardiac catheterization; gastroscopic,
colonoscopic, bronchoscopic, or genitourinary diagnostic or therapeutic procedures considered at low bleeding risk.
dBridging needs to be started as soon as INR reaches a subtherapeutic value and on the first post-operative day or as soon as considered safe.
eMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent
(<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism).
Table 11 Peri-operative management of antithrombotic treatment in patients with a mechanical heart valve undergo-
ing non-cardiac surgery based on type of procedure and underlying risk
Minimally invasive proceduresa Major NCS or invasive proceduresa
Pre-procedure Post-procedure Pre-procedure Post-procedure
Low thromboembolic risk
New-generation aortic OAC No interruption Continue VKA Interrupt VKA at least 3– Resume VKA as soon as
MHV and no additional of VKA 4 days prior to procedure feasible, within 24 h
risk factorsb with target INR <1.5 on
the day of surgery
Bridging — — No bridging may be No bridging may be
considered considered, unless unable
to administer OAC
Supporting — Topical antifibrinolytic or — Mechanical and
measures haemostatic agents may pharmacological VTE
be considered to improve prophylaxis, if indicated
local haemostasis
Moderate-to-high thromboembolic risk
MHV in mitral or OAC No interruption Continue VKA Interrupt VKA at least Resume VKA within 24 h
tricuspid position or of VKA 4 days prior to procedure
other thromboembolic with target INR <1.5 the
risk factorsb day of the procedure
Bridging — — Bridging with LMWH or Bridging with UFH or
UFH if CKD stage IV or V, LMWH post-operatively
starting at INR below the within 24 h
therapeutic range
Supporting — Topical antifibrinolytic or — Appropriate mechanical
measures haemostatic agents may and pharmacological
be considered to improve VTE prophylaxis
local haemostasis
AF, atrial fibrillation; CKD, chronic kidney disease; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular
ejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac surgery; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE,
venous thromboembolism.
aSee Supplementary Table S6.
bInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein
thrombosis, pulmonary embolism).
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 61 ---
ESC Guidelines 4695
For patients with an MHV and low cardioembolic risk (e.g. a new- thromboembolic events, but statistical power was low.867,868
generation MHV in the aortic position without additional risk factors) Therefore, both strategies (OAC or ASA) are reasonable within
undergoing elective major NCS or invasive procedures, VKA interrup- 3 months of surgical aortic BHV implantation. In the absence of rando-
tion (3–4 days before surgery)816,857,858,861–864 and resumption861–863 mized evidence, patients undergoing mitral or tricuspid BHV implant-
within 24 h may be performed without bridging to reduce post-surgical ation should receive OAC for at least 3 months due to the increased
bleeding without increasing the risk of thrombosis (see Figure 18). risk of AF and thromboembolisms.
14.3.2. Biological heart valves
14.3.2.2. Patients with a transcatheter heart valve and no indication
The management of antithrombotic treatment after BHV implantation for oral anticoagulation
or valve repair is summarized in Recommendation Table 16 and Figure 19.
Based on evidence from RCTs, lifelong low-dose ASA is the recom-
mended antithrombotic treatment after TAVI in patients without
14.3.2.1. Patients with a surgical biological heart valve and no OAC indication. In the Antiplatelet Therapy for Patients Undergoing
indication for oral anticoagulation Transcatheter Aortic Valve Implantation (POPular TAVI) trial (cohort
The optimal antithrombotic strategy early after surgical implantation of A), the incidence of bleeding and the composite of bleeding or
an aortic BHV remains controversial due to the lack of high-quality evi- thromboembolic events were both reduced with ASA compared
dence. Multiple observational studies support the short-term use of with DAPT at 1 year.869 One RCT [Global multicenter, open-label, ran-
VKAs to reduce the risk of thromboembolism,865,866 while data on domized, event-driven, active-controlled study comparing a
DOACs are missing. A small RCT and a meta-analysis found that rivAroxaban-based antithrombotic strategy to an antipLatelet-based
VKA treatment for 3 months significantly increased major bleeding strategy after transcatheter aortIc vaLve rEplacement (TAVR) to
compared with low-dose ASA, without reducing mortality or Optimize clinical outcomes, GALILEO], which investigated a systematic
MV/TV Aortic
MVR/TVR SAVR TAVI
surgical repair surgical repair
Indication for long-term anticoagulation
OAC OAC OAC OAC OAC
long term long term long term long term long term
(Class I) (Class I) (Class I) (Class I) (Class I)
High bleeding risk
OAC ASA or OAC ASA for ASA
for 3 months for 3 months 12 months for 3 months
(Class IIa) (Class IIa) (Class I) (Class IIa)
ASA long term
ASA long term OAC ASA
after first
according to bleeding risk for 3 months for 3 months
12 months
(Class IIb) (Class IIa) (Class IIb)
(Class IIa)
Figure 19 Antithrombotic therapy following biological heart valve implantation or surgical valve repair. ASA, acetylsalicylic acid; MV, mitral valve;
MVR, mitral valve replacement; OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation;
TV, tricuspid valve; TVR, tricuspid valve replacement.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 62 ---
4696 E S C G u id e l in e s
antithrombotic strategy of rivaroxaban (10 mg/day) in combination Recommendation Table 16 — Recommendations for
with low-dose ASA compared with DAPT with clopidogrel for the first the management of antithrombotic therapy in patients
3 months, was halted prematurely due to an increased risk of death or with a biological heart valve or valve repair
thromboembolic complications, and an increased risk of bleeding in
the rivaroxaban/ASA group.870 The systematic use of DOACs after Recommendations Classa Levelb
TAVI in patients without indication for OAC is therefore not recom-
Surgical biological heart valve without indication for oral
mended. Data on antithrombotic management after implantation of
anticoagulation
transcatheter mitral BHVs or tricuspid BHVs are limited. Vitamin K an-
Low-dose ASA (75–100 mg/day) or OAC
tagonist treatment for ≥3 months is commonly prescribed, while
using a VKA should be considered for the first
DOACs may represent an alternative allowing for earlier discharge
and a lower risk of short-term bleeding complications (median follow- 3 months after surgical implantation of an aortic IIa B
up, 4.7 months).871 BHV in patients without clear indication for
For patients without baseline OAC undergoing mitral or tricuspid
OAC.865,866
transcatheter valve implantation, OAC (either with DOAC or VKA) A VKA should be considered for the first 3 months
is initiated and usually pursued for at least 6 months or indefinitely after surgical implantation of a mitral or tricuspid
IIa B
(in particular after valve implantation in the tricuspid position), while BHV in patients without clear indication for
patients undergoing TEER usually receive single long-term antiplatelet OAC.867,868
therapy with ASA. Lifelong low-dose ASA (75–100 mg/day) may be
considered 3 months after surgical implantation of an
IIb C
14.3.2.3. Patients with a surgical biological heart valve and an aortic or mitral BHV in patients without clear
indication for oral anticoagulation indication for OAC.
Lifelong OAC is recommended for patients with surgical BHVs with Transcatheter aortic valve implantation without indication for
other indications for OAC. The evidence supports the use of oral anticoagulation
DOACs in preference to VKAs in patients with AF, even during the
Low-dose ASA (75–100 mg/day) is recommended
early post-operative period.872–877 A previously existing therapy with
for 12 months after TAVI in patients without I A
a DOAC may be continued after BHV implantation and should be re-
indication for OAC.869,880–883
started, as soon as considered surgically safe, usually within 2–3 days of
surgery.860 Long-term (after the first 12 months) low-dose ASA
(75–100 mg/day) should be considered after TAVI in IIa C
patients without clear indication for OAC.
14.3.2.4. Patients with a transcatheter biological heart valve and an
DAPT is not recommended to prevent thrombosis
indication for oral anticoagulation III B
after TAVI, unless there is a clear indication.881
In the POPular TAVI trial (cohort B), the incidence of bleeding over a per-
Routine use of OAC is not recommended after TAVI
iod of 1 month or 1 year was lower with OAC than with OAC plus clo- III A
pidogrel.878 Oral anticoagulation alone was non-inferior to OAC plus in patients without baseline indication.869,880
clopidogrel with respect to ischaemic events, but the non-inferiority mar- Surgical repair without indication for oral anticoagulation
gin was large. In Edoxaban vs Standard of Care and Their Effects on OAC, with either VKAs or DOACs, should be
Clinical Outcomes in Patients Having Undergone Transcatheter Aortic considered during the first 3 months after surgical IIa B
Valve Implantation–Atrial Fibrillation (ENVISAGE-TAVI-AF),879 edoxaban MV or TV repair.884–888
was non-inferior to VKA regarding the composite primary endpoint
Low-dose ASA (75–100 mg/day) should be
(death from any cause, myocardial infarction, ischaemic stroke, systemic
considered for the first 3 months after surgical AV IIa C
thromboembolic event, valve thrombosis, or major bleeding), but the in- repair in patients without indication for OAC.
cidence of major bleeding was higher with edoxaban than with VKA. The
Low-dose ASA (75–100 mg/day) may be considered
Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic
after surgical MV or TV repair in preference to OAC
Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation IIb B
for Aortic Stenosis (ATLANTIS) trial880 showed that apixaban was not in patients without clear indication for OAC and at
high bleeding risk.884–888
superior to VKA after TAVI when there was a pre-existing indication
for OAC, and there was a signal of higher non-cardiovascular mortality Surgical biological heart valve with indication for oral
with apixaban. Therefore, no definitive recommendation can be made anticoagulation
concerning the use of VKAs vs DOACs in patients who have undergone OAC continuation is recommended in patients with
TAVI with a pre-existing indication for OAC. a clear indication for OAC undergoing surgical BHV I B
Antithrombotic therapy after transcatheter MV or TV implantation implantation.877,889,890
remains empirical because data are limited. A high proportion of pa-
DOACs should be considered over VKAs after
tients are already under OAC because of AF (almost 50% of the popu-
3 months following surgical implantation of a BHV in IIa B
lation with MR and 80%–90% of the candidates for TR treatment).
patients with AF.872–874,876,891
Common practice is to continue the pre-existing anticoagulation regi-
DOAC continuation may be considered after
men. Vitamin K antagonists and DOACs have been used in this setting
with or without combination with ASA.871 However, the high bleeding surgical BHV implantation in patients with an IIb B
risk of this usually elderly population needs to be taken into indication for DOAC. 877,889,890
consideration. Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 63 ---
ESC Guidelines 4697
leaflet fibrosis or calcification, and stent or strut fracture or deform-
Transcatheter biological heart valve with indication for oral
ation. BHV (transcatheter or surgical) SVD is more frequent than
anticoagulation
MHV SVD. The incidence of SVD may be underestimated by the simple
OAC is recommended for TAVI patients who have
I B analysis of patients with valve-related deaths or those undergoing rein-
other indications for OAC.879,892–894
tervention. To ensure timely diagnosis, serial measurement should be
Surgical repair with indication for oral anticoagulation and/or performed and compared with the TTE performed at discharge, or
antiplatelet therapy within 1–3 months after valve implantation.
Continuation of OAC or antiplatelet therapy should The criteria for haemodynamic deterioration associated with
aortic and mitral SVD can be found in Table 12.895,896 The diagno-
be considered after surgical valve repair in patients
IIa B sis of moderate or severe haemodynamic deterioration should
with a clear indication for an antithrombotic
therapy.890 prompt referral to an experienced Heart Valve Centre for evalu-
ation and treatment, and to exclude all causes of non-structural
AF, atrial fibrillation; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; valve dysfunction, particularly PVL or PPM, as well as thrombosis
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; MV, mitral valve; OAC,
and endocarditis. This step requires the use of advanced
oral anticoagulation; TAVI, transcatheter aortic valve implantation; TV, tricuspid valve; VKA,
vitamin K antagonist. imaging techniques (TOE, CCT, and/or PET-CT) to document
aClass of recommendation. SVD-related morphological changes and elucidate its mechanism.
bLevel of evidence. Structural valve deterioration associated with corresponding clinic-
al criteria (e.g. new onset or worsening of symptoms, LV or RV
dilation/dysfunction, or PH) indicates BHV failure with potential
14.4. Management of prosthetic valve
need for reintervention. Decisions about the treatment modality
dysfunction and complications (redo surgery or transcatheter valve-in-valve implantation) should
Prosthetic valve dysfunction can occur due to intrinsic permanent be made within the interdisciplinary Heart Team, depending on re-
changes to the prosthetic valve (defined as SVD) or non-structural valve operation risk and anatomical considerations,445,897 including the
dysfunction resulting from any abnormality not intrinsic to the pros- risk of coronary obstruction,144,442,446,461 as well as prosthesis
thetic valve itself. Valve thrombosis and endocarditis are considered type and size.898–900 When considering a valve-in-valve procedure
separate entities due to their specific presentation and management, for a degenerated aortic BHV, the possibility of creating a PPM in
but may both result in SVD. small valves should be anticipated and may impact intervention or
valve selection.448
Given the larger sizes of BHVs in mitral or tricuspid positions, trans-
14.4.1. Structural valve deterioration femoral/transseptal valve-in-valve implantation represents an attractive
Structural valve deterioration has been defined by several consensus alternative to redo open surgery.570,900–903 In the case of mitral
documents812,895,896 and includes wear and tear, leaflet disruption, valve-in-valve implantation the risk of LVOT obstruction, although
Table 12 Criteria for the diagnosis of moderate or severe aortic and mitral haemodynamic valve deterioration
Moderate Severe
Aortic BHV Increase in mean transvalvular gradient ≥10 mmHg Increase in mean transvalvular gradient ≥20 mmHg
SVD or non-structural valve resulting in mean gradient ≥20 mmHg resulting in mean gradient ≥30 mmHg
dysfunction (except PVL or PPM),a AND AND
thrombosis, or endocarditis Decrease in EOA ≥0.3 cm2 or ≥25%, and/or decrease in Decrease in EOA ≥0.6 cm2 or ≥50%, and/or decrease in
DVI ≥0.1 or ≥20%, compared with echocardiographic DVI ≥0.2 or ≥40%, compared with echocardiographic
assessment performed 1–3 months post-procedure assessment performed 1–3 months post-procedure
OR OR
New occurrence or increase of ≥1 grade of New occurrence or increase of ≥2 grades of intraprosthetic
intraprosthetic AR resulting in ≥ moderate AR AR resulting in ≥ moderate-to-severe AR
Mitral BHV Increase in DVI ≥0.4 or ≥20%, resulting in DVI ≥2.2, or Increase in DVI ≥0.8 or ≥40%, resulting in DVI ≥2.7, or
SVD or non-structural valve decrease in EOA ≥0.5 cm2 or ≥25%, resulting in EOA decrease in EOA ≥1.0 cm2 or ≥50%, resulting in EOA
dysfunction (except PVL or PPM),b <1.5 cm2, usually associated with increase of transmitral <1 cm2, usually associated with increase of transmitral
thrombosis, or endocarditis gradient ≥5 mmHg gradient ≥10 mmHg
OR OR
New occurrence or increase of ≥1 grade of New occurrence or increase of ≥2 grades of intraprosthetic
intraprosthetic MR resulting in ≥moderate MR MR resulting in ≥moderate-to-severe MR
Adapted from 895,896.
AR, aortic regurgitation; AV, aortic valve; BHV, biological heart valve; DVI, Doppler velocity index; EOA, effective orifice area; MR, mitral regurgitation; PPM, prosthesis–patient mismatch;
PVL, paravalvular leak; SVD, structural valve deterioration.
aObstruction by pannus; dilatation of the aortic root after stentless BHV; or AV-sparing operations.
bLeaflet entrapment by pannus, chordae, or suture.
5202STCAE/CSE©
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 64 ---
4698 E S C G u id e l in e s
infrequent, should be carefully ruled out, especially in patients with 14.4.4. Valve thrombosis
small and hypertrophic ventricles.904 Valve thrombosis occurs mainly in MHVs,913,914 but can also be ob-
served in BHVs.915,916 The spectrum of BHV thrombosis ranges
14.4.2. Non-structural valve dysfunction from incidental CCT findings, such as hypo-attenuated leaflet thick-
14.4.2.1. Prosthesis–patient mismatch ening (HALT) with or without reduced leaflet motion but normal
gradients, to clinically apparent presentations with elevated
Prosthesis–patient mismatch should be prevented whenever pos-
gradients, symptoms of valve obstruction, or thromboembolic
sible after either transcatheter or surgical valve-replacement pro-
events.917–919
cedures (see Section 8.5.1.2). When occurring in the aortic
position, severe PPM is associated with decreased quality of life, in-
14.4.4.1. Hypo-attenuated leaflet thickening
creased rate of rehospitalization and reintervention, and possible
reduction in long-term survival, although findings are not consistent Hypo-attenuated leaflet thickening is detected by CCT in 10%–30% of
throughout all studies.454,905–909 Moderate PPM is more common, aortic BHVs depending on antithrombotic management, the definition
but seems to have a limited impact on outcomes. The projected of HALT, the timepoint of assessment, and the type of valve.917,919–921
indexed EOA may be predicted prior to valve implantation to The significance and clinical implications of these findings with respect
avoid severe PPM,908 although this concept has been challenged.910 to thromboembolic risk and valve durability remain uncertain.
Less is known about the prevalence and consequences of PPM in Accordingly, routine use of CCT to detect HALT is not indi-
the mitral and tricuspid positions, and established definitions are cated.918–920 In patients with relevant increases in gradients, in
lacking. whom HALT and restricted leaflet motion is confirmed by CCT,
Prosthesis–patient mismatch is an infrequent indication for rein- elective use of DOACs or VKAs should be considered to resolve leaf-
tervention. However, reoperation should be considered in symp- let thrombosis.918,921,922
tomatic patients with severe PPM, particularly if the patient is low
risk.394,437,438 14.4.4.2. Clinically significant valve thrombosis
Obstructive valve thrombosis should be suspected in any patient
14.4.2.2. Paravalvular leak and haemolysis with any type of prosthetic valve who presents with new-onset
dyspnoea or HF symptoms, an embolic event, or an unexpected in-
The diagnosis of PVL requires systematic TOE, because TTE may be
crease in transvalvular gradients. If TTE findings are uncertain, the
inconclusive. Haemolytic anaemia can often be detected in patients
diagnosis should be confirmed by TOE and/or CCT to distinguish
with prosthetic valves and is best assessed by measuring lactate de-
between thrombus, pannus, and degeneration.923–925
hydrogenase and haptoglobin serum levels, but rarely leads to symp-
Cinefluoroscopy can detect impaired MHV leaflet motion and re-
toms. Intervention is needed if a PVL causes haemolysis requiring
duced opening angles.
blood transfusions or symptoms, or if secondary to valve endocarditis.
Adequate anticoagulation must be promptly restored in all patients
Transcatheter PVL closure is a valid alternative to surgery in the case
with MHV thrombosis and subtherapeutic INR. Although surgery re-
of significant regurgitation or haemolysis, if feasible depending on the
mains the first-line option in critically ill patients, emergency valve re-
size and location of the leak, but requires specific expertise and plan-
placement is associated with increased risk, whereas bleeding and
ning. Care must be taken not to interfere with mechanical leaflet mo-
systemic embolism are increased with fibrinolysis.926–928 Slow, low-
tion in MHV patients. Reported results for transcatheter PVL closure
dose infusion appears to lower complication rates, while preserving
are inconsistent, with several patients returning with recurrent PVL
thrombolytic success rates.928–931a It is recommended that the deci-
and/or haemolysis.911 When surgery or transcatheter intervention
sion between surgery and fibrinolysis is taken within the Heart
are contraindicated, medical therapy aims to counteract the effect
Team, and individualized by weighing clinical factors and local expert-
of haemolysis (iron supplementation and erythropoietin) or reduce
ise (Figure 20).
it (beta-blockers).912
Management of non-obstructive thrombosis or obstructive
thrombosis of an MHV without pronounced HF symptoms de-
14.4.3. Endocarditis pends mainly on the occurrence of a thromboembolic event
Antibiotic prophylaxis is recommended in all patients with a pros- and the size of the thrombus. Surgery should be considered for
thetic valve (including transcatheter valve prostheses) and after valve a large (>10 mm) non-obstructive prosthetic valve thrombus
repair using prosthetic material or with previous episode(s) of infect- that is complicated by embolism or persists despite optimal
ive endocarditis, and should also be considered after transcatheter OAC.913,932,933
MV or TV repair.5 It is recommended in such patients when under- Anticoagulation using a VKA is the first-line treatment for clinically
going dental extractions, oral surgery, or other procedures requiring relevant BHV thrombosis, unless urgent reintervention or fibrinoly-
manipulation of the gingival or peri-apical region of the teeth. sis is required due to progressive acute HF or haemodynamic
Particular attention to dental and cutaneous hygiene, and strict instability.934–938 Because clinically relevant BHV thrombosis is asso-
aseptic measures during any invasive procedure, are also advised in ciated with recurrence and may contribute to prosthetic degener-
this population. Additional details on endocarditis prophylaxis are ation, indefinite anticoagulation may be considered after a
mentioned in the 2023 ESC Guidelines for the management of confirmed episode, but this strategy must be balanced against the
endocarditis.5 risk of bleeding.936,939
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 65 ---
ESC Guidelines 4699
Signs and symptoms of MHV thrombosis
TTE plus
TOE and/or CCT or fluoroscopy (Class I)
Large thrombus (≥10 mm) Surgery
complicated by embolism (Class IIa)
Acute heart failure with NYHA Class III or IV Heart Team evaluation
due to obstructive thrombosis (Class I)
Evidence for inadequate OAC
Surgery
Favoured if:
• Recurrent event
• Possible pannus
Bridge until target INR, Increase VKA intensity or • Cardiogenic shock
identify and correct causes add low-dose ASA • Large thrombus
of inadequate OAC (Class IIa) • Thromboembolic event
• Contraindication to fibrinolysis
OR
Fibrinolysis
Continue VKA ± ASA with more intense monitoring
(low-dose slow infusion)
Favoured if:
• High surgical risk
Repeat imaging for monitoring of thrombus resolution • Right-sided valve prosthesis
or persistence
Persistent thrombus with
clinically relevant obstruction or Heart Team evaluation
thromboembolic event
Figure 20 Management of left-sided obstructive and non-obstructive mechanical heart valve thrombosis. ASA, acetylsalicylic acid; CCT, cardiac com-
puted tomography; INR, international normalized ratio; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral anticoagulation;
TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VKA, vitamin K antagonist.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 66 ---
4700 E S C G u id e l in e s
Recommendation Table 17 — Recommendations for the management of prosthetic valve dysfunction (see also
Supplementary data online, Evidence Table 25)
Recommendations Classa Levelb
Haemolysis and paravalvular leak
It is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team
I C
evaluation, including patient risk, leak morphology, and local expertise.
Reoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF
I C
symptoms.
Transcatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 IIa B
Mechanical heart valve failure
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. I C
Biological heart valve failure
Reintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. I C
Transcatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve
dysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart IIa B
Team.447,448,450,451,941
Transcatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction
IIa B
at intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944
Reoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. IIa C
Valve thrombosis
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945–948 I C
Mechanical heart valve thrombosis
Heart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine
I B
appropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926–929,931,949–954
Surgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 IIa C
Biological heart valve thrombosis
OAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 I B
OAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until
IIa B
resolution.918,920–922
4D, four-dimensional; BHV, biological heart valve; CT, computed tomography; HF, heart failure; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral
anticoagulation; PVL, paravalvular leak; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
15. Management during the ability to perform activities in daily life or by exercise testing. Screening
for frailty using validated tools is advisable.90 Decisions on pre- and peri-
non-cardiac surgery
operative management, surveillance, and continuation of chronic cardio-
vascular medical treatment should be taken after multidisciplinary discus- In patients with significant VHD who undergo NCS, the risk of peri-
sion involving cardiologists, surgeons, and cardiac anaesthesiologists, as
operative cardiovascular complications is increased and related to
well as the team who will be in charge of the NCS. Patients receiving
both the timing of the procedure (i.e. urgent vs non-urgent) and type
OAC treatment should be managed as described in Section 14.
of surgery (low, intermediate, or high risk), as well as patient-specific
factors (type and severity of VHD, LV function, etc.).194,957–959
Detailed recommendations related to NCS are available in the 2022
15.2. Specific valve lesions
ESC Guidelines on cardiovascular assessment and management of patients
undergoing non-cardiac surgery.960 15.2.1. Aortic stenosis
In patients with severe symptomatic AS, the treatment depends on the
urgency and risk of NCS. If life-saving time-sensitive NCS is needed, it
15.1. Pre-operative evaluation
should be performed under careful haemodynamic monitoring avoiding
Echocardiography should be performed in all patients with VHD requiring rapid changes of volume status, with prompt treatment of arrhythmia re-
NCS. Patient- and surgery-specific factors, along with risk calculators, can gardless of AS severity. In cases of urgent high-risk NCS, TAVI or balloon
be used to guide the treatment strategy. Determination of functional cap- aortic valvuloplasty should be considered in patients with critical AS prior
acity is a pivotal step for pre-operative risk assessment, measured either by to surgery, considering the risk of developing severe acute AR after
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 67 ---
ESC Guidelines 4701
balloon aortic valvuloplasty.194,961 Urgent low- and intermediate-risk Symptomatic patients or those with SPAP of >50 mmHg should undergo
NCS can be performed relatively safely in patients with severe AS.962 PMC or other appropriate valve intervention before high-risk NCS, if pos-
Patients in whom NCS can be deferred (i.e. non-urgent NCS) sible.965,966 Asymptomatic patients with MVA ≤1.5 cm2 can undergo
should undergo pre-operative Heart Team evaluation to determine low-to-moderate-risk NCS under careful monitoring, especially if PMC
whether SAVR or TAVI is preferable. TAVI may be preferred to is unsuitable. Multidisciplinary management is advised for patients with sig-
SAVR if faster recovery plays a role, particularly in elderly patients nificant MS who are ineligible for valve intervention.
in whom complex or high-risk NCS is planned.963 The treatment of
asymptomatic patients with severe AS should be individualized
(Figure 21).964 15.2.3. Aortic and mitral regurgitation
Non-cardiac surgery can usually be performed safely in asymptomatic pa-
tients with severe MR or AR and preserved LV function. If NCS is urgent,
15.2.2. Mitral stenosis patients should undergo surgery under strict haemodynamic monitoring,
Heart rate and fluid balance should be controlled to prevent pulmonary regardless of symptom status. In cases of elective (non-urgent) NCS in
oedema during NCS and arterial vasodilators should be avoided. patients with severe ventricular SMR, medical therapy should be opti-
Non-cardiac surgery is safe in patients with an MVA of >1.5 cm2, and in mized. If symptoms persist and NCS is intermediate or high risk, TEER
asymptomatic patients with MVA ≤1.5 cm2 and SPAP of <50 mmHg. should be considered after Heart Team discussion based on clinical
Patient with severe AS requiring NCS
Urgent NCS Elective NCS
Symptoms
or LV dysfunction
Risk of NCS Risk of NCS
Patient risk for
HIGH
AV procedure
(TAVI/SAVR)
HIGH LOW-MODERATE
HIGH LOW
Consider TAVI
or balloon aortic
valvuloplasty Heart Team
NCS under
before NCS NCS decision:
strict monitoring
if doable, or NCS SAVR or TAVI
under strict
monitoring
Figure 21 Management of non-cardiac surgery in patients with severe aortic stenosis. AS, aortic stenosis; AV, aortic valve; LV, left ventricular; NCS,
non-cardiac surgery; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 68 ---
4702 E S C G u id e l in e s
and anatomical selection criteria.194,584 Valve treatment should be per- cardiologist and a multidisciplinary Pregnancy Heart Team. The import-
formed for patients with AR meeting the criteria for valve intervention ance of midwives and other specialized nursing personnel is increasingly
before any elective intermediate- or high-risk NCS.966,967 recognized for high-quality direct patient interactions. Shared decision-
making is especially important when addressing the cardiovascular risk
of pregnancy and the benefit–risk ratios of therapeutic options and
15.3. Peri-operative monitoring
modes of delivery (Figure 22).
Heart rate control (particularly in MS) and careful fluid management
(particularly in AS and MR with reduced LVEF) are needed throughout
16.1. Management before pregnancy
the procedure. The involvement of specialized cardiovascular anaesthe-
siologists should be considered in complex situations because TOE Ideally, women should undergo a thorough physical examination by
monitoring may be considered. Pulmonary artery catheterization is their general practitioner for VHD screening prior to pregnancy. A spe-
not routinely used. cialized evaluation including TTE should be performed by a cardiologist
in the case of clinical suspicion.968,969
If VHD is diagnosed, pre-pregnancy counselling is imperative.
16. Management of valvular heart
Unplanned pregnancies in patients with VHD should be discouraged.
disease during pregnancy Contraception methods should be recommended after discussion
with the patient in the presence of a significant maternal and/or foetal
Specific ESC Guidelines on this topic are available (the 2025 ESC risk. In patients contemplating pregnancy, the maternal risk should be
Guidelines on cardiovascular disease during pregnancy) and should be con- assessed using the modified WHO classification and other scores such
sulted for further details.968 Pregnancies in patients with VHD should as the CARPREG or DEVI risk score (see Supplementary data online,
be considered high risk and managed under the close supervision of a Table S7).970
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:28)(cid:26)(cid:25)(cid:24)(cid:29)
(cid:31)(cid:30)(cid:29)(cid:18)(cid:25)(cid:17)(cid:27)(cid:25)(cid:29)(cid:16)(cid:21)(cid:15)(cid:17)(cid:27)(cid:23)(cid:26)(cid:14)(cid:14)(cid:29)(cid:14)(cid:14)(cid:19)(cid:29)(cid:27)(cid:21) (cid:23)(cid:26)(cid:25)(cid:22)(cid:21)(cid:26)(cid:20)(cid:19)(cid:24)(cid:21)(cid:26)(cid:27)
(cid:6)(cid:8)(cid:25)(cid:14)(cid:25)(cid:24)(cid:21)(cid:8)(cid:19)(cid:29)(cid:24)(cid:26)(cid:27)(cid:27)(cid:14)(cid:25)(cid:14)(cid:10)(cid:2)(cid:19)(cid:12)(cid:25)(cid:29)(cid:28)(cid:13)(cid:26)(cid:20)(cid:1)(cid:19)(cid:9)(cid:12)(cid:20)(cid:29)(cid:25)(cid:24)(cid:21)(cid:8)(cid:19)
(cid:27)(cid:127)(cid:21)(cid:22)(cid:25)(cid:14)(cid:21)(cid:28)(cid:25)(cid:13)(cid:14)(cid:1)(cid:19)(cid:129)(cid:6)(cid:141)
(cid:143)(cid:144)(cid:19)(cid:24)(cid:8)(cid:25)(cid:14)(cid:25)(cid:24)(cid:21)(cid:8)(cid:19)(cid:29)(cid:11)(cid:29)(cid:9)(cid:25)(cid:24)(cid:25)(cid:13)(cid:14)(cid:19)(cid:13)(cid:144)(cid:19)(cid:157) (cid:2)(cid:19)€€(cid:129)(cid:1)(cid:19)(cid:27)(cid:127)(cid:27)(cid:26)(cid:24)(cid:25)(cid:29)(cid:27)
(cid:24) (cid:143)(cid:14)(cid:21) (cid:19)(cid:9) (cid:24)(cid:21)(cid:21) (cid:29)(cid:24) (cid:27)(cid:25)(cid:28) (cid:19)(cid:20) (cid:13)(cid:19) (cid:144)(cid:21) (cid:19)(cid:17)(cid:29)(cid:29) (cid:27)(cid:27) ‚(cid:29) (cid:14)(cid:29) (cid:25)(cid:22) (cid:28)(cid:27)(cid:27) (cid:19)(cid:157)(cid:14) (cid:28)
(cid:2)(cid:19)(cid:26)(cid:25)(cid:29)(cid:3)(cid:19)(cid:21)(cid:29)(cid:29)(cid:27)(cid:29)(cid:29)(cid:22)(cid:27)(cid:14)(cid:28) (cid:31)(cid:30)(cid:29)
(cid:28) (cid:27) (cid:26) (cid:27)(cid:25)(cid:24)(cid:23)(cid:22)(cid:29)(cid:26)(cid:30)(cid:21)(cid:23)(cid:20)(cid:29)
(cid:26)
ƒ(cid:22)„ (cid:31)(cid:1)(cid:19)(cid:6)(cid:7)…(cid:23)…(cid:129)(cid:141)(cid:19)(cid:143)(cid:143)(cid:1)(cid:19) (cid:129)(cid:157)(cid:143)†
(cid:19)(cid:23)
(cid:6)(cid:13)(cid:26)(cid:26)(cid:27)(cid:24)(cid:28)(cid:25)(cid:13)(cid:14)(cid:19)(cid:13)(cid:144)(cid:19)(cid:29)(cid:27)(cid:15)(cid:27)(cid:26)(cid:27)(cid:19)(cid:18)(cid:5)(cid:1)(cid:19)(cid:7)(cid:5)(cid:1)(cid:19)(cid:21)(cid:13)(cid:26)(cid:28)(cid:25)(cid:24)(cid:19)(cid:17)(cid:25)(cid:8)(cid:21)(cid:28)(cid:21)(cid:28)(cid:25)(cid:13)(cid:14) (cid:6)(cid:21)(cid:26)(cid:17)(cid:25)(cid:13)(cid:8)(cid:13)(cid:10)(cid:20)
(cid:16)(cid:25)(cid:28)(cid:12)(cid:19)(cid:12)(cid:25)(cid:10)(cid:12)(cid:19)(cid:26)(cid:25)(cid:29)(cid:3)(cid:19)(cid:13)(cid:144)(cid:19)(cid:21)(cid:13)(cid:26)(cid:28)(cid:25)(cid:24)(cid:19)(cid:17)(cid:25)(cid:29)(cid:29)(cid:27)(cid:24)(cid:28)(cid:25)(cid:13)(cid:14)
(cid:8)(cid:26)(cid:27)(cid:26)(cid:28)(cid:29)(cid:19)(cid:29)(cid:27)(cid:21)(cid:23)(cid:7)(cid:9)(cid:30)(cid:15)(cid:27)(cid:28)(cid:23)(cid:16)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:27)(cid:25)(cid:24)
(cid:5)(cid:27)(cid:26)(cid:25)(cid:21)(cid:8)(cid:19)(cid:22)(cid:13)(cid:14)(cid:25)(cid:28)(cid:13)(cid:26)(cid:25)(cid:14)(cid:10)(cid:19)ƒ(cid:29)(cid:20)(cid:22)(cid:9)(cid:28)(cid:13)(cid:22)(cid:29)(cid:1)(cid:19)(cid:30)(cid:25)(cid:13)(cid:22)(cid:21)(cid:26)(cid:3)(cid:27)(cid:26)(cid:29)(cid:1)(cid:19)€€(cid:129)†
(cid:26)(cid:11)(cid:10)(cid:19)(cid:28)(cid:12)(cid:27)(cid:26)(cid:21)(cid:9)(cid:20)(cid:19)ƒ(cid:21)(cid:14)(cid:28)(cid:25)(cid:24)(cid:13)(cid:21)(cid:10)(cid:11)(cid:8)(cid:21)(cid:28)(cid:25)(cid:13)(cid:14)† (cid:5)
(cid:12)
(cid:21)(cid:26)
(cid:27)
(cid:9)(cid:21)(cid:28)(cid:25)(cid:27)(cid:14)(cid:28)
(cid:13)(cid:29)(cid:12)(cid:15)(cid:11)(cid:29)(cid:30)(cid:24)(cid:10)(cid:16)(cid:17)(cid:14)(cid:21)(cid:18)(cid:16)(cid:26)(cid:30)(cid:21)(cid:9)(cid:19)
(cid:17)(cid:19)
(cid:17)(cid:27)(cid:24)(cid:25)(cid:29)(cid:25)(cid:13)(cid:14)(cid:4)(cid:22)(cid:21)(cid:3)(cid:25)(cid:14)(cid:10)(cid:19)(cid:16)(cid:25)(cid:28)
(cid:12)(cid:19)(cid:28)(cid:12)(cid:27)(cid:19)
(cid:157)(cid:21)(cid:10)(cid:25)(cid:14)(cid:21)(cid:8)(cid:19)(cid:17)(cid:27)(cid:8)(cid:25)(cid:15)(cid:27)(cid:26)(cid:20)(cid:19)(cid:11)(cid:29)(cid:11)(cid:21)(cid:8)(cid:8)(cid:20)(cid:19)(cid:9)(cid:26)(cid:27)(cid:144)(cid:27)(cid:26)(cid:26)(cid:27)(cid:17)
…(cid:27)(cid:10)(cid:25)(cid:13)(cid:14)(cid:21)(cid:8)(cid:19)(cid:21)(cid:14)(cid:21)(cid:27)(cid:29)(cid:28)(cid:12)(cid:27)(cid:29)(cid:25)(cid:21)
(cid:18)(cid:13)(cid:14)(cid:25)(cid:28)(cid:13)(cid:26)(cid:25)(cid:14)(cid:10)(cid:19)(cid:17)(cid:11)(cid:26)(cid:25)(cid:14)(cid:10)(cid:19)(cid:17)(cid:27)(cid:8)(cid:25)(cid:15)(cid:27)(cid:26)(cid:20)(cid:19)(cid:21)(cid:14)(cid:17)(cid:19)(cid:27)(cid:21)(cid:26)(cid:8)(cid:20)
(cid:9)(cid:13)(cid:29)(cid:28)(cid:4)(cid:17)(cid:27)(cid:8)(cid:25)(cid:15)(cid:27)(cid:26)(cid:20)
(cid:129)(cid:127)(cid:28)(cid:27)(cid:14)(cid:17)(cid:27)(cid:17)(cid:19)(cid:25)(cid:14)(cid:4)(cid:12)(cid:13)(cid:29)(cid:9)(cid:25)(cid:28)(cid:21)(cid:8)(cid:19)(cid:29)(cid:11)(cid:26)(cid:15)(cid:27)(cid:25)(cid:8)(cid:8)(cid:21)(cid:14)(cid:24)(cid:27)‡(cid:28)(cid:26)(cid:27)(cid:21)(cid:28)(cid:22)(cid:27)(cid:14)(cid:28)
(cid:7)(cid:14)(cid:21)(cid:27)(cid:29)(cid:28)(cid:12)(cid:27)(cid:29)(cid:25)(cid:13)(cid:8)(cid:13)(cid:10)(cid:25)(cid:29)(cid:28)(cid:19)(cid:21)(cid:14)(cid:17)
(cid:13)(cid:28)(cid:12)(cid:27)(cid:26)(cid:19)(cid:29)(cid:9)(cid:27)(cid:24)(cid:25)(cid:21)(cid:8)(cid:25)(cid:29)(cid:28)(cid:29)
(cid:18)(cid:25)(cid:17)(cid:16)(cid:25)(cid:15)(cid:27)(cid:29)(cid:19)(cid:21)(cid:14)(cid:17)
(cid:13)(cid:28)(cid:12)(cid:27)(cid:26)(cid:19)(cid:14)(cid:11)(cid:26)(cid:29)(cid:25)(cid:14)(cid:10)(cid:19)(cid:9)(cid:27)(cid:26)(cid:29)(cid:13)(cid:14)(cid:14)(cid:27)(cid:8)
Figure 22 The Pregnancy Heart Team model of care. AS, aortic stenosis; ECG, electrocardiogram; MS, mitral stenosis; TTE, transthoracic echocar-
diography; VHD, valvular heart disease.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 69 ---
ESC Guidelines 4703
Before recommending pregnancy, the following conditions need to 16.2.2. Patients with prosthetic valves
be corrected: Pregnant patients with MHVs should be followed in a centre with cor-
• MS with MVA <1.5 cm2, even when asymptomatic.971 responding expertise. In a cohort of 212 women with MHVs, valve
thrombosis occurred in 10 (4.7%) pregnancies and haemorrhagic
• Severe AS with symptoms, or abnormal exercise test, or LV systolic
dysfunction.972 events occurred in 49 (23.1%).976 Therapeutic OAC during pregnancy
is essential to avoid thrombosis. The higher efficacy of VKAs compared
• Heritable aortic disorders and high risk of aortic dissection: prophylactic
with LMWH to prevent thrombosis must be balanced against increased
aortic repair is recommended prior to pregnancy in women with
foetal risks.981
Marfan syndrome and an aortic diameter of >45 mm, and may be con-
In patients requiring ≤5 mg/day of warfarin, OAC with warfarin
sidered in women with an aortic diameter between 40 and 45 mm
when risk factors for dissection exist.973 Aneurysmal dilation in women throughout pregnancy, changing to UFH before delivery, is advocated,
with BAV should be corrected when the aortic diameter is ≥50 mm.974 in order to reduce the risk of thrombosis. In patients requiring higher
doses, switching to dose-adjusted LMWH at least twice per day with
Close follow-up in dedicated units and beta-blocker therapy during
strict anti-Xa monitoring during the first trimester is recommended
pregnancy and post-partum are recommended unless contraindicated,
to avoid the teratogenic effect of VKAs (for corresponding flowcharts
although strong evidence is only available for Marfan syndrome.
see the 2025 ESC Guidelines for the management of cardiovascular dis-
eases during pregnancy968).
Valvular regurgitant lesions are generally well tolerated during preg-
Lifetime management of women with a BHV considering pregnancy
nancy. Prophylactic intervention is therefore not recommended in the
is central and transcatheter valve-in-valve implantation may be consid-
absence of class I or IIa indications. ered as a bridge to MHV implantation.982
The first therapeutic option for MS in a woman considering preg-
nancy should be PMC. When implantation of a prosthetic valve is ne-
cessary, BHVs are recommended, although early SVD remains a 17. Sex-specific considerations
serious concern.975 Mechanical heart valves must be avoided due to
in patients with valvular heart
the high risk of maternal and foetal complications linked to the potential
teratogenic effects of VKAs, as well as the increased risk of bleeding.976 disease
The Ross procedure may be considered for the treatment of AV dis-
ease at centres with expertise. Although men and women are equally likely to experience VHD, sex-
specific prevalence exists according to valve type and disease patho-
physiology.644,648,983 Women more frequently suffer from MV disease
16.2. Management during pregnancy such as prolapse, RHD or TR, while men more often present with AS or
AR, especially associated with BAV.984 Men also suffer from endocardi-
16.2.1. Patients with native valve disease
tis of any valve more frequently.985
Pregnancy can worsen the clinical course of left-sided stenotic valvular
Female sex is associated with higher mortality in the presence of vari-
lesions because increased cardiac output causes an increment of trans-
ous VHDs,986 including early post-treatment,987 and is included as a
valvular gradient of ∼50%, mainly between the first and second trime-
risk factor in surgical risk prediction tools such as the STS and
sters. Regurgitant lesions are less likely to cause complications, except
EuroSCORE calculators. However, risk scores are often derived
in high-risk cases (LV systolic dysfunction, PH, and cardiac events before
from populations including a majority of men.988 In addition, risk pre-
pregnancy).977
diction scores are susceptible to referral bias that results in a well-
Mild MS is generally well tolerated.978 Heart failure occurs in
established higher risk of undertreatment or delayed treatment of
one-third of pregnant women with an MVA of <1.5 cm2 and in one-half
VHD in women.983,984,986
of those with an MVA of <1.0 cm2, most often during the second tri-
mester.971 Percutaneous mitral commissurotomy should be consid-
17.1. Aortic valve disease
ered if symptoms or SPAP of >50 mmHg persist despite optimal
medical therapy (diuretics and beta-1-selective beta-blockers), prefer- Female patients with severe AS present more often with shortness of
ably after the 20th week of pregnancy. breath, whereas males more frequently have angina, presumably due to
Regarding AS, pregnancy is generally well tolerated if prior exercise the higher incidence of CAD.989 The pathophysiology of AS seems to
tolerance was normal, even in severe AS, while HF has been reported differ according to sex, with women having less calcium and more fibro-
to occur in up to 25% of symptomatic patients.972 In symptomatic sis.990 Concentric ventricular hypertrophy and remodelling are also
patients despite medical therapy (i.e. diuretics), TAVI seems to be more frequently observed in women than in men, resulting in higher
the preferred option in very selected patients, although evidence is LVEF but smaller LV cavity and stroke volume.991 Consequently, para-
lacking. Percutaneous balloon valvuloplasty may be an alternative op- doxical low-flow, low-gradient constellations are frequent and may
tion. Procedures should be performed in an experienced valve both contribute to the underdiagnosis of severe AS in women and delay
centre.972,979,980 an intervention.992 The use of sex-specific thresholds to define flow
Surgery under cardiopulmonary bypass is associated with a high rate limitation (<40 mL/m2 for men and <32 mL/m2 for women) has there-
of foetal loss and should be restricted to conditions that threaten the fore been suggested,292 and the use of CCT to quantify the calcium
mother’s life if transcatheter intervention is not possible or has failed. score should be performed in women with discordant echocardio-
Vaginal delivery is the first choice for the majority of patients. graphic parameters.777
Caesarean section is preferred if there is an obstetric indication, Women are less likely to be referred to a cardiologist and
and in the case of severe MS or AS, ascending aortic diameter of undergo investigations. Surgical aortic valve replacement is per-
>45 mm, severe PH, or if delivery starts while the patient is being formed less frequently in women, especially if echocardiographic
treated with OAC. parameters are discordant.993 In patients presenting with severe
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 70 ---
4704 E S C G u id e l in e s
AS and Class I indications for SAVR, a significantly higher proportion 18. Key messages
of men than women are referred for evaluation by a cardiac
surgeon.994,995 Heart Team and Heart Valve Centre
Male patients derive a clearer benefit from SAVR compared with wo-
• An integrated regional Heart Valve Network incorporating out-
men, who have higher in-hospital and long-term mortality and morbid-
patient Heart Valve Clinics and specialist Heart Valve Centres allows
ity,987,996 possibly explained by more severe concentric hypertrophy991
optimal patient care.
and a smaller aortic annulus predisposing to PPM.997 Conversely, in a
• Heart Valve Centres should fulfil institutional and local statutory re-
randomized trial (RHEIA) that compared TAVI with SAVR in 443 wo-
quirements, and strive for high procedural volume and excellent clin-
men with a mean age of 73 years, TAVI was superior in reducing the
ical outcomes.
primary endpoint composed of death, stroke, or rehospitalization at
• Heart Team recommendations should be based upon these guideline
1 year, predominantly driven by a reduction in rehospitalization for
recommendations, relevant updated evidence, key medical consid-
valve- or procedure-related symptoms or worsening HF.998 Several ob-
erations, and patient preferences.
servational studies suggest that elderly women have lower mortality
• Core members of the Heart Team include the primary clinical cardi-
after TAVI,999 even if the rates of major vascular complications and
ologist, cardiologists with subspecialty expertise in VHD, specialists in
bleeding tend to be higher.997
advanced cardiovascular imaging and peri-procedural imaging guid-
Indexed cut-offs to indicate treatment of AR are validated, but only
ance, and surgeons and interventional cardiologists with training
partially account for sex differences. Newer studies using echocardio-
and expertise in valve interventions.
graphic volumes1000 and CMR1001 suggest that women may experience
• A network approach that distinguishes between higher- and
higher event rates at lower cut-offs compared with men, but this re-
lower-volume centres is appropriate, with more complex proce-
quires further investigation.
dures focused in the most experienced (i.e. upper quartile)
centres. Information on the network organization should be com-
17.2. Mitral valve disease municated to patients, as well as referring cardiologists and general
practitioners.
Patients with RHD are often young women and have a high prevalence
of major cardiovascular complications with far-reaching impacts on re-
productive health and access to care.282 Although women experience Aortic regurgitation
favourable outcomes compared with men when treated by percutan-
• Assessment of AR severity with TTE remains challenging and current
eous balloon valvuloplasty, access to these procedures is still limited
cut-offs for intervention are mostly based on 2D measurements, al-
in low-income countries.662
though 3D echocardiography and CMR allow more accurate evalu-
Fibroelastic disease with MV prolapse is also more frequent in wo-
ation of LV volumes and LVEF.
men, and may be accompanied by morphological abnormalities of
• Mechanisms of AR may be closely related to the aortic diameters that
the MA associated with fibrosis of the papillary muscles or the infer-
should be measured accurately at all levels of the aortic root (annulus,
obasal LV that may act as the substrate for sudden cardiac death,
sinuses, and sinotubular junction).
even in the absence of severe MR.1002 Recent evidence has sup-
• Indication for operation is based on symptoms, LV volumes, LVEF,
ported considering lower women-specific cut-offs for intervention
and aortic diameters. Although valve replacement remains the stand-
with regard to LVESD (36 mm; indexed LVESD, 1.8 cm/m2), while
ard treatment, AV repair (or AV sparing when associated with root
the LVEF cut-off was similar to men (58%), albeit with higher
aneurysm) is being increasingly used to avoid prosthesis-related com-
mortality.548
plications, especially in experienced centres.
Ventricular SMR associated with low LVEF is more frequent in men
• Current transcatheter options for AR are limited and applicable only
with HF,1003 while atrial SMR due to chronic AF and/or HFpEF affects
in patients who are ineligible for surgery.
more women (58% vs 42% male).579
Female sex is a risk factor for the development of MAC and was re-
Aortic stenosis
ported to account for 68% of the patients included in a large-scale
transcatheter MV replacement in MAC registry.1004 Furthermore, wo- • Diagnosis of severe AS requires integrative evaluation of pressure
men present with a faster disease progression.1005 gradients (the most robust measurements), AVA, flow conditions,
the extent of valve calcification, and LV function.
• Selection of the most appropriate mode of intervention should take
17.3. Tricuspid valve disease
into account clinical characteristics (age and estimated life expect-
Tricuspid regurgitation is more prevalent in women,208 and female ancy, concomitant conditions), access and valve anatomy (particularly
sex is associated with accelerated disease progression.1006–1008 the feasibility of transfemoral TAVI and calcification patterns), and
Hypotheses to explain these observations include the overall higher surgical risk, as well as repeat procedure options and risks (lifetime
prevalence of HFpEF and AF in women.1009 Women are usually management).
diagnosed at an older age and the cause of TR is most frequently
a consequence of left valvular disease or annular dilatation attributable
Mitral regurgitation
to RA dilatation.1010 No differences have been detected to date
in terms of adverse events after surgery1011 or transcatheter TV • The echocardiographic diagnostic workup of patients with MR in-
interventions.1012,1013 cludes multiparametric assessment of MR severity, evaluation of
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 71 ---
ESC Guidelines 4705
MV anatomy (often with 3D TOE), identification of the mechanism risk–benefit ratio of intervention and lifetime management
(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac considerations.
damage. • Patients with mixed moderate AS and AR have similar detrimental
• Surgical MV repair is the preferred method of treatment in severe outcomes compared with those with severe isolated AS.
PMR. Transcatheter edge-to-edge repair is recommended in patients • In transcatheter procedures, which allow a sequential approach,
who are inoperable or high risk according to the Heart Team. downstream lesions should be treated first to prevent potential
• Surgical MV repair is the procedure of choice for asymptomatic pa- haemodynamic deterioration and allow improvement of upstream
tients with primary MR and signs of cardiac damage, including mod- lesions due to changing loading conditions and reverse
erate or more TR. remodelling.
• In patients with ventricular SMR, GDMT (including CRT if indicated)
is the initial and essential treatment step. In symptomatic patients Antithrombotic treatment in patients with a mechanical
without CAD needing revascularization, M-TEER is recommended. heart valve
In patients with concomitant complex CAD and those not suitable
• International normalized ratio therapeutic range should be balanced
for TEER, mitral surgery may be considered.
to the type and anatomical site of MHV, as well to the thrombotic risk
• In patients with atrial SMR, MV surgery, AF ablation if indicated, and
profile of the individual patient.
LAAO should be considered after optimization of medical therapy.
• Patient training, self-monitoring, and education can increase INR sta-
Transcatheter edge-to-edge repair may be considered in patients at
bility and TTR.
high surgical risk.
• Minor or minimally invasive NCS procedures do not require VKA
interruption in patients with an MHV.
Mitral stenosis
• In patients with an MHV undergoing elective major NCS, bridging
• Most patients with severe rheumatic MS and favourable valve anat- may be omitted if the thromboembolic risk is low.
omy should undergo PMC, which is the standard of care. Surgery
is recommended for symptomatic patients with contraindications Non-cardiac surgery
or unfavourable anatomical and clinical characteristics for PMC.
• The risk of peri-operative cardiovascular complications related to
• Decision-making in patients with unfavourable anatomy should take
surgery and to patient-specific factors should be evaluated and com-
into account local PMC experience.
municated to the patient and surgical team.
• In selected patients with clinically severe degenerative MS and MAC,
• In patients with symptomatic severe AS requiring urgent high-risk
transcatheter intervention or surgery may improve symptoms.
NCS, BAV or TAVI should be considered prior to surgery. In patients
planned for elective NCS, AV intervention is recommended prior to
Tricuspid regurgitation
NCS.
• Concomitant TV repair is the preferred method for patients with
left-sided valve pathology and associated moderate or severe TR. Pregnancy
• The use of risk scores for the assessment of RV and secondary organ
• In women with VHD, decisions regarding management before and dur-
dysfunction should be strongly encouraged in patients with isolated
ing pregnancy should be taken after discussion by the multidisciplinary
severe TV disease.
Pregnancy Heart Team. Unplanned pregnancies should be discouraged.
• In isolated severe TR without severe RV dysfunction, surgery should
• The following conditions should be corrected prior to considering
be performed at an early stage in patients at low operative risk.
pregnancy:
• In isolated severe TR patients at increased surgical risk, tricuspid
– clinically severe MS (MVA <1.5 cm2), even when asymptomatic
TEER or transcatheter replacement should be considered to im-
– severe symptomatic AS, or asymptomatic patients with impaired
prove quality of life and RV remodelling, in the absence of severe
LV function or a pathological exercise test
RV dysfunction or pre-capillary PH.
– heritable aortic disorders and high risk of aortic dissection.
• Vaginal delivery is the first choice for the majority of patients.
Tricuspid stenosis
Indications for Caesarean section include pre-term labour in patients
• TS is a very rare manifestation of acquired VHD in high-income on OAC, severe MS or AS, aggressive aortic pathology, acute intract-
countries. able HF, and severe PH.
• TS is mainly associated with rheumatic valve disease, carcinoid syn- • Women with MHVs should be managed in expert centres.
drome, or enzymatic disorders such as Fabry’s or Whipple’s disease.
• Treatment of symptomatic TS mainly involves surgical TV 19. Gaps in evidence
replacement.
General aspects
Multiple and mixed valvular heart disease
• Patient-reported outcome measures are infrequently reported
• Transvalvular gradients and velocities reflect the combined burden of in VHD studies. Patient-reported outcome measure-oriented studies
regurgitation and stenosis in mixed aortic and mitral disease. are required to improve quality of life and patient satisfaction.
• Treatment decisions should be based on the assessment of symptom • Methods to address underdiagnosis and undertreatment of VHD
and functional status, cardiac damage, anatomical suitability, and the need to be identified and implemented.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 72 ---
4706 E S C G u id e l in e s
Heart Team and Heart Valve Centre • More data are required on the role of TEER in patients with advanced HF.
• Long-term results of TEER need to be further assessed, including the
• Structured research is required to investigate the relationship be-
clinical relevance of transmitral gradients after treatment of both pri-
tween procedural volume and clinical outcomes, in order to define
mary and secondary MR.
minimum annual thresholds for individual operators and institutions
• Results of ongoing trials comparing MV surgery with TEER in non-
undertaking surgical and transcatheter valve interventions.
high risk primary MR patients are awaited.
• There is a pressing need to ensure higher dispersion and adoption of
• Data on the mid- and long-term clinical impacts of transcatheter MV
interventions for VHD, especially in middle- and low-income countries.
replacement are required.
• More data on the clinical impacts of surgical and transcatheter treat-
Conditions associated with valvular heart disease
ment of atrial SMR are required.
• CAD:
– The prognostic value of functional assessment of stable, moderate Mitral stenosis
coronary stenosis in VHD patients remains to be determined.
• The potential role of TMVI using dedicated devices in high-risk
– The optimal strategy (invasive vs non-invasive) for CAD assess-
patients is to be determined, particularly those with severe
ment in specific VHD populations remains to be elucidated.
MAC.
– The optimal timing of PCI in patients with CAD undergoing TAVI
is yet to be determined.
Tricuspid regurgitation
– The benefit of complete coronary revascularization with CABG in
patients with combined VHD and CAD requires further research. • The long-term risks and benefits of concomitant TV surgery in pa-
• AF: tients with less than moderate TR and annular dilatation undergoing
– It is unclear which patients with chronic persistent AF and con- left-sided valve surgery need to be determined.
comitant VHD are deemed to be suitable for rhythm control • Further investigations are required on the outcomes of TV interven-
therapy. tion in asymptomatic patients with severe TR and RV dysfunction or
– The protective effect against stroke of OAC with VKA or DOACs significant dilation.
in patients after surgical or transcatheter LAAO remains to be • The importance of addressing concomitant AF in patients with TR
determined. needs to be investigated.
• Cardiogenic shock and acute HF: • More data are required on the indications, timing, and long-term out-
– The optimal treatment strategy in VHD patients presenting with comes of TV repair and replacement for TV disease.
cardiogenic shock and acute HF is unknown. • Better understanding is required of the respective role of surgery vs
transcatheter TV therapy for TR treatment.
Aortic regurgitation
Tricuspid stenosis
• Impact of early LV remodelling on prognosis in asymptomatic AR pa-
tients is unknown. • The role of transcatheter TV replacement remains unexplored in pa-
• Prognostic value of CMR-derived indices in asymptomatic patients tients with TS. The most efficient way to achieve ventricular pacing in
needs to be determined. patients after TV replacement needs to be investigated.
• More data are required on long-term results of surgical AV repair for AR.
• More evidence is required on transcatheter treatment options for Multiple and mixed valvular heart disease
AR, in particular using dedicated devices.
• Further evaluation of the impact on outcomes and indication for
intervention, as well as timing and modalities of intervention, is
Aortic stenosis
required.
• Better understanding of the pathophysiology of AS is needed to pro-
pose innovative medical therapy. Prosthetic valves
• Further research is required on:
• Further development of current prosthetic valve devices is required
– Refined prognostic markers to guide timing of intervention in
to address their main complications (e.g. improved tissue processing
asymptomatic patients.
to reduce degeneration of bioprostheses or new mechanical valve
– The role of revascularization in patients with severe AS and asymp-
designs to reduce risk of thrombosis).
tomatic concomitant CAD.
• Antithrombotic drugs in MHV patients:
– Further data on the long-term durability of transcatheter valves in
– Whether UFH or LMWH should be preferred as bridging therapy
comparison with surgical BHVs in younger patients.
after MHV implantation, as well as their timing and dosage, remains
– The role of TAVI in patients with BAV AS and patients <70 years
to be established.
of age.
– For patients with MHV undergoing major NCS, the optimal post-
– Results of intervention (valve or coronary) after TAVI or SAVR.
operative management and bridging of VKA needs further
– Determining the optimal lifetime management strategy for AS
investigation.
patients.
– The role of pharmacogenomics for VKORC1, CYP2C9, and
CYP4F2 in patients with highly variable INR, and low TTR or major
Mitral regurgitation
vascular complications despite good adherence, should be further
• The association between primary MR and ventricular arrhythmias re- investigated.
quires more investigation, including the impact of intervention on – More data on the risks and benefits of slow thrombolysis for valve
ventricular arrhythmias. thrombosis are required.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 73 ---
ESC Guidelines 4707
Pregnancy • Additional data are needed to validate sex-specific cut-offs indicating
interventions.
• More data are required on optimal management of anticoagulation in
• Further research is needed to investigate sex-related differences in
pregnant women with MHVs. Prospective studies comparing differ-
the prognosis and treatment of specific valve diseases, especially
ent antithrombotic regimens are lacking.
TR.
Non-cardiac surgery
20. ‘What to do’ and ‘What not
• Clinical utility of scales for peri-operative risk evaluation needs to be
to do’ messages from the
determined.
Guidelines
Sex-specific considerations
Class I and Class III recommendations from throughout the guideline
• The development of sex-adjusted surgical risk prediction tools is required. document are summarized in Table 13.
Table 13 ‘What to do’ and ‘what not to do’
Recommendations Classa Levelb
Recommendations for the management of coronary artery disease in patients with valvular heart disease
CCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. I B
Invasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of
I C
obstructive CAD.
Invasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. I C
CABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. I C
Recommendations for the management of atrial fibrillation in patients with native valvular heart disease
DOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. I A
Concomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent
I A
symptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons.
Surgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent
I B
cardioembolic stroke and systemic thromboembolism.
The use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. III B
Recommendations on indications for surgery in severe aortic regurgitation
AV surgery is recommended in symptomatic patients with severe AR regardless of LV function. I B
AV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients
I B
with small body size (BSA <1.68 m2)] or resting LVEF ≤50%.
Valve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable
I B
results are expected.
AV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending
I C
aorta.
Recommendations for intervention and mode of intervention in severe aortic stenosis
Symptomatic patients with severe aortic stenosis
Intervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s, and
max I B
AVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)].
Intervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF
I B
(<50%) after careful confirmation that AS is severe.
Asymptomatic patients with severe aortic stenosis
Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. I B
Mode of intervention in patients with symptomatic severe aortic stenosis
It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have
I C
on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team.
It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural
I C
characteristics, incorporating lifetime management considerations and estimated life expectancy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 74 ---
4708 E S C G u id e l in e s
TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable. I A
SAVR is recommended in patients <70 years of age, if the surgical risk is low. I B
SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. I B
Concomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery
SAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the
I C
ascending aorta.
Recommendations for intervention in severe mitral regurgitation
Primary mitral regurgitation
MV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. I B
MV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. I B
MV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or
I B
LVEF ≤60%).
Surgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi
<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled:
• AF
I B
• SPAP at rest >50 mmHg
• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)
• concomitant TR ≥ moderate.
Ventricular secondary mitral regurgitation and concomitant coronary artery disease
MV surgery is recommended in patients with severe ventricular SMR undergoing CABG. I B
Ventricular secondary mitral regurgitation without concomitant coronary artery disease
TEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with
impaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specific clinical and I A
echocardiographic criteria.
Recommendations for mitral stenosis
Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis
PMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. I B
PMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. I C
MV surgery is recommended in symptomatic patients who are not suitable for PMC. I C
Recommendations for tricuspid regurgitation
Indications for intervention in tricuspid regurgitation
Careful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,
I C
and likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention.
Patients with left-sided valvular heart disease requiring tricuspid valve surgery
Concomitant TV surgery is recommended in patients with severe primary or secondary TR. I B
Patients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery)
TV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. I C
Recommendations on tricuspid stenosis
Surgery is recommended in symptomatic patients with severe TS. I C
Surgery is recommended in patients with severe TS undergoing left-sided valve intervention. I C
Recommendations for surgery of concomitant left-sided valvular heart disease
Concomitant aortic stenosis
SAVR is recommended in patients with severe AS undergoing surgery for another valve. I C
Concomitant aortic regurgitation
AV surgery is recommended in patients with severe AR undergoing surgery for another valve. I C
Concomitant mitral regurgitation
MV surgery is recommended in patients with severe MR undergoing surgery for another valve. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 75 ---
ESC Guidelines 4709
Recommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation
Intervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean
I B
gradient ≥40 mmHg or V ≥4.0 m/s.
max
Intervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with V ≥4.0 m/s,
max I C
and LVEF <50% not attributable to other cardiac disease.
Recommendations for prosthetic valve selection
Mechanical heart valves
An MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. I C
Biological heart valves
A BHV is recommended according to the desire of the informed patient. I C
A BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated
I C
short life expectancy.
Recommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement
Lifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. I A
INR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve efficacy. I A
It is recommended that INR targets are based on the type and position of the MHV, and the patient’s risk factors and comorbidities. I A
Patient education is recommended to improve the quality of OAC. I A
Following cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as
I B
considered safe.
DOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. III A
Recommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective
non-cardiac surgery or invasive procedures
Continuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or
I A
minimal bleeding.
It is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment
I B
within 24 h after surgery, or as soon as considered safe.
Recommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair
Transcatheter aortic valve implantation without indication for oral anticoagulation
Low-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. I A
DAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. III A
Routine use of OAC is not recommended after TAVI in patients without baseline indication. III A
Surgical biological heart valve with indication for oral anticoagulation
OAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. I B
Transcatheter biological heart valve with indication for oral anticoagulation
OAC is recommended for TAVI patients who have other indications for OAC. I B
Recommendations on management of prosthetic valve dysfunction
Haemolysis and paravalvular leak
It is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team
I C
evaluation, including patient risk, leak morphology, and local expertise.
Reoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF
I C
symptoms.
Mechanical heart valve failure
Reoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. I C
Biological heart valve failure
Reintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. I C
Valve thrombosis
TOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 76 ---
4710 E S C G u id e l in e s
Mechanical heart valve thrombosis
Heart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine
I B
appropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).
Biological heart valve thrombosis
OAC using VKA is recommended in BHV thrombosis before considering reintervention. I B
4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body
surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography;
DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/
left atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area;
NCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral
regurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery
pressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid
regurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
21. Evidence tables Medical Center, Amsterdam, Netherlands; Benoit Mores,
(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther
Evidence tables are available at European Heart Journal online. Pérez-David, Cardiology Department, Hospital Universitario La
Paz, IdiPaz (Hospital la Paz Research Institute), Facultad de
22. Data availability statement Medicina Universidad Europea de Madrid, Madrid, Spain; Janine
Pöss, Department of internal medicine/cardiology, Heart Centre
No new data were generated or analysed in support of this research. Leipzig at University of Leipzig, Leipzig, Germany; Bernard
D. Prendergast, Heart Vascular & Thoracic Institute, Cleveland
Clinic London, London, United Kingdom; Department of
23. Author information
Cardiology, St Thomas’ Hospital, London, United Kingdom;
Bianca Rocca, Department of Medicine and Surgery, LUM
Jonas Lanz, Department of Cardiology, Bern University Hospital,
University Casamassima (Ba), Italy; Xavier Rossello, Cardiology
Bern, Switzerland; Mateo Marin-Cuartas, University
Department, Hospital Universitari Son Espases, Palma de Mallorca,
Department of Cardiac Surgery, Leipzig Heart Center, Leipzig,
Spain; Health Research Institute of the Balearic Islands (IdISBa),
Germany; Ana Abreu, Faculdade de Medicina da Universidade de
Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain;
Lisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal;
Mikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis,
Serviço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS
France; Holger Thiele, Department of Internal Medicine/
Santa Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute
Cardiology, Heart Centre Leipzig at Leipzig University, Leipzig,
of Cardiology, ASST Spedali Civili, Brescia, Italy; Department of
Germany; Leipzig Heart Science, Leipzig, Germany; Christophe
medical and surgical specialties, radiological sciences, and public
Michel Tribouilloy, Cardiology department, Amiens University
health, University of Brescia, Italy; Nina Ajmone Marsan,
Hospital, Amiens, France; and Wojtek Wojakowski, Division of
Department of Cardiology, Leiden University Medical Center,
Cardiology and Structural Heart Diseases, Medical University of
Leiden, Netherlands; Fabio Barili, Department of Biomedical and
Silesia, Katowice, Poland.
Clinical Sciences, Università Degli Studi Di Milano, Milan, Italy;
University Cardiac Surgery Unit, IRCCS Ospedale Galeazzi -
Sant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard 24. Appendix
T.H. Chan School of Public Health Boston, MA, United States of
America; Nikolaos Bonaros, Department of Cardiac Surgery, ESC/EACTS Scientific Document Group
Medical University of Innsbruck, Innsbruck, Austria; University Includes Document Reviewers, ESC National Cardiac Societies and
Hospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, EACTS Network of National Cardiac Surgery Societies
Cardiology department, Universitair Ziekenhuis Brussel, Brussels, Document Reviewers: Alec Vahanian (ESC Review
Belgium; Ruggero De Paulis, Department of cardiac surgery, Co-ordinator) (France), Carlos-A. Mestres (EACTS Review
European Hospital, Rome, Italy; Unicamillus University, Rome, Co-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa
Italy; Habib Gamra, Cardiology University of Monastir, Monastir, (United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs
Tunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, (Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy),
London, United Kingdom; Anders Jeppsson, Cardiothoracic sur- Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne
gery, Sahlgrenska University Hospital, Gothenburg, Sweden; (Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi
Molecular and clinical medicine, Institute of medicine, Sahlgrenska (Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch
Academy, University of Gothenburg, Gothenburg, Sweden; F. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina
Robert J.M. Klautz, Department of Cardiothoracic Surgery, Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja
Leiden University Medical Center, Leiden, Netherlands; Ibanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars
Department of Cardiothoracic Surgery, Amsterdam University Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf
5202STCAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 77 ---
ESC Guidelines 4711
Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), John Turkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine:
William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun Ukrainian Association of Cardiology, Elena G. Nesukay; United
(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham Kingdom of Great Britain and Northern Ireland: British
(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen Cardiovascular Society, Madalina Garbi; Uzbekistan: Association of
(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet Cardiologists of Uzbekistan, Guzal Mullabayeva.
(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), EACTS Network of National Cardiac Surgery Societies ac-
Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba tively involved in the review process of the 2025 ESC/EACTS
(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina Guidelines for the management for valvular heart disease:
Urena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints Austria: Austrian Society of Cardiac and Thoracic Vascular
(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), Surgery, Martin Grabenwoeger; Belgium: Belgian Association for
Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) Cardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The
Contributor either withdrew or was engaged in only a part of the re- Czech Society for Cardiovascular Surgery, Jan Vojacek; France: The
view process: Davide Capodanno French Society for Thoracic and Cardiovascular Surgery; André
ESC National Cardiac Societies actively involved in the review Vincentelli; Germany: German Society for Thoracic and
process of the 2025 ESC/EACTS Guidelines for the management for Cardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of
valvular heart disease: Thoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: Society for Cardiac Surgery, Alessandro Parolari; Netherlands:
Algerian Society of Cardiology, Brahim Kichou; Armenia: Armenian Netherlands Association for Cardio-thoracic surgery, Jerry Braun;
Cardiologists Association, Aram L. Chilingaryan; Austria: Austrian North Macedonia: North Macedonian Society of Cardiac
Society of Cardiology, Philipp Emanuel Bartko; Azerbaijan: Surgery, Aleksandar Nikolic; Norway: Norwegian Association for
Azerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian Cardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade
Society of Cardiology, Caroline M. Van de Heyning; Bosnia and Portuguesa de Cirurgia Cardíaca Torácica e Vascular, Miguel Sousa-Uva;
Herzegovina: Association of Cardiologists of Bosnia and Serbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic;
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of Spain: Sociedad Española de Cirugía Cardiovascular y Endovascular,
Cardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko Juan J. Legarra; Switzerland: Swiss Society for Thoracic and
Bulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; Cardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society
Czechia: Czech Society of Cardiology, Hana Linkova; Denmark: for Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani
Danish Society of Cardiology, Emil Fosbøl; Egypt: Egyptian Society ESC Clinical Practice Guidelines (CPG) Committee:
of Cardiology, Hesham Bahaa; Estonia: Estonian Society of Ulf Landmesser (Chairperson) (Germany), Stefan James
Cardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko (Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa
Piuhola; France: French Society of Cardiology, Erwan Donal; (United Kingdom), Folkert W. Asselbergs (Netherlands), Colin
Georgia: Georgian Society of Cardiology, Shalva Petriashvili; Baigent (United Kingdom), Michael A. Borger (Germany), Giuseppe
Germany: German Cardiac Society, Tanja Katharina Rudolph; Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland),
Greece: Hellenic Society of Cardiology, Maria Drakopoulou; Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja
Hungary: Hungarian Society of Cardiology, Attila Kertész; Iceland: Hennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United
Icelandic Society of Cardiology, Hjalti Guðmundsson; Ireland: Irish Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy
Cardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy (Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard
Carasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; (Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark),
Kazakhstan: Association of Cardiologists of Kazakhstan, Madina Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino
Sugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, (Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski
Gani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina (Poland), and Katja Zeppenfeld (Netherlands)
Kerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; EACTS Council: Volkmar Falk (President) (Germany), Patrick
Lithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; Myers (Secretary General) (Switzerland), Joseph Bavaria (United
Luxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; States of America), Korkut Bostanci (Türkiye), Filip Casselman
Malta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova (Belgium), Mario Gaudino (United States of America), Jurgen Hoerer
(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; (Germany), Nabil Hussein (United Kingdom), Virginia Litle (United
Netherlands: Netherlands Society of Cardiology, Sebastian States of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian
Streukens; North Macedonia: National Society of Cardiology of Schoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya
North Macedonia, Emilija Antova; Norway: Norwegian Society of Warburton (United Kingdom)
Cardiology, Håvard Dalen; Poland: Polish Cardiac Society, Tomasz
Kukulski; Portugal: Portuguese Society of Cardiology, Cristina
Gavina; Romania: Romanian Society of Cardiology, Bogdan 25. References
A. Popescu; San Marino: San Marino Society of Cardiology,
Roberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; 1.Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter
aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J
Slovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia:
Med 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052
Slovenian Society of Cardiology, Matjaž Bunc; Spain: Spanish Society 2.Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter
of Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of aortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389:
Cardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss 1949–960. https://doi.org/10.1056/NEJMoa2307447
3.Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al.
Society of Cardiology, Raban Jeger; Tunisia: Tunisian Society of
Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl
Cardiology and Cardio-Vascular Surgery, Leila Abid; Türkiye: J Med 2017;376:1321–31. https://doi.org/10.1056/NEJMoa1700456
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 78 ---
4712 E S C G u id e l in e s
4.Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 4-Year out- 23.Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon
comes of patients with aortic stenosis in the Evolut low risk trial. J Am Coll Cardiol 2023; volume and operative mortality in the United States. N Engl J Med 2003;349:2117–27.
82:2163–65. https://doi.org/10.1016/j.jacc.2023.09.813 https://doi.org/10.1056/NEJMsa035205
5.Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 24.Khera R, Pandey A, Koshy T, Ayers C, Nallamothu BK, Das SR, et al. Role of hospital
ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: volumes in identifying low-performing and high-performing aortic and mitral valve sur-
3948–4042. https://doi.org/10.1093/eurheartj/ehad193 gical centers in the United States. JAMA Cardiol 2017;2:1322–31. https://doi.org/10.
6.Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC 1001/jamacardio.2017.4003
Guidelines for the management of chronic coronary syndromes: developed by the 25.Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital
task force for the management of chronic coronary syndromes of the European procedural volume on care process and mortality for patients undergoing elective sur-
Society of Cardiology (ESC) Endorsed by the European Association for gery for mitral regurgitation. Circulation 2007;115:881–7. https://doi.org/10.1161/
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3415–537. https://doi.org/ CIRCULATIONAHA.106.634436
10.1093/eurheartj/ehae177 26.Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, et al. Relation of
7.Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024
mitral valve surgery volume to repair rate, durability, and survival. J Am Coll Cardiol
ESC Guidelines for the management of atrial fibrillation developed in collaboration
2017;69:2397–406. https://doi.org/10.1016/j.jacc.2017.02.026
with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J
27.Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, et al. Operator
2024;45:3314–414. https://doi.org/10.1093/eurheartj/ehae176
experience and outcomes of transcatheter mitral valve repair in the United States. J Am
8.Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC
Coll Cardiol 2019;74:2955–65. https://doi.org/10.1016/j.jacc.2019.09.014
Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J
28.Bonow RO, O’Gara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, et al. 2019
2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179
AATS/ACC/SCAI/STS Expert Consensus Systems of Care document: operator and
9.Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al.
institutional recommendations and requirements for transcatheter mitral valve inter-
2020 ESC Guidelines for the management of adult congenital heart disease: the Task
vention: a joint report of the American Association for Thoracic Surgery, the
Force for the management of adult congenital heart disease of the European Society of
American College of Cardiology, the Society for Cardiovascular Angiography and
Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital
Interventions, and The Society of Thoracic Surgeons. J Am Coll Cardiol 2020;76:
Cardiology (AEPC), International Society for Adult Congenital Heart Disease
96–117. https://doi.org/10.1016/j.jacc.2019.12.002
(ISACHD). Eur Heart J 2020;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554
29.Grayburn PA, Mack MJ, Manandhar P, Kosinski AS, Sannino A, Smith RL 2nd, et al.
10.Généreux P, Sharma RP, Cubeddu RJ, Aaron L, Abdelfattah OM, Koulogiannis KP, et al.
The mortality burden of untreated aortic stenosis. J Am Coll Cardiol 2023;82:2101–9. Comparison of transcatheter edge-to-edge mitral valve repair for primary mitral regur-
https://doi.org/10.1016/j.jacc.2023.09.796 gitation outcomes to hospital volumes of surgical mitral valve repair. Circ Cardiovasc Interv
11.d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. 2024;17:e013581. https://doi.org/10.1161/circinterventions.123.013581
Large-scale community echocardiographic screening reveals a major burden of undiag- 30.Wild MG, Stolz L, Rosch S, Rudolph F, Goebel B, Köll B, et al. Transcatheter valve re-
nosed valvular heart disease in older people: the OxVALVE Population Cohort Study. pair for tricuspid regurgitation: 1-year results from a large European real-world regis-
Eur Heart J 2016;37:3515–22. https://doi.org/10.1093/eurheartj/ehw229 try. J Am Coll Cardiol 2025;85:220–31. https://doi.org/10.1016/j.jacc.2024.10.068
12.Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al. 31.Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al.
Contemporary presentation and management of valvular heart disease: the Procedural experience for transcatheter aortic valve replacement and relation to out-
EURObservational research programme valvular heart disease II survey. Circulation comes: the STS/ACC TVT registry. J Am Coll Cardiol 2017;70:29–41. https://doi.org/10.
2019;140:1156–69. https://doi.org/10.1161/CIRCULATIONAHA.119.041080 1016/j.jacc.2017.04.056
13.Gaede L, Di Bartolomeo R, van der Kley F, Elsässer A, Iung B, Möllmann H. Aortic valve 32.Mao J, Redberg RF, Carroll JD, Marinac-Dabic D, Laschinger J, Thourani V, et al.
stenosis: what do people know? A heart valve disease awareness survey of over 8,800 Association between hospital surgical aortic valve replacement volume and transcath-
people aged 60 or over. EuroIntervention 2016;12:883–9. https://doi.org/10.4244/ eter aortic valve replacement outcomes. JAMA Cardiol 2018;3:1070–8. https://doi.org/
eijy16m06_02 10.1001/jamacardio.2018.3562
14.Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, et al. Outcomes of 33.Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, et al. Procedural volume
patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA and outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380:
Cardiol 2018;3:1060–8. https://doi.org/10.1001/jamacardio.2018.3152 2541–50. https://doi.org/10.1056/NEJMsa1901109
15.Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, et al. ESC Working 34.Edwards FH, Ferraris VA, Kurlansky PA, Lobdell KW, He X, O’Brien SM, et al. Failure
Group on Valvular Heart Disease Position Paper—heart valve clinics: organization, to rescue rates after coronary artery bypass grafting: an analysis from the Society of
structure, and experiences. Eur Heart J 2013;34:1597–606. https://doi.org/10.1093/ Thoracic Surgeons adult cardiac surgery database. Ann Thorac Surg 2016;102:
eurheartj/ehs443 458–64. https://doi.org/10.1016/j.athoracsur.2016.04.051
16.Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pierard LA, et al. 35.Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective
Standards defining a ‘Heart Valve Centre’: ESC Working Group on Valvular Heart aortic root replacement in North America: analysis of STS adult cardiac surgery data-
Disease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart
base. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018.
J 2017;38:2177–83. https://doi.org/10.1093/eurheartj/ehx370
12.039
17.Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, et al. 2019 36.Geirsson A, Ahlsson A, Franco-Cereceda A, Fuglsang S, Gunn J, Hansson EC, et al.
AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care document: a proposal
Hospital volumes and later year of operation correlates with better outcomes in acute
to optimize care for patients with valvular heart disease: a joint report of the American
Type A aortic dissection. Eur J Cardiothorac Surg 2018;53:276–81. https://doi.org/10.
Association for Thoracic Surgery, American College of Cardiology, American Society
1093/ejcts/ezx231
of Echocardiography, Society for Cardiovascular Angiography and Interventions, and
37.Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the
Society of Thoracic Surgeons. J Am Coll Cardiol 2019;73:2609–35. https://doi.org/10.
volume-outcome effect in cardiovascular surgery: the role of failure to rescue. JAMA
1016/j.jacc.2018.10.007
Surg 2014;149:119–23. https://doi.org/10.1001/jamasurg.2013.3649
18.Dreyfus G, Windecker S. How to shape the future of cardiology and cardiac surgery?
38.Wakeam E, Asafu-Adjei D, Ashley SW, Cooper Z, Weissman JS. The association of
Eur Heart J 2020;41:3693–701. https://doi.org/10.1093/eurheartj/ehaa707
intensivists with failure-to-rescue rates in outlier hospitals: results of a national survey
19.Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/
of intensive care unit organizational characteristics. J Crit Care 2014;29:930–5. https://
EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:
561–632. https://doi.org/10.1093/eurheartj/ehab395 doi.org/10.1016/j.jcrc.2014.06.010
20.Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, et al. 39.Ward ST, Dimick JB, Zhang W, Campbell DA, Ghaferi AA. Association between hos-
Composition, structure, and function of heart teams: a joint position paper of the pital staffing models and failure to rescue. Ann Surg 2019;270:91–4. https://doi.org/10.
ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with 1097/sla.0000000000002744
complex coronary artery disease requiring myocardial revascularization. Eur Heart J 40.Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European
Acute Cardiovasc Care 2021;10:83–93. https://doi.org/10.1093/ehjacc/zuaa013 Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41:
21.Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletra F, et al. The structural 12–85. https://doi.org/10.1093/eurheartj/ehz859
heart disease interventional imager rationale, skills and training: a position paper of 41.Ali N, Aktaa S, Younsi T, Beska B, Batra G, Blackman DJ, et al. European Society of
the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging Cardiology quality indicators for the care and outcomes of adults undergoing trans-
2021;22:471–9. https://doi.org/10.1093/ehjci/jeab005 catheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes 2024;10:
22.Hahn RT, Mahmood F, Kodali S, Lang R, Monaghan M, Gillam LD, et al. Core compe- 723–36. https://doi.org/10.1093/ehjqcco/qcae006
tencies in echocardiography for imaging structural heart disease interventions: an ex- 42.Messika-Zeitoun D, Baumgartner H, Burwash IG, Vahanian A, Bax J, Pibarot P, et al.
pert consensus statement. JACC Cardiovasc Imaging 2019;12:2560–70. https://doi.org/ Unmet needs in valvular heart disease. Eur Heart J 2023;44:1862–73. https://doi.org/
10.1016/j.jcmg.2019.10.008 10.1093/eurheartj/ehad121
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 79 ---
ESC Guidelines 4713
43.van Dijk WB, Schuit E, van der Graaf R, Groenwold RHH, Laurijssen S, Casadei B, et al. 62.Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended stan-
Applicability of European Society of Cardiology guidelines according to gross national dards for the performance of transesophageal echocardiographic screening for struc-
income. Eur Heart J 2022;44:598–607. https://doi.org/10.1093/eurheartj/ehac606 tural heart intervention: from the American Society of Echocardiography. J Am Soc
44.Sengupta PP, Kluin J, Lee SP, Oh JK, Smits A. The future of valvular heart disease as- Echocardiogr 2022;35:1–76. https://doi.org/10.1016/j.echo.2021.07.006
sessment and therapy. Lancet 2024;403:1590–602. https://doi.org/10.1016/s0140- 63.Nicoara A, Skubas N, Ad N, Finley A, Hahn RT, Mahmood F, et al. Guidelines for the
6736(23)02754-x use of transesophageal echocardiography to assist with surgical decision-making in the
45.Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al. operating room: a surgery-based approach: from the American Society of
Multi-modality imaging assessment of native valvular regurgitation: an EACVI and Echocardiography in collaboration with the Society of Cardiovascular
ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging Anesthesiologists and the Society of Thoracic Surgeons. J Am Soc Echocardiogr 2020;
2022;23:e171–232. https://doi.org/10.1093/ehjci/jeab253 33:692–734. https://doi.org/10.1016/j.echo.2020.03.002
46.Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. 64.Popescu BA, Stefanidis A, Fox KF, Cosyns B, Delgado V, Di Salvo GD, et al. Training,
Recommendations for noninvasive evaluation of native valvular regurgitation: a report competence, and quality improvement in echocardiography: the European Association
from the American Society of Echocardiography developed in collaboration with the of Cardiovascular Imaging Recommendations: update 2020. Eur Heart J Cardiovasc
Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30: Imaging 2020;21:1305–19. https://doi.org/10.1093/ehjci/jeaa266
303–71. https://doi.org/10.1016/j.echo.2017.01.007 65.Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, et al. Educational needs
47.Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, et al. and application of guidelines in the management of patients with mitral regurgitation. A
European Association of Echocardiography recommendations for training, compe- European mixed-methods study. Eur Heart J 2018;39:1295–303. https://doi.org/10.
tence, and quality improvement in echocardiography. Eur J Echocardiogr 2009;10: 1093/eurheartj/ehx763
893–905. https://doi.org/10.1093/ejechocard/jep151 66.Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al.
48.Chambers JB, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734–44; discussion 744–735. https://
Appropriateness criteria for the use of cardiovascular imaging in heart valve disease doi.org/10.1093/ejcts/ezs043
in adults: a European Association of Cardiovascular Imaging report of literature review 67.Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of
and current practice. Eur Heart J Cardiovasc Imaging 2017;18:489–98. https://doi.org/ EuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons Risk
10.1093/ehjci/jew309
Score in Cardiac Surgery Patients. Ann Thorac Surg 2016;102:573–9. https://doi.org/
49.Agricola E, Ancona F, Bartel T, Brochet E, Dweck M, Faletra F, et al. Multimodality im-
10.1016/j.athoracsur.2016.01.105
aging for patient selection, procedural guidance, and follow-up of transcatheter inter-
68.O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of
ventions for structural heart disease: a consensus document of the EACVI Task Force
Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery.
on Interventional Cardiovascular Imaging: part 1: access routes, transcatheter aortic
Ann Thorac Surg 2009;88:S23–42. https://doi.org/10.1016/j.athoracsur.2009.05.056
valve implantation, and transcatheter mitral valve interventions. Eur Heart J
69.Duchnowski P, Hryniewiecki T, Kuśmierczyk M, Szymanski P. Performance of the
Cardiovasc Imaging 2023;24:e209–68. https://doi.org/10.1093/ehjci/jead096
EuroSCORE II and the Society of Thoracic Surgeons score in patients undergoing aor-
50.Zoghbi WA, Jone PN, Chamsi-Pasha MA, Chen T, Collins KA, Desai MY, et al.
tic valve replacement for aortic stenosis. J Thorac Dis 2019;11:2076–81. https://doi.org/
Guidelines for the evaluation of prosthetic valve function with cardiovascular imaging:
10.21037/jtd.2019.04.48
a report from the American Society of Echocardiography developed in collaboration
70.Provenchere S, Chevalier A, Ghodbane W, Bouleti C, Montravers P, Longrois D, et al.
with the Society for Cardiovascular Magnetic Resonance and the Society of
Is the EuroSCORE II reliable to estimate operative mortality among octogenarians?
Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2024;37:2–63.
PLoS One 2017;12:e0187056. https://doi.org/10.1371/journal.pone.0187056
https://doi.org/10.1016/j.echo.2023.10.004
71.Taleb Bendiab T, Brusset A, Estagnasié P, Squara P, Nguyen LS. Performance of
51.Faletra FF, Agricola E, Flachskampf FA, Hahn R, Pepi M, Ajmone Marsan N, et al.
EuroSCORE II and Society of Thoracic Surgeons risk scores in elderly patients under-
Three-dimensional transoesophageal echocardiography: how to use and when to
going aortic valve replacement surgery. Arch Cardiovasc Dis 2021;114:474–81. https://
use—a clinical consensus statement from the European Association of
doi.org/10.1016/j.acvd.2020.12.004
Cardiovascular Imaging of the European Society of Cardiology. Eur Heart J
72.Roques F, Michel P, Goldstone AR, Nashef SAM. The logistic EuroSCORE. Eur Heart J
Cardiovasc Imaging 2023;24:e119–97. https://doi.org/10.1093/ehjci/jead090
2003;24:882–3. https://doi.org/10.1016/S0195-668X(02)00799-6
52.Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise
73.Al-Azizi K, Shih E, DiMaio JM, Squiers JJ, Moubarak G, Kluis A, et al. Assessment of TVT
testing and stress echocardiography in valvular heart disease. J Am Coll Cardiol 2009;54:
and STS risk score performances in patients undergoing transcatheter aortic valve re-
2251–60. https://doi.org/10.1016/j.jacc.2009.07.046
placement. JSCAI 2023;2:100600. https://doi.org/10.1016/j.jscai.2023.100600
53.Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging clas-
74.Compagnone M, Moretti C, Marcelli C, Taglieri N, Ghetti G, Corsini A, et al. Surgical
sification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38:
risk scores applied to transcatheter aortic valve implantation: friends or foes?
3351–8. https://doi.org/10.1093/eurheartj/ehx381
Short-term and long-term outcomes from a single-center registry. J Invasive Cardiol
54.Stolz L, Doldi PM, Orban M, Karam N, Puscas T, Wild MG, et al. Staging heart failure
2019;31:E282–88.
patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge
75.Tarantini G, Lefèvre T, Terkelsen CJ, Frerker C, Ohlmann P, Mojoli M, et al. One-year repair. JACC Cardiovasc Interv 2023;16:140–51. https://doi.org/10.1016/j.jcin.2022.10.
outcomes of a European transcatheter aortic valve implantation cohort according to
032
55.Dietz MF, Prihadi EA, van der Bijl P, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic surgical risk. Circ Cardiovasc Interv 2019;12:e006724. https://doi.org/10.1161/
implications of staging right heart failure in patients with significant secondary tricuspid CIRCINTERVENTIONS.118.006724
regurgitation. JACC Heart Fail 2020;8:627–36. https://doi.org/10.1016/j.jchf.2020.02. 76.Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of
008 poor outcomes after transcatheter aortic valve replacement: results from the
56.Généreux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prog- PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129:
nostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022; 2682–90. https://doi.org/10.1161/circulationaha.113.007477
80:783–800. https://doi.org/10.1016/j.jacc.2022.05.006 77.Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack MJ, Shahian DM, et al.
57.Genereux P, Cohen DJ, Pibarot P, Redfors B, Bax JJ, Zhao Y, et al. Cardiac damage and Development and validation of a risk prediction model for in-hospital mortality after
quality of life after aortic valve replacement in the PARTNER trials. J Am Coll Cardiol transcatheter aortic valve replacement. JAMA Cardiol 2016;1:46–52. https://doi.org/10.
2023;81:743–52. https://doi.org/10.1016/j.jacc.2022.11.059 1001/jamacardio.2015.0326
58.Kwak S, Everett RJ, Treibel TA, Yang S, Hwang D, Ko T, et al. Markers of myocardial 78.Iung B, Laouénan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, et al.
damage predict mortality in patients with aortic stenosis. J Am Coll Cardiol 2021;78: Predictive factors of early mortality after transcatheter aortic valve implantation: indi-
545–58. https://doi.org/10.1016/j.jacc.2021.05.047 vidual risk assessment using a simple score. Heart 2014;100:1016–23. https://doi.org/
59.Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, et al. Distribution 10.1136/heartjnl-2013-305314
and prognostic significance of left ventricular global longitudinal strain in asymptomatic 79.Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, et al. Prediction of poor
significant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc outcome after transcatheter aortic valve replacement. J Am Coll Cardiol 2016;68:
Imaging 2019;12:84–92. https://doi.org/10.1016/j.jcmg.2018.11.005 1868–77. https://doi.org/10.1016/j.jacc.2016.07.762
60.Prihadi EA, van der Bijl P, Dietz M, Abou R, Vollema EM, Marsan NA, et al. Prognostic 80.Raposeiras-Roubin S, Adamo M, Freixa X, Arzamendi D, Benito-González T,
implications of right ventricular free wall longitudinal strain in patients with significant Montefusco A, et al. A score to assess mortality after percutaneous mitral valve repair.
functional tricuspid regurgitation. Circ Cardiovasc Imaging 2019;12:e008666. https://doi. J Am Coll Cardiol 2022;79:562–73. https://doi.org/10.1016/j.jacc.2021.11.041
org/10.1161/CIRCIMAGING.118.008666 81.Shah N, Madhavan MV, Gray WA, Brener SJ, Ahmad Y, Lindenfeld J, et al. Prediction of
61.Little SH, Rigolin VH, Garcia-Sayan E, Hahn RT, Hung J, Mackensen GB, et al. death or HF hospitalization in patients with severe FMR: the COAPT risk score. JACC
Recommendations for special competency in echocardiographic guidance of structural Cardiovasc Interv 2022;15:1893–905. https://doi.org/10.1016/j.jcin.2022.08.005
heart disease interventions: from the American Society of Echocardiography. J Am Soc 82.Hausleiter J, Lachmann M, Stolz L, Bedogni F, Rubbio AP, Estévez-Loureiro R, et al.
Echocardiogr 2023;36:350–65. https://doi.org/10.1016/j.echo.2023.01.014 Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 80 ---
4714 E S C G u id e l in e s
treated by transcatheter edge-to-edge repair: the EuroSMR risk score. Eur Heart J 101. Henri C, Piérard LA, Lancellotti P, Mongeon F-P, Pibarot P, Basmadjian AJ. Exercise
2024;45:922–36. https://doi.org/10.1093/eurheartj/ehad871 testing and stress imaging in valvular heart disease. Can J Cardiol 2014;30:1012–26.
83.Adamo M, Rubbio AP, Zaccone G, Pighi M, Massussi M, Tomasoni D, et al. Prediction https://doi.org/10.1016/j.cjca.2014.03.013
of mortality and heart failure hospitalisations in patients undergoing M-TEER: external 102. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur
validation of the COAPT risk score. EuroIntervention 2023;18:1408–17. https://doi.org/ Heart J 2005;26:1309–13. https://doi.org/10.1093/eurheartj/ehi250
10.4244/EIJ-D-22-00992 103. Redfors B, Pibarot P, Gillam LD, Burkhoff D, Bax JJ, Lindman BR, et al. Stress testing in
84.Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. asymptomatic aortic stenosis. Circulation 2017;135:1956–76. https://doi.org/10.1161/
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricus- CIRCULATIONAHA.116.025457
pid valve surgery. Eur Heart J 2022;43:654–62. https://doi.org/10.1093/eurheartj/ 104. Lund O, Nielsen TT, Emmertsen K, Flø C, Rasmussen B, Jensen FT, et al. Mortality and
ehab679 worsening of prognostic profile during waiting time for valve replacement in aortic
85.Dreyfus J, Bohbot Y, Coisne A, Lavie-Badie Y, Flagiello M, Bazire B, et al. Predictive va- stenosis. Thorac Cardiovasc Surg 1996;44:289–95. https://doi.org/10.1055/s-2007-
lue of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve sur- 1012039
gery. Heart 2023;109:951–8. https://doi.org/10.1136/heartjnl-2022-322167 105. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical
86.Lantelme P, Aubry M, Peng JC, Riche B, Souteyrand G, Jaafar P, et al. Comorbidities recommendations for cardiopulmonary exercise testing data assessment in specific pa-
may offset expected improved survival after transcatheter aortic valve replacement. tient populations. Eur Heart J 2018;39:1144–61. https://doi.org/10.1093/eurheartj/
Eur Heart J Open 2022;2:oeac029. https://doi.org/10.1093/ehjopen/oeac029 ehw180
87.Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in transcatheter aortic 106. Hoedemakers S, Pugliese NR, Stassen J, Vanoppen A, Claessens J, Gojevic T, et al.
valve replacement. Cardiol Clin 2020;38:75–87. https://doi.org/10.1016/j.ccl.2019.09.011 mPAP/CO slope and oxygen uptake add prognostic value in aortic stenosis.
88.Kim DH, Afilalo J, Shi SM, Popma JJ, Khabbaz KR, Laham RJ, et al. Evaluation of changes Circulation 2024;149:1172–82. https://doi.org/10.1161/CIRCULATIONAHA.123.
in functional status in the year after aortic valve replacement. JAMA Intern Med 2019; 067130
179:383–91. https://doi.org/10.1001/jamainternmed.2018.6738 107. Lancellotti P, Dulgheru R, Go YY, Sugimoto T, Marchetta S, Oury C, et al. Stress echo-
89.Scotti A, Coisne A, Granada JF, Driggin E, Madhavan MV, Zhou Z, et al. Impact of mal- cardiography in patients with native valvular heart disease. Heart 2018;104:807–13.
nutrition in patients with heart failure and secondary mitral regurgitation: the COAPT https://doi.org/10.1136/heartjnl-2017-311682
Trial. J Am Coll Cardiol 2023;82:128–38. https://doi.org/10.1016/j.jacc.2023.04.047 108. Gentry JL III, Phelan D, Desai MY, Griffin BP. The role of stress echocardiography in
89a.Pagnesi M, Adamo M, Stolz L, Pancaldi E, Kresoja KP, von Stein J, et al. Malnutrition
valvular heart disease: a current appraisal. Cardiology 2017;137:137–50. https://doi.
and outcomes in patients with tricuspid regurgitation undergoing transcatheter
org/10.1159/000460274
tricuspid valve repair. Eur J Heart Fail 2025. https://doi.org/10.1002/ejhf.3623. Epub
109. Lancellotti P, Magne J. Stress echocardiography in regurgitant valve disease. Circ
ahead of print. PMID: 39980251.
Cardiovasc Imaging 2013;6:840–9. https://doi.org/10.1161/CIRCIMAGING.113.000474
90.Sündermann SH, Bäck C, Bischoff-Ferrari HA, Dehbi HM, Szekely A, Völler H, et al.
110. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M, et al. Determinants
Preinterventional frailty assessment in patients scheduled for cardiac surgery or trans-
and prognostic significance of exercise pulmonary hypertension in asymptomatic se-
catheter aortic valve implantation: a consensus statement of the European Association
vere aortic stenosis. Circulation 2012;126:851–9. https://doi.org/10.1161/
for Cardio-Thoracic Surgery (EACTS) and the European Association of Preventive
CIRCULATIONAHA.111.088427
Cardiology (EAPC) of the European Society of Cardiology (ESC). Eur J Cardiothorac
111. Coisne A, Aghezzaf S, Galli E, Mouton S, Richardson M, Dubois D, et al. Prognostic va-
Surg 2023;64:ezad181. https://doi.org/10.1093/ejcts/ezad181
lues of exercise echocardiography and cardiopulmonary exercise testing in patients
91.Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi-
with primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2022;23:1552–61.
ology: definition, assessment and clinical implications for general cardiology. A consen-
https://doi.org/10.1093/ehjci/jeab231
sus document of the Council for Cardiology Practice (CCP), Association for Acute
112. Saeed S, Rajani R, Seifert R, Parkin D, Chambers JB. Exercise testing in patients with
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied
asymptomatic moderate or severe aortic stenosis. Heart 2018;104:1836–42. https://
Professions (ACNAP), European Association of Preventive Cardiology (EAPC),
doi.org/10.1136/heartjnl-2018-312939
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases
113. Saeed S, Chambers JB. Exercise testing in aortic stenosis: safety, tolerability, clinical
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO),
benefits and prognostic value. J Clin Med 2022;11:4983. https://doi.org/10.3390/
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology,
jcm11174983
WG Thrombosis, of the European Society of Cardiology, European Primary Care
114. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10.
evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients
1093/eurjpc/zwaa167
with severe aortic stenosis undergoing transcatheter aortic valve implantation.
92.Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, et al. Frailty and
EuroIntervention 2018;13:1512–9. https://doi.org/10.4244/EIJ-D-17-00542
related outcomes in patients undergoing transcatheter valve therapies in a nationwide
115. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, et al. Functional
cohort. Eur Heart J 2019;40:2231–9. https://doi.org/10.1093/eurheartj/ehz187
assessment of coronary artery disease in patients undergoing transcatheter aortic
93.Brusco NK, Atkinson V, Woods J, Myles PS, Hodge A, Jones C, et al. Implementing
valve implantation: influence of pressure overload on the evaluation of lesions severity. PROMS for elective surgery patients: feasibility, response rate, degree of recovery
Circ Cardiovasc Interv 2016;9:e004088. https://doi.org/10.1161/circinterventions.116.
and patient acceptability. J Patient Rep Outcomes 2022;6:73. https://doi.org/10.1186/
004088
s41687-022-00483-6
116. Ahmad Y, Götberg M, Cook C, Howard JP, Malik I, Mikhail G, et al. Coronary hemo-
94.Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, et al. Use of the Kansas
dynamics in patients with severe aortic stenosis and coronary artery disease undergo-
City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic
stenosis. Circ Heart Fail 2013;6:61–7. https://doi.org/10.1161/circheartfailure.112.970053 ing transcatheter aortic valve replacement: implications for clinical indices of coronary
95.Arnold SV, Spertus JA, Gosch K, Dunlay SM, Olds DM, Jones PG, et al. Validation of the stenosis severity. JACC Cardiovasc Interv 2018;11:2019–31. https://doi.org/10.1016/j.
Kansas City Cardiomyopathy Questionnaire in patients with tricuspid regurgitation. jcin.2018.07.019
JAMA Cardiol 2025;10:117–25 https://doi.org/10.1001/jamacardio.2024.4266 117. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in acute aortic regurgi-
96.Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C, et al. tation. J Am Coll Cardiol 1995;25:1387–92. https://doi.org/10.1016/0735-
Association of B-type natriuretic peptide with survival in patients with degenerative 1097(95)00018-Y
mitral regurgitation. J Am Coll Cardiol 2016;68:1297–307. https://doi.org/10.1016/j. 118. Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, et al. Restricted cor-
jacc.2016.06.047 onary flow reserve in patients with mitral regurgitation improves after mitral recon-
97.Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natri- structive surgery. J Am Coll Cardiol 1998;32:1923–30. https://doi.org/10.1016/S0735-
uretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am 1097(98)00490-2
Coll Cardiol 2014;63:2016–25. https://doi.org/10.1016/j.jacc.2014.02.581 119. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart
98.Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic value of N-terminal pro– catheterization for the diagnosis of pulmonary hypertension: controversies and prac-
B-type natriuretic peptide in elderly patients with valvular heart disease. J Am Coll tical issues. Heart Fail Clin 2018;14:467–77. https://doi.org/10.1016/j.hfc.2018.03.011
Cardiol 2020;75:1659–72. https://doi.org/10.1016/j.jacc.2020.02.031 120. Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, et al. Priorities for
99.Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. patient-centered research in valvular heart disease: a report from the National Heart,
Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic Lung, and Blood Institute Working Group. J Am Heart Assoc 2020;9:e015975. https://
stenosis undergoing valve replacement. Heart 2015;101:1382–8. https://doi.org/10. doi.org/10.1161/JAHA.119.015975
1136/heartjnl-2015-307742 121. Dharmarajan K, Foster J, Coylewright M, Green P, Vavalle JP, Faheem O, et al. The
100. Lindman BR, Clavel MA, Abu-Alhayja’a R, Cote N, Dagenais F, Novak E, et al. medically managed patient with severe symptomatic aortic stenosis in the TAVR
Multimarker approach to identify patients with higher mortality and rehospitalization era: patient characteristics, reasons for medical management, and quality of shared de-
rate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv cision making at heart valve treatment centers. PLoS One 2017;12:e0175926. https://
2018;11:2172–81. https://doi.org/10.1016/j.jcin.2018.07.039 doi.org/10.1371/journal.pone.0175926
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 81 ---
ESC Guidelines 4715
122. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart aortic valve replacement: a comprehensive meta-analysis. Curr Probl Cardiol 2022;47:
valvular surgery by using coronary computed tomographic angiography versus invasive 101339. https://doi.org/10.1016/j.cpcardiol.2022.101339
coronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ 142. Tomii D, Pilgrim T, Borger MA, De Backer O, Lanz J, Reineke D, et al. Aortic stenosis
jaha.120.019531 and coronary artery disease: decision-making between surgical and transcatheter man-
123. Opolski MP, Staruch AD, Jakubczyk M, Min James K, Gransar H, Staruch M, et al. CT agement. Circulation 2024;150:2046–69. https://doi.org/10.1161/circulationaha.124.
angiography for the detection of coronary artery stenoses in patients referred for car- 070502
diac valve surgery. JACC Cardiovasc Imaging 2016;9:1059–70. https://doi.org/10.1016/j. 143. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al.
jcmg.2015.09.028 Management of coronary artery disease in patients undergoing transcatheter aortic
124. Meijboom Willem B, Mollet Nico R, Van Mieghem Carlos AG, Kluin J, Weustink Annick valve implantation. A clinical consensus statement from the European Association of
C, Pugliese F, et al. Pre-operative computed tomography coronary angiography to de- Percutaneous Cardiovascular Interventions in collaboration with the ESC Working
tect significant coronary artery disease in patients referred for cardiac valve surgery. J Group on Cardiovascular Surgery. EuroIntervention 2023;19:37–52. https://doi.org/
Am Coll Cardiol 2006;48:1658–65. https://doi.org/10.1016/j.jacc.2006.06.054 10.4244/eij-d-22-00958
125. Gatti M, Gallone G, Poggi V, Bruno F, Serafini A, Depaoli A, et al. Diagnostic accuracy of 144. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannu-
coronary computed tomography angiography for the evaluation of obstructive coron- lation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC
ary artery disease in patients referred for transcatheter aortic valve implantation: a sys- Cardiovasc Interv 2020;13:2542–55. https://doi.org/10.1016/j.jcin.2020.07.006
tematic review and meta-analysis. Eur Radiol 2022;32:5189–200. https://doi.org/10. 145. Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, et al. Coronary
1007/s00330-022-08603-y cannulation following TAVR using self-expanding devices with commissural alignment:
126. Diller GP, Gerwing M, Boroni Grazioli S, De-Torres-Alba F, Radke RM, Vormbrock J, the RE-ACCESS 2 study. JACC Cardiovasc Interv 2024;17:727–37. https://doi.org/10.
et al. Utility of coronary computed tomography angiography in patients undergoing 1016/j.jcin.2023.12.015
transcatheter aortic valve implantation: a meta-analysis and meta-regression based 146. Tang GHL, Amat-Santos IJ, Backer OD, Avvedimento M, Redondo A, Barbanti M, et al.
on published data from 7458 patients. J Clin Med 2024;13:631. https://doi.org/10. Rationale, definitions, techniques, and outcomes of commissural alignment in TAVR.
3390/jcm13020631 JACC Cardiovasc Interv 2022;15:1497–518. https://doi.org/10.1016/j.jcin.2022.06.001
127. Kondoleon NP, Layoun H, Spilias N, Sipko J, Kanaan C, Harb S, et al. Effectiveness of 147. Campwala SZ, Bansal RC, Wang N, Razzouk A, Pai RG. Factors affecting regression of
pre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc mitral regurgitation following isolated coronary artery bypass surgery. Eur J
Interv 2023;16:1990–2000. https://doi.org/10.1016/j.jcin.2023.05.030 Cardiothorac Surg 2005;28:783–7. https://doi.org/10.1016/j.ejcts.2005.10.010
128. Malebranche D, Hoffner MKM, Huber AT, Cicovic A, Spano G, Bernhard B, et al. 148. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, et al.
Diagnostic performance of quantitative coronary artery disease assessment using Surgical revascularization is associated with maximal survival in patients with ischemic
computed tomography in patients with aortic stenosis undergoing transcatheter mitral regurgitation: a 20-year experience. Circulation 2014;129:2547–56. https://doi.
aortic-valve implantation. BMC Cardiovasc Disord 2022;22:178. https://doi.org/10. org/10.1161/CIRCULATIONAHA.113.005223
1186/s12872-022-02623-8 149. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, et al. Management and
129. Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, et al. Routine outcomes in patients with moderate or severe functional mitral regurgitation and se-
screening of coronary artery disease with computed tomographic coronary angiog- vere left ventricular dysfunction. Eur Heart J 2015;36:2733–41. https://doi.org/10.1093/
raphy in place of invasive coronary angiography in patients undergoing transcatheter eurheartj/ehv343
aortic valve replacement. Circ Cardiovasc Interv 2015;8:e002025. https://doi.org/10. 150. Yousefzai R, Bajaj N, Krishnaswamy A, Goel SS, Agarwal S, Aksoy O, et al. Outcomes of
1161/circinterventions.114.002025 patients with ischemic mitral regurgitation undergoing percutaneous coronary inter-
130. Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, et al. Coronary revas- vention. Am J Cardiol 2014;114:1011–7. https://doi.org/10.1016/j.amjcard.2014.07.012
cularization in patients undergoing aortic valve replacement for severe aortic stenosis. 151. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
JACC Cardiovasc Interv 2021;14:2083–96. https://doi.org/10.1016/j.jcin.2021.07.058 Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:
131. Miyagawa S, Masai T, Fukuda H, Yamauchi T, Iwakura K, Itoh H, et al. Coronary micro- 3720–826. https://doi.org/10.1093/eurheartj/ehad191
circulatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. 152. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al.
Ann Thorac Surg 2009;87:715–9. https://doi.org/10.1016/j.athoracsur.2008.11.078 Prevalence, characteristics, and outcomes of valvular heart disease in patients with at-
132. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary rial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed
artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J treatment for atrial fibrillation). J Am Heart Assoc 2017;6:e006475. https://doi.org/10.
Am Coll Cardiol 2013;61:837–48. https://doi.org/10.1016/j.jacc.2012.10.049 1161/jaha.117.006475
133. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, et al. The prognostic 153. Naser JA, Castrichini M, Ibrahim HH, Scott CG, Lin G, Lee E, et al. Secondary tricuspid
impact of concomitant coronary artery bypass grafting during aortic valve surgery: im- regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm. Eur
plications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg 2015; Heart J 2024;45:2878–90. https://doi.org/10.1093/eurheartj/ehae346
149:451–60. https://doi.org/10.1016/j.jtcvs.2014.08.073 154. Naser JA, Pislaru C, Roslan A, Ciobanu AO, Jouni H, Nkomo VT, et al. Unfavorable
134. Lønborg J, Jabbari R, Sabbah M, Veien KT, Niemelä M, Freeman P, et al. PCI in patients tricuspid annulus dynamics: a novel concept to explain development of tricuspid regur-
undergoing transcatheter aortic-valve implantation. N Engl J Med 2024;391:2189–200. gitation in atrial fibrillation. J Am Soc Echocardiogr 2022;35:664–6. https://doi.org/10.
https://doi.org/10.1056/NEJMoa2401513 1016/j.echo.2022.02.009
135. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. 155. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in
ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
VAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14: Heart 2018;104:1292–9. https://doi.org/10.1136/heartjnl-2017-312272
1965–74. https://doi.org/10.1016/j.jcin.2021.06.041 156. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in com-
136. Okuno T, Demirel C, Tomii D, Heg D, Häner J, Siontis GCM, et al. Long-term risk of parison with warfarin in patients with atrial fibrillation and valvular heart disease: find-
unplanned percutaneous coronary intervention after transcatheter aortic valve re- ings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
placement. EuroIntervention 2022;18:797–803. https://doi.org/10.4244/eij-d-22-00342 Atrial Fibrillation (ARISTOTLE) trial. Circulation 2015;132:624–32. https://doi.org/10.
137. Persits I, Layoun H, Kondoleon NP, Spilias N, Badwan O, Sipko J, et al. Impact of un- 1161/CIRCULATIONAHA.114.014807
treated chronic obstructive coronary artery disease on outcomes after transcatheter 157. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al.
aortic valve replacement. Eur Heart J 2024;45:1890–900. https://doi.org/10.1093/ Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular
eurheartj/ehae019 heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant ther-
138. Ogami T, Kliner DE, Toma C, Sanon S, Smith AJC, Serna-Gallegos D, et al. Acute cor- apy). Circulation 2016;134:589–98. https://doi.org/10.1161/CIRCULATIONAHA.115.
onary syndrome after transcatheter aortic valve implantation (results from over 020950
40,000 patients). Am J Cardiol 2023;193:126–32. https://doi.org/10.1016/j.amjcard. 158. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, et al.
2023.02.003 Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI
139. Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Incidence and 48 trial. J Am Coll Cardiol 2017;69:1372–82. https://doi.org/10.1016/j.jacc.2016.12.031
outcomes of acute coronary syndrome after transcatheter aortic valve replacement. 159. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al.
JACC Cardiovasc Interv 2020;13:938–50. https://doi.org/10.1016/j.jcin.2019.11.027 Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with
140. Yassen M, Moustafa A, Venkataramany B, Schodowski E, Royfman R, Eltahawy E. non-valvular atrial fibrillation but underlying native mitral and aortic valve disease par-
Clinical outcomes of transcatheter aortic valve replacement with and without percu- ticipating in the ROCKET AF trial. Eur Heart J 2014;35:3377–85. https://doi.org/10.
taneous coronary intervention—an updated meta-analysis and systematic review. Curr 1093/eurheartj/ehu305
Probl Cardiol 2023;48:101980. https://doi.org/10.1016/j.cpcardiol.2023.101980 160. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left at-
141. Altibi AM, Ghanem F, Hammad F, Patel J, Song HK, Golwala H, et al. Clinical outcomes rial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021;
of revascularization with percutaneous coronary intervention prior to transcatheter 384:2081–91. https://doi.org/10.1056/NEJMoa2101897
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 82 ---
4716 E S C G u id e l in e s
161. Martín Gutiérrez E, Castaño M, Gualis J, Martinez-Comendador JM, Maiorano P, European Hematology Association (EHA), the European Society for Therapeutic
Castillo L, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society
a meta-analysis of 280 585 patients. Eur J Cardiothorac Surg 2020;57:252–62. https://doi. (IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
org/10.1093/ejcts/ezz289 183. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter
162. Connolly SJ, Healey JS, Belley-Cote EP, Balasubramanian K, Paparella D, Brady K, et al. compared with surgical aortic valve replacement in patients with previous chest-
Oral anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation directed radiation therapy. JACC CardioOncol 2021;3:397–407. https://doi.org/10.
2023;148:1298–304. https://doi.org/10.1161/CIRCULATIONAHA.122.060315 1016/j.jaccao.2021.07.005
163. Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. 184. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after trans-
Concomitant left atrial appendage occlusion and transcatheter aortic valve replace- catheter aortic valve replacement in cancer survivors with prior chest radiation ther-
ment among patients with atrial fibrillation. Circulation 2024;149:734–43. https://doi. apy: a systematic review and meta-analysis. Cardiooncology 2020;6:8. https://doi.org/10.
org/10.1161/circulationaha.123.067312 1186/s40959-020-00062-y
164. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and 185. Ullah W, Thalambedu N, Zahid S, Muhammadzai Hamza Zahid U, Sandhyavenu H,
safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibril- Kumar A, et al. Trends and outcomes of TAVI and SAVR in cancer and noncancer pa-
lation: a population-based cohort study. Ann Intern Med 2021;174:910–9. https://doi. tients. JACC Adv 2023;2:100167. https://doi.org/10.1016/j.jacadv.2022.100167
org/10.7326/m20-6194 186. Lind A, Totzeck M, Mahabadi AA, Janosi RA, El Gabry M, Ruhparwar A, et al. Impact of
165. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, cancer in patients undergoing transcatheter aortic valve replacement: a single-center
et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J study. JACC CardioOncol 2020;2:735–43. https://doi.org/10.1016/j.jaccao.2020.11.008
Med 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051 187. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al.
166. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ Jr, Gillinov AM, Brennan JM, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral
Associations between surgical ablation and operative mortality after mitral valve pro- valve diseases, 1990–2017. Circulation 2020;141:1670–80. https://doi.org/10.1161/
cedures. Ann Thorac Surg 2018;105:1790–6. https://doi.org/10.1016/j.athoracsur.2017. CIRCULATIONAHA.119.043391
12.035 188. Rwebembera J, Marangou J, Mwita JC, Mocumbi AO, Mota C, Okello E, et al. 2023
167. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic
Surgical ablation of atrial fibrillation in the United States: trends and propensity heart disease. Nat Rev Cardiol 2023;21:250–63. https://doi.org/10.1038/s41569-023-
matched outcomes. Ann Thorac Surg 2017;104:493–500. https://doi.org/10.1016/j.
00940-9
athoracsur.2017.05.016 189. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, et al. Effectiveness of
168. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al.
systematic echocardiographic screening for rheumatic heart disease in Nepalese
Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015;
schoolchildren: a cluster randomized clinical trial. JAMA Cardiol 2021;6:420–26.
372:1399–409. https://doi.org/10.1056/NEJMoa1500528
https://doi.org/10.1001/jamacardio.2020.7050
169. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al.
190. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary
Concomitant atrial fibrillation surgery for people undergoing cardiac surgery.
antibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022;386:
Cochrane Database Syst Rev 2016;2016:CD011814. https://doi.org/10.1002/
230–40. https://doi.org/10.1056/NEJMoa2102074
14651858.CD011814.pub2
191. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al.
170. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the
Contemporary diagnosis and management of rheumatic heart disease: implications
cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve
for closing the gap: a scientific statement from the American Heart Association.
disease. J Thorac Cardiovasc Surg 2018;155:608–17. https://doi.org/10.1016/j.jtcvs.2017.
Circulation 2020;142:e337–57. https://doi.org/10.1161/cir.0000000000000921
07.084
192. World Health Organization. WHO Guideline on the Prevention and Diagnosis of
171. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, et al. A minimally
Rheumatic Fever and Rheumatic Heart Disease. https://www.who.int/publications/i/
invasive Cox maze IV procedure is as effective as sternotomy while decreasing major
item/9789240100077 (28 March 2025, date last accessed).
morbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955–61; discussion
193. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart
962–952. https://doi.org/10.1016/j.jtcvs.2014.05.064
failure and valvular heart disease: a scientific statement of the Heart Failure
172. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for
Association, the Association for Acute CardioVascular Care and the European
atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations
Association of Percutaneous Cardiovascular Interventions of the European Society
(Phila) 2010;5:84–96. https://doi.org/10.1097/IMI.0b013e3181d9199b
of Cardiology. Eur J Heart Fail 2023;25:1025–48. https://doi.org/10.1002/ejhf.2918
173. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ab-
194. Lüsebrink E, Lanz H, Kellnar A, Karam N, Kapadia S, Makkar R, et al. (December 11,
lation of atrial fibrillation: a systematic review and meta-analysis of randomized con-
2024) Management of acute decompensated valvular heart disease. Eur J Heart Fail,
trolled trials. Europace 2018;20:1442–50. https://doi.org/10.1093/europace/eux336
https://doi.org/10.1002/ejhf.3549
174. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical
195. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes follow-
atrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014;
ing urgent/emergent transcatheter aortic valve replacement: insights from the STS/ 78:1364–71. https://doi.org/10.1253/circj.cj-13-1533
175. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ab- ACC TVT registry. JACC Cardiovasc Interv 2018;11:1175–85. https://doi.org/10.1016/
lation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: j.jcin.2018.03.002
350–7. 196. Elbadawi A, Elgendy IY, Mentias A, Saad M, Mohamed AH, Choudhry MW, et al.
176. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart Outcomes of urgent versus nonurgent transcatheter aortic valve replacement.
2016;102:269–76. https://doi.org/10.1136/heartjnl-2015-308765 Catheter Cardiovasc Interv 2020;96:189–95. https://doi.org/10.1002/ccd.28563
177. Lee C, Hahn RT. Valvular heart disease associated with radiation therapy: a contem- 197. Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics,
porary review. Struct Heart 2023;7:100104. https://doi.org/10.1016/j.shj.2022.100104 procedural characteristics, and clinical outcomes when cardiogenic shock precedes
178. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert TAVR in the United States. JACC Cardiovasc Interv 2020;13:1314–25. https://doi.org/
consensus for multi-modality imaging evaluation of cardiovascular complications of 10.1016/j.jcin.2020.02.033
radiotherapy in adults: a report from the European Association of Cardiovascular 198. Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of trans-
Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; catheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J
26:1013–32. https://doi.org/10.1016/j.echo.2013.07.005 2023;44:3181–95. https://doi.org/10.1093/eurheartj/ehad387
179. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term 199. Buchwald AB, Meyer T, Scholz K, Schorn B, Unterberg C. Efficacy of balloon valvulo-
survival of patients with radiation heart disease undergoing cardiac surgery: a cohort plasty in patients with critical aortic stenosis and cardiogenic shock—the role of shock
study. Circulation 2013;127:1476–85. https://doi.org/10.1161/CIRCULATIONAHA. duration. Clin Cardiol 2001;24:214–8. https://doi.org/10.1002/clc.4960240308
113.001435 200. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic
180. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am
Long-term outcomes of patients with mediastinal radiation-associated severe aortic Coll Cardiol 1994;23:1071–5. https://doi.org/10.1016/0735-1097(94)90592-4
stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J 201. Llah ST, Sharif S, Ullah S, Sheikh SA, Shah MA, Shafi OM, et al. TAVR vs balloon aortic
Am Heart Assoc 2017;6:e005396. https://doi.org/10.1161/JAHA.116.005396 valvotomy for severe aortic stenosis and cardiogenic shock: an insight from the nation-
181. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, et al. al inpatient sample database. Cardiovasc Revasc Med 2023;55:1–7. https://doi.org/10.
Outcomes of patients with mediastinal radiation-associated mitral valve disease under- 1016/j.carrev.2023.05.006
going cardiac surgery. Circulation 2019;140:1288–90. https://doi.org/10.1161/ 202. Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following
CIRCULATIONAHA.119.040546 edge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: a na-
182. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. tionwide analysis. J Am Heart Assoc 2021;10:e019882. https://doi.org/10.1161/jaha.120.
2022 ESC Guidelines on cardio-oncology developed in collaboration with the 019882
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 83 ---
ESC Guidelines 4717
203. Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo mortality in patients identified to have aortic regurgitation: a large population cohort
M, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation study. J Am Coll Cardiol 2011;58:2084–91. https://doi.org/10.1016/j.jacc.2011.07.043
shortly after acute myocardial infarction. Eur Heart J 2021;43:641–50. https://doi. 223. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al.
org/10.1093/eurheartj/ehab496 Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices
204. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a and patient management. An expert consensus meeting report of the Heart Failure
palliative approach into heart failure care: a European Society of Cardiology Heart Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:
Failure Association position paper. Eur J Heart Fail 2020;22:2327–39. https://doi.org/ 1169–86. https://doi.org/10.1002/ejhf.1531
10.1002/ejhf.1994 224. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Outcomes after
205. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interven- aortic valve replacement in patients with severe aortic regurgitation and markedly re-
tions to promote health-related quality of life in patients living with heart failure: a sys- duced left ventricular function. Circulation 2002;106:2687–93. https://doi.org/10.1161/
tematic review and meta-analysis. Heart Lung Circ 2020;29:1633–47. https://doi.org/10. 01.cir.0000038498.59829.38
1016/j.hlc.2020.04.019 225. Kaneko T, Ejiofor JI, Neely RC, McGurk S, Ivkovic V, Stevenson LW, et al. Aortic re-
206. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart gurgitation with markedly reduced left ventricular function is not a contraindication
failure. Heart Fail Clin 2015;11:479–98. https://doi.org/10.1016/j.hfc.2015.03.010 for aortic valve replacement. Ann Thorac Surg 2016;102:41–7. https://doi.org/10.
207. Brännström M, Boman K. Effects of person-centred and integrated chronic heart fail- 1016/j.athoracsur.2015.12.068
ure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail 226. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J.
2014;16:1142–51. https://doi.org/10.1002/ejhf.151 Long-term outcome of surgically treated aortic regurgitation: influence of guideline ad-
208. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical herence toward early surgery. J Am Coll Cardiol 2006;47:1012–7. https://doi.org/10.
determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart 1016/j.jacc.2005.10.049
Study). Am J Cardiol 1999;83:897–902. https://doi.org/10.1016/s0002-9149(98) 227. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing
01064-9 timing of surgical correction in patients with severe aortic regurgitation: role of symp-
209. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Gräni C, et al. Early detection of toms. J Am Coll Cardiol 1997;30:746–52. https://doi.org/10.1016/s0735-1097(97)
subclinical myocardial damage in chronic aortic regurgitation and strategies for timely 00205-2
treatment of asymptomatic patients. Circulation 2018;137:184–96. https://doi.org/10. 228. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality
1161/circulationaha.117.029858 and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study.
210. Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG, et al. Long-term Circulation 1999;99:1851–7. https://doi.org/10.1161/01.cir.99.14.1851
outcomes after aortic valve surgery in patients with asymptomatic chronic aortic re- 229. Fiedler AG, Bhambhani V, Laikhter E, Picard MH, Wasfy MM, Tolis G, et al. Aortic valve
gurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal replacement associated with survival in severe regurgitation and low ejection fraction.
strain. JACC Cardiovasc Imaging 2020;13:12–21. https://doi.org/10.1016/j.jcmg.2018. Heart 2018;104:835–40. https://doi.org/10.1136/heartjnl-2017-312024
12.021 230. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Fett SL, Bailey KR, et al.
211. deCampos D, Teixeira R, Saleiro C, Botelho A, Gonçalve L. Global longitudinal strain in Excess mortality due to coronary artery disease after valve surgery. Secular trends in
chronic asymptomatic aortic regurgitation: systematic review. Echo Res Pract 2020;7: valvular regurgitation and effect of internal mammary artery bypass. Circulation 1998;
39–48. https://doi.org/10.1530/erp-20-0024 98:II108–15.
212. Lee SY, Park SJ, Kim EK, Chang SA, Lee SC, Ahn JH, et al. Predictive value of exercise 231. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricu-
stress echocardiography in asymptomatic patients with severe aortic regurgitation and lar ejection fraction and valve lesion in patients with aortic valve replacement. Am J
preserved left ventricular systolic function without LV dilatation. Int J Cardiovasc Cardiol 1980;45:1120–5. https://doi.org/10.1016/0002-9149(80)90468-3
Imaging 2019;35:1241–7. https://doi.org/10.1007/s10554-019-01565-1 232. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural
213. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG, et al. Prospective history of asymptomatic patients with chronic aortic regurgitation and normal left ven-
validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic tricular systolic function. Circulation 1991;84:1625–35. https://doi.org/10.1161/01.cir.
patients with chronic severe aortic regurgitation. J Am Coll Cardiol 2011;58:1705–14. 84.4.1625
https://doi.org/10.1016/j.jacc.2011.07.016 233. Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J, et al.
214. Kočková R, Línková H, Hlubocká Z, Mědílek K, Tuna M, Vojáček J, et al. Multiparametric Improved outcomes after aortic valve surgery for chronic aortic regurgitation with se-
strategy to predict early disease decompensation in asymptomatic severe aortic regur- vere left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465–71. https://doi.org/10.
gitation. Circ Cardiovasc Imaging 2022;15:e014901. https://doi.org/10.1161/circimaging. 1016/j.jacc.2007.01.026
122.014901 234. Sambola A, Tornos P, Ferreira-Gonzalez I, Evangelista A. Prognostic value of preopera-
215. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality tive indexed end-systolic left ventricle diameter in the outcome after surgery in pa-
imaging of diseases of the thoracic aorta in adults: from the American Society of tients with chronic aortic regurgitation. Am Heart J 2008;155:1114–20. https://doi.
Echocardiography and the European Association of Cardiovascular Imaging: endorsed org/10.1016/j.ahj.2007.12.025
by the Society of Cardiovascular Computed Tomography and Society for 235. Yang LT, Michelena HI, Scott CG, Enriquez-Sarano M, Pislaru SV, Schaff HV, et al.
Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https:// Outcomes in chronic hemodynamically significant aortic regurgitation and limitations
doi.org/10.1016/j.echo.2014.11.015 of current guidelines. J Am Coll Cardiol 2019;73:1741–52. https://doi.org/10.1016/j.jacc.
216. Czerny M, Grabenwöger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. 2019.01.024
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of 236. Mentias A, Feng K, Alashi A, Rodriguez LL, Gillinov AM, Johnston DR, et al. Long-term
the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ outcomes in patients with aortic regurgitation and preserved left ventricular ejection
ejcts/ezad426 fraction. J Am Coll Cardiol 2016;68:2144–53. https://doi.org/10.1016/j.jacc.2016.08.045
217. le Polain de Waroux JB, Pouleur AC, Goffinet C, Vancraeynest D, Van Dyck M, Robert 237. de Meester C, Gerber BL, Vancraeynest D, Pouleur AC, Noirhomme P, Pasquet A,
A, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical re- et al. Do guideline-based indications result in an outcome penalty for patients with se-
pairability, and outcome implications of transesophageal echocardiography. Circulation vere aortic regurgitation? JACC Cardiovasc Imaging 2019;12:2126–38. https://doi.org/
2007;116:I264–9. https://doi.org/10.1161/CIRCULATIONAHA.106.680074 10.1016/j.jcmg.2018.11.022
218. Lansac E, Di Centa I, Raoux F, Al Attar N, Acar C, Joudinaud T, et al. A lesional clas- 238. Yang LT, Anand V, Zambito EI, Pellikka PA, Scott CG, Thapa P, et al. Association of
sification to standardize surgical management of aortic insufficiency towards valve re- echocardiographic left ventricular end-systolic volume and volume-derived ejection
pair. Eur J Cardiothorac Surg 2008;33:872–8; discussion 878–880. https://doi.org/10. fraction with outcome in asymptomatic chronic aortic regurgitation. JAMA Cardiol
1016/j.ejcts.2007.12.033 2021;6:189–98. https://doi.org/10.1001/jamacardio.2020.5268
219. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, 239. Yang LT, Lee CC, Su CH, Amano M, Nabeshima Y, Kitano T, et al. Analysis of left ven-
et al. International consensus statement on nomenclature and classification of the con- tricular indexes and mortality among Asian adults with hemodynamically significant
genital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and chronic aortic regurgitation. JAMA Netw Open 2023;6:e234632. https://doi.org/10.
research purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10.1093/ 1001/jamanetworkopen.2023.4632
ejcts/ezab038 240. Hashimoto G, Enriquez-Sarano M, Stanberry LI, Oh F, Wang M, Acosta K, et al.
220. Ehrlich T, de Kerchove L, Vojacek J, Boodhwani M, El-Hamamsy I, De Paulis R, et al. Association of left ventricular remodeling assessment by cardiac magnetic resonance
State-of-the art bicuspid aortic valve repair in 2020. Prog Cardiovasc Dis 2020;63: with outcomes in patients with chronic aortic regurgitation. JAMA Cardiol 2022;7:
457–64. https://doi.org/10.1016/j.pcad.2020.04.010 924–33. https://doi.org/10.1001/jamacardio.2022.2108
221. Evangelista Masip A, Galian-Gay L, Guala A, Lopez-Sainz A, Teixido-Turà G, Ruiz 241. Malahfji M, Crudo V, Kaolawanich Y, Nguyen DT, Telmesani A, Saeed M, et al. Influence
Muñoz A, et al. Unraveling bicuspid aortic valve enigmas by multimodality imaging: clin- of cardiac remodeling on clinical outcomes in patients with aortic regurgitation. J Am
ical implications. J Clin Med 2022;11:456. https://doi.org/10.3390/jcm11020456 Coll Cardiol 2023;81:1885–98. https://doi.org/10.1016/j.jacc.2023.03.001
222. Elder DHJ, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, et al. The impact of 242. Vermes E, Iacuzio L, Levy F, Bohbot Y, Renard C, Gerber B, et al. Role of cardiovascular
renin-angiotensin-aldosterone system blockade on heart failure outcomes and magnetic resonance in native valvular regurgitation: a comprehensive review of
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 84 ---
4718 E S C G u id e l in e s
protocols, grading of severity, and prediction of valve surgery. Front Cardiovasc Med meta-analysis. J Am Heart Assoc 2023;12:e8066. https://doi.org/10.1161/jaha.122.
2022;9:881141. https://doi.org/10.3389/fcvm.2022.881141 027715
243. Flynn CD, Tian DH, Wilson-Smith A, David T, Matalanis G, Misfeld M, et al. Systematic 263. El-Hamamsy I, Toyoda N, Itagaki S, Stelzer P, Varghese R, Williams EE, et al.
review and meta-analysis of surgical outcomes in Marfan patients undergoing aortic Propensity-matched comparison of the Ross procedure and prosthetic aortic valve re-
root surgery by composite-valve graft or valve sparing root replacement. Ann placement in adults. J Am Coll Cardiol 2022;79:805–15. https://doi.org/10.1016/j.jacc.
Cardiothorac Surg 2017;6:570–81. https://doi.org/10.21037/acs.2017.11.06 2021.11.057
244. Chauvette V, Kluin J, de Kerchove L, El Khoury G, Schäfers HJ, Lansac E, et al. 264. Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al.
Outcomes of valve-sparing surgery in heritable aortic disorders: results from the Safety and efficacy of transcatheter aortic valve replacement in the treatment of
AVIATOR registry. Eur J Cardiothorac Surg 2022;62:ezac366. https://doi.org/10.1093/ pure aortic regurgitation in native valves and failing surgical bioprostheses: results
ejcts/ezac366 from an international registry study. JACC Cardiovasc Interv 2017;10:1048–56. https://
245. Wilson-Smith AR, Wilson-Smith CJ, Strode Smith J, Ng D, Muston BT, Eranki A, et al. doi.org/10.1016/j.jcin.2017.03.004
The outcomes of three decades of the David and Yacoub procedures in bicuspid aortic 265. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al.
valve patients—a systematic review and meta-analysis. Ann Cardiothorac Surg 2023;12: Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J
286–94. https://doi.org/10.21037/acs-2023-avs2-19 Am Coll Cardiol 2017;70:2752–63. https://doi.org/10.1016/j.jacc.2017.10.006
246. Zuo Y, Tan R, Qin C. Outcomes of valve-sparing aortic root replacement in patients 266. Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aor-
with bicuspid aortic valve and tricuspid aortic valve: a systematic review and tic valve replacement for pure native aortic valve regurgitation: the PANTHEON inter-
meta-analysis. J Cardiothorac Surg 2023;18:206. https://doi.org/10.1186/s13019-023- national project. JACC Cardiovasc Interv 2023;16:1974–85. https://doi.org/10.1016/j.jcin.
02329-8 2023.07.026
247. Mastrobuoni S, Govers PJ, Veen KM, Jahanyar J, van Saane S, Segreto A, et al. 267. Garcia S, Ye J, Webb J, Reardon M, Kleiman N, Goel S, et al. Transcatheter treatment
Valve-sparing aortic root replacement using the reimplantation (David) technique: a of native aortic valve regurgitation: the North American experience with a novel de-
systematic review and meta-analysis on survival and clinical outcome. Ann vice. JACC Cardiovasc Interv 2023;16:1953–60. https://doi.org/10.1016/j.jcin.2023.05.
Cardiothorac Surg 2023;12:149–58. https://doi.org/10.21037/acs-2023-avs1-0038 018
248. Aicher D, Fries R, Rodionycheva S, Schmidt K, Langer F, Schafers HJ. Aortic valve repair 268. Adam M, Tamm AR, Wienemann H, Unbehaun A, Klein C, Arnold M, et al.
leads to a low incidence of valve-related complications. Eur J Cardiothorac Surg 2010;37: Transcatheter aortic valve replacement for isolated aortic regurgitation using a new
self-expanding TAVR system. JACC Cardiovasc Interv 2023;16:1965–73. https://doi.
127–32. https://doi.org/10.1016/j.ejcts.2009.06.021
org/10.1016/j.jcin.2023.07.038
249. de Meester C, Pasquet A, Gerber BL, Vancraeynest D, Noirhomme P, El Khoury G,
269. Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, et al.
et al. Valve repair improves the outcome of surgery for chronic severe aortic regurgi-
Transcatheter aortic valve implantation in patients with high-risk symptomatic native
tation: a propensity score analysis. J Thorac Cardiovasc Surg 2014;148:1913–20. https://
aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet
doi.org/10.1016/j.jtcvs.2014.02.010
2024;403:1451–9. https://doi.org/10.1016/s0140-6736(23)02806-4
250. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and re-
270. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, et al. Should
operation pattern after 20 years of experience with aortic valve-sparing root replace-
the ascending aorta be replaced more frequently in patients with bicuspid aortic valve
ment in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155:
disease? J Thorac Cardiovasc Surg 2004;128:677–83. https://doi.org/10.1016/j.jtcvs.
1403–11.e1401. https://doi.org/10.1016/j.jtcvs.2017.12.039
2004.07.009
251. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al.
271. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the
Valve-sparing root replacement versus composite valve grafting in aortic root dilation:
appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac
a meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j.
Cardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/
athoracsur.2019.11.054
S0022-5223(97)70360-X
252. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al.
272. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture
Early and late results after David vs Bentall procedure: a propensity matched analysis.
or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann
Ann Thorac Surg 2019;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020
Thorac Surg 2002;73:17–27; discussion 27–18. https://doi.org/10.1016/s0003-
253. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al.
4975(01)03236-2
Long-term experience with valve-sparing reimplantation technique for the treatment
273. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone,
of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23.
rather than body surface area, suffices for risk estimation in ascending aortic aneurysm.
https://doi.org/10.1016/j.jtcvs.2018.10.155
J Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140
254. Lansac E, Di Centa I, Sleilaty G, Lejeune S, Khelil N, Berrebi A, et al. Long-term results
274. Popović ZB, Desai MY, Griffin BP. Decision making with imaging in asymptomatic aor-
of external aortic ring annuloplasty for aortic valve repair. Eur J Cardiothorac Surg 2016;
tic regurgitation. JACC Cardiovasc Imaging 2018;11:1499–513. https://doi.org/10.1016/j.
50:350–60. https://doi.org/10.1093/ejcts/ezw070
jcmg.2018.05.027
255. Lee H, Cho YH, Sung K, Kim WS, Park KH, Jeong DS, et al. Clinical outcomes of root
275. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality
reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac imaging in thoracic aortic diseases: a clinical consensus statement from the European
Surg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057 Association of Cardiovascular Imaging and the European Society of Cardiology work-
256. Norton EL, Patel PM, Levine D, Wei JW, Binongo JN, Leshnower BG, et al. Bentall ver-
ing group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging
sus valve-sparing aortic root replacement for root pathology with moderate-to-severe 2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024
aortic insufficiency: a propensity-matched analysis. Eur J Cardiothorac Surg 2023;64: 276. Weisenberg D, Omelchenko A, Shapira Y, Vaturi M, Monakier D, Bental T, et al.
ezad231. https://doi.org/10.1093/ejcts/ezad231 Mid-term echocardiographic progression of patients with moderate aortic regurgita-
257. Arabkhani B, Klautz RJM, de Heer F, De Kerchove L, El Khoury G, Lansac E, et al. A tion: implications for aortic valve surgery. J Heart Valve Dis 2013;22:192–4.
multicentre, propensity score matched analysis comparing a valve-sparing approach 277. Budts W, Pieles GE, Roos-Hesselink JW, Sanz de la Garza M, D’Ascenzi F,
to valve replacement in aortic root aneurysm: insight from the AVIATOR database. Giannakoulas G, et al. Recommendations for participation in competitive sport in ado-
Eur J Cardiothorac Surg 2023;63:ezac514. https://doi.org/10.1093/ejcts/ezac514 lescent and adult athletes with Congenital Heart Disease (CHD): position statement of
258. Levine D, Patel P, Zhao Y, Chung M, Singh S, Childress P, et al. Valve-sparing aortic root the Sports Cardiology & Exercise Section of the European Association of Preventive
replacement versus composite valve graft with bioprosthesis in patients under age 50. J Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on
Thorac Cardiovasc Surg 2023;168:992–1002.e1. https://doi.org/10.1016/j.jtcvs.2023.07. Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and
016 Prevention Working Group of the Association for European Paediatric and
259. Schneider U, Hofmann C, Schöpe J, Niewald AK, Giebels C, Karliova I, et al. Long-term Congenital Cardiology (AEPC). Eur Heart J 2020;41:4191–9. https://doi.org/10.1093/
results of differentiated anatomic reconstruction of bicuspid aortic valves. JAMA Cardiol eurheartj/ehaa501
2020;5:1366–73. https://doi.org/10.1001/jamacardio.2020.3749 278. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al.
260. Mazine A, Rocha RV, El-Hamamsy I, Ouzounian M, Yanagawa B, Bhatt DL, et al. Ross Familial non-syndromal thoracic aortic aneurysms and dissections—incidence and
procedure vs mechanical aortic valve replacement in adults: a systematic review and family screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j.
meta-analysis. JAMA Cardiol 2018;3:978–87. https://doi.org/10.1001/jamacardio.2018. ijcard.2016.06.086
2946 279. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve and
261. Takkenberg JJM, Klieverik LMA, Schoof PH, van Suylen RJ, van Herwerden LA, aortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10.1093/
Zondervan PE, et al. The Ross procedure: a systematic review and meta-analysis. eurheartj/ehad320
Circulation 2009;119:222–8. https://doi.org/10.1161/CIRCULATIONAHA.107. 280. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic
726349 valves in adults having isolated aortic valve replacement for aortic stenosis, with or
262. Yokoyama Y, Kuno T, Toyoda N, Fujisaki T, Takagi H, Itagaki S, et al. Ross procedure without associated aortic regurgitation. Circulation 2005;111:920–5. https://doi.org/
versus mechanical versus bioprosthetic aortic valve replacement: a network 10.1161/01.Cir.0000155623.48408.C5
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 85 ---
ESC Guidelines 4719
281. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 301. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, et al. Impact of
2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059 aortic valve calcification and sex on hemodynamic progression and clinical outcomes in
282. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. AS. J Am Coll Cardiol 2017;69:2096–8. https://doi.org/10.1016/j.jacc.2017.02.037
Characteristics, complications, and gaps in evidence-based interventions in rheumatic 302. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, et al. The
heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur complex nature of discordant severe calcified aortic valve disease grading: new insights
Heart J 2015;36:1115–22a. https://doi.org/10.1093/eurheartj/ehu449 from combined Doppler echocardiographic and computed tomographic study. J Am
283. Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic sten- Coll Cardiol 2013;62:2329–38. https://doi.org/10.1016/j.jacc.2013.08.1621
osis progression: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023; 303. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, et al. Computed
16:314–28. https://doi.org/10.1016/j.jcmg.2022.10.009 tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc
284. Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, et al. Imaging 2018;11:e007146. https://doi.org/10.1161/CIRCIMAGING.117.007146
Multi-modality imaging in aortic stenosis: an EACVI clinical consensus document. Eur 304. Shen M, Oh JK, Guzzetti E, Singh GK, Pawade T, Tastet L, et al. Computed tomography
Heart J Cardiovasc Imaging 2023;24:1430–43. https://doi.org/10.1093/ehjci/jead153 aortic valve calcium scoring in patients with bicuspid aortic valve stenosis. Struct Heart
285. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, et al. Cardiac amyloid- 2022;6:100027. https://doi.org/10.1016/j.shj.2022.100027
osis and aortic stenosis: a state-of-the-art review. Eur Heart J Open 2023;3:oead106. 305. Shen M, Tastet L, Capoulade R, Larose É, Bédard É, Arsenault M, et al. Effect of age and
https://doi.org/10.1093/ehjopen/oead106 aortic valve anatomy on calcification and haemodynamic severity of aortic stenosis.
286. Desai MY, Alashi A, Popovic ZB, Wierup P, Griffin BP, Thamilarasan M, et al. Heart 2017;103:32–9. https://doi.org/10.1136/heartjnl-2016-309665
Outcomes in patients with obstructive hypertrophic cardiomyopathy and concomi- 306. Wanchaitanawong W, Kanjanavanit R, Srisuwan T, Wongcharoen W, Phrommintikul
tant aortic stenosis undergoing surgical myectomy and aortic valve replacement. J A. Diagnostic role of aortic valve calcium scoring in various etiologies of aortic stenosis.
Am Heart Assoc 2021;10:e018435. https://doi.org/10.1161/JAHA.120.018435 Sci Rep 2023;13:8019. https://doi.org/10.1038/s41598-023-34118-7
287. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. 307. Ye Z, Clavel MA, Foley TA, Pibarot P, Enriquez-Sarano M, Michelena HI. Computed
Recommendations on the echocardiographic assessment of aortic valve stenosis: a fo- tomography calcium scoring in aortic stenosis: bicuspid versus tricuspid morphology.
cused update from the European Association of Cardiovascular Imaging and the Heart 2024;110:594–602. https://doi.org/10.1136/heartjnl-2023-323281
American Society of Echocardiography. J Am Soc Echocardiogr 2017;30:372–92. 308. Maznyczka A, Tomii D, Angellotti D, Baekke PS, Nakase M, Samim D, et al. Fibrotic vs
https://doi.org/10.1016/j.echo.2017.02.009 calcific aortic stenosis: characteristics and outcomes in patients undergoing transcath-
288. Rusinaru D, Bohbot Y, Djelaili F, Delpierre Q, Altes A, Serbout S, et al. Normative ref- eter aortic valve replacement. JACC Cardiovasc Interv 2024;17:2969–71. https://doi.org/
erence values of cardiac output by pulsed-wave Doppler echocardiography in adults. 10.1016/j.jcin.2024.09.041
Am J Cardiol 2021;140:128–33. https://doi.org/10.1016/j.amjcard.2020.10.046 309. Rusinaru D, Malaquin D, Marechaux S, Debry N, Tribouilloy C. Relation of dimension-
289. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano M, et al. less index to long-term outcome in aortic stenosis with preserved LVEF. JACC
Dobutamine stress echocardiography for management of low-flow, low-gradient aor- Cardiovasc Imaging 2015;8:766–75. https://doi.org/10.1016/j.jcmg.2015.01.023
tic stenosis. J Am Coll Cardiol 2018;71:475–85. https://doi.org/10.1016/j.jacc.2017.11. 310. Thellier N, Altes A, Rietz M, Menet A, Layec J, Outteryck F, et al. Additive prognostic
052 value of left ventricular dispersion and deformation in patients with severe aortic sten-
290. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, osis. JACC Cardiovasc Imaging 2023;17:235–45. https://doi.org/10.1016/j.jcmg.2023.09.
et al. Validation of conventional and simplified methods to calculate projected valve 010
area at normal flow rate in patients with low flow, low gradient aortic stenosis: the 311. Vollema EM, Amanullah MR, Prihadi EA, Ng ACT, van der Bijl P, Sin YK, et al.
multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. J Am Soc Incremental value of left ventricular global longitudinal strain in a newly proposed sta-
Echocardiogr 2010;23:380–6. https://doi.org/10.1016/j.echo.2010.02.002 ging classification based on cardiac damage in patients with severe aortic stenosis. Eur
291. Ash J, Sandhu GS, Arriola-Montenegro J, Agakishiev D, Clavel MA, Pibarot P, et al. Heart J Cardiovasc Imaging 2020;21:1248–58. https://doi.org/10.1093/ehjci/jeaa220
Performance of computed tomographic angiography-based aortic valve area for as- 312. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and
sessment of aortic stenosis. J Am Heart Assoc 2023;12:e029973. https://doi.org/10. consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography
1161/jaha.123.029973 in cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126–38. https://doi.org/10.
292. Guzzetti E, Poulin A, Annabi MS, Zhang B, Kalavrouziotis D, Couture C, et al. 1016/j.jcmg.2015.05.014
Transvalvular flow, sex, and survival after valve replacement surgery in patients with 313. Harada K, Saitoh T, Tanaka J, Shibayama K, Berdejo J, Shiota T. Valvuloarterial imped-
severe aortic stenosis. J Am Coll Cardiol 2020;75:1897–909. https://doi.org/10.1016/j. ance, but not aortic stenosis severity, predicts syncope in patients with aortic stenosis.
jacc.2020.02.065 Circ Cardiovasc Imaging 2013;6:1024–31. https://doi.org/10.1161/circimaging.113.
293. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, et al. Differential left 000584
ventricular remodelling and longitudinal function distinguishes low flow from normal- 314. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to
flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013; predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54:
34:1906–14. https://doi.org/10.1093/eurheartj/eht094 1003–11. https://doi.org/10.1016/j.jacc.2009.04.079
294. Tribouilloy C, Rusinaru D, Marechaux S, Castel AL, Debry N, Maizel J, et al. 315. Pibarot P, Salaun E, Dahou A, Avenatti E, Guzzetti E, Annabi MS, et al.
Low-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection Echocardiographic results of transcatheter versus surgical aortic valve replacement
fraction: characteristics, outcome, and implications for surgery. J Am Coll Cardiol 2015; in low-risk patients: the PARTNER 3 trial. Circulation 2020;141:1527–37. https://doi.
65:55–66. https://doi.org/10.1016/j.jacc.2014.09.080 org/10.1161/circulationaha.119.044574
295. Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, et al. Outcome of patients 316. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, et al. EAE/ASE
with low-gradient “severe” aortic stenosis and preserved ejection fraction. Circulation recommendations for the use of echocardiography in new transcatheter interventions
2011;123:887–95. https://doi.org/10.1161/CIRCULATIONAHA.110.983510 for valvular heart disease. Eur Heart J 2011;32:2189–214. https://doi.org/10.1093/
296. Bohbot Y, Kubala M, Rusinaru D, Maréchaux S, Vanoverschelde JL, Tribouilloy C. eurheartj/ehr259
Survival and management of patients with discordant high-gradient aortic stenosis: a 317. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al.
propensity-matched study. JACC Cardiovasc Imaging 2021;14:1672–4. https://doi.org/ Natriuretic peptides predict symptom-free survival and postoperative outcome in se-
10.1016/j.jcmg.2021.02.010 vere aortic stenosis. Circulation 2004;109:2302–8. https://doi.org/10.1161/01.CIR.
297. Unger P, Powers A, Le Nezet E, Lacasse-Rioux E, Galloo X, Clavel MA. Prevalence and 0000126825.50903.18
outcomes of patients with discordant high-gradient aortic stenosis. J Am Coll Cardiol 318. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognos-
2024;83:1109–19. https://doi.org/10.1016/j.jacc.2024.01.025 tic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J
298. Ito S, Oh JK, Michelena HI, Egbe AC, Connolly HM, Pellikka PA, et al. High-gradient Cardiol 2009;104:972–7. https://doi.org/10.1016/j.amjcard.2009.05.044
aortic stenosis with valve area >1.0 cm2: the “forgotten” discordant hemodynamic 319. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic im-
phenotype. JACC Cardiovasc Imaging 2025;18:166–76. https://doi.org/10.1016/j.jcmg. portance of quantitative exercise Doppler echocardiography in asymptomatic valvular
2024.07.025 aortic stenosis. Circulation 2005;112:I377–82. https://doi.org/10.1161/circulationaha.
299. Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. 104.523274
Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic 320. Le VD, Jensen GV, Kjøller-Hansen L. Prognostic usefulness of cardiopulmonary exer-
stenosis: the TOPAS-TAVI registry. J Am Coll Cardiol 2018;71:1297–308. https://doi. cise testing for managing patients with severe aortic stenosis. Am J Cardiol 2017;120:
org/10.1016/j.jacc.2018.01.054 844–9. https://doi.org/10.1016/j.amjcard.2017.05.047
300. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, et al. 321. Hoedemakers S, Verwerft J, Reddy YNV, Delvaux R, Stroobants S, Jogani S, et al.
Impact of aortic valve calcification, as measured by MDCT, on survival in patients Cardiac dysfunction rather than aortic valve stenosis severity drives exercise intoler-
with aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; ance and adverse hemodynamics. Eur Heart J Cardiovasc Imaging 2023;25:302–12.
64:1202–13. https://doi.org/10.1016/j.jacc.2014.05.066 https://doi.org/10.1093/ehjci/jead276
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 86 ---
4720 E S C G u id e l in e s
322. Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and im- multicenter study using dobutamine stress hemodynamics. Circulation 2003;108:
pact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging 2019;12:283–96. 319–24. https://doi.org/10.1161/01.CIR.0000079171.43055.46
https://doi.org/10.1016/j.jcmg.2018.11.026 342. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, et al.
323. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A, et al. Extracellular myocardial Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis
volume in patients with aortic stenosis. J Am Coll Cardiol 2020;75:304–16. https://doi. without contractile reserve on dobutamine stress echocardiography. J Am Coll
org/10.1016/j.jacc.2019.11.032 Cardiol 2009;53:1865–73. https://doi.org/10.1016/j.jacc.2009.02.026
324. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, et al. Myocardial 343. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, et al. Influence of pre-
scar and remodelling predict long-term mortality in severe aortic stenosis beyond 10 operative left ventricular contractile reserve on postoperative ejection fraction in low-
years. Eur Heart J 2024;45:2019–22. https://doi.org/10.1093/eurheartj/ehae067 gradient aortic stenosis. Circulation 2006;113:1738–44. https://doi.org/10.1161/
325. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. circulationaha.105.568824
Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J 344. Fougeres E, Tribouilloy C, Monchi M, Petit-Eisenmann H, Baleynaud S, Pasquet A, et al.
Am Coll Cardiol 2021;77:128–39. https://doi.org/10.1016/j.jacc.2020.11.006 Outcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J
326. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert 2012;33:2426–33. https://doi.org/10.1093/eurheartj/ehs176
consensus recommendations for the suspicion and diagnosis of transthyretin cardiac 345. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, et al. Aortic valve
amyloidosis. Circ Heart Fail 2019;12:e006075. https://doi.org/10.1161/circheartfailure. replacement for low-flow/low-gradient aortic stenosis operative risk stratification and
119.006075 long-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466–72.
327. Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz-Sánchez J, Fazzari F, et al. https://doi.org/10.1016/j.jacc.2007.10.067
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a 346. Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al.
systematic review and meta-analysis. ESC Heart Fail 2022;9:3188–97. https://doi.org/ Outcomes from transcatheter aortic valve replacement in patients with low-flow, low-
10.1002/ehf2.13876 gradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy
328. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. from the TOPAS-TAVI registry. JAMA Cardiol 2019;4:64–70. https://doi.org/10.1001/
Computed tomography imaging in the context of Transcatheter Aortic Valve jamacardio.2018.4320
Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR). JACC 347. Sato K, Sankaramangalam K, Kandregula K, Bullen JA, Kapadia SR, Krishnaswamy A,
Cardiovasc Imaging 2019;12:1–24. https://doi.org/10.1016/j.jcmg.2018.12.003 et al. Contemporary outcomes in low-gradient aortic stenosis patients who under-
329. Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A, et al. Coronary obstruc- went dobutamine stress echocardiography. J Am Heart Assoc 2019;8:e011168.
tion from TAVR in native aortic stenosis: development and validation of multivariate https://doi.org/10.1161/JAHA.118.011168
348. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al.
prediction model. JACC Cardiovasc Interv 2023;16:415–25. https://doi.org/10.1016/j.
Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic
jcin.2022.11.018
stenosis: a meta-analysis. JACC Cardiovasc Interv 2021;14:1481–92. https://doi.org/10.
330. Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac mag-
1016/j.jcin.2021.04.038
netic resonance imaging versus computed tomography to guide transcatheter aortic
349. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P. Outcome of
valve replacement: a randomized, open-label, noninferiority trial. Circulation 2023;
patients with aortic stenosis, small valve area, and low-flow, low-gradient despite pre-
148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA.123.066498
served left ventricular ejection fraction. J Am Coll Cardiol 2012;60:1259–67. https://doi.
331. Gleitman S, Elbaz-Greener G, Ghanim D, Kusniec F, Rabin A, Sudarsky D, et al. Similar
org/10.1016/j.jacc.2011.12.054
procedural success of transcutaneous aortic valve replacement with prosthesis valve
350. Chadha G, Bohbot Y, Rusinaru D, Marechaux S, Tribouilloy C. Outcome of normal-
sizing by either three-dimensional transesophageal echocardiography modeling or
flow low-gradient severe aortic stenosis with preserved left ventricular ejection frac-
computed tomography. J Am Soc Echocardiogr 2020;33:1149–51. https://doi.org/10.
tion: a propensity-matched study. J Am Heart Assoc 2019;8:e012301. https://doi.org/10.
1016/j.echo.2020.05.026
1161/JAHA.119.012301
332. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive
351. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Outcome
lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:
of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during
1343–56. https://doi.org/10.1056/NEJMoa0804602
prolonged follow-up. Circulation 2005;111:3290–5. https://doi.org/10.1161/
333. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A ran-
circulationaha.104.495903
domized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med
352. Heuvelman HJ, van Geldorp MW, Kappetein AP, Geleijnse ML, Galema TW, Bogers AJ,
2005;352:2389–97. https://doi.org/10.1056/NEJMoa043876
et al. Clinical course of patients diagnosed with severe aortic stenosis in the Rotterdam
334. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on
area: insights from the AVARIJN study. Neth Heart J 2012;20:487–93. https://doi.org/
progression of aortic stenosis: results of the aortic stenosis progression observation:
10.1007/s12471-012-0309-3
measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:
353. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective
306–14. https://doi.org/10.1161/CIRCULATIONAHA.109.900027
study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exer-
335. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab
cise predictors of outcome. Circulation 1997;95:2262–70. https://doi.org/10.1161/01.
or alendronic acid on the progression of aortic stenosis: a double-blind randomized cir.95.9.2262
controlled trial. Circulation 2021;143:2418–27. https://doi.org/10.1161/CIRCU
354. Bohbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K, Trouillet C,
LATIONAHA.121.053708
et al. Relationship between left ventricular ejection fraction and mortality in asymp-
336. Diederichsen ACP, Lindholt JS, Möller S, Øvrehus KA, Auscher S, Lambrechtsen J, et al.
tomatic and minimally symptomatic patients with severe aortic stenosis. JACC
Vitamin K2 and D in patients with aortic valve calcification: a randomized double- Cardiovasc Imaging 2019;12:38–48. https://doi.org/10.1016/j.jcmg.2018.07.029
blinded clinical trial. Circulation 2022;145:1387–97. https://doi.org/10.1161/ 355. Capoulade R, Le Ven F, Clavel MA, Dumesnil JG, Dahou A, Thebault C, et al.
CIRCULATIONAHA.121.057008 Echocardiographic predictors of outcomes in adults with aortic stenosis. Heart
337. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 2016;102:934–42. https://doi.org/10.1136/heartjnl-2015-308742
ESC Guidelines for the management of elevated blood pressure and hypertension. Eur 356. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, et al. Effect of left ven-
Heart J 2024;45:3912–4018. https://doi.org/10.1093/eurheartj/ehae178 tricular ejection fraction on postoperative outcome in patients with severe aortic sten-
338. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC osis undergoing aortic valve replacement. Circ Cardiovasc Imaging 2015;8:e002917.
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; https://doi.org/10.1161/CIRCIMAGING.114.002917
42:3227–337. https://doi.org/10.1093/eurheartj/ehab484 357. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Prognostic
339. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 impact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de- Cardiovasc Interv 2018;11:145–57. https://doi.org/10.1016/j.jcin.2017.08.036
veloped by the Task Force for the diagnosis and treatment of acute and chronic heart 358. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced
failure of the European Society of Cardiology (ESC) with the special contribution of left ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018;
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726. 71:1313–21. https://doi.org/10.1016/j.jacc.2018.01.045
https://doi.org/10.1093/eurheartj/ehab368 359. De Azevedo D, Boute M, Tribouilloy C, Maréchaux S, Pouleur AC, Bohbot Y, et al.
340. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Quantifying the survival loss linked to late therapeutic indication in high-gradient se-
Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute vere aortic stenosis. JACC Adv 2024;3:100830. https://doi.org/10.1016/j.jacadv.2024.
and chronic heart failure: developed by the Task Force for the diagnosis and treatment 100830
of acute and chronic heart failure of the European Society of Cardiology (ESC) with 360. Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, et al.
the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N
Heart J 2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195 Engl J Med 2024;392:217–27. https://doi.org/10.1056/NEJMoa2405880
341. Monin JL, Quéré JP, Monchi M, Petit H, Baleynaud S, Chauvel C, et al. Low-gradient 361. Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, et al. Early interven-
aortic stenosis: operative risk stratification and predictors for long-term outcome: a tion in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 87 ---
ESC Guidelines 4721
EVOLVED randomized clinical trial. JAMA 2024;333:213–21. https://doi.org/10.1001/ 383. Mori M, Gupta A, Wang Y, Vahl T, Nazif T, Kirtane AJ, et al. Trends in transcatheter
jama.2024.22730 and surgical aortic valve replacement among older adults in the United States. J Am Coll
362. Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, et al. Early surgery or conservative Cardiol 2021;78:2161–72. https://doi.org/10.1016/j.jacc.2021.09.855
care for asymptomatic aortic stenosis. N Engl J Med 2020;382:111–9. https://doi.org/ 384. Pilgrim T, Windecker S. Expansion of transcatheter aortic valve implantation: new in-
10.1056/NEJMoa1912846 dications and socio-economic considerations. Eur Heart J 2018;39:2643–45. https://
363. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve re- doi.org/10.1093/eurheartj/ehy228
placement versus conservative treatment in asymptomatic severe aortic stenosis: the 385. Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT,
AVATAR Trial. Circulation 2022;145:648–58. https://doi.org/10.1161/ et al. Annual number of candidates for transcatheter aortic valve implantation per
CIRCULATIONAHA.121.057639 country: current estimates and future projections. Eur Heart J 2018;39:2635–42.
364. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of https://doi.org/10.1093/eurheartj/ehy107
outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–7. 386. Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, et al. Mapping interven-
https://doi.org/10.1056/NEJM200008313430903 tional cardiology in Europe: the European Association of Percutaneous Cardiovascular
365. Nakatsuma K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al. B-type Interventions (EAPCI) Atlas project. Eur Heart J 2020;41:2579–88. https://doi.org/10.
natriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart 2019; 1093/eurheartj/ehaa475
105:384–90. https://doi.org/10.1136/heartjnl-2018-313746 387. Benfari G, Essayagh B, Michelena HI, Ye Z, Inojosa JM, Ribichini FL, et al. Severe aortic
366. Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratifica- stenosis: secular trends of incidence and outcomes. Eur Heart J 2024;45:1877–86.
tion of patients with valvular aortic stenosis. Circ Heart Fail 2015;8:373–80. https://doi. https://doi.org/10.1093/eurheartj/ehad887
org/10.1161/CIRCHEARTFAILURE.114.001649 388. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter
367. Banovic M, Putnik S, Da Costa BR, Penicka M, Deja MA, Kotrc M, et al. Aortic valve aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N
replacement versus conservative treatment in asymptomatic severe aortic stenosis: Engl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232
long-term follow-up of the AVATAR trial. Eur Heart J 2024;45:4526–35. https://doi. 389. Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, et al. 5-Year out-
org/10.1093/eurheartj/ehae585 comes of self-expanding transcatheter versus surgical aortic valve replacement in high-
368. Généreux P, Banovic M, Kang DH, Giustino G, Prendergast BD, Lindman BR, et al. risk patients. J Am Coll Cardiol 2018;72:2687–96. https://doi.org/10.1016/j.jacc.2018.08.
Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: 2146
a systematic review and meta-analysis. J Am Coll Cardiol 2024;85:912–22. https://doi. 390. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes
org/10.1016/j.jacc.2024.11.006
of transcatheter aortic valve replacement or surgical aortic valve replacement for high
369. Smith WTI, Ferguson TBJ, Ryan T, Landolfo CK, Peterson ED. Should coronary artery
surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.
bypass graft surgery patients with mild or moderate aortic stenosis undergo concomi-
Lancet 2015;385:2477–84. https://doi.org/10.1016/S0140-6736(15)60308-7
tant aortic valve replacement? A decision analysis approach to the surgical dilemma. J
391. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter
Am Coll Cardiol 2004;44:1241–7. https://doi.org/10.1016/j.jacc.2004.06.031
versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:
370. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al.
2187–98. https://doi.org/10.1056/NEJMoa1103510
Moderate aortic stenosis in patients with heart failure and reduced ejection fraction.
392. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter
J Am Coll Cardiol 2021;77:2796–803. https://doi.org/10.1016/j.jacc.2021.04.014
or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;
371. Jacquemyn X, Strom JB, Strange G, Playford D, Stewart S, Kutty S, et al. Moderate aor-
374:1609–20. https://doi.org/10.1056/NEJMoa1514616
tic valve stenosis is associated with increased mortality rate and lifetime loss: system-
393. Toff WD, Hildick-Smith D, Kovac J, Mullen MJ, Wendler O, Mansouri A, et al. Effect of
atic review and meta-analysis of reconstructed time-to-event data of 409 680 patients.
transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause
J Am Heart Assoc 2024;13:e033872. https://doi.org/10.1161/jaha.123.033872
mortality in patients with aortic stenosis: a randomized clinical trial. JAMA 2022;327:
372. Amanullah MR, Pio SM, Ng ACT, Sin KYK, Marsan NA, Ding ZP, et al. Prognostic im-
1875–87. https://doi.org/10.1001/jama.2022.5776
plications of associated cardiac abnormalities detected on echocardiography in pa-
394. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter
tients with moderate aortic stenosis. JACC Cardiovasc Imaging 2021;14:1724–37.
aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J
https://doi.org/10.1016/j.jcmg.2021.04.009
Med 2019;380:1706–15. https://doi.org/10.1056/NEJMoa1816885
373. Van Mieghem NM, Elmariah S, Spitzer E, Pibarot P, Nazif TM, Bax JJ, et al.
395. Blankenberg S, Seiffert M, Vonthein R, Baumgartner H, Bleiziffer S, Borger MA, et al.
Transcatheter aortic valve replacement in patients with systolic heart failure and mod-
Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med 2024;390:
erate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol 2024;85:878–90. https://doi.
1572–83. https://doi.org/10.1056/NEJMoa2400685
org/10.1016/j.jacc.2024.10.070
396. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year out-
374. Graversen PL, Butt JH, Østergaard L, Jensen AD, Warming PE, Strange JE, et al.
comes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:
Changes in aortic valve replacement procedures in Denmark from 2008 to 2020.
799–809. https://doi.org/10.1056/NEJMoa1910555
Heart 2023;109:557–63. https://doi.org/10.1136/heartjnl-2022-321594
397. Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, et al.
375. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, et al. Long-term
Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac
patients: 5-year outcomes of the SURTAVI randomized clinical trial. JAMA Cardiol
Surg 2015;99:1239–47. https://doi.org/10.1016/j.athoracsur.2014.10.070
2022;7:1000–8. https://doi.org/10.1001/jamacardio.2022.2695
376. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, et al.
398. Thyregod HGH, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ,
Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N
Engl J Med 2017;377:1847–57. https://doi.org/10.1056/NEJMoa1613792 et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the
377. Mazine A, David TE, Stoklosa K, Chung J, Lafreniere-Roula M, Ouzounian M. Improved NOTION trial. Eur Heart J 2024;45:1116–24. https://doi.org/10.1093/eurheartj/
outcomes following the Ross procedure compared with bioprosthetic aortic valve re- ehae043
placement. J Am Coll Cardiol 2022;79:993–1005. https://doi.org/10.1016/j.jacc.2021.12. 399. Ahmad Y, Howard JP, Arnold AD, Madhavan MV, Cook CM, Alu M, et al.
026 Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk pa-
378. Notenboom ML, Melina G, Veen KM, De Robertis F, Coppola G, De Siena P, et al. tients: a meta-analysis of randomized trials. Eur Heart J 2023;44:836–52. https://doi.
Long-term clinical and echocardiographic outcomes following the Ross procedure: a org/10.1093/eurheartj/ehac642
post hoc analysis of a randomized clinical trial. JAMA Cardiology 2023;9:6–14. https:// 400. Barili F, Brophy JM, Ronco D, Myers PO, Uva MS, Almeida RMS, et al. Risk of bias in
doi.org/10.1001/jamacardio.2023.4090 randomized clinical trials comparing transcatheter and surgical aortic valve replace-
379. Alkhouli M, Zack CJ, Sarraf M, Bashir R, Nishimura RA, Eleid MF, et al. Morbidity and ment: a systematic review and meta-analysis. JAMA Netw Open 2023;6:e2249321.
mortality associated with balloon aortic valvuloplasty: a national perspective. Circ https://doi.org/10.1001/jamanetworkopen.2022.49321
Cardiovasc Interv 2017;10:e004481. https://doi.org/10.1161/CIRCINTERVENTIONS. 401. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al.
116.004481 Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treat-
380. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in ment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J
TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol 2019;40:3143–53. https://doi.org/10.1093/eurheartj/ehz275
2022;80:2054–6. https://doi.org/10.1016/j.jacc.2022.08.787 402. Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, et al.
381. Gaede L, Blumenstein J, Eckel C, Grothusen C, Tiyerili V, Sötemann D, et al. Association of paravalvular regurgitation with 1-year outcomes after transcatheter
Transcatheter-based aortic valve replacement vs. isolated surgical aortic valve replace- aortic valve replacement with the SAPIEN 3 valve. JAMA Cardiol 2017;2:1208–16.
ment in 2020. Clin Res Cardiol 2022;111:924–33. https://doi.org/10.1007/s00392-022- https://doi.org/10.1001/jamacardio.2017.3425
02006-1 403. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular re-
382. Nguyen V, Willner N, Eltchaninoff H, Burwash IG, Michel M, Durand E, et al. Trends in gurgitation after transcatheter aortic valve replacement with the Edwards sapien valve
aortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J
2022;43:666–79. https://doi.org/10.1093/eurheartj/ehab773 2015;36:449–56. https://doi.org/10.1093/eurheartj/ehu384
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 88 ---
4722 E S C G u id e l in e s
404. Lerman TT, Levi A, Kornowski R. Meta-analysis of short- and long-term clinical out- 424. Okuno T, Asami M, Heg D, Lanz J, Praz F, Hagemeyer D, et al. Impact of left ventricular
comes of the self-expanding Evolut R/pro valve versus the balloon-expandable outflow tract calcification on procedural outcomes after transcatheter aortic valve re-
Sapien 3 valve for transcatheter aortic valve implantation. Int J Cardiol 2023;371: placement. JACC Cardiovasc Interv 2020;13:1789–99. https://doi.org/10.1016/j.jcin.
100–8. https://doi.org/10.1016/j.ijcard.2022.09.035 2020.04.015
405. Faroux L, Chen S, Muntané-Carol G, Regueiro A, Philippon F, Sondergaard L, et al. 425. Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, et al.
Clinical impact of conduction disturbances in transcatheter aortic valve replacement Anatomical and procedural features associated with aortic root rupture during
recipients: a systematic review and meta-analysis. Eur Heart J 2020;41:2771–81. balloon-expandable transcatheter aortic valve replacement. Circulation 2013;128:
https://doi.org/10.1093/eurheartj/ehz924 244–53. https://doi.org/10.1161/circulationaha.113.002947
406. Greason KL, Lahr BD, Stulak JM, Cha YM, Rea RF, Schaff HV, et al. Long-term mortality 426. Kirmani BH, Jones SG, Muir A, Malaisrie SC, Chung DA, Williams RJ, et al. Limited ver-
effect of early pacemaker implantation after surgical aortic valve replacement. Ann sus full sternotomy for aortic valve replacement. Cochrane Database Syst Rev 2023;12:
Thorac Surg 2017;104:1259–64. https://doi.org/10.1016/j.athoracsur.2017.01.083 CD011793. https://doi.org/10.1002/14651858.CD011793.pub3
407. Rück A, Saleh N, Glaser N. Outcomes following permanent pacemaker implantation 427. Paparella D, Malvindi PG, Santarpino G, Moscarelli M, Guida P, Fattouch K, et al. Full
after transcatheter aortic valve replacement: SWEDEHEART observational study. sternotomy and minimal access approaches for surgical aortic valve replacement: a
JACC Cardiovasc Interv 2021;14:2173–81. https://doi.org/10.1016/j.jcin.2021.07.043 multicentre propensity-matched study. Eur J Cardiothorac Surg 2020;57:709–16.
408. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. https://doi.org/10.1093/ejcts/ezz286
Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients 428. Vincent F, Ternacle J, Denimal T, Shen M, Redfors B, Delhaye C, et al. Transcatheter
with severe aortic stenosis at intermediate risk. Circulation 2019;139:877–88. https:// aortic valve replacement in bicuspid aortic valve stenosis. Circulation 2021;143:
doi.org/10.1161/CIRCULATIONAHA.118.035236 1043–61. https://doi.org/10.1161/CIRCULATIONAHA.120.048048
409. Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost- 429. Alperi A, Voisine P, Kalavrouziotis D, Dumont E, Dagenais F, Perron J, et al. Aortic
effectiveness of transcatheter aortic valve replacement in low surgical risk patients valve replacement in low-risk patients with severe aortic stenosis outside randomized
with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes 2021;7:556–63. trials. J Am Coll Cardiol 2021;77:111–23. https://doi.org/10.1016/j.jacc.2020.10.056
https://doi.org/10.1093/ehjqcco/qcaa058 430. Makkar RR, Yoon SH, Leon MB, Chakravarty T, Rinaldi M, Shah PB, et al. Association
410. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deteri- between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic sten-
oration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 osis and mortality or stroke. JAMA 2019;321:2193–202. https://doi.org/10.1001/jama.
trial. J Am Coll Cardiol 2020;76:1830–43. https://doi.org/10.1016/j.jacc.2020.08.049 2019.7108
411. Fatima B, Mohananey D, Khan FW, Jobanputra Y, Tummala R, Banerjee K, et al. 431. Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, et al. Outcomes of trans-
catheter aortic valve replacement in patients with bicuspid aortic valve disease: a re-
Durability data for bioprosthetic surgical aortic valve: a systematic review. JAMA
port from the Society of Thoracic Surgeons/American College of Cardiology
Cardiol 2019;4:71–80. https://doi.org/10.1001/jamacardio.2018.4045
Transcatheter Valve Therapy Registry. Circulation 2020;141:1071–9. https://doi.org/
412. Kedhi E, Hermanides RS, Dambrink JE, Singh SK, Ten Berg JM, van Ginkel D, et al.
10.1161/CIRCULATIONAHA.119.040333
TransCatheter aortic valve implantation and fractional flow reserve-guided percutan-
432. Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, et al.
eous coronary intervention versus conventional surgical aortic valve replacement and
Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves
coronary bypass grafting for treatment of patients with aortic valve stenosis and com-
from the STS/ACC TVT registry. JACC Cardiovasc Interv 2020;13:1749–59. https://
plex or multivessel coronary disease (TCW): an international, multicentre, prospect-
doi.org/10.1016/j.jcin.2020.03.022
ive, open-label, non-inferiority, randomised controlled trial. Lancet 2025;404:
433. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar AA, Giannini F, et al. Outcomes
2593–602. https://doi.org/10.1016/s0140-6736(24)02100-7
after transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy: a
413. Martinsson A, Nielsen SJ, Milojevic M, Redfors B, Omerovic E, Tonnessen T, et al. Life
systematic review and meta-analysis. JACC Cardiovasc Interv 2021;14:2144–55.
expectancy after surgical aortic valve replacement. J Am Coll Cardiol 2021;78:2147–57.
https://doi.org/10.1016/j.jcin.2021.07.052
https://doi.org/10.1016/j.jacc.2021.09.861
434. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes
414. Glaser N, Persson M, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Loss in
in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve
life expectancy after surgical aortic valve replacement: SWEDEHEART study. J Am Coll
stenosis. J Am Coll Cardiol 2017;69:2579–89. https://doi.org/10.1016/j.jacc.2017.03.017
Cardiol 2019;74:26–33. https://doi.org/10.1016/j.jacc.2019.04.053
435. Jilaihawi H, Chen M, Webb J, Himbert D, Ruiz CE, Rodés-Cabau J, et al. A bicuspid aor-
415. Attinger-Toller A, Ferrari E, Tueller D, Templin C, Muller O, Nietlispach F, et al.
tic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging 2016;9:
Age-related outcomes after transcatheter aortic valve replacement: insights from
1145–58. https://doi.org/10.1016/j.jcmg.2015.12.022
the SwissTAVI registry. JACC Cardiovasc Interv 2021;14:952–60. https://doi.org/10.
436. Sá MPBO, Zhigalov K, Cavalcanti LRP, Escorel Neto AC, Rayol SC, Weymann A, et al.
1016/j.jcin.2021.01.042
Impact of aortic annulus enlargement on the outcomes of aortic valve replacement: a
416. Jørgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie Ø, Tang M, et al.
meta-analysis. Semin Thorac Cardiovasc Surg 2021;33:316–25. https://doi.org/10.1053/j.
Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic sten-
semtcvs.2020.06.046
osis: the NOTION-2 trial. Eur Heart J 2024;45:3804–14. https://doi.org/10.1093/
437. Head SJ, Reardon MJ, Deeb GM, Van Mieghem NM, Popma JJ, Gleason TG, et al.
eurheartj/ehae331 Computed tomography-based indexed aortic annulus size to predict prosthesis-
417. Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery
patient mismatch. Circ Cardiovasc Interv 2019;12:e007396. https://doi.org/10.1161/
access for transcatheter aortic valve replacement: Society of the Thoracic Surgeons/
circinterventions.118.007396
American College of Cardiology TVT registry report. JACC Cardiovasc Interv 2019; 438. Herrmann HC, Mehran R, Blackman DJ, Bailey S, Möllmann H, Abdel-Wahab M, et al.
12:662–9. https://doi.org/10.1016/j.jcin.2019.01.219 Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus. N
418. Gleason TG, Schindler JT, Hagberg RC, Deeb GM, Adams DH, Conte JV, et al. Engl J Med 2024;390:1959–71. https://doi.org/10.1056/NEJMoa2312573
Subclavian/axillary access for self-expanding transcatheter aortic valve replacement 439. Yokoyama Y, Kuno T, Zaid S, Kaneko T, Takagi H, Tang GHL, et al. Surgical explant-
renders equivalent outcomes as transfemoral. Ann Thorac Surg 2018;105:477–83. ation of transcatheter aortic bioprosthesis: a systematic review and meta-analysis.
https://doi.org/10.1016/j.athoracsur.2017.07.017 JTCVS Open 2021;8:207–27. https://doi.org/10.1016/j.xjon.2021.09.023
419. Kirker E, Korngold E, Hodson RW, Jones BM, McKay R, Cheema M, et al. Transcarotid 440. Marin-Cuartas M, Tang GHL, Kiefer P, Fukuhara S, Lange R, Harrington KB, et al.
versus subclavian/axillary access for transcatheter aortic valve replacement with Transcatheter heart valve explant with infective endocarditis-associated prosthesis
SAPIEN 3. Ann Thorac Surg 2020;110:1892–7. https://doi.org/10.1016/j.athoracsur. failure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J 2024;
2020.05.141 45:2519–32. https://doi.org/10.1093/eurheartj/ehae292
420. Debry N, Trimech TR, Gandet T, Vincent F, Hysi I, Delhaye C, et al. Transaxillary com- 441. Hirji SA, Percy ED, McGurk S, Malarczyk A, Harloff MT, Yazdchi F, et al. Incidence,
pared with transcarotid access for TAVR: a propensity-matched comparison from a characteristics, predictors, and outcomes of surgical explantation after transcatheter
French multicentre registry. EuroIntervention 2020;16:842–9. https://doi.org/10.4244/ aortic valve replacement. J Am Coll Cardiol 2020;76:1848–59. https://doi.org/10.1016/
eij-d-20-00117 j.jacc.2020.08.048
421. Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, et al. Femoral 442. Jawitz OK, Gulack BC, Grau-Sepulveda MV, Matsouaka RA, Mack MJ, Holmes DR Jr,
versus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am et al. Reoperation after transcatheter aortic valve replacement: an analysis of the
Coll Cardiol 2019;74:2728–39. https://doi.org/10.1016/j.jacc.2019.09.054 Society of Thoracic Surgeons database. JACC Cardiovasc Interv 2020;13:1515–25.
422. Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O’Neill WW, et al. https://doi.org/10.1016/j.jcin.2020.04.029
Transcaval access and closure for transcatheter aortic valve replacement: a prospect- 443. Hawkins RB, Deeb GM, Sukul D, Patel HJ, Gualano SK, Chetcuti SJ, et al. Redo surgical
ive investigation. J Am Coll Cardiol 2017;69:511–21. https://doi.org/10.1016/j.jacc.2016. aortic valve replacement after prior transcatheter versus surgical aortic valve replace-
10.024 ment. JACC Cardiovasc Interv 2023;16:942–53. https://doi.org/10.1016/j.jcin.2023.03.
423. Lederman RJ, Babaliaros VC, Lisko JC, Rogers T, Mahoney P, Foerst JR, et al. Transcaval 015
versus transaxillary TAVR in contemporary practice: a propensity-weighted analysis. 444. Bapat VN, Zaid S, Fukuhara S, Saha S, Vitanova K, Kiefer P, et al. Surgical explantation
JACC Cardiovasc Interv 2022;15:965–75. https://doi.org/10.1016/j.jcin.2022.03.014 after TAVR failure: mid-term outcomes from the EXPLANT-TAVR international
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 89 ---
ESC Guidelines 4723
registry. JACC Cardiovasc Interv 2021;14:1978–91. https://doi.org/10.1016/j.jcin.2021. 465. Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al.
07.015 Eight-year outcomes for patients with aortic valve stenosis at low surgical risk rando-
445. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after mized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42:
transcatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg 2024; 2912–9. https://doi.org/10.1093/eurheartj/ehab375
118:155–62. https://doi.org/10.1016/j.athoracsur.2024.03.024 466. O’Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deteri-
446. Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, et al. oration after self-expanding transcatheter or surgical aortic valve implantation in pa-
Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunc- tients at intermediate or high risk. JAMA Cardiol 2023;8:111–9. https://doi.org/10.
tion. J Am Coll Cardiol 2020;75:1882–93. https://doi.org/10.1016/j.jacc.2020.02.051 1001/jamacardio.2022.4627
447. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. 467. Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodés-Cabau J. Aortic bioprosthetic
Transcatheter ViV versus redo surgical AVR for the management of failed biological valve durability: incidence, mechanisms, predictors, and management of surgical and
prosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc transcatheter valve degeneration. J Am Coll Cardiol 2017;70:1013–28. https://doi.org/
Interv 2020;13:765–74. https://doi.org/10.1016/j.jcin.2019.10.030 10.1016/j.jacc.2017.07.715
448. Sá MBPO, Van den Eynde J, Simonato M, Cavalcanti LRP, Doulamis IP, Weixler V, et al. 468. Pibarot P, Magne J, Leipsic J, Cote N, Blanke P, Thourani VH, et al. Imaging for predict-
Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve ing and assessing prosthesis-patient mismatch after aortic valve replacement. JACC
replacement: an updated meta-analysis. JACC Cardiovasc Interv 2021;14:211–20. https:// Cardiovasc Imaging 2019;12:149–62. https://doi.org/10.1016/j.jcmg.2018.10.020
doi.org/10.1016/j.jcin.2020.10.020 469. Freitas-Ferraz Afonso B, Tirado-Conte G, Dagenais F, Ruel M, Al-Atassi T, Dumont E,
449. Percy ED, Harloff MT, Hirji S, McGurk S, Yazdchi F, Newell P, et al. Nationally repre- et al. Aortic stenosis and small aortic annulus. Circulation 2019;139:2685–702. https://
sentative repeat transcatheter aortic valve replacement outcomes: report from the doi.org/10.1161/CIRCULATIONAHA.118.038408
centers for Medicare and Medicaid services. JACC Cardiovasc Interv 2021;14: 470. Tang GHL, Zaid S, Fuchs A, Yamabe T, Yazdchi F, Gupta E, et al. Alignment of trans-
1717–26. https://doi.org/10.1016/j.jcin.2021.06.011 catheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orienta-
450. Makkar RR, Kapadia S, Chakravarty T, Cubeddu RJ, Kaneko T, Mahoney P, et al. tion and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030–42. https://doi.
Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable org/10.1016/j.jcin.2020.02.005
valves: a registry study. Lancet 2023;402:1529–40. https://doi.org/10.1016/s0140- 471. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-Year out-
6736(23)01636-7 comes of transcatheter aortic valve replacement compared with standard treatment
451. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, et al. Transcatheter for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled
valve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J trial. Lancet 2015;385:2485–91. https://doi.org/10.1016/S0140-6736(15)60290-2
Am Coll Cardiol 2020;76:489–99. https://doi.org/10.1016/j.jacc.2020.06.010 472. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al.
452. Dismorr M, Glaser N, Franco-Cereceda A, Sartipy U. Effect of prosthesis-patient mis- Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl
match on long-term clinical outcomes after bioprosthetic aortic valve replacement. J J Med 2012;366:1696–704. https://doi.org/10.1056/NEJMoa1202277
Am Coll Cardiol 2023;81:964–75. https://doi.org/10.1016/j.jacc.2022.12.023 473. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve dis-
453. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The ease. Eur Heart J 1987;8:471–83. https://doi.org/10.1093/oxfordjournals.eurheartj.
impact of prosthesis-patient mismatch on long-term survival after aortic valve replace- a062307
ment: a systematic review and meta-analysis of 34 observational studies comprising 27 474. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with
186 patients with 133 141 patient-years. Eur Heart J 2012;33:1518–29. https://doi.org/ asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 1990;15:
10.1093/eurheartj/ehs003 1012–7. https://doi.org/10.1016/0735-1097(90)90234-g
454. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, 475. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, et al. Predictors of
et al. Prosthesis–patient mismatch in patients undergoing transcatheter aortic valve re- mortality and symptomatic outcome of patients with low-flow severe aortic stenosis
placement: from the STS/ACC TVT registry. J Am Coll Cardiol 2018;72:2701–11. undergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.
https://doi.org/10.1016/j.jacc.2018.09.001 https://doi.org/10.1161/JAHA.117.007977
455. Ternacle J, Pibarot P, Herrmann HC, Kodali S, Leipsic J, Blanke P, et al. 476. Eleid MF, Padang R, Al-Hijji M, Pislaru SV, Greason KL, Maltais S, et al. Hemodynamic
Prosthesis-patient mismatch after aortic valve replacement in the PARTNER 2 trial response in low-flow low-gradient aortic stenosis with preserved ejection fraction
and registry. JACC Cardiovasc Interv 2021;14:1466–77. https://doi.org/10.1016/j.jcin. after TAVR. J Am Coll Cardiol 2019;73:1731–2. https://doi.org/10.1016/j.jacc.2019.01.
2021.03.069 034
456. Akodad M, Sellers S, Landes U, Meier D, Tang Gilbert HL, Gada H, et al. 477. Rusinaru D, Bohbot Y, Ringle A, Marechaux S, Diouf M, Tribouilloy C. Impact of low
Balloon-expandable valve for treatment of Evolut valve failure. JACC Cardiovasc Interv stroke volume on mortality in patients with severe aortic stenosis and preserved left
2022;15:368–77. https://doi.org/10.1016/j.jcin.2021.12.021 ventricular ejection fraction. Eur Heart J 2018;39:1992–9. https://doi.org/10.1093/
457. Ribeiro HB, Rodés-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, et al. Incidence, eurheartj/ehy123
predictors, and clinical outcomes of coronary obstruction following transcatheter aor- 478. Zheng Q, Djohan AH, Lim E, Ding ZP, Ling LH, Shi L, et al. Effects of aortic valve re-
tic valve replacement for degenerative bioprosthetic surgical valves: insights from the placement on severe aortic stenosis and preserved systolic function: systematic review
VIVID registry. Eur Heart J 2018;39:687–95. https://doi.org/10.1093/eurheartj/ehx455 and network meta-analysis. Sci Rep 2017;7:5092. https://doi.org/10.1038/s41598-017-
458. Ochiai T, Oakley L, Sekhon N, Komatsu I, Flint N, Kaewkes D, et al. Risk of coronary 05021-9
obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. 479. Salaun E, Clavel MA, Hahn RT, Jaber WA, Asch FM, Rodriguez L, et al. Outcome of
JACC Cardiovasc Interv 2020;13:2617–27. https://doi.org/10.1016/j.jcin.2020.09.022 flow-gradient patterns of aortic stenosis after aortic valve replacement: an analysis
459. Akodad M, Sellers S, Gulsin GS, Tzimas G, Landes U, Chatfield Andrew G, et al. Leaflet of the PARTNER 2 trial and registry. Circ Cardiovasc Interv 2020;13:e008792. https://
and neoskirt height in transcatheter heart valves. JACC Cardiovasc Interv 2021;14: doi.org/10.1161/CIRCINTERVENTIONS.119.008792
2298–300. https://doi.org/10.1016/j.jcin.2021.07.034 480. Annabi MS, Côté N, Dahou A, Bartko PE, Bergler-Klein J, Burwash IG, et al.
460. Tang GH, Spencer J, Rogers T, Grubb KJ, Gleason P, Gada H, et al. Feasibility of cor- Comparison of early surgical or transcatheter aortic valve replacement versus conser-
onary access following redo-TAVR for Evolut failure: a computed tomography simu- vative management in low-flow, low-gradient aortic stenosis using inverse probability
lation study. Circ Cardiovasc Interv 2023;16:e013238. https://doi.org/10.1161/ of treatment weighting: results from the TOPAS prospective observational cohort
CIRCINTERVENTIONS.123.013238 study. J Am Heart Assoc 2020;9:e017870. https://doi.org/10.1161/jaha.120.017870
461. De Backer O, Landes U, Fuchs A, Yoon SH, Mathiassen ON, Sedaghat A, et al. 481. Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of trans-
Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tom- catheter aortic valve replacement in patients with paradoxical low-flow low-gradient
ography. JACC Cardiovasc Interv 2020;13:2528–38. https://doi.org/10.1016/j.jcin.2020. versus high-gradient aortic stenosis and preserved left ventricular function. Circ
06.016 Cardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/circinterventions.120.
462. Fukui M, Okada A, Thao KR, Burns MR, Koike H, Wang C, et al. Feasibility of redo- 010042
transcatheter aortic valve replacement in Sapien valves based on in vivo computed 482. Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C. Impact of
tomography assessment. Circ Cardiovasc Interv 2023;16:e013497. https://doi.org/10. mean transaortic pressure gradient on long-term outcome in patients with severe aor-
1161/CIRCINTERVENTIONS.123.013497 tic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017;6:
463. Chhatriwalla AK, Allen KB, Depta JP, Rodriguez E, Thourani VH, Whisenant BK, et al. e005850. https://doi.org/10.1161/JAHA.117.005850
Outcomes of bioprosthetic valve fracture in patients undergoing valve-in-valve TAVR. 483. Costa GNF, Cardoso JFL, Oliveiros B, Gonçalves L, Teixeira R. Early surgical interven-
JACC Cardiovasc Interv 2023;16:530–9. https://doi.org/10.1016/j.jcin.2022.12.019 tion versus conservative management of asymptomatic severe aortic stenosis: a sys-
464. Khan JM, Babaliaros VC, Greenbaum AB, Spies C, Daniels D, Depta JP, et al. Preventing tematic review and meta-analysis. Heart 2023;109:314–21. https://doi.org/10.1136/
coronary obstruction during transcatheter aortic valve replacement: results from the heartjnl-2022-321411
multicenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941–8. 484. Bohbot Y, Rusinaru D, Delpierre Q, Marechaux S, Tribouilloy C. Risk stratification of
https://doi.org/10.1016/j.jcin.2021.02.035 severe aortic stenosis with preserved left ventricular ejection fraction using peak aortic
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 90 ---
4724 E S C G u id e l in e s
jet velocity: an outcome study. Circ Cardiovasc Imaging 2017;10:e006760. https://doi. 505. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, et al. Aortic valve sur-
org/10.1161/CIRCIMAGING.117.006760 gery and survival in patients with moderate or severe aortic stenosis and left ventricu-
485. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self- lar dysfunction. Eur Heart J 2016;37:2276–86. https://doi.org/10.1093/eurheartj/
expanding prosthesis. N Engl J Med 2014;371:967–8. https://doi.org/10.1056/ ehv701
NEJMc1408396 506. Oz A, Tsoumas I, Lampropoulos K, Xanthos T, Karpettas N, Papadopoulos D. Cardiac
486. Thyregod HGH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, rehabilitation after TAVI—a systematic review and meta-analysis. Curr Probl Cardiol
et al. Transcatheter versus surgical aortic valve replacement in patients with severe 2023;48:101531. https://doi.org/10.1016/j.cpcardiol.2022.101531
aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical 507. Monteagudo Ruiz JM, Galderisi M, Buonauro A, Badano L, Aruta P, Swaans MJ, et al.
trial. J Am Coll Cardiol 2015;65:2184–94. https://doi.org/10.1016/j.jacc.2015.03.014 Overview of mitral regurgitation in Europe: results from the European Registry of mi-
487. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, et al. tral regurgitation (EuMiClip). Eur Heart J Cardiovasc Imaging 2018;19:503–7. https://doi.
Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 org/10.1093/ehjci/jey011
low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:55–61. 508. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve pro-
https://doi.org/10.1016/j.athoracsur.2014.06.050 lapse and sudden cardiac death: a systematic review and meta-analysis. Heart 2019;
488. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. 105:144–51. https://doi.org/10.1136/heartjnl-2017-312932
Transcatheter aortic valve replacement versus surgical valve replacement in 509. Van der Bijl P, Stassen J, Haugaa KH, Essayagh B, Basso C, Thiene G, et al. Mitral annular
intermediate-risk patients: a propensity score analysis. Lancet 2016;387:2218–25. disjunction in the context of mitral valve prolapse: identifying the at-risk patient. JACC
https://doi.org/10.1016/s0140-6736(16)30073-3 Cardiovasc Imaging 2024;17:1229–45. https://doi.org/10.1016/j.jcmg.2024.03.006
489. Coylewright M, Grubb KJ, Arnold SV, Batchelor W, Dhoble A, Horne A Jr, et al. 510. Antoine C, Benfari G, Michelena HI, Maalouf JF, Nkomo VT, Thapa P, et al. Clinical out-
Outcomes of balloon-expandable transcatheter aortic valve replacement in younger come of degenerative mitral regurgitation. Circulation 2018;138:1317–26. https://doi.
patients in the low-risk era. JAMA Cardiol 2025;10:127–35. https://doi.org/10.1001/ org/10.1161/CIRCULATIONAHA.117.033173
jamacardio.2024.4237 511. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V,
490. Ullah W, DiMeglio M, Sana MK, Muhammadzai HZU, Kochar K, Zahid S, et al. et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation.
Outcomes after transcatheter aortic valve implantation in patients excluded from clin- N Engl J Med 2005;352:875–83. https://doi.org/10.1056/NEJMoa041451
ical trials. JACC Adv 2023;2:100271. https://doi.org/10.1016/j.jacadv.2023.100271 512. O’Gara PT, Grayburn PA, Badhwar V, Afonso LC, Carroll JD, Elmariah S, et al. 2017
491. Reents W, Barth S, Griese DP, Winkler S, Babin-Ebell J, Kerber S, et al. Transfemoral ACC Expert Consensus Decision Pathway on the management of mitral regurgitation:
versus transapical transcatheter aortic valve implantation: a single-centre experience.
a report of the American College of Cardiology Task Force on Expert Consensus
Eur J Cardiothorac Surg 2019;55:744–50. https://doi.org/10.1093/ejcts/ezy363
Decision Pathways. J Am Coll Cardiol 2017;70:2421–49. https://doi.org/10.1016/j.jacc.
492. Allen KB, Chhatriwalla AK, Cohen D, Saxon J, Hawa Z, Kennedy KF, et al. Transcarotid
2017.09.019
versus transapical and transaortic access for transcatheter aortic valve replacement.
513. Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI, Crestanello JA,
Ann Thorac Surg 2019;108:715–22. https://doi.org/10.1016/j.athoracsur.2019.02.007
et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical
493. Overtchouk P, Folliguet T, Pinaud F, Fouquet O, Pernot M, Bonnet G, et al.
context and outcome. Eur Heart J 2019;40:2194–202. https://doi.org/10.1093/
Transcarotid approach for transcatheter aortic valve replacement with the Sapien 3
eurheartj/ehz314
prosthesis. JACC Cardiovasc Interv 2019;12:413–9. https://doi.org/10.1016/j.jcin.2018.
514. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, et al. Long-term out-
11.014
comes of mitral regurgitation by type and severity. Am Heart J 2018;203:39–48. https://
494. Kumar N, Khera R, Fonarow GC, Bhatt DL. Comparison of outcomes of transfemoral
doi.org/10.1016/j.ahj.2018.05.001
versus transapical approach for transcatheter aortic valve implantation. Am J Cardiol
515. Bakkestrom R, Banke A, Christensen NL, Pecini R, Irmukhamedov A, Andersen M,
2018;122:1520–6. https://doi.org/10.1016/j.amjcard.2018.07.025
et al. Hemodynamic characteristics in significant symptomatic and asymptomatic pri-
495. van Wely M, van Nieuwkerk AC, Rooijakkers M, van der Wulp K, Gehlmann H,
mary mitral valve regurgitation at rest and during exercise. Circ Cardiovasc Imaging
Verkroost M, et al. Transaxillary versus transfemoral access as default access in
2018;11:e007171. https://doi.org/10.1161/CIRCIMAGING.117.007171
TAVI: a propensity matched analysis. Int J Cardiol 2024;394:131353. https://doi.org/
516. Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, et al.
10.1016/j.ijcard.2023.131353
Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally
496. Allen KB, Watson D, Vora AN, Mahoney P, Chhatriwalla AK, Schwartz JG, et al.
symptomatic patients with degenerative mitral regurgitation combined invasive-
Transcarotid versus transaxillary access for transcatheter aortic valve replacement
noninvasive hemodynamic monitoring. Circ Cardiovasc Imaging 2018;11:e007282.
with a self-expanding valve: a propensity-matched analysis. JTCVS Tech 2023;21:
https://doi.org/10.1161/CIRCIMAGING.117.007282
45–55. https://doi.org/10.1016/j.xjtc.2023.07.019
517. Butcher SC, Essayagh B, Steyerberg EW, Benfari G, Antoine C, Grigioni F, et al. Factors
497. Salihu A, Ferlay C, Kirsch M, Shah PB, Skali H, Fournier S, et al. Outcomes and safety of
influencing post-surgical survival in degenerative mitral regurgitation. Eur Heart J 2023;
transcaval transcatheter aortic valve replacement: a systematic review and
44:871–81. https://doi.org/10.1093/eurheartj/ehad004 meta-analysis. Can J Cardiol 2024;40:2054–62. https://doi.org/10.1016/j.cjca.2024.05.
518. Grigioni F, Clavel MA, Vanoverschelde JL, Tribouilloy C, Pizarro R, Huebner M, et al.
016
The MIDA mortality risk score: development and external validation of a prognostic
498. Abraham B, Sous M, Sedhom R, Megaly M, Roman S, Sweeney J, et al. Meta-analysis on
model for early and late death in degenerative mitral regurgitation. Eur Heart J 2018;
transcarotid versus transfemoral and other alternate accesses for transcatheter aortic
valve implantation. Am J Cardiol 2023;192:196–205. https://doi.org/10.1016/j.amjcard. 39:1281–91. https://doi.org/10.1093/eurheartj/ehx465
519. Del Rio-Pertuz G, Nugent K, Argueta-Sosa E. Right heart catheterization in clinical
2023.01.023
499. Williams MR, Jilaihawi H, Makkar R, O’Neill WW, Guyton R, Malaisrie SC, et al. The practice: a review of basic physiology and important issues relevant to interpretation.
PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in Am J Cardiovasc Dis 2023;13:122–37.
low-surgical-risk patients. JACC Cardiovasc Interv 2022;15:523–32. https://doi.org/10. 520. Mentias A, Patel K, Patel H, Gillinov AM, Rodriguez LL, Svensson LG, et al. Prognostic
1016/j.jcin.2022.01.279 utility of brain natriuretic peptide in asymptomatic patients with significant mitral re-
500. Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, et al. Transcatheter gurgitation and preserved left ventricular ejection fraction. Am J Cardiol 2016;117:
aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic 258–63. https://doi.org/10.1016/j.amjcard.2015.10.040
valve stenosis. JACC Cardiovasc Interv 2020;13:1019–27. https://doi.org/10.1016/j.jcin. 521. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al.
2020.02.008 Prospective comparison of valve regurgitation quantitation by cardiac magnetic reson-
501. Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, et al. Temporal ance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging 2013;6:
trends and outcomes of transcatheter versus surgical aortic valve replacement for bi- 48–57. https://doi.org/10.1161/CIRCIMAGING.112.975623
cuspid aortic valve stenosis. JACC Cardiovasc Interv 2019;12:1811–22. https://doi.org/ 522. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implica-
10.1016/j.jcin.2019.06.037 tions of magnetic resonance-derived quantification in asymptomatic patients with or-
502. Tchétché D, Ziviello F, De Biase C, De Backer O, Hovasse T, Leroux L, et al. ganic mitral regurgitation: comparison with Doppler echocardiography-derived
Transcatheter aortic valve implantation with the Evolut platform for bicuspid aortic integrative approach. Circulation 2018;137:1349–60. https://doi.org/10.1161/
valve stenosis: the international, multicentre, prospective BIVOLUTX registry. CIRCULATIONAHA.117.029332
EuroIntervention 2023;19:502–11. https://doi.org/10.4244/eij-d-23-00021 523. Naoum C, Blanke P, Cavalcante JL, Leipsic J. Cardiac computed tomography and mag-
503. Yang L-T, Boler A, Medina-Inojosa Jose R, Scott Christopher G, Maurer Matthew J, netic resonance imaging in the evaluation of mitral and tricuspid valve disease. Circ
Eleid Mackram F, et al. Aortic stenosis progression, cardiac damage, and survival. Cardiovasc Imaging 2017;10:e005331. https://doi.org/10.1161/CIRCIMAGING.116.
JACC Cardiovasc Imaging 2021;14:1113–26. https://doi.org/10.1016/j.jcmg.2021.01.017 005331
504. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor long- 524. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in
term survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019;74: patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol
1851–63. https://doi.org/10.1016/j.jacc.2019.08.004 2018;72:823–34. https://doi.org/10.1016/j.jacc.2018.06.048
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 91 ---
ESC Guidelines 4725
525. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, et al. Assessment of in patients with degenerative mitral regurgitation. Eur J Heart Fail 2024;26:2563–9.
mitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev https://doi.org/10.1002/ejhf.3393
Cardiol 2020;17:298–312. https://doi.org/10.1038/s41569-019-0305-z 547. Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le Tourneau T,
526. Feuchtner GM, Alkadhi H, Karlo C, Sarwar A, Meier A, Dichtl W, et al. Cardiac CT et al. Prognostic implications of left atrial enlargement in degenerative mitral regurgi-
angiography for the diagnosis of mitral valve prolapse: comparison with echocardiog- tation. J Am Coll Cardiol 2019;74:858–70. https://doi.org/10.1016/j.jacc.2019.06.032
raphy. Radiology 2010;254:374–83. https://doi.org/10.1148/radiol.2541090393 548. Abadie BQ, Cremer PC, Vakamudi S, Gillinov AM, Svensson LG, Cho L. Sex-specific
527. Gollmann-Tepeköylü C, Nägele F, Höfer D, Holfeld J, Hirsch J, Oezpeker CU, et al. A prognosis of left ventricular size and function following repair of degenerative mitral
qualitative improvement program for minimally invasive mitral surgery: technical ad- regurgitation. J Am Coll Cardiol 2024;83:303–12. https://doi.org/10.1016/j.jacc.2023.
vancements ameliorate outcome and operative times. Interdiscip Cardiovasc Thorac 10.033
Surg 2023;36:ivad030. https://doi.org/10.1093/icvts/ivad030 549. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, et al. The mitral
528. Tarzia P, Ciampi P, Lanza O, Canali E, Canestrelli S, Calò L. Multi-modality imaging for annulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–9. https://
pre-procedural planning of transcatheter mitral valve interventions. Eur Heart J Suppl doi.org/10.1016/j.jacc.2018.07.070
2023;25:C205–11. https://doi.org/10.1093/eurheartjsupp/suad021 550. Essayagh B, Sabbag A, Antoine C, Benfari G, Batista R, Yang LT, et al. The mitral annular
529. Eleid MF, Foley TA, Said SM, Pislaru SV, Rihal CS. Severe mitral annular calcification: disjunction of mitral valve prolapse: presentation and outcome. JACC Cardiovasc
multimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc Imaging 2021;14:2073–87. https://doi.org/10.1016/j.jcmg.2021.04.029
Imaging 2016;9:1318–37. https://doi.org/10.1016/j.jcmg.2016.09.001 551. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J, et al. Presentation and
530. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K, et al. Genome-wide association outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637–49. https://
study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur doi.org/10.1016/j.jacc.2020.06.029
Heart J 2022;43:1668–80. https://doi.org/10.1093/eurheartj/ehac049 552. Weiner MM, Boateng P, Pandis D, Miller MA, Adams DH. Impact of mitral valve repair
531. Badhwar V, Chikwe J, Gillinov AM, Vemulapalli S, O’Gara PT, Mehaffey JH, et al. Risk of on the Pickelhaube sign. Eur Heart J 2019;40:2267. https://doi.org/10.1093/eurheartj/
surgical mitral valve repair for primary mitral regurgitation. J Am Coll Cardiol 2023;81: ehy458
636–48. https://doi.org/10.1016/j.jacc.2022.11.017 553. Pandis D, David N, Ei-Eshmawi A, Miller MA, Boateng P, Costa AC, et al. Noncomplex
532. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, et al. ventricular arrhythmia associated with greater freedom from recurrent ectopy at 1
Twenty-year outcome after mitral repair versus replacement for severe degenerative year after mitral repair surgery. JTCVS Open 2024;19:94–113. https://doi.org/10.
mitral regurgitation: analysis of a large, prospective, multicenter, international registry. 1016/j.xjon.2024.04.005
554. Bonaros N, Hoefer D, Oezpeker C, Gollmann-Tepekoylu C, Holfeld J, Dumfarth J,
Circulation 2017;135:410–22. https://doi.org/10.1161/CIRCULATIONAHA.116.
et al. Predictors of safety and success in minimally invasive surgery for degenerative mi-
023340
tral disease. Eur J Cardiothorac Surg 2022;61:637–44. https://doi.org/10.1093/ejcts/
533. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of
ezab438
mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 2019;74:
555. Berretta P, Kempfert J, Van Praet F, Salvador L, Lamelas J, Nguyen TC, et al.
1044–53. https://doi.org/10.1016/j.jacc.2019.06.052
Risk-related clinical outcomes after minimally invasive mitral valve surgery: insights
534. Deja MA, Malinowski M, Widenka K, Stozynski N, Bartus K, Kapelak B, et al.
from the Mini-Mitral International Registry. Eur J Cardiothorac Surg 2023;63:ezad090.
Comparison of repair vs replacement in calcific and rheumatic mitral disease. Ann
https://doi.org/10.1093/ejcts/ezad090
Thorac Surg 2023;116:954–61. https://doi.org/10.1016/j.athoracsur.2023.04.048
556. Pfannmueller B, Misfeld M, Verevkin A, Garbade J, Holzhey DM, Davierwala P, et al.
535. Brescia AA, Watt TMF, Murray SL, Rosenbloom LM, Kleeman KC, Allgeyer H, et al.
Loop neochord versus leaflet resection techniques for minimally invasive mitral valve
Rheumatic mitral valve repair or replacement in the valve-in-valve era. J Thorac
repair: long-term results. Eur J Cardiothorac Surg 2021;59:180–6. https://doi.org/10.
Cardiovasc Surg 2022;163:591–602.e1. https://doi.org/10.1016/j.jtcvs.2020.04.118
1093/ejcts/ezaa255
536. Chen SW, Chen CY, Chien-Chia Wu V, Chou AH, Cheng YT, Chang SH, et al. Mitral
557. Akowuah EF, Maier RH, Hancock HC, Kharatikoopaei E, Vale L, Fernandez-Garcia C,
valve repair versus replacement in patients with rheumatic heart disease. J Thorac
et al. Minithoracotomy vs conventional sternotomy for mitral valve repair: a rando-
Cardiovasc Surg 2022;164:57–67.e11. https://doi.org/10.1016/j.jtcvs.2020.07.117
mized clinical trial. JAMA 2023;329:1957–66. https://doi.org/10.1001/jama.2023.7800
537. Yun KL, Sintek CF, Miller DC, Pfeffer TA, Kochamba GS, Khonsari S, et al. Randomized
558. Olsthoorn JR, Heuts S, Houterman S, Maessen JG, Sardari Nia P. Effect of minimally
trial comparing partial versus complete chordal-sparing mitral valve replacement: ef-
invasive mitral valve surgery compared to sternotomy on short- and long-term out-
fects on left ventricular volume and function. J Thorac Cardiovasc Surg 2002;123:
comes: a retrospective multicentre interventional cohort study based on
707–14. https://doi.org/10.1067/mtc.2002.121048
Netherlands Heart Registration. Eur J Cardiothorac Surg 2022;61:1099–106. https://
538. Makkar RR, Chikwe J, Chakravarty T, Chen Q, O’Gara PT, Gillinov M, et al.
doi.org/10.1093/ejcts/ezab507
Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA 2023;
559. Lang M, Vitanova K, Voss B, Feirer N, Rheude T, Krane M, et al. Beyond the 10-year
329:1778–88. https://doi.org/10.1001/jama.2023.7089
horizon: mitral valve repair solely with chordal replacement and annuloplasty. Ann
539. von Bardeleben RS, Mahoney P, Morse MA, Price MJ, Denti P, Maisano F, et al. 1-Year
Thorac Surg 2023;115:96–103. https://doi.org/10.1016/j.athoracsur.2022.05.036
outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from
560. Newell P, Percy E, Hirji S, Harloff M, McGurk S, Malarczyk A, et al. Outcomes of mitral
the EXPAND G4 study. JACC Cardiovasc Interv 2023;16:2600–10. https://doi.org/10. valve repair among high- and low-volume surgeons within a high-volume institution.
1016/j.jcin.2023.09.029
Ann Thorac Surg 2023;115:412–19. https://doi.org/10.1016/j.athoracsur.2022.05.057
540. Zahr F, Smith RL, Gillam LD, Chadderdon S, Makkar R, von Bardeleben RS, et al.
561. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, et al. Outcome of watch-
One-year outcomes from the CLASP IID randomized trial for degenerative mitral re- ful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238–44.
gurgitation. JACC Cardiovasc Interv 2023;15:2803–16. https://doi.org/10.1016/j.jcin. https://doi.org/10.1161/CIRCULATIONAHA.105.599175
2023.10.002 562. Grigioni F, Benfari G, Vanoverschelde JL, Tribouilloy C, Avierinos JF, Bursi F, et al.
541. Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, et al. Mitral valve surgery after Long-term implications of atrial fibrillation in patients with degenerative mitral regur-
transcatheter edge-to-edge repair: mid-term outcomes from the CUTTING-EDGE gitation. J Am Coll Cardiol 2019;73:264–74. https://doi.org/10.1016/j.jacc.2018.10.067
international registry. JACC Cardiovasc Interv 2021;14:2010–21. https://doi.org/10. 563. Ratwatte S, Strange G, Playford D, Stewart S, Celermajer DS. Prevalence of pulmonary
1016/j.jcin.2021.07.029 hypertension in mitral regurgitation and its influence on outcomes. Open Heart 2023;
542. Wild MG, Kreidel F, Hell MM, Praz F, Mach M, Adam M, et al. Transapical mitral valve 10:e002268. https://doi.org/10.1136/openhrt-2023-002268
implantation for treatment of symptomatic mitral valve disease: a real-world multicen- 564. Essayagh B, Antoine C, Benfari G, Maalouf J, Michelena HI, Crestanello JA, et al.
tre experience. Eur J Heart Fail 2022;24:899–907. https://doi.org/10.1002/ejhf.2434 Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial deter-
543. Ludwig S, Perrin N, Coisne A, Ben Ali W, Weimann J, Duncan A, et al. Clinical out- minant of survival. Eur Heart J 2020;41:1918–29. https://doi.org/10.1093/eurheartj/
comes of transcatheter mitral valve replacement: two-year results of the ehaa192
CHOICE-MI Registry. EuroIntervention 2023;19:512–25. https://doi.org/10.4244/EIJ- 565. Essayagh B, Benfari G, Antoine C, Grigioni F, Le Tourneau T, Roussel JC, et al. The
D-22-01037 MIDA-Q mortality risk score: a quantitative prognostic tool for the mitral valve pro-
544. Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos J-F, et al. lapse spectrum. Circulation 2023;147:798–811. https://doi.org/10.1161/CIRCULA
Association between early surgical intervention vs watchful waiting and outcomes TIONAHA.122.062612
for mitral regurgitation due to flail mitral valve leaflets. JAMA 2013;310:609–16. 566. Benfari G, Sorajja P, Pedrazzini G, Taramasso M, Gavazzoni M, Biasco L, et al.
https://doi.org/10.1001/jama.2013.8643 Association of transcatheter edge-to-edge repair with improved survival in older pa-
545. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C, et al. tients with severe, symptomatic degenerative mitral regurgitation. Eur Heart J 2022;
Survival implication of left ventricular end-systolic diameter in mitral regurgitation 43:1626–35. https://doi.org/10.1093/eurheartj/ehab910
due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009; 567. Speziale G, Nasso G, Esposito G, Conte M, Greco E, Fattouch K, et al. Results of mitral
54:1961–68. https://doi.org/10.1016/j.jacc.2009.06.047 valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus
546. Tribouilloy C, Rusinaru D, Grigioni F, Avierinos JF, Vanoverschelde JL, Benfari G, et al. conventional median sternotomy: a randomized trial. J Thorac Cardiovasc Surg 2011;
Indexing left ventricular end-systolic dimension to body size: association with mortality 142:77–83. https://doi.org/10.1016/j.jtcvs.2010.08.033
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 92 ---
4726 E S C G u id e l in e s
568. Zilberszac R, Heinze G, Binder T, Laufer G, Gabriel H, Rosenhek R. Long-term out- 589. Masiero G, Montonati C, Rubbio AP, Adamo M, Grasso C, Denti P, et al. Impact of
come of active surveillance in severe but asymptomatic primary mitral regurgitation. transcatheter edge-to-edge mitral valve repair on atrial functional mitral regurgitation
JACC Cardiovasc Imaging 2018;11:1213–21. https://doi.org/10.1016/j.jcmg.2018.05.014 from the GIOTTO registry. Am J Cardiol 2024;211:219–27. https://doi.org/10.1016/j.
569. Sengupta A, Yazdchi F, Alexis SL, Percy E, Premkumar A, Hirji S, et al. Reoperative mi- amjcard.2023.11.007
tral surgery versus transcatheter mitral valve replacement: a systematic review. J Am 590. Yoon SH, Makar M, Kar S, Chakravarty T, Oakley L, Sekhon N, et al. Outcomes after
Heart Assoc 2021;10:e019854. https://doi.org/10.1161/JAHA.120.019854 transcatheter edge-to-edge mitral valve repair according to mitral regurgitation eti-
570. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, et al. ology and cardiac remodeling. JACC Cardiovasc Interv 2022;15:1711–22. https://doi.
Transcatheter mitral valve replacement after surgical repair or replacement: compre- org/10.1016/j.jcin.2022.07.004
hensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the 591. Chen QF, Zhou X, Katsouras CS, Ni C, Zhu H, Liu C, et al. Atrial and ventricular func-
VIVID registry. Circulation 2021;143:104–16. https://doi.org/10.1161/ tional mitral regurgitation: prevalence, characteristics, outcomes, and disease progres-
CIRCULATIONAHA.120.049088 sion. Eur Heart J Cardiovasc Imaging 2024;26:545–56. https://doi.org/10.1093/ehjci/
571. Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, Öztürk C, et al. Recurrent mitral re- jeae309
gurgitation after MitraClip: predictive factors, morphology, and clinical implication. Circ 592. von Stein P, von Stein J, Hohmann C, Wienemann H, Guthoff H, Körber MI, et al. Atrial
Cardiovasc Interv 2022;15:e010895. https://doi.org/10.1161/CIRCINTERVENTIONS. functional mitral regurgitation subtypes undergoing transcatheter edge-to-edge repair:
121.010895 suboptimal outcomes in atriogenic hamstringing. JACC Cardiovasc Imaging 2025;18:
572. Zaid S, Avvedimento M, Vitanova K, Akansel S, Bhadra OD, Ascione G, et al. Impact of 16–29. https://doi.org/10.1016/j.jcmg.2024.06.019
mitral regurgitation etiology on mitral surgery after transcatheter edge-to-edge repair: 593. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, et al. Patient pro-
from the CUTTING-EDGE registry. JACC Cardiovasc Interv 2023;16:1176–88. https:// filing in heart failure for tailoring medical therapy. A consensus document of the Heart
doi.org/10.1016/j.jcin.2023.02.029 Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:
573. Bartkowiak J, Reineke D, Tomii D, Brugger N, Pilgrim T, Terbeck S, et al. Electrosurgical 872–81. https://doi.org/10.1002/ejhf.2206
laceration and stabilization of MitraClip followed by valve implantation for iatrogenic 594. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety,
mitral stenosis. JACC Cardiovasc Interv 2022;15:110–12. https://doi.org/10.1016/j.jcin. tolerability and efficacy of up-titration of guideline-directed medical therapies for acute
2021.10.011 heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet
574. Lisko JC, Greenbaum AB, Guyton RA, Kamioka N, Grubb KJ, Gleason PT, et al. 2022;400:1938–52. https://doi.org/10.1016/s0140-6736(22)02076-1
Electrosurgical detachment of MitraClips from the anterior mitral leaflet prior to 595. Spinka G, Bartko PE, Heitzinger G, Prausmuller S, Winter MP, Arfsten H, et al.
transcatheter mitral valve implantation. JACC Cardiovasc Interv 2020;13:2361–70. Guideline directed medical therapy and reduction of secondary mitral regurgitation.
https://doi.org/10.1016/j.jcin.2020.06.047 Eur Heart J Cardiovasc Imaging 2022;23:755–64. https://doi.org/10.1093/ehjci/jeac068
575. Huang AL, Dal-Bianco JP, Levine RA, Hung JW. Secondary mitral regurgitation: cardiac 596. Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Clinical im-
remodeling, diagnosis, and management. Struct Heart 2022;7:100129. https://doi.org/ pact of changes in mitral regurgitation severity after medical therapy optimization in
10.1016/j.shj.2022.100129 heart failure. Clin Res Cardiol 2022;111:912–23. https://doi.org/10.1007/s00392-
576. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmüller S, et al. Burden, 022-01991-7
treatment use, and outcome of secondary mitral regurgitation across the spectrum of 597. Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, et al. Impact of car-
heart failure: observational cohort study. BMJ 2021;373:n1421. https://doi.org/10. diac resynchronization therapy on the severity of mitral regurgitation. Europace 2011;
1136/bmj.n1421 13:829–38. https://doi.org/10.1093/europace/eur047
577. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, et al. Atrial 598. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021
functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J
2019;73:2465–76. https://doi.org/10.1016/j.jacc.2019.02.061 2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364
578. Mori M, Zogg CK, Amabile A, Fereydooni S, Agarwal R, Weininger G, et al. Impact of 599. Michalski B, Stankovic I, Pagourelias E, Ciarka A, Aarones M, Winter S, et al.
secondary mitral regurgitation on survival in atrial and ventricular dysfunction. PLoS Relationship of mechanical dyssynchrony and LV remodeling with improvement of mi-
One 2022;17:e0277385. https://doi.org/10.1371/journal.pone.0277385 tral regurgitation after CRT. JACC Cardiovasc Imaging 2022;15:212–20. https://doi.org/
579. Moonen A, Ng MKC, Playford D, Strange G, Scalia GM, Celermajer DS. Atrial function- 10.1016/j.jcmg.2021.08.010
al mitral regurgitation: prevalence, characteristics and outcomes from the National 600. Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, Holman ER, Pierard LA, et al. Acute
Echo Database of Australia. Open Heart 2023;10:e002180. https://doi.org/10.1136/ effects of initiation and withdrawal of cardiac resynchronization therapy on papillary
openhrt-2022-002180 muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol 2007;50:2071–7.
580. Okamoto C, Okada A, Nishimura K, Moriuchi K, Amano M, Takahama H, et al. https://doi.org/10.1016/j.jacc.2007.08.019
Prognostic comparison of atrial and ventricular functional mitral regurgitation. Open 601. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al.
Heart 2021;8:e001574. https://doi.org/10.1136/openhrt-2021-001574 Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl
581. Farhan S, Silbiger JJ, Halperin JL, Zhang L, Dukkipati SR, Vogel B, et al. Pathophysiology, J Med 2018;379:2297–306. https://doi.org/10.1056/NEJMoa1805374
echocardiographic diagnosis, and treatment of atrial functional mitral regurgitation: 602. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, et al. Percutaneous
JACC state-of-the-art review. J Am Coll Cardiol 2022;80:2314–30. https://doi.org/10. repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years.
1016/j.jacc.2022.09.046 Eur J Heart Fail 2019;21:1619–27. https://doi.org/10.1002/EJHF.1616
582. Naser JA, Michelena HI, Lin G, Scott CG, Lee E, Kennedy AM, et al. Incidence, risk fac- 603. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional
tors, and outcomes of atrial functional mitral regurgitation in patients with atrial fibril- mitral regurgitation: a new conceptual framework that reconciles the results of the
lation or sinus rhythm. Eur Heart J Cardiovasc Imaging 2023;24:1450–7. https://doi.org/ MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353–62. https://doi.
10.1093/ehjci/jead199 org/10.1016/j.jcmg.2018.11.006
583. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter 604. Senni M, Adamo M, Metra M, Alfieri O, Vahanian A. Treatment of functional mitral re-
mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307–18. gurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR
https://doi.org/10.1056/NEJMoa1806640 and COAPT trials? Eur J Heart Fail 2019;21:852–61. https://doi.org/10.1002/EJHF.1491
584. Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-year 605. Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with dia-
follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med metrically opposed results. Eur Heart J Cardiovasc Imaging 2019;20:620–24. https://doi.
2023;388:2037–48. https://doi.org/10.1056/NEJMoa2300213 org/10.1093/ehjci/jez073
585. Cavalcante JL, Kusunose K, Obuchowski NA, Jellis C, Griffin BP, Flamm SD, et al. 606. Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Transcatheter
Prognostic impact of ischemic mitral regurgitation severity and myocardial infarct valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med
quantification by cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2020; 2024;391:1799–809. https://doi.org/10.1056/NEJMoa2314328
13:1489–501. https://doi.org/10.1016/j.jcmg.2019.11.008 607. Anker MS, Porthun J, Bonnet G, Schulze PC, Rassaf T, Landmesser U. Percutaneous
586. Kim K, Kitai T, Kaji S, Pak M, Toyota T, Sasaki Y, et al. Outcomes and predictors of transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure:
cardiac events in medically treated patients with atrial functional mitral regurgitation. a meta-analysis of 3 randomized controlled trials. J Am Coll Cardiol 2024;84:
Int J Cardiol 2020;316:195–202. https://doi.org/10.1016/j.ijcard.2020.06.042 2364–68. https://doi.org/10.1016/j.jacc.2024.08.026
587. Mesi O, Gad MM, Crane AD, Ramchand J, Puri R, Layoun H, et al. Severe atrial func- 608. Koell B, Orban M, Weimann J, Kassar M, Karam N, Neuss M, et al. Outcomes stratified
tional mitral regurgitation: clinical and echocardiographic characteristics, management by adapted inclusion criteria after mitral edge-to-edge repair. J Am Coll Cardiol 2021;78:
and outcomes. JACC Cardiovasc Imaging 2021;14:797–808. https://doi.org/10.1016/j. 2408–21. https://doi.org/10.1016/j.jacc.2021.10.011
jcmg.2021.02.008 609. Scotti A, Latib A, Rubbio AP, Testa L, Adamo M, Denti P, et al. Derivation and valid-
588. Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D, et al. Transcatheter mitral ation of a clinical risk score for COAPT-ineligible patients who underwent transcath-
valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc eter edge-to-edge repair. Am J Cardiol 2023;186:100–8. https://doi.org/10.1016/j.
Imaging 2022;15:1843–51. https://doi.org/10.1016/j.jcmg.2022.05.009 amjcard.2022.10.024
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 93 ---
ESC Guidelines 4727
610. Godino C, Munafò A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A, Arzamendi fibrillation-propensity score analysis. J Am Heart Assoc 2024;13:e035695. https://doi.
D, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: org/10.1161/jaha.124.035695
1-year outcomes from the International MitraBridge registry. J Heart Lung Transplant 631. Chen J, Wang Y, Lv M, Yang Z, Zhu S, Wei L, et al. Mitral valve repair and surgical ab-
2020;39:1353–62. https://doi.org/10.1016/j.healun.2020.09.005 lation for atrial functional mitral regurgitation. Ann Transl Med 2020;8:1420. https://doi.
611. Ailawadi G, Lim DS, Mack MJ, Trento A, Kar S, Grayburn PA, et al. One-year outcomes org/10.21037/atm-20-2958
after MitraClip for functional mitral regurgitation. Circulation 2019;139:37–47. https:// 632. Benito-González T, Carrasco-Chinchilla F, Estévez-Loureiro R, Pascual I, Arzamendi D,
doi.org/10.1161/CIRCULATIONAHA.117.031733 Garrote-Coloma C, et al. Clinical and echocardiographic outcomes of transcatheter
612. Goel K, Lindenfeld J, Makkar R, Naik H, Atmakuri S, Mahoney P, et al. Transcatheter mitral valve repair in atrial functional mitral regurgitation. Int J Cardiol 2021;345:
edge-to-edge repair in 5,000 patients with secondary mitral regurgitation: COAPT 29–35. https://doi.org/10.1016/j.ijcard.2021.09.056
post-approval study. J Am Coll Cardiol 2023;82:1281–97. https://doi.org/10.1016/j. 633. Popolo Rubbio A, Testa L, Grasso C, Sisinni A, Tusa M, Agricola E, et al. Transcatheter
jacc.2023.07.015 edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from
613. Adamo M, Tomasoni D, Stolz L, Stocker TJ, Pancaldi E, Koell B, et al. Impact of trans- the multi-center MITRA-TUNE registry. Int J Cardiol 2022;349:39–45. https://doi.
catheter edge-to-edge mitral valve repair on guideline-directed medical therapy upti- org/10.1016/j.ijcard.2021.11.027
tration. JACC Cardiovasc Interv 2023;16:896–905. https://doi.org/10.1016/j.jcin.2023.01. 634. Rudolph F, Geyer M, Baldus S, De Luca VM, Doenst T, Pfister R, et al. Transcatheter
362 repair versus surgery for atrial versus ventricular functional mitral regurgitation: a post
614. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, et al. The hoc analysis of the MATTERHORN trial. Circulation 2024;151:418–20. https://doi.org/
REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral an- 10.1161/circulationaha.124.072648
nuloplasty in functional mitral regurgitation. JACC Heart Fail 2019;7:945–55. https:// 635. Tanaka T, Sugiura A, Vogelhuber J, Öztürk C, Böhm L, Wilde N, et al. Outcomes of
doi.org/10.1016/j.jchf.2019.06.011 transcatheter edge-to-edge repair for atrial functional mitral regurgitation.
615. Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, et al. EuroIntervention 2024;20:e250–60. https://doi.org/10.4244/eij-d-23-00819
Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation 636. Gemelli M, Gallo M, Addonizio M, Van den Eynde J, Pradegan N, Danesi TH, et al.
and severe left ventricular enlargement. JACC Heart Fail 2021;9:453–62. https://doi.org/ Surgical ablation for atrial fibrillation during mitral valve surgery: a systematic review
10.1016/j.jchf.2021.03.002 and meta-analysis of randomized controlled trials. Am J Cardiol 2023;209:104–13.
616. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral https://doi.org/10.1016/j.amjcard.2023.09.088
valve annuloplasty on mortality risk in patients with mitral regurgitation and left ven- 637. Suwalski P, Kowalewski M, Jasiński M, Staromlynski J, Zembala M, Widenka K, et al.
tricular systolic dysfunction. J Am Coll Cardiol 2005;45:381–7. https://doi.org/10.1016/j. Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis
jacc.2004.09.073
from the Polish National Registry of Cardiac Surgery Procedures (KROK). J
617. Baldus S, Doenst T, Pfister R, Gummert J, Kessler M, Boekstegers P, et al.
Thorac Cardiovasc Surg 2019;157:1007–18.e1004. https://doi.org/10.1016/j.jtcvs.
Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation.
2018.07.099
N Engl J Med 2024;391:1787–98. https://doi.org/10.1056/NEJMoa2408739
638. Hamada S, Ueyama H, Aikawa T, Kampaktsis PN, Misumida N, Takagi H, et al.
618. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al.
Outcomes of transcatheter edge-to-edge repair for atrial functional mitral regurgita-
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N
tion: a meta-analysis of observational studies. Catheter Cardiovasc Interv 2023;102:
Engl J Med 2014;370:23–32. https://doi.org/10.1056/NEJMoa1312808
751–60. https://doi.org/10.1002/ccd.30806
619. von Stumm M, Dudde F, Holst T, Sequeira-Gross T, Pausch J, Muller L, et al. Predicting
639. Sodhi N, Asch FM, Ruf T, Petrescu A, von Bardeleben S, Lim DS, et al. Clinical out-
clinical outcome by indexed mitral valve tenting in functional mitral valve regurgitation.
comes with transcatheter edge-to-edge repair in atrial functional MR from the
Open Heart 2021;8:e001483. https://doi.org/10.1136/openhrt-2020-001483
EXPAND study. JACC Cardiovasc Interv 2022;15:1723–30. https://doi.org/10.1016/j.
620. Girdauskas E, Pausch J, Reichenspurner H, Kempfert J, Kuntze T, Owais T, et al.
jcin.2022.07.023
Subannular repair for functional mitral regurgitation with reduced systolic ventricle
640. Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regur-
function: rationale and design of REFORM-MR registry. J Cardiothorac Surg 2022;17:
gitation repair on survival in the surgical treatment for ischemic heart failure trial.
343. https://doi.org/10.1186/s13019-022-02045-9
Circulation 2012;125:2639–48. https://doi.org/10.1161/CIRCULATIONAHA.111.
621. Pausch J, Sequeira Gross T, Müller L, von Stumm M, Kloth B, Reichenspurner H, et al.
072256
Subannular repair for functional mitral regurgitation type IIIb in patients with ischaemic
641. Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. Coronary ar-
versus dilated cardiomyopathy. Eur J Cardiothorac Surg 2021;60:122–30. https://doi.org/
tery bypass surgery with or without mitral valve annuloplasty in moderate functional
10.1093/ejcts/ezab048
ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral
622. Kopjar T, Gasparovic H, Mestres CA, Milicic D, Biocina B. Meta-analysis of concomi-
Evaluation (RIME) trial. Circulation 2012;126:2502–10. https://doi.org/10.1161/
tant mitral valve repair and coronary artery bypass surgery versus isolated coronary
circulationaha.112.143818
artery bypass surgery in patients with moderate ischaemic mitral regurgitation. Eur J
642. Virk SA, Tian DH, Sriravindrarajah A, Dunn D, Wolfenden HD, Suri RM, et al.
Cardiothorac Surg 2016;50:212–22. https://doi.org/10.1093/ejcts/ezw022
Mitral valve surgery and coronary artery bypass grafting for moderate-to-severe
623. Altarabsheh SE, Deo SV, Dunlay SM, Erwin PJ, Obeidat YM, Navale S, et al.
ischemic mitral regurgitation: meta-analysis of clinical and echocardiographic out- Meta-analysis of usefulness of concomitant mitral valve repair or replacement for
moderate ischemic mitral regurgitation with coronary artery bypass grafting. Am J comes. J Thorac Cardiovasc Surg 2017;154:127–36. https://doi.org/10.1016/j.jtcvs.
Cardiol 2017;119:734–41. https://doi.org/10.1016/j.amjcard.2016.11.024 2017.03.039
624. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. 643. Adamo M, Fiorelli F, Melica B, D’Ortona R, Lupi L, Giannini C, et al. COAPT-like profile
Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. predicts long-term outcomes in patients with secondary mitral regurgitation undergo-
N Engl J Med 2016;374:1932–41. https://doi.org/10.1056/NEJMoa1602003 ing MitraClip implantation. JACC Cardiovasc Interv 2021;14:15–25. https://doi.org/10.
625. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, 1016/J.JCIN.2020.09.050
et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis 644. Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M,
of five randomised controlled trials. Lancet 2022;400:757–67. https://doi.org/10. et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol 2021;18:853–64.
1016/S0140-6736(22)01429-5 https://doi.org/10.1038/s41569-021-00570-z
626. Soulat-Dufour L, Lang S, Addetia K, Ederhy S, Adavane-Scheuble S, Chauvet-Droit M, 645. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, et al. The
et al. Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regur- VALVAFRIC study: a registry of rheumatic heart disease in Western and Central
gitation in patients with atrial fibrillation. J Am Coll Cardiol 2022;79:951–61. https://doi. Africa. Arch Cardiovasc Dis 2016;109:321–9. https://doi.org/10.1016/j.acvd.2015.
org/10.1016/j.jacc.2021.12.029 12.004
627. Kagiyama N, Kaneko T, Amano M, Sato Y, Ohno Y, Obokata M, et al. Clinical outcomes 646. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European
of mitral valve surgery in atrial functional mitral regurgitation in the REVEAL-AFMR Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43:
registry. JAMA Netw Open 2024;7:e2428032. https://doi.org/10.1001/ 716–99. https://doi.org/10.1093/eurheartj/ehab892
jamanetworkopen.2024.28032 647. Churchill TW, Yucel E, Deferm S, Levine RA, Hung J, Bertrand PB. Mitral valve dysfunc-
628. Wagner CM, Brescia AA, Watt TMF, Bergquist C, Rosenbloom LM, Ceniza NN, et al. tion in patients with annular calcification: JACC review topic of the week. J Am Coll
Surgical strategy and outcomes for atrial functional mitral regurgitation: all functional Cardiol 2022;80:739–51. https://doi.org/10.1016/j.jacc.2022.05.032
mitral regurgitation is not the same! J Thorac Cardiovasc Surg 2024;167:647–55. https:// 648. Andell P, Li X, Martinsson A, Andersson C, Stagmo M, Zoller B, et al. Epidemiology of
doi.org/10.1016/j.jtcvs.2022.02.056 valvular heart disease in a Swedish nationwide hospital-based register study. Heart
629. Balogh Z, Mizukami T, Bartunek J, Collet C, Beles M, Albano M, et al. Mitral valve repair 2017;103:1696–703. https://doi.org/10.1136/heartjnl-2016-310894
of atrial functional mitral regurgitation in heart failure with preserved ejection fraction. 649. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al.
J Clin Med 2020;9:3432. https://doi.org/10.3390/jcm9113432 Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clin-
630. Ye Q, Li Y, Zhang W, Zhao Y, Zhao C, Li Z, et al. Catheter ablation or surgical therapy ical practice. J Am Soc Echocardiogr 2009;22:1–23; quiz 101–102. https://doi.org/10.
in severe atrial functional mitral regurgitation caused by long-standing persistent atrial 1016/j.echo.2008.11.029
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 94 ---
4728 E S C G u id e l in e s
650. Otto CM, Davis KB, Reid CL, Slater JN, Kronzon I, Kisslo KB, et al. Relation between outcomes. J Am Heart Assoc 2019;8:e010736. https://doi.org/10.1161/JAHA.118.
pulmonary artery pressure and mitral stenosis severity in patients undergoing balloon 010736
mitral commissurotomy. Am J Cardiol 1993;71:874–8. https://doi.org/10.1016/0002- 670. Okura H, Nakada Y, Nogi M, Ishihara S, Okamura A, Okayama S, et al. Prevalence of
9149(93)90844-3 mitral annular calcification and its association with mitral valvular disease.
651. Bouleti C, Iung B, Laouenan C, Himbert D, Brochet E, Messika-Zeitoun D, et al. Late Echocardiography 2021;38:1907–12. https://doi.org/10.1111/echo.15236
results of percutaneous mitral commissurotomy up to 20 years: development and val- 671. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history
idation of a risk score predicting late functional results from a series of 912 patients. of severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:3048–57. https://doi.org/10.
Circulation 2012;125:2119–27. https://doi.org/10.1161/CIRCULATIONAHA.111. 1016/j.jacc.2020.04.049
055905 672. Chehab O, Roberts-Thomson R, Bivona A, Gill H, Patterson T, Pursnani A, et al.
652. Nunes MC, Tan TC, Elmariah S, do Lago R, Margey R, Cruz-Gonzalez I, et al. The echo Management of patients with severe mitral annular calcification: JACC state-of-the-art
score revisited: impact of incorporating commissural morphology and leaflet displace- review. J Am Coll Cardiol 2022;80:722–38. https://doi.org/10.1016/j.jacc.2022.06.009
ment to the prediction of outcome for patients undergoing percutaneous mitral val- 673. Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, et al. Clinical impact
vuloplasty. Circulation 2014;129:886–95. https://doi.org/10.1161/CIRCULATION of mitral calcium volume in patients undergoing transcatheter aortic valve implant-
AHA.113.001252 ation. J Cardiovasc Comput Tomogr 2021;15:356–65. https://doi.org/10.1016/j.jcct.
653. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon 2020.10.003
dilatation of the mitral valve: an analysis of echocardiographic variables related to out- 674. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, et al.
come and the mechanism of dilatation. Br Heart J 1988;60:299–308. https://doi.org/10. Prognostic importance of the transmitral pressure gradient in mitral annular calcifica-
1136/hrt.60.4.299 tion with associated mitral valve dysfunction. Eur Heart J 2020;41:4321–8. https://doi.
654. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clin- org/10.1093/eurheartj/ehaa819
ical use of stress echocardiography in non-ischaemic heart disease: recommendations 675. Urena M, Himbert D, Brochet E, Carrasco JL, Iung B, Nataf P, et al. Transseptal trans-
from the European Association of Cardiovascular Imaging and the American Society of catheter mitral valve replacement using balloon-expandable transcatheter heart valves:
Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191–229. https://doi.org/ a step-by-step approach. JACC Cardiovasc Interv 2017;10:1905–19. https://doi.org/10.
10.1093/ehjci/jew190 1016/j.jcin.2017.06.069
655. Brochet E, Détaint D, Fondard O, Tazi-Mezalek A, Messika-Zeitoun D, Iung B, et al. 676. Guerrero ME, Grayburn P, Smith RLI, Sorajja P, Wang DD, Ahmad Y, et al. Diagnosis,
Early hemodynamic changes versus peak values: what is more useful to predict occur- classification, and management strategies for mitral annular calcification. JACC
rence of dyspnea during stress echocardiography in patients with asymptomatic mitral
Cardiovasc Interv 2023;16:2195–210. https://doi.org/10.1016/j.jcin.2023.06.044
stenosis? J Am Soc Echocardiogr 2011;24:392–8. https://doi.org/10.1016/j.echo.2011.01. 677. Uchimuro T, Fukui T, Shimizu A, Takanashi S. Mitral valve surgery in patients with se-
006
vere mitral annular calcification. Ann Thorac Surg 2016;101:889–95. https://doi.org/10.
656. Al Rawahi MN, Al-Maqbali JS, Al Noumani J, Al Alawi AM, Essebag V. Novel oral antic-
1016/j.athoracsur.2015.08.071
oagulants in patients with atrial fibrillation and moderate to severe mitral stenosis: a
678. Fukui M, Cavalcante JL, Ahmed A, Bae R, Bapat VN, Gössl M, et al. Clinical outcomes of
systematic review. Cureus 2023;15:e33222. https://doi.org/10.7759/cureus.33222
mitral valve disease with mitral annular calcification. Am J Cardiol 2022;174:107–13.
657. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, et al. Outcomes of direct oral an-
https://doi.org/10.1016/j.amjcard.2022.03.041
ticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:1123–31. https://
679. Kato N, Pellikka PA, Scott CG, Lee AT, Jain V, Eleid MF, et al. Impact of mitral inter-
doi.org/10.1016/j.jacc.2018.12.047
vention on outcomes of patients with mitral valve dysfunction and annulus calcification.
658. Vilvanathan VK, Srinivas Prabhavathi Bhat BC, Nanjappa MC, Pandian B, Bagi V, Kasturi
Catheter Cardiovasc Interv 2022;99:1807–16. https://doi.org/10.1002/ccd.30093
S, et al. A randomized placebo-controlled trial with amiodarone for persistent atrial
680. Brener MI, Hamandi M, Hong E, Pizano A, Harloff MT, Garner EF, et al. Early outcomes
fibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty.
following transatrial transcatheter mitral valve replacement in patients with severe mi-
Indian Heart J 2016;68:671–7. https://doi.org/10.1016/j.ihj.2016.02.013
tral annular calcification. J Thorac Cardiovasc Surg 2024;167:1263–1275.e3. https://doi.
659. Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, et al.
org/10.1016/j.jtcvs.2022.07.038
Evaluation of early direct current cardioversion for maintenance of sinus rhythm in
681. Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-Year pro-
rheumatic atrial fibrillation following successful balloon mitral valvotomy. Indian
spective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-MAC outcomes:
Heart J 2016;68:486–92. https://doi.org/10.1016/j.ihj.2015.11.013
MITRAL trial final results. JACC Cardiovasc Interv 2023;16:2211–27. https://doi.org/10.
660. Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D, et al. Usefulness
1016/j.jcin.2023.06.041
of left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis.
682. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of
Am J Cardiol 2010;106:1152–6. https://doi.org/10.1016/j.amjcard.2010.06.024
tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc
661. Badheka AO, Shah N, Ghatak A, Patel NJ, Chothani A, Mehta K, et al. Balloon mitral
Imaging 2019;12:433–42. https://doi.org/10.1016/j.jcmg.2018.06.014
valvuloplasty in the United States: a 13-year perspective. Am J Med 2014;127:
683. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al.
1126.e1121–1126.e1112. https://doi.org/10.1016/j.amjmed.2014.05.015
Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc
662. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, et al. Twenty year
Imaging 2020;21:157–65. https://doi.org/10.1093/ehjci/jez216 follow-up after successful percutaneous balloon mitral valvuloplasty in a large contem-
684. Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, et al. Clinical pres-
porary series of patients with mitral stenosis. Int J Cardiol 2014;177:881–5. https://doi.
entation and outcome of tricuspid regurgitation in patients with systolic dysfunction.
org/10.1016/j.ijcard.2014.10.040
663. Bouleti C, Iung B, Himbert D, Messika-Zeitoun D, Brochet E, Garbarz E, et al. Eur Heart J 2018;39:3584–92. https://doi.org/10.1093/eurheartj/ehy434
Relationship between valve calcification and long-term results of percutaneous mitral 685. Kadri AN, Menon V, Sammour YM, Gajulapalli RD, Meenakshisundaram C, Nusairat L,
commissurotomy for rheumatic mitral stenosis. Circ Cardiovasc Interv 2014;7:381–9. et al. Outcomes of patients with severe tricuspid regurgitation and congestive heart
https://doi.org/10.1161/CIRCINTERVENTIONS.113.000858 failure. Heart 2019;105:1813–7. https://doi.org/10.1136/heartjnl-2019-315004
664. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Detaint D, et al. 686. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of
Reinterventions after percutaneous mitral commissurotomy during long-term follow- referral of patients with severe isolated tricuspid valve regurgitation to surgeons
up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart (from a French nationwide database). Am J Cardiol 2018;122:323–6. https://doi.org/
J 2013;34:1923–30. https://doi.org/10.1093/eurheartj/eht097 10.1016/j.amjcard.2018.04.003
665. Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, et al. Temporal trends 687. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, et al.
on percutaneous mitral commissurotomy: 30 years of experience. J Am Heart Assoc Significant lead-induced tricuspid regurgitation is associated with poor prognosis at
2019;8:e012031. https://doi.org/10.1161/JAHA.119.012031 long-term follow-up. Heart 2014;100:960–8. https://doi.org/10.1136/heartjnl-2013-
666. Ambari AM, Setianto B, Santoso A, Dwiputra B, Radi B, Alkatiri AA, et al. Survival ana- 304673
lysis of patients with rheumatic MS after PBMV compared with MVS in a 688. Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M, et al. Tricuspid valve dis-
low-to-middle-income country. Neth Heart J 2019;27:559–64. https://doi.org/10. ease and cardiac implantable electronic devices. Eur Heart J 2024;45:346–65. https://
1007/s12471-019-01315-x doi.org/10.1093/eurheartj/ehad783
667. Song H, Kang DH, Kim JH, Park KM, Song JM, Choi KJ, et al. Percutaneous mitral val- 689. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treat-
vuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgita- ment for tricuspid valve disease. EuroIntervention 2021;17:791–808. https://doi.org/
tion. Circulation 2007;116:I246–50. https://doi.org/10.1161/CIRCULATIONAHA.107. 10.4244/EIJ-D-21-00695
678151 690. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, et al. Factors associated with
668. Soesanto AM, Roeswita D, Atmosudigdo IS, Adiarto S, Sahara E. Clinical and hemo- development of late significant tricuspid regurgitation after successful left-sided valve
dynamic factors associated with low gradient severe rheumatic mitral stenosis. Int J surgery. Heart 2009;95:931–6. https://doi.org/10.1136/hrt.2008.152793
Angiol 2022;32:43–7. https://doi.org/10.1055/s-0042-1751231 691. Galloo X, Dietz MF, Fortuni F, Prihadi EA, Cosyns B, Delgado V, et al. Prognostic im-
669. El Sabbagh A, Reddy YNV, Barros-Gomes S, Borlaug BA, Miranda WR, Pislaru SV, et al. plications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J
Low-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and Cardiovasc Imaging 2023;24:733–41. https://doi.org/10.1093/ehjci/jead016
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 95 ---
ESC Guidelines 4729
692. Schlotter F, Dietz MF, Stolz L, Kresoja KP, Besler C, Sannino A, et al. Atrial functional analysis and risk model. Ann Thorac Surg 2024;118:873–81. https://doi.org/10.1016/j.
tricuspid regurgitation: novel definition and impact on prognosis. Circ Cardiovasc Interv athoracsur.2024.04.014
2022;15:e011958. https://doi.org/10.1161/CIRCINTERVENTIONS.122.011958 711. Anguita-Gámez M, Giraldo MA, Nombela-Franco L, Eixeres Esteve A, Cuerpo G,
693. Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD, et al. Lopez-Menendez J, et al. Validation of the TRI-SCORE in patients undergoing surgery
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided for isolated tricuspid regurgitation. Heart 2023;109:1401–6. https://doi.org/10.1136/
heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart heartjnl-2022-322067
Failure Association (HFA) and the European Association of Percutaneous 712. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin
Cardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail 2024;26:18–33. effects on pulmonary artery pressure in patients with heart failure: results from the
https://doi.org/10.1002/ejhf.3106 EMBRACE-HF trial. Circulation 2021;143:1673–86. https://doi.org/10.1161/
694. Fortuni F, Dietz MF, Prihadi EA, van der Bijl P, De Ferrari GM, Knuuti J, et al. Prognostic circulationaha.120.052503
implications of a novel algorithm to grade secondary tricuspid regurgitation. JACC 713. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter re-
Cardiovasc Imaging 2021;14:1085–95. https://doi.org/10.1016/j.jcmg.2020.12.011 pair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. https://
695. Peri Y, Sadeh B, Sherez C, Hochstadt A, Biner S, Aviram G, et al. Quantitative assess- doi.org/10.1056/NEJMoa2300525
ment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe 714. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, et al. Isolated tricuspid
and torrential tricuspid regurgitation grade. Eur Heart J Cardiovasc Imaging 2020;21: valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J
768–76. https://doi.org/10.1093/ehjci/jez267 2020;41:4304–17. https://doi.org/10.1093/eurheartj/ehaa643
696. Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, et al. 715. Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, et al. Outcomes of iso-
TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. lated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 pa-
Eur Heart J 2024;45:586–97. https://doi.org/10.1093/eurheartj/ehad585 tients from 35 studies. EuroIntervention 2022;18:840–51. https://doi.org/10.4244/EIJ-D-
697. Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, et al. Tricuspid 22-00442
Valve Academic Research Consortium definitions for tricuspid regurgitation and trial 716. Chen Q, Bowdish ME, Malas J, Roach A, Gill G, Rowe G, et al. Isolated tricuspid opera-
endpoints. Eur Heart J 2023;44:4508–32. https://doi.org/10.1093/eurheartj/ehad653 tions: the Society of Thoracic Surgeons adult cardiac surgery database analysis. Ann
698. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European Thorac Surg 2023;115:1162–70. https://doi.org/10.1016/j.athoracsur.2022.12.041
Association of Cardiovascular Imaging expert consensus paper: a comprehensive re- 717. Hahn RT, Wilkoff BL, Kodali S, Birgersdotter-Green UM, Ailawadi G, Addetia K, et al.
view of cardiovascular magnetic resonance normal values of cardiac chamber size Managing implanted cardiac electronic devices in patients with severe tricuspid regur-
and aortic root in adults and recommendations for grading severity. Eur Heart J gitation: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:2002–14. https://doi.
Cardiovasc Imaging 2019;20:1321–31. https://doi.org/10.1093/ehjci/jez232 org/10.1016/j.jacc.2024.02.045
699. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, 718. Taramasso M, Gavazzoni M, Pozzoli A, Dreyfus GD, Bolling SF, George I, et al.
Jerosch-Herold M, et al. Reference ranges (“normal values”) for cardiovascular mag- Tricuspid regurgitation: predicting the need for intervention, procedural success,
netic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson and recurrence of disease. JACC Cardiovasc Imaging 2019;12:605–21. https://doi.org/
2020;22:87. https://doi.org/10.1186/s12968-020-00683-3 10.1016/j.jcmg.2018.11.034
700. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 719. Bannehr M, Edlinger CR, Kahn U, Liebchen J, Okamoto M, Hähnel V, et al. Natural
Recommendations for cardiac chamber quantification by echocardiography in adults: course of tricuspid regurgitation and prognostic implications. Open Heart 2021;8:
an update from the American Society of Echocardiography and the European e001529. https://doi.org/10.1136/openhrt-2020-001529
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16: 720. Park SJ, Oh JK, Kim SO, Lee SA, Kim HJ, Lee S, et al. Determinants of clinical outcomes
233–70. https://doi.org/10.1093/ehjci/jev014 of surgery for isolated severe tricuspid regurgitation. Heart 2021;107:403–10. https://
701. Addetia K, Miyoshi T, Citro R, Daimon M, Gutierrez Fajardo P, Kasliwal RR, et al. doi.org/10.1136/heartjnl-2020-317715
Two-dimensional echocardiographic right ventricular size and systolic function mea- 721. McCarthy PM, Bhudia SK, Rajeswaran J, Hoercher KJ, Lytle BW, Cosgrove DM, et al.
surements stratified by sex, age, and ethnicity: results of the World Alliance of Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg
Societies of Echocardiography study. J Am Soc Echocardiogr 2021;34:1148–1157.e1. 2004;127:674–85. https://doi.org/10.1016/j.jtcvs.2003.11.019
https://doi.org/10.1016/j.echo.2021.06.013 722. Kwak JJ, Kim YJ, Kim MK, Kim HK, Park JS, Kim KH, et al. Development of tricuspid
702. Addetia K, Miyoshi T, Amuthan V, Citro R, Daimon M, Gutierrez Fajardo P, et al. regurgitation late after left-sided valve surgery: a single-center experience with long-
Normal values of three-dimensional right ventricular size and function measurements: term echocardiographic examinations. Am Heart J 2008;155:732–7. https://doi.org/
results of the World Alliance Societies of Echocardiography study. J Am Soc 10.1016/j.ahj.2007.11.010
Echocardiogr 2023;36:858–866.e1. https://doi.org/10.1016/j.echo.2023.04.011 723. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dila-
703. Dietz MF, Prihadi EA, van der Bijl P, Goedemans L, Mertens BJA, Gursoy E, et al. tation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;79:
Prognostic implications of right ventricular remodeling and function in patients with 127–32. https://doi.org/10.1016/j.athoracsur.2004.06.057
significant secondary tricuspid regurgitation. Circulation 2019;140:836–45. https:// 724. Dreyfus GD, Essayagh B, Benfari G, Dulguerov F, Haley SR, Dommerc C, et al.
doi.org/10.1161/CIRCULATIONAHA.119.039630 Outcome of consistent guideline-based tricuspid management in patients undergoing
704. Eriksen-Volnes T, Grue JF, Hellum Olaisen S, Letnes JM, Nes B, Løvstakken L, et al. degenerative mitral regurgitation correction. JTCVS Open 2021;7:125–38. https://doi.
Normalized echocardiographic values from guideline-directed dedicated views for car- org/10.1016/j.xjon.2021.07.010
diac dimensions and left ventricular function. JACC Cardiovasc Imaging 2023;16: 725. Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, et al.
1501–15. https://doi.org/10.1016/j.jcmg.2022.12.020 Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N
705. Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, et al. Clinical characteristics, Engl J Med 2022;386:327–39. https://doi.org/10.1056/NEJMoa2115961
diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regur- 726. Pettinari M, De Kerchove L, Lazam S, Pasquet A, Gerber B, Vanoverschelde JL, et al.
gitation and implications for transcatheter tricuspid valve repair. Eur Heart J 2020;41: Mid-term results of a randomized trial of tricuspid annuloplasty for less-than-severe
2785–95. https://doi.org/10.1093/eurheartj/ehaa138 functional tricuspid regurgitation at the time of mitral valve surgery. Eur J
706. Stocker TJ, Hertell H, Orban M, Braun D, Rommel KP, Ruf T, et al. Cardiopulmonary Cardiothorac Surg 2019;55:851–8. https://doi.org/10.1093/ejcts/ezy378
hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in 727. Ailawadi G, Voisine P, Raymond S, Gelijns AC, Moskowitz AJ, Falk V, et al. Pacemaker
chronic heart failure. JACC Cardiovasc Interv 2021;14:29–38. https://doi.org/10.1016/j. implantation associated with tricuspid repair in the setting of mitral valve surgery: in-
jcin.2020.09.033 sights from a Cardiothoracic Surgical Trials Network randomized trial. J Thorac
707. Brener MI, Lurz P, Hausleiter J, Rodés-Cabau J, Fam N, Kodali SK, et al. Right Cardiovasc Surg 2022;167:2104–16.e5. https://doi.org/10.1016/j.jtcvs.2022.11.031
ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing 728. Ragnarsson S, Taha A, Nielsen SJ, Amabile A, Geirsson A, Krane M, et al. Pacemaker
transcatheter tricuspid valve repair. J Am Coll Cardiol 2022;79:448–61. https://doi. implantation following tricuspid valve annuloplasty. JTCVS Open 2023;16:276–89.
org/10.1016/j.jacc.2021.11.031 https://doi.org/10.1016/j.xjon.2023.08.017
708. Stolz L, Weckbach LT, Karam N, Kalbacher D, Praz F, Lurz P, et al. Invasive right ven- 729. Iribarne A, Alabbadi SH, Moskowitz AJ, Ailawadi G, Badhwar V, Gillinov M, et al.
tricular to pulmonary artery coupling in patients undergoing transcatheter Permanent pacemaker implantation and long-term outcomes of patients undergoing
edge-to-edge tricuspid valve repair. JACC Cardiovasc Imaging 2023;16:564–6. https:// concomitant mitral and tricuspid valve surgery. J Am Coll Cardiol 2024;83:1656–68.
doi.org/10.1016/j.jcmg.2022.10.004 https://doi.org/10.1016/j.jacc.2024.02.042
709. Dreyfus J, Juarez-Casso F, Sala A, Carnero-Alcazar M, Eixerés-Esteve A, Bohbot Y, et al. 730. Kassab J, Harb SC, Desai MY, Gillinov AM, Layoun H, El Dahdah J, et al. Incidence, risk
Benefit of isolated surgical valve repair or replacement for functional tricuspid regur- factors, and outcomes associated with permanent pacemaker implantation following
gitation and long-term outcomes stratified by the TRI-SCORE. Eur Heart J 2024;45: tricuspid valve surgery. J Am Heart Assoc 2024;13:e032760. https://doi.org/10.1161/
4512–22. https://doi.org/10.1093/eurheartj/ehae578 jaha.123.032760
710. Thourani VH, Bonnell L, Wyler von Ballmoos MC, Mehaffey JH, Bowdish M, Kurlansky 731. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annulo-
P, et al. Outcomes of isolated tricuspid valve surgery: a Society of Thoracic Surgeons plasty on tricuspid regurgitation, right ventricular function, and pulmonary artery
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 96 ---
4730 E S C G u id e l in e s
hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 2015;65:1931–8. 754. McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al.
https://doi.org/10.1016/j.jacc.2015.01.059 Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional
732. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following surgical bioprosthetic valves: an international, multicenter registry study. Circulation
pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol 2017;69: 2016;133:1582–93. https://doi.org/10.1161/CIRCULATIONAHA.115.019353
2331–41. https://doi.org/10.1016/j.jacc.2017.02.055 755. Pereyra M, Farina JM, Chao CJ, Ayoub C, Arsanjani R. Percutaneous transcatheter pul-
733. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year out- monary and tricuspid valve replacements in a patient with carcinoid heart disease. Eur
comes for tricuspid repair with a transcatheter edge-to-edge valve repair from the Heart J Case Rep 2023;7:ytad511. https://doi.org/10.1093/ehjcr/ytad511
transatlantic TRILUMINATE trial. Circ Cardiovasc Interv 2023;16:e012888. https://doi. 756. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late out-
org/10.1161/CIRCINTERVENTIONS.122.012888 comes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;66:
734. Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Möllmann H, et al. Short-term 2189–96. https://doi.org/10.1016/j.jacc.2015.09.014
outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023;82: 757. Yunoki K, Naruko T, Itoh A, Ohashi J, Fujimoto K, Shirai N, et al. Percutaneous trans-
281–91. https://doi.org/10.1016/j.jacc.2023.05.008 catheter balloon valvuloplasty for bioprosthetic tricuspid valve stenosis. Circulation
735. Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-Year 2006;114:e558–9. https://doi.org/10.1161/CIRCULATIONAHA.106.618611
outcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol 2023;81:1766–76. 758. Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al.
https://doi.org/10.1016/j.jacc.2023.02.049 Characteristics, management, and outcomes of patients with multiple native valvular
736. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. (March 30, 2025) heart disease: a substudy of the EURObservational Research Programme Valvular
Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regur- Heart Disease II Survey. Eur Heart J 2022;43:2756–66. https://doi.org/10.1093/
gitation: the TRILUMINATE pivotal randomized trial. Circulation, https://doi.org/10. eurheartj/ehac209
1161/CIRCULATIONAHA.125.074536 759. Iung B, Baron G, Tornos P, Gohlke-Bärwolf C, Butchart EG, Vahanian A. Valvular heart
737. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter disease in the community: a European experience. Curr Probl Cardiol 2007;32:609–61.
edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized https://doi.org/10.1016/j.cpcardiol.2007.07.002
clinical trial. JAMA 2025;333:124–32. https://doi.org/10.1001/jama.2024.21189 760. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, et al.
738. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst
Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med 2015;107:djv008. https://doi.org/10.1093/jnci/djv008
2024;392:115–26. https://doi.org/10.1056/NEJMoa2401918 761. Unger P, Pibarot P, Tribouilloy C, Lancellotti P, Maisano F, Iung B, et al. Multiple and
739. Park SJ, Gentry JLI, Varma N, Wazni O, Tarakji KG, Mehta A, et al. Transvenous extrac- mixed valvular heart diseases. Circ Cardiovasc Imaging 2018;11:e007862. https://doi.
tion of pacemaker and defibrillator leads and the risk of tricuspid valve regurgitation. org/10.1161/CIRCIMAGING.118.007862
JACC Clin Electrophysiol 2018;4:1421–8. https://doi.org/10.1016/j.jacep.2018.07.011 762. Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T, et al. Valvular heart
740. Aboulhosn J, Cabalka AK, Levi DS, Himbert D, Testa L, Latib A, et al. Transcatheter disease: shifting the focus to the myocardium. Eur Heart J 2023;44:28–40. https://doi.
valve-in-ring implantation for the treatment of residual or recurrent tricuspid valve org/10.1093/eurheartj/ehac504
dysfunction after prior surgical repair. JACC Cardiovasc Interv 2017;10:53–63. https:// 763. de Marchi SF, Windecker S, Aeschbacher BC, Seiler C. Influence of left ventricular re-
doi.org/10.1016/j.jcin.2016.10.036 laxation on the pressure half time of aortic regurgitation. Heart 1999;82:607–13.
741. Chen S, Dershowitz L, George I. Transcatheter valve implantation for degenerated tri- https://doi.org/10.1136/hrt.82.5.607
cuspid bioprosthesis and failed tricuspid ring. Ann Cardiothorac Surg 2021;10:651–7. 764. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease: aortic
https://doi.org/10.21037/acs-2021-tviv-11 regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol
742. Rao VN, Giczewska A, Chiswell K, Felker GM, Wang A, Glower DD, et al. Long-term Clin 2020;38:33–46. https://doi.org/10.1016/j.ccl.2019.09.002
outcomes of phenoclusters in severe tricuspid regurgitation. Eur Heart J 2023;44: 765. Unger P, Clavel M-A. Mixed aortic valve disease: a diagnostic challenge, a prognostic
1910–23. https://doi.org/10.1093/eurheartj/ehad133 threat. Structural Heart 2020;4:468–74. https://doi.org/10.1080/24748706.2020.
743. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, et al. Tricuspid 1817643
annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgi- 766. Flachskampf FA, Weyman AE, Gillam L, Liu CM, Abascal VM, Thomas JD. Aortic regur-
tation in patients with tricuspid annular dilatation undergoing mitral valve repair. J gitation shortens Doppler pressure half-time in mitral stenosis: clinical evidence, in vi-
Thorac Cardiovasc Surg 2011;141:1431–9. https://doi.org/10.1016/j.jtcvs.2010.05.050 tro simulation and theoretic analysis. J Am Coll Cardiol 1990;16:396–404. https://doi.
744. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, et al. Outcomes org/10.1016/0735-1097(90)90592-d
of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. 767. Tribouilloy C, Shen WF, Rey JL, Adam MC, Lesbre JP. Mitral to aortic velocity-time in-
Ann Thorac Surg 2020;109:1227–32. https://doi.org/10.1016/j.athoracsur.2019.07.035 tegral ratio: a non-geometric pulsed-Doppler regurgitant index in isolated pure mitral
745. Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, et al. regurgitation. Eur Heart J 1994;15:1335–9. https://doi.org/10.1093/oxfordjournals.
Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann eurheartj.a060390
Thorac Surg 2019;108:11–5. https://doi.org/10.1016/j.athoracsur.2019.03.004 768. Benfari G, Clavel M-A, Nistri S, Maffeis C, Vassanelli C, Enriquez-Sarano M, et al.
746. Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M, et al. Outcome of Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow
patients undergoing isolated tricuspid repair or replacement surgery. Eur J preserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging 2018;19:
Cardiothorac Surg 2022;62:ezac230. https://doi.org/10.1093/ejcts/ezac230 569–73. https://doi.org/10.1093/ehjci/jex172
747. Abdelbar A, Kenawy A, Zacharias J. Minimally invasive tricuspid valve surgery. J Thorac 769. Mohan JC, Mukherjee S, Kumar A, Arora R, Patel AR, Pandian NG. Does chronic mitral
Dis 2021;13:1982–92. https://doi.org/10.21037/jtd-20-1331 regurgitation influence Doppler pressure half-time–derived calculation of the mitral
748. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. valve area in patients with mitral stenosis? Am Heart J 2004;148:703–9. https://doi.
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid org/10.1016/j.ahj.2003.12.043
regurgitation. J Am Coll Cardiol 2019;74:2998–3008. https://doi.org/10.1016/j.jacc.2019. 770. Hauge SW, Estensen ME, Persson R, Abebe S, Mekonnen D, Nega B, et al. The import-
09.028 ance of concomitant mitral regurgitation for estimates of mitral valve area by pressure
749. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral half time in patients with chronic rheumatic heart disease. Int J Cardiol 2024;398:
tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J 131600. https://doi.org/10.1016/j.ijcard.2023.131600
2023;44:4862–73. https://doi.org/10.1093/eurheartj/ehad667 771. Dahou A, Magne J, Clavel MA, Capoulade R, Bartko PE, Bergler-Klein J, et al. Tricuspid
750. Donal E, Sitges M, Panis V, Schueler R, Lapp H, Moellmann H, et al. Characterization of regurgitation is associated with increased risk of mortality in patients with low-flow
tricuspid valve anatomy and coaptation gap in subjects receiving tricuspid transcath- low-gradient aortic stenosis and reduced ejection fraction: results of the multicenter
eter edge-to-edge repair: observations from the bRIGHT TriClip study. J Am Soc TOPAS study (True or Pseudo-Severe Aortic Stenosis). JACC Cardiovasc Interv 2015;
Echocardiogr 2024;37:397–404. https://doi.org/10.1016/j.echo.2023.12.002 8:588–96. https://doi.org/10.1016/j.jcin.2014.08.019
751. Wild MG, Löw K, Rosch S, Gercek M, Higuchi S, Massberg S, et al. Multicenter experi- 772. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease: incidence, prognostic
ence with the transcatheter leaflet repair system for symptomatic tricuspid regurgita- implications, mechanism, and management. J Am Coll Cardiol 2009;53:401–8. https://
tion. JACC Cardiovasc Interv 2022;15:1352–63. https://doi.org/10.1016/j.jcin.2022.05. doi.org/10.1016/j.jacc.2008.09.048
041 773. Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence.
752. Sarralde JA, Bernal JM, Llorca J, Pontón A, Diez-Solorzano L, Giménez-Rico JR, et al. Cardiovasc Res 2017;113:1474–85. https://doi.org/10.1093/cvr/cvx160
Repair of rheumatic tricuspid valve disease: predictors of very long-term mortality 774. Furukawa A, Abe Y, Ito K, Hosogi S, Yamamoto K, Ito H. Mechanisms of changes in
and reoperation. Ann Thorac Surg 2010;90:503–8. https://doi.org/10.1016/j. functional mitral regurgitation by preload alterations. J Cardiol 2018;71:570–6.
athoracsur.2010.03.105 https://doi.org/10.1016/j.jjcc.2017.12.005
753. Saran N, Dearani JA, Said SM, Greason KL, Pochettino A, Stulak JM, et al. Long-term 775. Wunderlich NC, Beigel R, Siegel RJ. Management of mitral stenosis using 2D and 3D
outcomes of patients undergoing tricuspid valve surgery. Eur J Cardiothorac Surg echo-Doppler imaging. JACC Cardiovasc Imaging 2013;6:1191–205. https://doi.org/10.
2019;56:950–8. https://doi.org/10.1093/ejcts/ezz081 1016/j.jcmg.2013.07.008
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 97 ---
ESC Guidelines 4731
776. Cho IJ, Lee SE, Jeong H, Chang HJ. Determinants of clinical outcomes in patients with 798. World Health Organization. Life Expectancy at Birth. https://www.who.int/
mixed mitral valve disease. Echocardiography 2020;37:1164–70. https://doi.org/10. data/gho/indicator-metadata-registry/imr-details/3131 (28 March 2025, date
1111/echo.14673 last accessed).
777. Pawade T, Sheth T, Guzzetti E, Dweck Marc R, Clavel M-A. Why and how to measure 799. Johansson I, Benz AP, Kovalova T, Balasubramanian K, Fukakusa B, Lynn MJ, et al.
aortic valve calcification in patients with aortic stenosis. JACC Cardiovasc Imaging 2019; Outcomes of patients with a mechanical heart valve and poor anticoagulation control
12:1835–48. https://doi.org/10.1016/j.jcmg.2019.01.045 on warfarin. Thromb Haemost 2024;124:613–24. https://doi.org/10.1055/s-0043-
779. Bandera F, Generati G, Pellegrino M, Garatti A, Labate V, Alfonzetti E, et al. Mitral re- 1777827
gurgitation in heart failure: insights from CPET combined with exercise echocardiog- 800. Persson M, Glaser N, Nilsson J, Friberg O, Franco-Cereceda A, Sartipy U. Comparison
raphy. Eur Heart J Cardiovasc Imaging 2017;18:296–303. https://doi.org/10.1093/ehjci/ of long-term performance of bioprosthetic aortic valves in Sweden from 2003 to 2018.
jew096 JAMA Netw Open 2022;5:e220962. https://doi.org/10.1001/jamanetworkopen.2022.
780. Bissessor N, Shanahan L, Wee YS, Stewart R, Lowe B, Kerr A, et al. The role of natri- 0962
uretic peptides in patients with chronic complex (mixed or multiple) heart valve dis- 801. Jiang Y, Wang S, Bian J, Chen S, Shao Y. Mechanical versus bioprosthetic aortic valve
ease. Congest Heart Fail 2010;16:50–4. https://doi.org/10.1111/j.1751-7133.2009. replacement in middle-aged adults: a systematic review and meta-analysis. J
00132.x Cardiovasc Dev Dis 2023;10:90. https://doi.org/10.3390/jcdd10020090
781. Myerson SG. CMR in evaluating valvular heart disease: diagnosis, severity, and out- 802. Kim MS, Kim HR, Lee SH, Lee S, Joo HC. Aortic valve replacement in patients aged 50
comes. JACC Cardiovasc Imaging 2021;14:2020–32. https://doi.org/10.1016/j.jcmg. to 69 years: analysis using Korean National Big Data. J Card Surg 2022;37:3623–30.
2020.09.029 https://doi.org/10.1111/jocs.16908
782. Grafton G, Cascino TM, Perry D, Ashur C, Koelling TM. Resting oxygen consumption 803. Vogt F, Santarpino G, Fujita B, Frerker C, Bauer T, Beckmann A, et al. Surgical aortic
and heart failure: importance of measurement for determination of cardiac output valve replacement in patients aged 50–69 years—insights from the German Aortic
with the use of the Fick principle. J Card Fail 2020;26:664–72. https://doi.org/10. Valve Registry (GARY). Eur J Cardiothorac Surg 2022;62:ezac286. https://doi.org/10.
1016/j.cardfail.2019.02.004 1093/ejcts/ezac286
783. Singh AD, Mian A, Devasenapathy N, Guyatt G, Karthikeyan G. Percutaneous mitral 804. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve re-
commissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a placement with mechanical vs. biological prostheses in patients aged 50–69 years.
systematic review and meta-analysis of randomised controlled trials. Heart 2020; Eur Heart J 2016;37:2658–67. https://doi.org/10.1093/eurheartj/ehv580
106:1094–101. https://doi.org/10.1136/heartjnl-2019-315906 805. Kiyose AT, Suzumura EA, Laranjeira L, Buehler AM, Santo JAE, Berwanger O, et al.
784. Winter MP, Bartko PE, Krickl A, Gatterer C, Donà C, Nitsche C, et al. Adaptive devel- Comparison of biological and mechanical prostheses for heart valve surgery: a system-
opment of concomitant secondary mitral and tricuspid regurgitation after transcath-
atic review of randomized controlled trials. Arq Bras Cardiol 2019;112:292–301. https://
eter aortic valve replacement. Eur Heart J Cardiovasc Imaging 2021;22:1045–53.
doi.org/10.5935/abc.20180272
https://doi.org/10.1093/ehjci/jeaa106
806. Bouhout I, Ghoneim A, Poirier N, Cartier R, Demers P, Perrault LP, et al. Impact of the
785. Khan F, Okuno T, Malebranche D, Lanz J, Praz F, Stortecky S, et al. Transcatheter aortic
learning curve on early outcomes following the Ross procedure. Can J Cardiol 2017;33:
valve replacement in patients with multivalvular heart disease. JACC Cardiovasc Interv
493–500. https://doi.org/10.1016/j.cjca.2016.11.014
2020;13:1503–14. https://doi.org/10.1016/j.jcin.2020.03.052
807. Tasoudis PT, Varvoglis DN, Vitkos E, Mylonas KS, Sá MP, Ikonomidis JS, et al.
786. Adamo M, Pagnesi M, Ghizzoni G, Estévez-Loureiro R, Raposeiras-Roubin S, Tomasoni
Mechanical versus bioprosthetic valve for aortic valve replacement: systematic review
D, et al. Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral
and meta-analysis of reconstructed individual participant data. Eur J Cardiothorac Surg
valve repair for secondary mitral regurgitation and its impact on mortality. Eur J
2022;62:ezac268. https://doi.org/10.1093/ejcts/ezac268
Heart Fail 2022;24:2175–84. https://doi.org/10.1002/ejhf.2637
808. Leviner DB, Witberg G, Levi A, Landes U, Schwartz N, Shiran A, et al. Mechanical vs
787. Kavsur R, Iliadis C, Spieker M, Brachtendorf BM, Tiyerili V, Metze C, et al. Predictors
bioprosthetic aortic valve replacement in patients younger than 70 years of age: a haz-
and prognostic relevance of tricuspid alterations in patients undergoing transcatheter
ard ratio meta-analysis. Can J Cardiol 2022;38:355–64. https://doi.org/10.1016/j.cjca.
edge-to-edge mitral valve repair. EuroIntervention 2021;17:827–34. https://doi.org/10.
2021.12.008
4244/eij-d-20-01094
809. Yu J, Qiao E, Wang W. Mechanical or biologic prostheses for mitral valve replacement:
788. Mehr M, Karam N, Taramasso M, Ouarrak T, Schneider S, Lurz P, et al. Combined tri-
a systematic review and meta-analysis. Clin Cardiol 2022;45:701–16. https://doi.org/10.
cuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis
1002/clc.23854
from the TriValve and TRAMI registries. JACC Cardiovasc Interv 2020;13:543–50.
810. Yanagawa B, Lee J, Ouzounian M, Bagai A, Cheema A, Verma S, et al. Mitral valve pros-
https://doi.org/10.1016/j.jcin.2019.10.023
thesis choice in patients <70 years: a systematic review and meta-analysis of 20 219
789. Besler C, Blazek S, Rommel KP, Noack T, von Roeder M, Luecke C, et al. Combined
patients. J Card Surg 2020;35:818–25. https://doi.org/10.1111/jocs.14478
mitral and tricuspid versus isolated mitral valve transcatheter edge-to-edge repair in
811. Ahmed A, Awad AK, Varghese KS, Sehgal VS, Hisham K, George J, et al. Bioprosthetic
patients with symptomatic valve regurgitation at high surgical risk. JACC Cardiovasc
versus mechanical valves for mitral valve replacement in patients <70 years: an up-
Interv 2018;11:1142–51. https://doi.org/10.1016/j.jcin.2018.04.010
dated pairwise meta-analysis. Gen Thorac Cardiovasc Surg 2024;72:95–103. https://
790. Egbe AC, Luis SA, Padang R, Warnes CA. Outcomes in moderate mixed aortic valve
doi.org/10.1007/s11748-023-01956-1 disease: is it time for a paradigm shift? J Am Coll Cardiol 2016;67:2321–9. https://doi.org/
812. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A,
10.1016/j.jacc.2016.03.509
Modine T, et al. Standardized definitions of structural deterioration and valve
791. Egbe AC, Poterucha JT, Warnes CA. Mixed aortic valve disease: midterm outcome and
failure in assessing long-term durability of transcatheter and surgical aortic
predictors of adverse events. Eur Heart J 2016;37:2671–8. https://doi.org/10.1093/
eurheartj/ehw079 bioprosthetic valves: a consensus statement from the European Association
792. Zilberszac R, Gabriel H, Schemper M, Zahler D, Czerny M, Maurer G, et al. Outcome of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the
of combined stenotic and regurgitant aortic valve disease. J Am Coll Cardiol 2013;61: European Society of Cardiology (ESC) and the European Association for
1489–95. https://doi.org/10.1016/j.jacc.2012.11.070 Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017;38:3382–90. https://doi.
793. Isaza N, Desai MY, Kapadia SR, Krishnaswamy A, Rodriguez LL, Grimm RA, et al. org/10.1093/eurheartj/ehx303
Long-term outcomes in patients with mixed aortic valve disease and preserved left 813. Meskin M, Dimasi A, Votta E, Jaworek M, Fusini L, Muratori M, et al. A novel multipara-
ventricular ejection fraction. J Am Heart Assoc 2020;9:e014591. https://doi.org/10. metric score for the detection and grading of prosthetic mitral valve obstruction in
1161/jaha.119.014591 cases with different disc motion abnormalities. Ultrasound Med Biol 2019;45:
794. Saijo Y, Isaza N, Conic JZ, Desai MY, Johnston D, Roselli EE, et al. Left ventricular lon- 1708–20. https://doi.org/10.1016/j.ultrasmedbio.2019.03.011
gitudinal strain in characterization and outcome assessment of mixed aortic valve dis- 814. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative bridging antic-
ease phenotypes. JACC Cardiovasc Imaging 2021;14:1324–34. https://doi.org/10.1016/j. oagulation after mechanical heart valve replacement: a systematic review and
jcmg.2021.01.020 meta-analysis. J Thromb Haemost 2015;13:1557–67. https://doi.org/10.1111/jth.
795. Bernard J, Jean G, Bienjonetti-Boudreau D, Jacques F, Tastet L, Salaun E, et al. 13047
Prognostic utility of N-terminal pro B-type natriuretic peptide ratio in mixed aortic 815. Li BX, Liu SD, Qi L, Sun S, Sun W, Li YM, et al. Comparison of different bridging antic-
valve disease. Open Heart 2023;10:e002361. https://doi.org/10.1136/openhrt-2023- oagulation therapies used after mechanical heart valve replacement in Chinese patients
002361 —a prospective cohort study. J Cardiothorac Surg 2020;15:40. https://doi.org/10.1186/
796. Onishi H, Naganuma T, Izumo M, Ouchi T, Yuki H, Mitomo S, et al. Prognostic rele- s13019-020-1084-7
vance of B-type natriuretic peptide in patients with moderate mixed aortic valve dis- 816. Tao E, Luo YL, Tao Z, Wan L. A meta-analysis of bridging anticoagulation between low
ease. ESC Heart Fail 2022;9:2474–83. https://doi.org/10.1002/ehf2.13946 molecular weight heparin and heparin. Medicine (Baltimore) 2020;99:e18729. https://
797. Carpentier AF, Pellerin M, Fuzellier JF, Relland JY. Extensive calcification of the doi.org/10.1097/MD.0000000000018729
mitral valve anulus: pathology and surgical management. J Thorac Cardiovasc Surg 817. Baudet EM, Puel V, McBride JT, Grimaud JP, Roques F, Clerc F, et al. Long-term results
1996;111:718–29; discussion 729–730. https://doi.org/10.1016/s0022-5223(96) of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1995;
70332-x 109:858–70. https://doi.org/10.1016/s0022-5223(95)70309-8
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 98 ---
4732 E S C G u id e l in e s
818. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic 838. Hanigan S, Kong X, Haymart B, Kline-Rogers E, Kaatz S, Krol G, et al. Standard versus
heart valves. Cochrane Database Syst Rev 2013;2013:CD003464. https://doi.org/10. higher intensity anticoagulation for patients with mechanical aortic valve replacement
1002/14651858.CD003464.pub2 and additional risk factors for thromboembolism. Am J Cardiol 2021;159:100–6. https://
819. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, et al. LOWERing doi.org/10.1016/j.amjcard.2021.08.023
the INtensity of oral anticoaGulant therapy in patients with bileaflet mechanical aortic 839. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al.
valve replacement: results from the “LOWERING-IT” Trial. Am Heart J 2010;160: Association of proton pump inhibitors with reduced risk of warfarin-related serious
171–8. https://doi.org/10.1016/j.ahj.2010.05.005 upper gastrointestinal bleeding. Gastroenterology 2016;151:1105–12.e1110. https://
820. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit doi.org/10.1053/j.gastro.2016.08.054
of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the qual- 840. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association
ity of international normalized ratio control achieved by centers and countries as mea- of antisecretory drugs with upper gastrointestinal bleeding in patients using oral antic-
sured by time in therapeutic range. Circulation 2008;118:2029–37. https://doi.org/10. oagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231–43.e1238.
1161/CIRCULATIONAHA.107.750000 https://doi.org/10.1016/j.amjmed.2022.05.031
821. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. 841. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; versus placebo to correct excessive anticoagulation in patients receiving warfarin: a
369:1206–14. https://doi.org/10.1056/NEJMoa1300615 randomized trial. Ann Intern Med 2009;150:293–300. https://doi.org/10.7326/0003-
822. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. 4819-150-5-200903030-00005
Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replace- 842. Khatib R, Ludwikowska M, Witt DM, Ansell J, Clark NP, Holbrook A, et al. Vitamin K
ment. J Am Coll Cardiol 2018;71:2717–26. https://doi.org/10.1016/j.jacc.2018.03.535 for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and
823. Schlitt A, von Bardeleben RS, Ehrlich A, Eimermacher A, Peetz D, Dahm M, et al. meta-analysis. Blood Adv 2019;3:789–96. https://doi.org/10.1182/bloodadvances.
Clopidogrel and aspirin in the prevention of thromboembolic complications after 2018025163
mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131–35. 843. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and
https://doi.org/10.1016/s0049-3848(03)00143-9 effective for outpatient management of patients with an INR>10. Thromb Res 2004;
824. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or 113:205–9. https://doi.org/10.1016/j.thromres.2004.03.004
warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023;2: 844. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific
EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067 and Standardization Committee of the International Society on Thrombosis and
825. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug–drug inter-
Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic
actions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol 2021;
medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. https://
87:4051–100. https://doi.org/10.1111/bcp.14833
doi.org/10.1111/j.1538-7836.2005.01204.x
826. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a
845. Brekelmans MPA, van Ginkel K, Daams JG, Hutten BA, Middeldorp S, Coppens M.
systematic review. Br J Clin Pharmacol 2021;87:352–74. https://doi.org/10.1111/bcp.
Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vita-
14404
min K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb
827. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al.
Thrombolysis 2017;44:118–29. https://doi.org/10.1007/s11239-017-1506-0
Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst
846. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al.
Rev 2016;7:CD003839. https://doi.org/10.1002/14651858.CD003839.pub3
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal.
828. Khouja C, Brunton G, Richardson M, Stokes G, Blanchard L, Burchett H, et al. Oral
A systematic review and meta-analysis. Thromb Haemost 2016;116:879–90. https://doi.
anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping,
org/10.1160/TH16-04-0266
self-monitoring, and stakeholder experiences. Syst Rev 2022;11:232. https://doi.org/
847. Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, et al. INR and vita-
10.1186/s13643-022-02098-w
min K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plas-
829. Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, et al. Genetic and non-genetic fac-
ma. Blood Adv 2023;7:2206–13. https://doi.org/10.1182/bloodadvances.2022009015
tors affecting the quality of anticoagulation control and vascular events in atrial fibril-
848. Sarode R, Milling TJJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and
lation. J Stroke Cerebrovasc Dis 2017;26:1383–90. https://doi.org/10.1016/j.
safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antago-
jstrokecerebrovasdis.2017.02.022
nists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb
830. Praxedes MFDS, Silva JLPD, Cruz AJAD, Viana CC, Barbosa HC, Guimaraes NS, et al.
study. Circulation 2013;128:1234–43. https://doi.org/10.1161/CIRCULATIONAHA.
Assessment of the relationship between the level of patient knowledge on warfarin
113.002283
therapy and the quality of oral anticoagulation: a systematic review and meta-analysis.
849. Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, et al. A
PLoS One 2023;18:e0289836. https://doi.org/10.1371/journal.pone.0289836
European consensus statement on the use of four-factor prothrombin complex con-
831. Marx N, Federici M, Schütt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC
centrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381–92.
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur
https://doi.org/10.1111/anae.15181
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
850. Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am 832. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin
as a bridging anticoagulant early after mechanical heart valve replacement. Circulation Soc Hematol Educ Program 2016;2016:605–11. https://doi.org/10.1182/asheducation-
2006;113:564–9. https://doi.org/10.1161/circulationaha.105.575571 2016.1.605
833. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience 851. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or
with enoxaparin in patients with mechanical heart valves who must withhold acenocu- defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:
marol. Heart 2003;89:527–30. https://doi.org/10.1136/heart.89.5.527 2084–93. https://doi.org/10.1056/NEJMoa1302946
834. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low 852. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al.
molecular weight heparin in patients with mechanical heart valves: systematic review Periprocedural stroke and bleeding complications in patients undergoing catheter ab-
and meta-analysis. J Thromb Haemost 2014;12:650–9. https://doi.org/10.1111/jth. lation of atrial fibrillation with different anticoagulation management: results from the
12544 Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients
835. Pengo V, Palareti G, Cucchini U, Molinatti M, Del Bono R, Baudo F, et al. Low-intensity Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:
oral anticoagulant plus low-dose aspirin during the first six months versus 2638–44. https://doi.org/10.1161/CIRCULATIONAHA.113.006426
standard-intensity oral anticoagulant therapy after mechanical heart valve replace- 853. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJJ, van Galen KPM.
ment: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants under-
(LIWACAP). Clin Appl Thromb Hemost 2007;13:241–8. https://doi.org/10.1177/ going minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018;7:
1076029607302544 CD012293. https://doi.org/10.1002/14651858.CD012293.pub2
836. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity 854. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T,
oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to
alone: a randomized trial in patients with mechanical prosthetic heart valves. J heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J
Thorac Cardiovasc Surg 1997;113:910–6. https://doi.org/10.1016/s0022- Cardiol 2012;110:1482–8. https://doi.org/10.1016/j.amjcard.2012.06.057
5223(97)70264-2 855. Makuloluwa AK, Tiew S, Briggs M. Peri-operative management of ophthalmic patients
837. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced on anti-thrombotic agents: a literature review. Eye (Lond) 2019;33:1044–59. https://
anticoagulation after mechanical aortic valve replacement: interim results from the doi.org/10.1038/s41433-019-0382-6
prospective randomized On-X valve anticoagulation clinical trial randomized Food 856. Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic
and Drug Administration investigational device exemption trial. J Thorac Cardiovasc endoscopy-related GI bleeding and thromboembolic events in patients using warfarin
Surg 2014;147:1202–10; discussion 1210–1201. https://doi.org/10.1016/j.jtcvs.2014. or direct oral anticoagulants: results from a large nationwide database analysis. Gut
01.004 2018;67:1805–12. https://doi.org/10.1136/gutjnl-2017-313999
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 99 ---
ESC Guidelines 4733
857. Dohler I, Roder D, Schlesinger T, Nassen CA, Germer CT, Wiegering A, et al. and mechanical valves: a meta-analysis. Circulation 2017;135:714–6. https://doi.org/
Risk-adjusted perioperative bridging anticoagulation reduces bleeding complications 10.1161/CIRCULATIONAHA.116.026793
without increasing thromboembolic events in general and visceral surgery. BMC 877. Suppah M, Kamal A, Saadoun R, Baradeiya AMA, Abraham B, Alsidawi S, et al. An
Anesthesiol 2023;23:56. https://doi.org/10.1186/s12871-023-02017-z evidence-based approach to anticoagulation therapy comparing direct oral anticoagu-
858. Shah S, Nayfeh T, Hasan B, Urtecho M, Firwana M, Saadi S, et al. Perioperative man- lants and vitamin K antagonists in patients with atrial fibrillation and bioprosthetic
agement of vitamin K antagonists and direct oral anticoagulants: a systematic review valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol
and meta-analysis. Chest 2023;163:1245–57. https://doi.org/10.1016/j.chest.2022.11. 2023;206:132–50. https://doi.org/10.1016/j.amjcard.2023.07.141
032 878. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al.
859. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on an- Anticoagulation with or without clopidogrel after transcatheter aortic-valve implant-
tithrombotic therapy and body mass: a clinical consensus statement of the ation. N Engl J Med 2020;382:1696–707. https://doi.org/10.1056/NEJMoa1915152
European Society of Cardiology Working Group on Cardiovascular 879. Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R,
Pharmacotherapy and the European Society of Cardiology Working Group on Lopez-Otero D, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after
Thrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614–45. https://doi.org/10. TAVR. N Engl J Med 2021;385:2150–60. https://doi.org/10.1056/NEJMoa2111016
1093/ehjcvp/pvae064 880. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs.
860. Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JK, et al. 2024 standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur
EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Heart J 2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242
Cardiothorac Surg 2024;67:ezae355. https://doi.org/10.1093/ejcts/ezae355 881. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al.
861. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N
Postoperative low molecular weight heparin bridging treatment for patients at high Engl J Med 2020;383:1447–57. https://doi.org/10.1056/NEJMoa2017815
risk of arterial thromboembolism (PERIOP2): double blind randomised controlled 882. Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, et al. Meta-analysis
trial. BMJ 2021;373:n1205. https://doi.org/10.1136/bmj.n1205 comparing single versus dual antiplatelet therapy following transcatheter aortic valve
862. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleed- implantation. Am J Cardiol 2018;122:310–5. https://doi.org/10.1016/j.amjcard.2018.
ing risk of periprocedural bridging anticoagulation: a systematic review and 04.006
meta-analysis. Clin Cardiol 2020;43:441–9. https://doi.org/10.1002/clc.23336 883. Rodés-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al.
863. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural hep- Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following trans-
arin bridging in patients receiving vitamin K antagonists: systematic review and catheter aortic valve replacement with a balloon-expandable valve: the ARTE
meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630–9. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve
https://doi.org/10.1161/CIRCULATIONAHA.112.105221 Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357–65.
864. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in https://doi.org/10.1016/j.jcin.2017.04.014
patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC 884. Meurin P, Tabet JY, Iliou MC, Pierre B, Corone S, Cristofini P, et al. Thromboembolic
Cardiovasc Disord 2017;17:295. https://doi.org/10.1186/s12872-017-0719-7 events early after mitral valve repair: incidence and predictive factors. Int J Cardiol 2008;
865. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early an- 126:45–52. https://doi.org/10.1016/j.ijcard.2007.03.115
ticoagulation of bioprosthetic aortic valves in older patients: results from the Society of 885. van der Wall SJ, Olsthoorn JR, Heuts S, Klautz RJM, Tomsic A, Jansen EK, et al.
Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; Antithrombotic therapy after mitral valve repair: VKA or aspirin? J Thromb
60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029 Thrombolysis 2018;46:473–81. https://doi.org/10.1007/s11239-018-1724-0
866. Rafiq S, Steinbrüchel DA, Lilleør NB, Moller CH, Lund JT, Thiis JJ, et al. Antithrombotic 886. Mazur PK, Arghami A, Macielak SA, Nei SD, Viehman JK, King KS, et al. Apixaban for
therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a rando- anticoagulation after robotic mitral valve repair. Ann Thorac Surg 2023;115:966–73.
mized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j. https://doi.org/10.1016/j.athoracsur.2022.07.045
thromres.2016.11.021 887. Paparella D, Di Mauro M, Bitton Worms K, Bolotin G, Russo C, Trunfio S, et al.
867. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treat- Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mi-
ment of early bioprosthetic malfunction in the mitral valve position due to thrombus tral valve repair. J Thorac Cardiovasc Surg 2016;151:1302–8.e1301. https://doi.org/10.
formation. Am J Cardiol 2013;112:1439–44. https://doi.org/10.1016/j.amjcard.2013.06. 1016/j.jtcvs.2015.12.036
014 888. Trevis J, Akowuah E. Which antithrombotic strategy provides the best outcomes after
868. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, et al. mitral valve repair in patients who remain in sinus rhythm? Interact Cardiovasc Thorac
Thromboembolic complications after surgical correction of mitral regurgitation inci- Surg 2022;35:ivac085. https://doi.org/10.1093/icvts/ivac085
dence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203–11. 889. Moser N, Omar MA, Koshman SL, Lin M, Youngson E, Kent W, et al. Direct oral antic-
https://doi.org/10.1016/j.jacc.2007.10.058 oagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic re-
869. Dangas GD, Tijssen JGP, Wöhrle J, Sondergaard L, Gilard M, Mollmann H, et al. A con- placement. J Thorac Cardiovasc Surg 2023;168:523–32.e3. https://doi.org/10.1016/j.
trolled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med jtcvs.2023.03.004
2020;382:120–9. https://doi.org/10.1056/NEJMoa1911425 890. Mentias A, Saad M, Michael M, Nakhla S, Menon V, Harb S, et al. Direct oral anticoa-
870. Alkhalil M, Edwards R, Puri R, Kalra A, Zaman A, Das R. Aspirin versus dual antiplatelet gulants versus warfarin in patients with atrial fibrillation and valve replacement or re-
therapy in patients undergoing trans-catheter aortic valve implantation, updated pair. J Am Heart Assoc 2022;11:e026666. https://doi.org/10.1161/jaha.122.026666
meta-analysis. Cardiovasc Drugs Ther 2022;36:279–83. https://doi.org/10.1007/ 891. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, et al.
s10557-021-07146-6 Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrilla-
871. El Bèze N, Himbert D, Suc G, Brochet E, Ajzenberg N, Cailliau A, et al. Comparison of tion’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J
direct oral anticoagulants vs vitamin K antagonists after transcatheter mitral valve re- 2015;36:1822–30. https://doi.org/10.1093/eurheartj/ehv163
placement. J Am Coll Cardiol 2024;83:334–46. https://doi.org/10.1016/j.jacc.2023.10. 892. Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, et al.
031 Oral anticoagulant type and outcomes after transcatheter aortic valve replacement.
872. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. JACC Cardiovasc Interv 2019;12:1566–76. https://doi.org/10.1016/j.jcin.2019.03.003
Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation 893. Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR
and bioprosthetic valves. Circulation 2017;135:1273–5. https://doi.org/10.1161/ patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?
CIRCULATIONAHA.116.026714 JACC Cardiovasc Interv 2021;14:1704–13. https://doi.org/10.1016/j.jcin.2021.05.025
873. Guimarães HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, 894. Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A.
Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after
mitral valve. N Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJM transcatheter aortic valve replacement: insights from the STS/ACC TVT registry. J
oa2029603 Am Heart Assoc 2022;11:e023561. https://doi.org/10.1161/jaha.121.023561
874. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, 895. VARC-3 Writing Committee; Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al.
et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibril- Valve academic research consortium 3: updated endpoint definitions for aortic valve
lation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb clinical research. J Am Coll Cardiol 2021;77:2717–46. https://doi.org/10.1016/j.jacc.
Haemost 2016;115:1056–63. https://doi.org/10.1160/TH16-01-0007 2021.02.038
875. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, et al. Efficacy and safety of edox- 896. Pibarot P, Herrmann HC, Wu C, Hahn RT, Otto CM, Abbas AE, et al. Standardized
aban in patients early after surgical bioprosthetic valve implantation or valve repair: a definitions for bioprosthetic valve dysfunction following aortic or mitral valve replace-
randomized clinical trial. J Thorac Cardiovasc Surg 2023;165:58–67.e54. https://doi.org/ ment: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:545–61. https://doi.org/
10.1016/j.jtcvs.2021.01.127 10.1016/j.jacc.2022.06.002
876. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients 897. Kaneko T, Bapat VN, Alakhtar AM, Zaid S, George I, Grubb KJ, et al. Transcatheter
with atrial fibrillation and valvular heart disease other than significant mitral stenosis heart valve explantation for transcatheter aortic valve replacement failure: a Heart
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 100 ---
4734 E S C G u id e l in e s
Valve Collaboratory expert consensus document on operative techniques. J Thorac 916. Rheude T, Pellegrini C, Stortecky S, Marwan M, Xhepa E, Ammon F, et al. Meta-analysis
Cardiovasc Surg 2024;169:878–89. https://doi.org/10.1016/j.jtcvs.2024.04.025 of bioprosthetic valve thrombosis after transcatheter aortic valve implantation. Am J
898. Bleiziffer S, Rudolph TK. Patient prosthesis mismatch after SAVR and TAVR. Front Cardiol 2021;138:92–9. https://doi.org/10.1016/j.amjcard.2020.10.018
Cardiovasc Med 2022;9:761917. https://doi.org/10.3389/fcvm.2022.761917 917. Blanke P, Leipsic JA, Popma JJ, Yakubov SJ, Deeb GM, Gada H, et al. Bioprosthetic aor-
899. Hirji SA, Percy ED, Zogg CK, Malarczyk A, Harloff MT, Yazdchi F, et al. Comparison of tic valve leaflet thickening in the Evolut Low Risk sub-study. J Am Coll Cardiol 2020;75:
in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve re- 2430–42. https://doi.org/10.1016/j.jacc.2020.03.022
placement vs. reoperative surgical aortic valve replacement: a contemporary assess- 918. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al.
ment of real-world outcomes. Eur Heart J 2020;41:2747–55. https://doi.org/10.1093/ Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves:
eurheartj/ehaa252 an observational study. Lancet 2017;389:2383–92. https://doi.org/10.1016/S0140-
900. Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE. Transcatheter 6736(17)30757-2
valve-in-valve versus redo surgical aortic valve replacement for the treatment of de- 919. Makkar RR, Blanke P, Leipsic J, Thourani V, Chakravarty T, Brown D, et al. Subclinical
generated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 car-
Cardiovasc Interv 2018;92:1404–11. https://doi.org/10.1002/ccd.27686 diac computed tomography substudy. J Am Coll Cardiol 2020;75:3003–15. https://doi.
901. Bleiziffer S, Simonato M, Webb JG, Rodes-Cabau J, Pibarot P, Kornowski R, et al. org/10.1016/j.jacc.2020.04.043
Long-term outcomes after transcatheter aortic valve implantation in failed biopros- 920. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, et al.
thetic valves. Eur Heart J 2020;41:2731–42. https://doi.org/10.1093/eurheartj/ehaa544 Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med
902. Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, et al. Thirty-day 2020;382:130–9. https://doi.org/10.1056/NEJMoa1911426
outcomes of transcatheter mitral valve replacement for degenerated mitral bioprosth- 921. Montalescot G, Redheuil A, Vincent F, Desch S, De Benedictis M, Eltchaninoff H, et al.
eses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mi- Apixaban and valve thrombosis after transcatheter aortic valve replacement: the
tral annular calcification (valve-in-mitral annular calcification) in the United States: data ATLANTIS-4D-CT randomized clinical trial substudy. JACC Cardiovasc Interv 2022;
from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter 15:1794–804. https://doi.org/10.1016/j.jcin.2022.07.014
Valve Therapy Registry. Circ Cardiovasc Interv 2020;13:e008425. https://doi.org/10. 922. Ruile P, Jander N, Blanke P, Schoechlin S, Reinöhl J, Gick M, et al. Course of early sub-
clinical leaflet thrombosis after transcatheter aortic valve implantation with or without 1161/CIRCINTERVENTIONS.119.008425
903. Eleid MF, Whisenant BK, Cabalka AK, Williams MR, Nejjari M, Attias D, et al. Early out- oral anticoagulation. Clin Res Cardiol 2017;106:85–95. https://doi.org/10.1007/s00392-
016-1052-3
comes of percutaneous transvenous transseptal transcatheter valve implantation in
923. Günduz S, Özkan M, Kalçik M, Gürsoy OM, Astarcioglu MA, Karakoyun S, et al.
failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcifica-
Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve
tion. JACC Cardiovasc Interv 2017;10:1932–42. https://doi.org/10.1016/j.jcin.2017.08.
dysfunction: thrombus or pannus. Circ Cardiovasc Imaging 2015;8:e003246. https://doi.
014
org/10.1161/CIRCIMAGING.115.003246
904. Little SH, Bapat V, Blanke P, Guerrero M, Rajagopal V, Siegel R. Imaging guidance for
924. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, et al.
transcatheter mitral valve intervention on prosthetic valves, rings, and annular calcifi-
Recommendations for the imaging assessment of prosthetic heart valves: a report
cation. JACC Cardiovasc Imaging 2021;14:22–40. https://doi.org/10.1016/j.jcmg.2019.10.
from the European Association of Cardiovascular Imaging endorsed by the Chinese
027
Society of Echocardiography, the Inter-American Society of Echocardiography, and
905. Fallon JM, DeSimone JP, Brennan JM, O’Brien S, Thibault DP, DiScipio AW, et al. The
the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging
incidence and consequence of prosthesis-patient mismatch after surgical aortic valve
2016;17:589–90. https://doi.org/10.1093/ehjci/jew025
replacement. Ann Thorac Surg 2018;106:14–22. https://doi.org/10.1016/j.athoracsur.
925. Tanis W, Habets J, van den Brink RBA, Symersky P, Budde RP, Chamuleau SA.
2018.01.090
Differentiation of thrombus from pannus as the cause of acquired mechanical pros-
906. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B.
thetic heart valve obstruction by non-invasive imaging: a review of the literature. Eur
Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic
Heart J Cardiovasc Imaging 2014;15:119–29. https://doi.org/10.1093/ehjci/jet127
heart valves. Circulation 2010;121:2123–9. https://doi.org/10.1161/
926. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B. Urgent
CIRCULATIONAHA.109.901272
surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic
907. Zorn GLI, Little SH, Tadros P, Deeb GM, Gleason TG, Heiser J, et al. Prosthesis–pa-
heart valve thrombosis: a systematic review and meta-analysis of observational studies.
tient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of
Eur Heart J 2013;34:1557–66. https://doi.org/10.1093/eurheartj/ehs486
a self-expanding prosthesis. J Thorac Cardiovasc Surg 2016;151:1014–23.e3,
927. Castilho FM, De Sousa MR, Mendonca AL, Ribeiro AL, Caceres-Loriga FM.
1023.e1011–1013. https://doi.org/10.1016/j.jtcvs.2015.10.070
Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review
908. Thourani VH, Abbas AE, Ternacle J, Hahn RT, Makkar R, Kodali SK, et al.
and meta-analysis. J Thromb Haemost 2014;12:1218–28. https://doi.org/10.1111/jth.
Patient-prosthesis mismatch after surgical aortic valve replacement: analysis of the
12577
PARTNER trials. Ann Thorac Surg 2024;117:1164–71. https://doi.org/10.1016/j. 928. Chopard R, Vidoni C, Besutti M, Ismail M, Ecarnot F, Favoulet B, et al. Surgery versus
athoracsur.2024.01.023 thrombolytic therapy for the management of left-sided prosthetic valve thrombosis
909. Tomii D, Okuno T, Heg D, Nakase M, Lanz J, Praz F, et al. Long-term outcomes of mea-
without hemodynamic compromise: a systematic review and meta-analysis. J Am
sured and predicted prosthesis-patient mismatch following transcatheter aortic valve
Heart Assoc 2024;13:e035143. https://doi.org/10.1161/jaha.124.035143
replacement. EuroIntervention 2023;19:746–56. https://doi.org/10.4244/eij-d-23- 929. Özkan M, Günduz S, Güner A, Kalcik M, Gursoy MO, Uygur B, et al. Thrombolysis or
00456 surgery in patients with obstructive mechanical valve thrombosis: the multicenter
910. Vriesendorp MD, De Lind Van Wijngaarden RAF, Head SJ, Kappetein AP, Hickey GL, HATTUSHA study. J Am Coll Cardiol 2022;79:977–89. https://doi.org/10.1016/j.jacc.
Rao V, et al. The fallacy of indexed effective orifice area charts to predict prosthesis– 2021.12.027
patient mismatch after prosthesis implantation. Eur Heart J Cardiovasc Imaging 2020;21: 930. Özkan M, Günduz S, Gürsoy OM, Karakoyun S, Astarcioglu MA, Kalcik M, et al.
1116–22. https://doi.org/10.1093/ehjci/jeaa044 Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic
911. Sorajja P, Bae R, Lesser JA, Pedersen WA. Percutaneous repair of paravalvular pros- MEchanical valve thrombosis and the prEdictors of outcomE: the ultra-slow
thetic regurgitation: patient selection, techniques and outcomes. Heart 2015;101: PROMETEE trial. Am Heart J 2015;170:409–18. https://doi.org/10.1016/j.ahj.2015.04.
665–73. https://doi.org/10.1136/heartjnl-2014-306270 025
912. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al. Clinical trial prin- 931. Sadeghipour P, Saedi S, Saneei L, Rafiee F, Yoosefi S, Parsaee M, et al. Fast vs. ultraslow
ciples and endpoint definitions for paravalvular leaks in surgical prosthesis. Eur Heart J thrombolytic infusion regimens in patients with obstructive mechanical prosthetic
2018;39:1224–45. https://doi.org/10.1093/eurheartj/ehx211 valve thrombosis: a pilot randomized clinical trial. Eur Heart J Cardiovasc
913. Laplace G, Lafitte S, Labèque JN, Perron JM, Baudet E, Deville C, et al. Clinical signifi- Pharmacother 2022;8:668–76. https://doi.org/10.1093/ehjcvp/pvab083
cance of early thrombosis after prosthetic mitral valve replacement: a postoperative 931a. Karthikeyan G, Rajashekar P, Devasenapathy N, Biswas S, Kidambi B, Singal A, et al.
monocentric study of 680 patients. J Am Coll Cardiol 2004;43:1283–90. https://doi. Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a ran-
org/10.1016/j.jacc.2003.09.064 domized trial. Eur Heart J 2025;46:3373–81. https://doi.org/10.1093/eurheartj/ehaf391
914. Symersky P, Budde RPJ, de Mol BAJM, Prokop M. Comparison of multidetector-row 932. Bemurat LR, Laffort PR, Deville CJ, Roques XG, Baudet EM, Roudaut RP. Management
computed tomography to echocardiography and fluoroscopy for evaluation of pa- of nonobstructive thrombosis of prosthetic mitral valve in asymptomatic patients in
tients with mechanical prosthetic valve obstruction. Am J Cardiol 2009;104:1128–34. the early postoperative period: a study in 20 patients. Echocardiography 1999;16:
https://doi.org/10.1016/j.amjcard.2009.05.061 339–46. https://doi.org/10.1111/j.1540-8175.1999.tb00823.x
915. Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, et al. 933. Mutuberría-Urdaniz M, Rodríguez-Palomares JF, Ferreira I, Bañeras J, Teixidó G,
Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic Gutiérrez L, et al. Non-obstructive prosthetic heart valve thrombosis (NOPVT): really
predictors. J Am Coll Cardiol 2015;66:2285–94. https://doi.org/10.1016/j.jacc.2015.09. a benign entity? Int J Cardiol 2015;197:16–22. https://doi.org/10.1016/j.ijcard.2015.06.
022 021
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 101 ---
ESC Guidelines 4735
934. Egbe AC, Connolly HM, Pellikka PA, Schaff HV, Hanna R, Maleszewski JJ, et al. have high international normalized ratio levels. J Card Surg 2020;35:2522–8. https://doi.
Outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically im- org/10.1111/jocs.14777
planted valves: a prospective study. JACC Cardiovasc Interv 2017;10:379–87. https:// 955. Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J.
doi.org/10.1016/j.jcin.2016.11.027 Usefulness of phenprocoumon for the treatment of obstructing thrombus in bio-
935. Jose J, Sulimov DS, El-Mawardy M, Sato T, Allali A, Holy EW, et al. Clinical bioprosthetic prostheses in the aortic valve position. Am J Cardiol 2012;109:257–62. https://doi.
heart valve thrombosis after transcatheter aortic valve replacement: incidence, char- org/10.1016/j.amjcard.2011.08.038
acteristics, and treatment outcomes. JACC Cardiovasc Interv 2017;10:686–97. https:// 956. Oliver JM, Gallego P, Gonzalez A, Dominguez FJ, Gamallo C, Mesa JM. Bioprosthetic
doi.org/10.1016/j.jcin.2017.01.045 mitral valve thrombosis: clinical profile, transesophageal echocardiographic features,
936. Petrescu I, Egbe AC, Ionescu F, Nkomo VT, Greason KL, Pislaru C, et al. Long-term and follow-up after anticoagulant therapy. J Am Soc Echocardiogr 1996;9:691–9.
outcomes of anticoagulation for bioprosthetic valve thrombosis. J Am Coll Cardiol https://doi.org/10.1016/s0894-7317(96)90066-8
2020;75:857–66. https://doi.org/10.1016/j.jacc.2019.12.037 957. Agarwal S, Rajamanickam A, Bajaj NS, Griffin BP, Catacutan T, Svensson LG, et al.
937. Pislaru SV, Hussain I, Pellikka PA, Maleszewski JJ, Hanna RD, Schaff HV, et al. Impact of aortic stenosis on postoperative outcomes after noncardiac surgeries. Circ
Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic Cardiovasc Qual Outcomes 2013;6:193–200. https://doi.org/10.1161/CIRC
valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015;47: OUTCOMES.111.000091
725–32. https://doi.org/10.1093/ejcts/ezu201 958. Taniguchi T, Morimoto T, Shiomi H, Ando K, Shirai S, Kanamori N, et al. Elective non-
938. Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol cardiac surgery in patients with severe aortic stenosis — observations from the
2017;69:2193–211. https://doi.org/10.1016/j.jacc.2017.02.051 CURRENT AS registry. Circ J 2020;84:1173–82. https://doi.org/10.1253/circj.CJ-20-
939. Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, et al. 0026
Transcatheter aortic heart valves: histological analysis providing insight to leaflet thick- 959. Luis SA, Dohaei A, Chandrashekar P, Scott CG, Padang R, Lokineni S, et al. Impact of
ening and structural valve degeneration. JACC Cardiovasc Imaging 2019;12:135–45. aortic valve replacement for severe aortic stenosis on perioperative outcomes follow-
https://doi.org/10.1016/j.jcmg.2018.06.028 ing major noncardiac surgery. Mayo Clin Proc 2020;95:727–37. https://doi.org/10.1016/
940. Alkhouli M, Rihal CS, Zack CJ, Eleid MF, Maor E, Sarraf M, et al. Transcatheter and sur- j.mayocp.2019.10.038
gical management of mitral paravalvular leak: long-term outcomes. JACC Cardiovasc 960. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC
Interv 2017;10:1946–56. https://doi.org/10.1016/j.jcin.2017.07.046 Guidelines on cardiovascular assessment and management of patients undergoing non-
941. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic cardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/eurheartj/
valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162–70. ehac270
https://doi.org/10.1001/jama.2014.7246 961. Okuno T, Demirel C, Tomii D, Erdoes G, Heg D, Lanz J, et al. Risk and timing of non-
942. Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, et al. Outcomes cardiac surgery after transcatheter aortic valve implantation. JAMA Netw Open 2022;5:
of transcatheter mitral valve replacement for degenerated bioprostheses, failed annu- e2220689. https://doi.org/10.1001/jamanetworkopen.2022.20689
loplasty rings, and mitral annular calcification. Eur Heart J 2019;40:441–51. https://doi. 962. Tashiro T, Pislaru SV, Blustin JM, Nkomo VT, Abel MD, Scott CG, et al. Perioperative
org/10.1093/eurheartj/ehy590 risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal
943. Whisenant B, Kapadia SR, Eleid MF, Kodali SK, McCabe JM, Krishnaswamy A, et al. in contemporary practice. Eur Heart J 2014;35:2372–81. https://doi.org/10.1093/
One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart eurheartj/ehu044
valve. JAMA Cardiol 2020;5:1245–52. https://doi.org/10.1001/jamacardio.2020.2974 963. Okuno T, Yahagi K, Horiuchi Y, Sato Y, Tanaka T, Koseki K, et al. The role of transcath-
944. McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. eter aortic valve replacement in the patients with severe aortic stenosis requiring ma-
Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or jor non-cardiac surgery. Cardiovasc Interv Ther 2019;34:345–51. https://doi.org/10.
valve-in-ring replacement. J Am Coll Cardiol 2019;73:148–57. https://doi.org/10.1016/ 1007/s12928-019-00575-z
j.jacc.2018.10.051 964. Calleja AM, Dommaraju S, Gaddam R, Cha S, Khandheria BK, Chaliki HP. Cardiac risk
945. Muratori M, Montorsi P, Teruzzi G, Celeste F, Doria E, Alamanni F, et al. Feasibility and in patients aged >75 years with asymptomatic, severe aortic stenosis undergoing non-
diagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion cardiac surgery. Am J Cardiol 2010;105:1159–63. https://doi.org/10.1016/j.amjcard.
by transthoracic and transesophageal echocardiography in suspected prosthetic valve 2009.12.019
dysfunction. Am J Cardiol 2006;97:94–100. https://doi.org/10.1016/j.amjcard.2005.07. 965. Sohrabi B, Kazemi B, Mehryar A, Teimouri-Dereshki A, Toufan M, Aslanabadi N.
112 Correlation between pulmonary artery pressure measured by echocardiography
946. Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quiñones MA, Zoghbi WA. and right heart catheterization in patients with rheumatic mitral valve stenosis (a pro-
Differentiating thrombus from pannus formation in obstructed mechanical prosthetic spective study). Echocardiography 2016;33:7–13. https://doi.org/10.1111/echo.13000
valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic 966. Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular
parameters. J Am Coll Cardiol 1998;32:1410–7. https://doi.org/10.1016/s0735- outcomes of patients with pulmonary hypertension undergoing noncardiac surgery.
1097(98)00385-4 Am J Cardiol 2019;123:1532–7. https://doi.org/10.1016/j.amjcard.2019.02.006
947. Suchá D, Symersky P, Vonken EJPA, Provoost E, Chamuleau SA, Budde RP. 967. Bajaj NS, Agarwal S, Rajamanickam A, Parashar A, Poddar KL, Griffin BP, et al. Impact of
Multidetector-row computed tomography allows accurate measurement of mechan- severe mitral regurgitation on postoperative outcomes after noncardiac surgery. Am J
ical prosthetic heart valve leaflet closing angles compared with fluoroscopy. J Comput Med 2013;126:529–35. https://doi.org/10.1016/j.amjmed.2012.12.005
Assist Tomogr 2014;38:451–6. https://doi.org/10.1097/RCT.0b013e3182ab5f15 968. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova
948. Daniel WG, Mügge A, Grote J, Hausmann D, Nikutta P, Laas J, et al. Comparison of R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis-
transthoracic and transesophageal echocardiography for detection of abnormalities eases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/
of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol eurheartj/ehy340
1993;71:210–5. https://doi.org/10.1016/0002-9149(93)90740-4 969. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy
949. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, et al. Thrombolytic outcomes in women with cardiovascular disease: evolving trends over 10 years in the
therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low- ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019;40:
dose, slow infusion of tissue-type plasminogen activator. Circulation 2013;128:532–40. 3848–55. https://doi.org/10.1093/eurheartj/ehz136
https://doi.org/10.1161/circulationaha.113.001145 970. Pande SN, Yavana Suriya J, Ganapathy S, Pillai AA, Satheesh S, Mondal N, et al.
950. Taherkhani M, Hashemi SR, Hekmat M, Safi M, Taherkhani A, Movahed MR. Validation of risk stratification for cardiac events in pregnant women with valvular
Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves: the lar- heart disease. J Am Coll Cardiol 2023;82:1395–406. https://doi.org/10.1016/j.jacc.
gest survival analysis to date. Tex Heart Inst J 2015;42:543–7. https://doi.org/10.14503/ 2023.07.023
THIJ-14-4659 971. van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy
951. Roudaut R, Roques X, Lafitte S, Choukroun E, Laborde N, Madona F, et al. Surgery for outcomes in women with rheumatic mitral valve disease: results from the Registry of
prosthetic valve obstruction. A single center study of 136 patients. Eur J Cardiothorac Pregnancy and Cardiac Disease. Circulation 2018;137:806–16. https://doi.org/10.1161/
Surg 2003;24:868–72. https://doi.org/10.1016/s1010-7940(03)00568-2 CIRCULATIONAHA.117.032561
952. Nishanth KR, Shankar M, Srinivasa KH, Manjunath CN, Ravindranath KS. Fibrinolysis in 972. Orwat S, Diller GP, van Hagen IM, Schmidt R, Tobler D, Greutmann M, et al. Risk of
left-sided mechanical prosthetic valve thrombosis with high INR. Eur Heart J Acute pregnancy in moderate and severe aortic stenosis: from the multinational ROPAC
Cardiovasc Care 2020;9:S58–62. https://doi.org/10.1177/2048872619846329 registry. J Am Coll Cardiol 2016;68:1727–37. https://doi.org/10.1016/j.jacc.2016.07.750
953. Separham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, et al. 973. Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJ.
Prosthetic valve thrombosis. J Card Surg 2015;30:246–50. https://doi.org/10.1111/jocs. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur
12510 Heart J 2005;26:914–20. https://doi.org/10.1093/eurheartj/ehi103
954. Farzaneh K, Mortazavi SH, Oraii A, Abbasi K, Salehi Omran A, Ahmadi Tafti SH, et al. 974. McKellar SH, MacDonald RJ, Michelena HI, Connolly HM, Sundt TMI. Frequency of car-
Safety of thrombolytic therapy in patients with prosthetic heart valve thrombosis who diovascular events in women with a congenitally bicuspid aortic valve in a single
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
--- Страница 102 ---
4736 E S C G u id e l in e s
community and effect of pregnancy on events. Am J Cardiol 2011;107:96–9. https://doi. 995. Hartzell M, Malhotra R, Yared K, Rosenfield HR, Walker JD, Wood MJ. Effect of gender
org/10.1016/j.amjcard.2010.08.061 on treatment and outcomes in severe aortic stenosis. Am J Cardiol 2011;107:1681–6.
975. Wichert-Schmitt B, Grewal J, Malinowski AK, Pfaller B, Losenno KL, Kiess MC, et al. https://doi.org/10.1016/j.amjcard.2011.01.059
Outcomes of pregnancy in women with bioprosthetic heart valves with or without 996. Lowenstern A, Sheridan P, Wang TY, Boero I, Vemulapalli S, Thourani VH, et al. Sex
valve dysfunction. J Am Coll Cardiol 2022;80:2014–24. https://doi.org/10.1016/j.jacc. disparities in patients with symptomatic severe aortic stenosis. Am Heart J 2021;237:
2022.09.019 116–26. https://doi.org/10.1016/j.ahj.2021.01.021
976. van Hagen IM, Roos-Hesselink JW, Ruys TPE, Merz WM, Goland S, Gabriel H, et al. 997. Onorati F, D’Errigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, et al. Different
Pregnancy in women with a mechanical heart valve: data of the European Society of impact of sex on baseline characteristics and major periprocedural outcomes of trans-
Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation 2015; catheter and surgical aortic valve interventions: results of the multicenter Italian
132:132–42. https://doi.org/10.1161/CIRCULATIONAHA.115.015242 OBSERVANT registry. J Thorac Cardiovasc Surg 2014;147:1529–39. https://doi.org/
977. Pfaller B, Dave Javier A, Grewal J, Gabarin N, Colman J, Kiess M, et al. Risk associated 10.1016/j.jtcvs.2013.05.039
with valvular regurgitation during pregnancy. J Am Coll Cardiol 2021;77:2656–64. 998. Tchetche D, Pibarot P, Bax JJ, Bonaros N, Windecker S, Dumonteil N, et al.
https://doi.org/10.1016/j.jacc.2021.03.327 Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur
978. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, et al. The effect Heart J 2025;46:2079–88. https://doi.org/10.1093/eurheartj/ehaf133
of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 999. Saad M, Nairooz R, Pothineni NVK, Almomani A, Kovelamudi S, Sardar P, et al.
2001;37:893–9. https://doi.org/10.1016/s0735-1097(00)01198-0 Long-term outcomes with transcatheter aortic valve replacement in women com-
979. Hoover E, Corlin T, Lohr J, Sabol B, Yamamura Y, Jacobs K, et al. TAVR beyond fetal pared with men: evidence from a meta-analysis. JACC Cardiovasc Interv 2018;11:
viability: an alternative to preterm delivery in symptomatic severe aortic stenosis. JACC 24–35. https://doi.org/10.1016/j.jcin.2017.08.015
Case Rep 2023;27:102104. https://doi.org/10.1016/j.jaccas.2023.102104 1000.Akintoye E, Saijo Y, Braghieri L, Badwan O, Patel H, Dabbagh MM, et al. Impact of age
980. Sajja A, Dassanayake M, Morales IA, Wenger NK, Smith C, Xie J, et al. Valve-in-valve and sex on left ventricular remodeling in patients with aortic regurgitation. J Am Coll
transcatheter aortic valve replacement during second trimester of pregnancy. JACC Cardiol 2023;81:1474–87. https://doi.org/10.1016/j.jacc.2023.02.037
Case Rep 2023;27:102074. https://doi.org/10.1016/j.jaccas.2023.102074 1001.Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Zafar A, Eslami P, et al. Sex
981. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. differences in left ventricular remodeling and outcomes in chronic aortic regurgita-
Anticoagulation for pregnant women with mechanical heart valves: a systematic review
tion. J Clin Med 2020;9:4100. https://doi.org/10.3390/jcm9124100
and meta-analysis. Eur Heart J 2017;38:1509–16. https://doi.org/10.1093/eurheartj/
1002.Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular ar-
ehx032
rhythmias, and sudden death. Circulation 2019;140:952–64. https://doi.org/10.1161/
982. Fuchs A, Urena M, Chong-Nguyen C, Kikoine J, Brochet E, Abtan J, et al. Valve-in-valve
CIRCULATIONAHA.118.034075
and valve-in-ring transcatheter mitral valve implantation in young women contemplat-
1003.Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex-based dif-
ing pregnancy. Circ Cardiovasc Interv 2020;13:e009579. https://doi.org/10.1161/
ferences in heart failure across the ejection fraction spectrum: phenotyping, and
CIRCINTERVENTIONS.120.009579
prognostic and therapeutic implications. JACC Heart Fail 2019;7:505–15. https://doi.
983. Mascherbauer J, Kammerlander A, Nitsche C, Bax J, Delgado V, Evangelista A, et al.
org/10.1016/j.jchf.2019.03.011
Sex-related differences in severe native valvular heart disease: the ESC-EORP
1004.El Sabbagh A, Al-Hijji M, Wang DD, Eleid M, Urena M, Himbert D, et al. Predictors of
Valvular Heart Disease II survey. Eur Heart J 2024;45:3818–33. https://doi.org/10.
left ventricular outflow tract obstruction after transcatheter mitral valve replacement
1093/eurheartj/ehae523
in severe mitral annular calcification: an analysis of the Transcatheter Mitral Valve
984. Cote N, Clavel MA. Sex differences in the pathophysiology, diagnosis, and manage-
Replacement in Mitral Annular Calcification Global Registry. Circ Cardiovasc Interv
ment of aortic stenosis. Cardiol Clin 2020;38:129–38. https://doi.org/10.1016/j.ccl.
2021;14:e010854. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010854
2019.09.008
1005.Willner N, Burwash IG, Beauchesne L, Chan V, Vulesevic B, Ascah K, et al. Natural
985. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation,
history of mitral annular calcification and calcific mitral valve disease. J Am Soc
aetiology and outcome of infective endocarditis. Results of the ESC-EORP
Echocardiogr 2022;35:925–32. https://doi.org/10.1016/j.echo.2022.05.007
EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.
1006.Offen S, Playford D, Strange G, Stewart S, Celermajer DS. Adverse prognostic impact
Eur Heart J 2019;40:3222–32. https://doi.org/10.1093/eurheartj/ehz620
of even mild or moderate tricuspid regurgitation: insights from the National
986. Avierinos JF, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences
Echocardiography Database of Australia. J Am Soc Echocardiogr 2022;35:810–17.
in morphology and outcomes of mitral valve prolapse. Ann Intern Med 2008;149:
https://doi.org/10.1016/j.echo.2022.04.003
787–95. https://doi.org/10.7326/0003-4819-149-11-200812020-00003
1007.Mutlak D, Khalil J, Lessick J, Kehat I, Agmon Y, Aronson D. Risk factors for the devel-
987. Brown JM, O’Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve
opment of functional tricuspid regurgitation and their population-attributable frac-
replacement in North America comprising 108,687 patients in 10 years: changes in
tions. JACC Cardiovasc Imaging 2020;13:1643–51. https://doi.org/10.1016/j.jcmg.
risks, valve types, and outcomes in the Society of Thoracic Surgeons National
2020.01.015
Database. J Thorac Cardiovasc Surg 2009;137:82–90. https://doi.org/10.1016/j.jtcvs.
1008.Prihadi EA, van der Bijl P, Gursoy E, Abou R, Mara Vollema E, Hahn RT, et al. 2008.08.015
988. O’Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, et al. The Society of Thoracic Development of significant tricuspid regurgitation over time and prognostic implica-
Surgeons 2018 adult cardiac surgery risk models: part 2—statistical methods and re- tions: new insights into natural history. Eur Heart J 2018;39:3574–81. https://doi.org/
sults. Ann Thorac Surg 2018;105:1419–28. https://doi.org/10.1016/j.athoracsur.2018. 10.1093/eurheartj/ehy352
03.003 1009.Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, et al. Sex dif-
989. Shan Y, Pellikka PA. Aortic stenosis in women. Heart 2020;106:970–6. https://doi.org/ ferences in heart failure with preserved ejection fraction pathophysiology: a detailed
10.1136/heartjnl-2019-315407 invasive hemodynamic and echocardiographic analysis. JACC Heart Fail 2019;7:
990. Voisine M, Hervault M, Shen M, Boilard AJ, Filion B, Rosa M, et al. Age, sex, and valve 239–49. https://doi.org/10.1016/j.jchf.2019.01.004
phenotype differences in fibro-calcific remodeling of calcified aortic valve. J Am Heart 1010.Dietz MF, Prihadi EA, van der Bijl P, Fortuni F, Marques AI, Ajmone Marsan N, et al.
Assoc 2020;9:e015610. https://doi.org/10.1161/JAHA.119.015610 Sex-specific differences in etiology and prognosis in patients with significant tricuspid
991. Capoulade R, Clavel MA, Le Ven F, Dahou A, Thebault C, Tastet L, et al. Impact of left regurgitation. Am J Cardiol 2021;147:109–15. https://doi.org/10.1016/j.amjcard.2021.
ventricular remodelling patterns on outcomes in patients with aortic stenosis. Eur 02.016
Heart J Cardiovasc Imaging 2017;18:1378–87. https://doi.org/10.1093/ehjci/jew288 1011.Pfannmueller B, Eifert S, Seeburger J, Misfeld M, Borger M, Mende M, et al.
992. Simard L, Côté N, Dagenais F, Mathieu P, Couture C, Trahan S, et al. Sex-related dis- Gender-dependent differences in patients undergoing tricuspid valve surgery.
cordance between aortic valve calcification and hemodynamic severity of aortic sten- Thorac Cardiovasc Surg 2013;61:37–41. https://doi.org/10.1055/s-0032-1324406
osis: is valvular fibrosis the explanation? Circ Res 2017;120:681–91. https://doi.org/10. 1012.Fortmeier V, Lachmann M, Körber MI, Unterhuber M, Schober AR, Stolz L, et al.
1161/CIRCRESAHA.116.309306 Sex-related differences in clinical characteristics and outcome prediction among pa-
993. Bienjonetti-Boudreau D, Fleury MA, Voisine M, Paquin A, Chouinard I, Tailleur M, et al. tients undergoing transcatheter tricuspid valve intervention. JACC Cardiovasc Interv
Impact of sex on the management and outcome of aortic stenosis patients. Eur Heart J 2023;16:909–23. https://doi.org/10.1016/j.jcin.2023.01.378
2021;42:2683–91. https://doi.org/10.1093/eurheartj/ehab242 1013.Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodes-Cabau J, et al.
994. Tribouilloy C, Bohbot Y, Rusinaru D, Belkhir K, Diouf M, Altes A, et al. Excess mortality Sex-related characteristics and short-term outcomes of patients undergoing trans-
and undertreatment of women with severe aortic stenosis. J Am Heart Assoc 2021;10: catheter tricuspid valve intervention for tricuspid regurgitation. Eur Heart J 2023;
e018816. https://doi.org/10.1161/JAHA.120.018816 44:822–32. https://doi.org/10.1093/eurheartj/ehac735
Downloaded
from
https://academic.oup.com/eurheartj/article/46/44/4635/8234488
by
guest
on
22
January
2026
